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Omega-3 Fatty Acids and Cancer Cell
Cytotoxicity: Implications for
Multi-Targeted Cancer Therapy
Donatella D’Eliseo and Francesca Velotti
Abstract: Cancer is a major disease worldwide. Despite progress in cancer therapy,
conventional cytotoxic therapies lead to unsatisfactory long-term survival, mainly
related to development of drug resistance by tumor cells and toxicity towards normal
cells. n-3 polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), can exert anti-neoplastic activity by inducing apoptotic
cell death in human cancer cells either alone or in combination with conventional
therapies. Indeed, n-3 PUFAs potentially increase the sensitivity of tumor cells to
conventional therapies, possibly improving their efficacy especially against cancers
resistant to treatment. Moreover, in contrast to traditional therapies, n-3 PUFAs
appear to cause selective cytotoxicity towards cancer cells with little or no toxicity on
normal cells. This review focuses on studies investigating the cytotoxic activity of
n-3 PUFAs against cancer cells via apoptosis, analyzing the molecular mechanisms
underlying this effective and selective activity. Here, we highlight the multiple
molecules potentially targeted by n-3 PUFAs to trigger cancer cell apoptosis. This
analysis can allow a better comprehension of the potential cytotoxic therapeutic role
of n-3 PUFAs against cancer, providing specific information and support to design
future pre-clinical and clinical studies for a better use of n-3 PUFAs in cancer therapy,
mainly combinational therapy.
Reprinted from J. Clin. Med. Cite as: D’Eliseo, D.; Velotti, F. Omega-3 Fatty Acids
and Cancer Cell Cytotoxicity: Implications for Multi-Targeted Cancer Therapy.
J. Clin. Med. 2016, 5, 15.
1. Introduction
Cancer is a major burden of disease worldwide and, in certain countries, it
ranks the second most common cause of death following cardiovascular diseases [1].
Furthermore, as elderly people are most susceptible to cancer and population aging
continues, cancer is projected to become the leading cause of death worldwide
in many countries. Despite progress made in recent years in cancer therapy,
traditional cytotoxic therapies such as chemo- and radio-therapy have multiple
limitations, leading to treatment failure, cancer relapse and unsatisfactory long-term
clinical results [2]. These limitations are mainly related to two important issues:
(1) conventional therapies lead to development of drug resistance by tumor cells
3
and/or fail to destroy cancer stem cells (CSCs) or tumor-initiating cells (TICs), a
population of self-renewing and drug resistant cancer cells [3,4]; (2) conventional
therapies can cause normal cells to die in massive number, leading to local and
systemic toxicity. Since cancer cell survival is driven by complex molecular
interactions between growth and death signals [5], most oncologists think that
targeting a single molecular component may not be sufficient to disrupt this process
and combinational therapies, targeting multiple molecules, pathways, or networks
are needed to eradicate the tumor and increase patients' survival [6].
Omega-3 (ω-3 or n-3) fatty acids (FAs) are an important family of
polyunsaturated fatty acids (PUFAs) and key nutrients, involved in normal growth
and development of various human tissues [7–9]. Longer chain n-3 polyunsaturated
fatty acids (PUFAs) are mainly composed of eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA). EPA has 20 carbon atoms and 5 double bonds (20:5n-3).
DHA has a chain with 22 carbon atoms and 6 double bounds (22:6n-3), which makes
it the longest chain and most unsaturated FA commonly found in biological systems.
In the human body, DHA is either derived from β-oxidation of EPA or acquired from
the diet. Cold-water oily fish are the main dietary source of essential n-3 PUFAs
in humans, providing thus relatively large amount of EPA and DHA [10]. Beyond
their role in physiological functions, n-3 PUFAs can affect some chronic diseases
such as cancer [8,9,11–13]. Indeed, n-3 PUFAs or purified EPA and DHA can exert
anti-neoplastic activity, playing a potential role either in cancer prevention or in
cancer therapy [11–13].
Several decades ago, on the basis of human epidemiological studies, dietary
oily fish and fish oil (FO) consumption have been associated with the protection
against the development of some types of cancer, mainly colorectal, mammary and
prostatic cancers [14,15]. Thereafter, most of the studies performed either in vitro or
in vivo have demonstrated the protection by n-3 PUFAs against cancer risk. However,
some reports question the effectiveness of these compounds in neoplastic prevention,
and others argue that an increased n-3 PUFAs intake could induce some types of
cancer [15–19]. Thus, the potential preventive role of n-3 PUFAs has become a
subject of intense interest and debate. The biological effects of n-3 PUFAs on normal
cells to prevent their transformation are not the topic of our dissertation, since
exhaustive reviews have been written and have critically analyzed the data in the
literature [15,16,20,21].
During recent years, extensive studies have also considered the potential
therapeutic activity of n-3 PUFAs against established solid and hematological
tumors [13,22]. A number of biological effects that could contribute to this activity
have been suggested, including induced alteration by n-3 PUFAs of cancer cell
invasion and metastasization, as well as proliferation and apoptosis [21–25]. The
induction of tumor cell apoptosis plays an important role in cancer therapy and
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represents a prominent target of many treatment strategies. Several studies have
demonstrated that n-3 PUFAs, EPA and DHA have inhibitory effects on tumor growth
by inducing cancer cell death via apoptosis, either alone [22–25] or in combination
with conventional anticancer therapies [26–31]. Although all these studies have
proposed molecular mechanisms that account for the pro-apoptotic activity of
n-3 PUFAs in cancer cells, the mechanisms are still not completely understood,
and a large number of molecular targets of n-3 PUFAs have been identified and
multiple mechanisms appear to underlie the induction of apoptosis by these FAs.
However, notably, the cytotoxic activity exerted by n-3 PUFAs is very peculiar for
two main reasons. First, it has the potential to increase the sensitivity of tumor
cells to conventional cytotoxic therapies, possibly improving the efficacy of these
therapies against some types of tumors, especially those otherwise resistant to
treatments [26–35]. Second, it appears to be selective, in that n-3 PUFAs cause
cytotoxicity against cancer cells with little or no toxicity on normal cells [28,36–45].
This is a very important point, since in order for a therapeutic agent to be truly
effective, it should be toxic to cancer cells without harming normal cells; conversely,
conventional chemotherapeutics kill cancer cells but also strike the healthy cells,
causing adverse effects and severe morbidity. All the above considerations greatly
support investigations carried out to assess the role of n-3 PUFAs as adjuvant, to
improve the efficacy and tolerability of traditional anticancer therapies.
This review focuses on studies investigating the cytotoxic activity via apoptosis
of n-3 PUFAs against cancer cells and analyzes the cellular and molecular mechanisms
underlying this activity. In particular, it will be highlighted the wide range of
molecules potentially targeted by n-3 PUFAs to induce cancer cell apoptosis. Firstly,
in Section 2, it will be examined the pro-apoptotic activity exerted by n-3 PUFAs
in different cancer models in vitro and in vivo, as well as the apoptotic pathways
triggered by these FAs. Concerning this point, it will be also considered the important
potential capability of EPA and DHA of inducing cytotoxicity towards drug-resistant
cancer cells such as CSCs or TICs. Next, in Section 3, it will be analyzed the
molecular events upstream the triggering of apoptosis by n-3 PUFAs, highlighting
the multiple potential molecular targets of these FAs. This review could allow a better
comprehension of the potential cytotoxic therapeutic role of the principal long chain
n-3 PUFAs EPA and DHA against cancer, providing specific information and support
to design future pre-clinical and clinical studies, which lead to the development
of a more proper and effective use of these FAs in human cancer therapy, mainly
combinational therapy.
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2. Induction of Cancer Cell Apoptosis by n-3 Polyunsaturated Fatty Acids
(PUFAs) and Triggering of the Intrinsic and Extrinsic Apoptotic Pathways
Apoptosis is a programmed cell death process, occurring in physiological and
pathological conditions [46]. Caspases are central to apoptosis mechanism, as they
are both the initiators and executioners of this process. There are three pathways by
which caspases can be activated. The two commonly described initiation pathways
are the intrinsic (or mitochondrial) and the extrinsic (or death receptor) apoptotic
pathways. Both pathways eventually lead to a common pathway or the execution
phase of apoptosis mediated by the executioner caspase-3, -6 and -7. A third
initiation pathway is the intrinsic endoplasmic reticulum (ER) pathway [46,47]. The
intrinsic or mitochondrial pathway is activated by endogenous stress signals such as
growth factor deprivation, DNA-damaging chemicals and reactive oxygen species
(ROS), which increase mitochondrial membrane permeability by modifying the
interplay between B cell lymphoma protein-2 (Bcl-2) family proteins, that interact
with mitochondrial membrane voltage-dependent anion channels. Bcl-2 family
proteins have either pro-apoptotic (e.g., Bak, Bax, or Bok) or anti-apoptotic (e.g., Bcl-2,
Bcl-xL, or Mcl-1) roles; a Bcl-2 subfamily, the BH3-only protein family (e.g., Bad, Bid,
Bim, Noxa or Puma) also modulate pro- and anti-apoptotic Bcl-2 protein interactions.
Pro-apoptotic stimuli shift the balance towards apoptic proteins, promoting the
mitochondrial outer membrane permeabilization (MOMP), the subsequent release of
cytochrome C into the cytosol, followed by its complex formation with procaspase-9
and apoptotic protease-activating factor 1 (APAF1), leading to the activation of
the initiator caspase-9; then, caspase-9 activates the executioner caspases. The
extrinsic pathway of apoptosis is activated by signal originated by death receptors
such as TNFα-receptors, CD95 (Fas) and TNF-related apoptosis-inducing ligand
(TRAIL)-receptors, following their interaction with their corresponding ligands,
TNFα, FasL and TRAIL. Receptor activation leads to recruitment, to receptor
associated lipid rafts, of adaptor molecules to form death-inducing signaling
complexes (DISCs), which contains TNF receptor-associated death domain (TRADD),
Fas-associated death domain (FADD), procaspase-8/FLICE and receptor-interacting
protein kinase 1 (RIPK1). This complex induces the activation of caspase-8 and -10,
which activate the executioner caspases. In addition, caspase-8 can also truncate Bid
(tBid), which can migrate to the mitochondria to associate with Bax, increasing
membrane permeability and converging thus to the activation of the intrinsic
apoptotic pathway. The intrinsic ER pathway of apoptosis is activated in response to
diverse arrays of stress such as oxidative stress, calcium influx and ER stress. The ER
has three main functions: (1) folding, glycosylation and sorting of proteins to their
proper destination; (2) synthesizing cholesterol and other lipids; and (3) maintenance
of Ca2+ homeostasis. Disruption of any of these processes causes ER stress and
activates the unfolded protein response (UPR). However, following prolonged ER
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stress, imbalanced calcium storage will activate calpain, which can inactivate Bcl-Xl
and also activate the executioner caspases, leading to apoptosis. Finally, the apoptotic
cascade is regulated by regulatory proteins, such as FLICE-like inhibitory proteins
(FLIPs), which inhibit the extrinsic apoptotic pathway by binding to FADD and
causing dissociation of the FADD/caspase-8 complex. Additionally, families of
inhibitor of apoptosis protein (IAP) (e.g., XIAP, cIAP, and survivin) bind to caspase-3
and -9, thereby inhibiting caspase activity. Moreover, XIAP associated factor 1 (XAF1)
negatively regulates the antiapoptotic function of XIAP.
Evasion of apoptosis by tumor cells is a hallmark of cancer [5] and defects in
cancer cell apoptosis have been described at any point along the apoptotic pathways,
including impaired receptor signaling, disrupted balance of anti- and pro-apoptotic
Bcl-2 family proteins, reduced expression of caspases and increased expression of
regulatory proteins (e.g., IAPs).
2.1. In Vitro and in Vivo Induction of Cancer Cell Apoptosis by n-3 PUFAs
n-3 PUFAs, EPA and DHA can induce apoptosis in tumor cells in vitro and
in vivo, in a dose- and time-dependent manner. They induce apoptosis in vitro, in
tumor cell lines derived from a wide range of solid tumors including colorectal
carcinoma [37,48–50], esophageal [51] and gastric cancers [52], hepatocellular
carcinoma [53–55], pancreatic cancer [56–58], cholangiocarcinoma [59], breast [60,61],
ovarian [62], prostate [63,64] and bladder [65] cancers, neuroblastoma [66]
and glioma [67], lung cancer [68,69], squamous cell carcinoma (SCC) [42] and
melanoma [70,71]. Apoptosis induced by n-3 PUFAs, EPA and DHA has been also
described in cancer cell lines derived from hematological tumors such as myeloid and
lymphoid leukemias and lymphomas [72–78], as well as multiple myeloma [44,79].
In addition, in these last years a great attention has been given to CSCs or TICs,
a small population of cancer cells with self-renewal and drug resistance properties,
involved in cancer initiation, maintenance, metastasis and recurrence [2–4,80].
Resistance of CSCs/TICs to standard anti-cancer therapies is responsible for
ineffectiveness of these treatments, leading to tumor recurrence and metastasis [2–4].
Therefore, in order to establish efficient therapeutic strategies that can prevent
tumor relapse and induce a long-lasting clinical response, it is important to
develop drugs that can specifically target and eliminate CSCs/TICs. Remarkably,
recent in vitro studies have indicated the capability of n-3 PUFAs to affect
colorectal and breast CSCs [81–85]. Indeed, it was shown that both EPA and DHA
(10–70 µM), separately, induced apoptosis in cancer stem-like cells derived from
the SW620 colon cancer cell line, and the effect was markedly increased when
they acted simultaneously. Moreover, both compounds enhanced the efficacy of
chemotherapeutics agents such as 5-fluorouracil (5-FU) and mitomycin C against
the same target cells [82]. Accordingly, it was observed that EPA alone and (with
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increased efficacy) in combination with 5-FU + oxaliplatin (OX) (FuOX) induced
apoptosis in FuOX-resistant HT-29 and HCT116 colorectal carcinoma cells, highly
enriched in CSCs [83]. In addition, de Carlo et al. [84] found that 25 µM EPA induced
the differentiation of colon CSCs, by upregulating cytokeratin 20 and mucin 2 and
downregulating CD133 expression; they hypothesized that the increased degree of
colon CSC differentiation could be strictly related to the EPA-induced sensitization
of CD133+ cells to 5-FU. More recently, in human triple negative breast cancers, it
has been shown that DHA inhibited mammosphere formation of TICs [85]. The
capability of n-3 PUFAs to eliminate CSCs/TICs and/or increase their sensitivity
to conventional antineoplastic drugs have a very important therapeutic potential,
further supporting the anticancer use of these FAs as adjuvants in cancer therapies.
Suppression of tumor cell growth by n-3 PUFAs has been confirmed in vivo, in
pre-clinical studies using cancer animal models mainly rapresented by transgenic
“fat-1” mice (bearing the Caenorhabditis elegans “n-3 desaturase” gene able to convert
n-6 to n-3 PUFAs, resulting thus in elevated n-3 PUFAs tissue content) and xenograft
nude mice implanted with different tumor cell types [13,22,24,41,86–89]. However,
it should be noted that most studies have been performed in experimental settings
evaluating the suppression of tumor development and only few investigations have
been realized in therapeutic settings, evaluating the capability of PUFAs to eradicate
established tumors [24,41,86–89].
Encouraging results concerning the in vivo anti-neoplastic activity of n-3 PUFAs
have been also obtained from clinical studies, even though they were mainly
set-up to investigate cancer prevention and support, rather than cancer
therapy [25,30,31,90–101]. Indeed, the outcomes mainly investigated included n-3
PUFAs membrane incorporation, immune and inflammatory responses, oxidative
status, as well as body weight and composition or quality of life [31,96,97,99–101].
Few studies addressed n-3 PUFAs supplementation and decrease of tumor size or
extension of patient survival [90–93,95,96,98,100] (Table 1).
Thus, although in these studies n-3 PUFAs supplementation was associated with
improvement of clinical outcome and prognosis, the conclusion is limited because of



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.2. Triggering of the Intrinsic and Extrinsic Apoptotic Pathways by n-3 PUFAs
Many studies have reported that n-3 PUFAs induced apoptosis by triggering the
intrinsic mitochondrial and ER pathways. In fact, EPA increased caspase-3 and -9, but
not caspase-8, while inducing apoptosis in Ramos lymphoma cells [102]. Different
studies in colon cancer (LS-174, HT-29, Caco-2 and COLO 201) cell lines showed that
dietary FO [103] or DHA [104,105] modified the expression of Bcl-2 family proteins
by increasing the levels of the pro-apoptotic proteins Bak and Bcl-xS and decreasing
those of the anti-apoptotic proteins Bcl-2 and Bcl-xL. Similarly, Sun et al. [54] observed
that DHA induced apoptosis in human Bel-7402 hepatocellular carcinoma cells,
by up-regulating caspase-3 and Bax expression levels and downregulating the
expression of Bcl-2 and Bim. Recently, Abdi et al. [44] demonstrated that EPA and
DHA induced apoptosis in myeloma (L363, OPM-1, OPM-2 and U266) cells through
mitochondrial perturbation and caspase-3 activation, whereas both compounds
did not affect the viability of normal human peripheral blood mononuclear cells.
Moreover, the analysis of gene modulation by n-3 PUFAs in myeloma cells revealed
the modulation of several signal pathways, including nuclear factor (NF)-κB, Notch,
Hedgehog, oxidative stress and Wnt, indicating the possible involvement of multiple
molecular signals in the initiation of apoptosis by the intrinsic pathway. Finally,
the activation of the intrinsic ER stress pathway has been also proposed underlying
DHA-induced apoptosis in colon cancer cells. Indeed, Jackobsen et al. [106] showed
that DHA, while inducing cell death in the aggressive SW620 colon cancer cell line,
also induced extensive changes in gene expression patterns (mRNA) of ER stress;
they also found abundant presence of phosphorylated eIF2α, increase in cytosolic
Ca2+ and disturbances in lipid metabolism, suggesting that cytotoxic effects of DHA
are associated with signaling pathways involving lipid metabolism and ER stress.
On the other hand, other studies have indicated the activation of the extrinsic
pathway in the induction of apoptosis by n-3 PUFAs. Indeed, increased expression
of both caspase-9 and caspase-8 was reported in EPA- [107] and DHA- [108] induced
apoptosis in human HL-60 leukemia and Caco-2 colon cancer cells, respectively.
In the case of colon cancer cell apoptosis, tBid expression was also enhanced,
indicating a contribution of caspase-8 also to the activation of the mitochondrial
pathway. Accordingly, in our laboratory we found the involvement of caspase-8 in
DHA-mediated apoptosis in pancreatic and bladder cancer cell lines [65].
Finally, both DHA and EPA could exert an important pro-apoptotic effect
in different colorectal cancer (Caco-2, HT-29, HCT116, LoVo, SW480) cells by
the downregulation of two key regulatory elements of the extrinsic and intrinsic
pathways, FLIP and XIAP, respectively; interestingly, DHA and EPA did not affect
the viability of normal human colon mucosal epithelium (NCM460) cells [39].
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3. Molecules, Signals and Networks Targeted by n-3 PUFAs: Upstream Events
in the Triggering of the Apoptotic Pathways
Cancer is often described as a disorder of the balance between cell growth
and death [5]. On the one hand, defects in signaling pathways promoting
cell growth and survival occur in cancer cells and high constitutive levels of
MEK/ERK, PI3K/Akt, JAK/STAT or IKK/IκB/NF-κB pathways are frequently
observed in human cancers [5,109]. On the other hand, as already mentioned in
Section 2, defects along the apoptotic pathways also occur in cancer cells, leading to
resistance to apoptosis [5,110]. Therefore, all the molecules, signals and networks
involved in cancer cell survival and death are potential targets for apoptosis-based
cancer therapies.
The mechanisms by which n-3 PUFAs induce apoptosis in tumor cells are not
fully determined in molecular terms; however, the proposed main routes of action
of n-3 PUFAs are: (1) incorporation into cell membranes, leading to changes in the
distribution and function of key survival and death signals; (2) generation of lethal
levels of intracellular oxidative stress; (3) modulation of eicosanoid metabolites;
(4) binding to nuclear receptors, leading to changes in gene expression. These routes
may underlie the pleiotropic and multifaceted effects of n-3 PUFAs, leading to the
induction of apoptosis in cancer cells and/or to the sensibilization of tumor cells to
traditional therapies. Therefore, in the context of these four routes of action of n-3
PUFAs, in this section we analyze studies investigating the mechanisms underlying
the induction of apoptosis, highlighting the potential upstream molecular events
targeted by n-3 PUFAs to trigger the apoptotic pathways in cancer cells.
3.1. Cell Membrane Enrichment in n-3 PUFAs and Changes in the Distribution and
Function of Key Survival and Death Signals in Cancer Cells
Once ingested, n-3 PUFAs, EPA and DHA are uptaken and incorporated
in tumor cell membranes by both passive or carrier-mediated transmembrane
translocation [29]. The FA composition of membrane phospholipids can influence
multiple cellular functions. It should be noted that DHA, for its high level of
unsaturation and presence of several CH-CH2-CH repeating units in its molecule,
possesses an extremely flexible structure, more flexible than EPA, and it can rapidly
isomerize through different conformational states [29]. Therefore, the enrichment
of n-3 PUFAs in tumor cell membranes and the high molecular disorder originating
from their (mainly DHA) incorporation into membrane phospholipids may affect
physical-chemical properties of membranes, including their fluidity, permeability,
deformability, as well as their lipid microdomain formation [29,111]. Plasma
membrane is composed of microdomains of saturated lipids that segregate together
to form “lipid rafts”. Lipid rafts are enriched in glycosylphosphatidylinositol-linked
proteins, contain several signaling proteins (e.g., epidermal growth factor receptor,
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EGFR) and play a key role in cell signal transduction, mainly by facilitating the
association of signal molecules (e.g., those involved in cell survival). Cholesterol
is a critical lipid component for lipid raft integrity and function, and DHA have
poor affinity for cholesterol and influences lipid rafts, modifying their biochemical
and biophysical features and changing their composition and/or the activity of
raft-related signaling molecules. Therefore, concerning the regulation of apoptosis,
n-3 PUFAs have the potential to modulate the function of death receptors, growth
factor receptors, cytokines and hormones receptors, as well as oncogenes, tumor
suppressor genes and signal transduction secondary messangers (e.g., adapter
proteins, receptor-associated enzymes, protein kinases and phosphatases). As
a consequence, n-3 PUFAs may alter the activation of transcription factors and
expression of genes as well as the phenotype of tumor cells [111]. Thus, cell
membrane enrichment in n-3 PUFAs can influence multiple cellular functions at
multiple biological levels. Moreover, noteworthy, it has been reported that there
are significant differences between tumor and normal cells in n-3 PUFAs uptake
and membrane distribution, being tumor cells deficient in PUFAs (especially in
arachidonic acid-ARA, EPA and DHA) as compared to normal cells, since they have
decreased activity of ∆5 and ∆6 desaturases. Although the exact reason for the low
activity of desaturases in cancer cells is not known, it has been proposed that it
might be a defence mechanism adopted by tumor cells to protect themselves from
toxic molecules such as free radicals derived from n-3 PUFAs peroxidation in cancer
cells (see Section 3.2) [112,113]. Therefore, the specific enrichment of tumor cell
membranes with n-3 PUFAs, EPA or DHA is one of the possible reasons underlying
the capability of n-3 PUFAs to induce cytotoxicity in tumor cells, with no or little
action on normal cells.
Discoveries over the last decade propose that n-3 PUFAs incorporation into
cancer cell membranes is essential for apoptosis by n3-PUFAs in different cancer
cell models [26,113–115]. However, currently, the precise mechanism of how a
selective change in DHA and EPA content of membranes translates to a change
in signaling events to induce apoptosis is not completely clear. Therefore, in the
next sections (from Section 3.1.1 to 3.1.6), we analyze the studies investigating this
issue. We take into consideration different possible actions by n-3 PUFAs, such as
the displacement of lipid raft associated onco-proteins as well as the modulation
of different survival signaling pathways in tumor cells, including Wnt/β-catenin,
MAPK/Erk, PI3K/Akt/mTOR, JAK-STAT and NF-κB pathways.
3.1.1. Changes in Lipid Raft-Associated Onco-Proteins by n-3 PUFAs
The involvement of the modulation of EGFR and HER-2 signals in n-3
PUFAs-induced apoptosis has been reported by different studies, performed
in different types of cancer (mainly breast cancer) cells. In 2007, Schley and
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coworkers [116] showed that apoptosis induced by a combination of EPA and DHA in
MDA-MB-231 breast cancer cells was due to changes in lipid raft composition, leading
to a decrease of EGFR levels as well as an increase of EGFR and p38 mitogen-activated
protein kinase (MAPK) phosphorylation. Accordingly, in oral SCC cells, it was
found that DHA- and EPA-induced apoptosis was mediated by amplification of the
EGFR/ERK/p90RS kinase (K) pathway (i.e., EGFR autophosphorylation, sustained
phosphorylation of ERK1/2 and of its downstream target p90RSK); to note, the
viability of normal keratinocytes was not affected [42]. In contrast with these results,
in three different (A549 lung, WiDr colon and MDA-MB-231 breast) cancer cell
models it was found that DHA-induced apoptosis was caused by the exclusion of
EGFR from caveolin-rich lipid raft fractions, resulting in a decreased association of
Ras with Sos1 and the subsequent downregulation of Erk signaling; these data were
confirmed in vivo, using xenograft athymic mice implanted with A549 cells [117].
Similarly, a reduction of EGFR activation was observed in EPA- or DHA-induced
apoptosis in breast cancer (MDA-MB-231 and MCF-7) cells, associated to a reduction
of Bcl2 and caspase-8 expression; moreover, DHA (probably related to its better
capability to change lipid raft properties), but not EPA, also slightly reduced EGFR
concentration [118]. More recently, in line with these results, it was found that
DHA had the capability of decreasing cell surface levels of lipid rafts via their
internalization and then fusion with lysosomes in MDA-MB-231 breast cancer cells.
This implied that DHA displaced several raft-associated onco-proteins, including
EGFR, Hsp90, Akt, and Src and also decreased total levels of those proteins via
multiple pathways, including the proteasomal and lysosomal pathways, thereby
decreasing their activities such as Hsp90 chaperone function [119]. Then, the
therapeutic potential of DHA in the treatment of HER-2 positive breast cancers
has been reported by two investigators. Ravacci [43], Mason [120] and coworkers
showed that DHA induced apoptosis in transformed human mammary epithelial
(HB4aC5.2) cells and in breast cancer (BT-474) cells, respectively, by the deplacement
of HER-2 from lipid rafts and the decrease of Akt and ERK1/2 activation; no effects
were observed in related untransformed (HB4a) cells.
New insight into the potential application of n-3 PUFAs in breast cancer
treatment was also provided by a recent investigation in MCF-7 and T47D breast
cancer cells, showing that DHA and EPA could shift the pro-survival estrogen signal
to a pro-apoptotic effect by increasing the G protein coupled estrogen receptor
1-cyclic adenosine monophosphate-protein kinase A (GPER1-cAMP-PKA) signaling
response, blunting EGFR, Erk 1/2 and AKT activity [121].
It is of interest that it has been also demonstrated that pre-treatment of estrogen
receptor negative MDA-MB-231 cells with DHA increased the anti-cancer effects
of doxorubicin, by increasing the plasma membrane raft content of CD95 and
FADD. [122].
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Finally, in prostate cancer (PC3 and LNCaP) cells, growth suppression by DHA
was due to changes in cell plasma membrane phospholipid content, leading to the
alteration of phosphatidylinositol phosphates (PIPs) content, PI(3,4,5)P3 (PIP3) and
Akt localization, inhibition of Akt phosphorylation and thus of the AKT survival
signaling pathway [123].
3.1.2. Inhibition of the Wnt/β-Catenin Pathway by n-3 PUFAs
Wnt functions causing an accumulation of β-catenin in the cytoplasm and
its eventual translocation into the nucleus, to act as a transcriptional coactivator
of transcription factors that belong to the T cell factor/lymphoid enhancer factor
(TCF/LEF) family. Dysregulation of Wnt signaling and β-catenin expression is
believed to be central in the regulation of tumor cell apoptosis [109].
In 2007, Calviello et al. [124] proposed that DHA exerted pro-apoptotic effects in
colon cancer cells through proteasomal-dependent degradation of β-catenin, leading
to down-regulation of the expression of TCF-β-catenin target genes such as survivin
(a IAP family member). Then, Lim [53,59], Song [125] and coworkers showed that
DHA- and EPA-induced apoptosis in human cholangiocarcinoma, hepatocellular and
pancreatic carcinoma cells was caused by the inhibition of the β-catenin signaling
pathway through two systems of β-catenin degradation, such as the activation (by
dephosphorylation) of glycogen synthase kinase-3β (GSK-3β) and the induction of
the formation of β-catenin/Axin/GSK-3β binding complex; similar results were
obtained in vivo, in Fat-1 transgenic mice implanted with mouse pancreatic cancer
(PANC02) cells [125]. More recently, the inhibition of the Wnt/β-catenin pathway
was also found to be involved in growth suppression of breast MCF-7 cancer cells
in vitro and in therapy experiments in vivo, performed in Babl/c mice bearing 4T1
mouse breast cancer and fed with a 5% FO diet [126].
3.1.3. Modulation of the Mitogen-Activated Protein Kinase (MAPK)/ERK (or
Ras/Raf/MEK/ERK) Pathway by n-3 PUFAs
The MAPK/ERK pathway includes many MAPK proteins (originally called
extracellular signal-regulated kinases, ERK), which function by adding phosphate
groups to a neighboring protein, leading to change the expression of genes specific
for molecules involved in cell cycle and apoptosis. This pathway represents a
necessary step in the development and progression of many cancers. Although
the activation of ERK is traditionally linked to cell survival and proliferation, recent
studies have demonstrated that this is not always the case and ERK activation can
also cause growth arrest or apoptosis [109]. Indeed, as reported below, both activation
and inhibition of ERK have been associated with n-3 PUFAs-induced tumour cell
apoptosis, suggesting that tissue- or cancer-specific mechanisms of n-3 PUFAs action
might occur.
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In 2008, Serini et al. [68] showed that DHA-induced apoptosis was due to
decreased levels of phosphorylated MAPKs, especially ERK1/2 and p38 in lung
cancer cells. Accordingly, n-3 PUFAs induced apoptosis in breast cancer cells
in vitro and in a Fat-1 mice breast cancer model, by inhibition of the MEK/ERK/Bad
signaling pathway; the inhibition was induced through the increased expression
of the integral membrane protein syndecan-1 (SDC-1) [127]. On the other hand, in
gastric cancer cells, DHA-induced apoptosis was caused by the activation of ERK
and c-Jun N-terminal kinase (JNK), leading to the activation of AP-1 transcription
factor, which induced the expression of apoptotic genes [52].
3.1.4. Inhibition of the PI3K/Akt/mTOR Pathway by n-3 PUFAs
PI3K (phosphatidylinositol-3-kinase) is one of the intracellular pathways
responsible for the transmission of anti-apoptotic signals by cell survival factors.
Phosphatase and tensin homologue deleted on chromosome ten (PTEN) is a lipid
phosphatase, which catalyzes the dephosphorylation of PIP3 and thus serves as
a major negative regulator of PI3K/Akt signaling; when it is phosphorylated, it
becomes inactive. Akt (or protein kinase B, PKB) is a serine/threonine kinase,
activated in response to cytokines and growth factors through its translocation to the
plasma membrane and its phosphorylation at two key residues (Thr308 and Ser473).
Akt activation promotes directly cell survival and protect cells from apoptosis
by inactivating components of the cell death machinery (e.g., caspase-9, Bad); in
addition, Akt promotes indirectly cell survival and protect cells from apoptosis
by activating transcription factors such as NF-κB, that induces the transcription of
pro-survival and anti-apoptotic genes. Mammalian target of rapamycin (mTOR) is a
protein kinase that integrates both intracellular and extracellular signals, and serves
as a central regulator of cell metabolism, growth and survival. It regulates the activity
of p70S6K and eukaryotic initiation factor (eIF)4E binding protein-1 (4E-BP1). The
mTOR pathway is deregulated and activated in several types of cancer, significantly
contributing to the enhancement of proliferation and the inhibition of autophagy;
overexpression of downstream mTOR effectors 4E-BP1, S6K and eIF4E4 leads to
poor cancer prognosis. Therefore, inhibition of mTOR activity disrupts the balance
between pro- and anti-apoptotic proteins, enhancing tumor cell death [109].
It was shown that EPA and DHA induced apoptosis in MDA-MB-231 breast
cancer cells in vitro [128,129] and in a xenograft animal model [129] by the
inhibition of the survival Akt/NF-κB signaling pathway, due to the inactivation
of PI3K, through increased PTEN expression by n-3 PUFAs. On the other
hand, DHA-mediated apoptosis in colon cancer (Caco-2) cells, was due to
the inactivation of PI3K induced by reduced PTEN phosphorylation by n-3
PUFAs. This inactivation promoted inhibition of Akt/PKB and thus of Bad
and forkhead transcription factor (FKHR); to note, the viability of normal colon
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(NCM460) cells was not compromised [40,130]. Then, the suppression of the
activity of (3’-phosphoinositide-dependent kinase 1)-PDK1/Akt/Bad signaling
was demonstrated underlying n-3 PUFA-induced apoptosis in prostate cancer
(PC3, LNCaP and DU145) cells in vitro and in vivo; moreover, the suppression was
dependent on the upregulation of SDC-1, and 15-LOX-1-mediated metabolism of
DHA was required for SDC-1 upregulation [64].
From recent studies, it has emerged that DHA can also simultaneously
induce apoptosis and autophagy in cancer cells, and this process involves mTOR
repression [131,132]. Indeed, DHA treatment in human cervical cancer cells led
to autophagy via p53-mediated (AMP-activated protein kinase)-AMPK/mTOR
signaling (i.e., mTOR inhibition and AMPK activation), and DHA-induced autophagy
sensitized tumor cells to apoptosis [131]. Then, in non-small cell lung cancer cells, it
was shown that DHA-induced apoptosis and autophagy were associated to mTOR
suppression induced by both AMPK activation and PI3K/Akt inhibition; these data
were confirmed in Fat-1 transgenic mice implanted with Lewis lung cancer cells [133].
3.1.5. Inhibition of the JAK-STAT Pathway by n-3 PUFAs
The JAK-STAT system consists of a receptor (activated by interferons,
interleukins, growth factors, or other chemical messengers), the Janus kinase (JAK)
and the signal transducer and activator of transcription (STAT) proteins. STAT
proteins once activated translocate into the nucleus, where they bind to DNA,
promoting the transcription of specific genes affecting basic cell functions such as
cell growth and death. The activation of STAT3 pathway in tumor cells is mainly due
to the effect of tumor released factors and plays a critical role in tumor cell-survival
and chemo-resistance [109].
A very recent work by Rescigno et al. [134] demonstrated that DHA-induced
apoptosis in aggressive SK-BR-3 breast cancer cells reduced both ERK1/2 and
STAT3 phosphorylation; interestingly, DHA only arrested cell cycle progression
of non-tumor MCF-10A breast cells, activating p21Waf1/Cip1 and p53. Moreover, it
was also shown that the elimination of aldehyde dehydrogenase positive cells and the
inhibition of mammosphere formation of TICs in human triple negative breast cancer
cells by DHA was due to the Src homology region 2 domain-containing protein
tyrosine phosphatase-1 (SHP-1)-dependent suppression of STAT3 activation and of
its downstream mediators c-Myc and cyclin D1 [85].
3.1.6. Inhibition of the NF-κB Pathway by n-3 PUFAs
NF-κB transcription factor plays a key role in many physiological processes,
including inflammation, cell proliferation and death. The aberrant regulation of
NF-kB and signaling pathways that control its activity are heavily implicated in
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promoting pro-survival signaling and may be critical for resistance to chronic
oxidative stress (i.e., drug resistance) [2].
In prostate cancer (LNCaP, DU145, PC3) cells, it was shown that DHA
synergistically enhanced the cytotoxic effect of docetaxel, through increased
apoptosis by suppression of genes involved in the NF-κB pathway [135]. Then,
always in prostate cancer (LNCaP and PacMetUT1) cells, it was reported that
exposure of cells to DHA attenuated H2O2-induced NF-κB transcriptional activity
and diminished the expression of the downstream anti-apoptotic target survivin;
this activity was specific, since it was not observed in normal human prostate (PrEC)
cells [136].
3.2. Cell Membrane Enrichment in n-3 PUFAs and Increased Oxidative Stress in
Tumor Cells
One of the main characteristics of n-3 PUFAs is the fact that they are
optimal substrates for oxidants inside the cell, undergoing thus nonenzymatic
lipid peroxidation into cell membranes; moreover, nonenzymatic lipid peroxidation
triggers a further increase of the formation of oxygen radicals and ROS [29]. Tumor
cells contain higher levels of ROS compared to normal cells, principally due to their
accelerated metabolism needed to maintain their high proliferation rate. Thus, ROS
in tumor cells can react with intracellular n-3 PUFAs giving rise to nonenzymatic
lipid peroxidation products that are highly toxic [38]. The methylene group, located
between two double bonds (–CH=CH–CH2–CH=CH–), is particularly vulnerable
to radical attack by reactive species, thus entailing the abstraction of hydrogen [29].
Moreover, DHA, possessing an additional double bond with respect to EPA, is
more susceptible to nonenzymatic lipid peroxidation, providing a variety of lipid
hydroxiperoxides and aldehydic breakdown products such as malonaldehyde (MDA;
a marker for lipid peroxidation) with toxic as well as prooxidant properties [13,24].
Indeed, the nonenzymatic lipid peroxidation triggers a further increase of the
generation of intracellular radical species; the further increase of intracellular ROS
levels and oxidative stress in tumor cells by n-3 PUFAs (EPA > DHA) causes the
disruption of the mitochondrial membrane potential, the release of cytochrome C and
thus the triggering of the intrinsic apoptotic pathway (see Section 2). Moreover, DHA
can be readly incorporated in mitochondrial membranes, altering their permeability
and decreasing the mitochondrial membrane potential [29]. It has been also reported
that DHA is mostly present in the mitochondrion in association with cardiolipins;
cardiolipin-DHA molecules are under attack of radical species, with the consequent
decrease of their binding affinity for cytochrome C, enhancement of its release and
the release of other pro-apoptotic factors (e.g., Smac/Diablo) from mitochondria to
cytosol, and the triggering of the intrinsic apoptotic pathway [29]. In addition, it is
known that ROS can also oxidize and inhibit key signaling pathways involved in cell
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proliferation, survival and apoptosis, such as MAPK and NF-κB pathways [55,137].
Therefore, all these considerations indicate that lipid peroxidation and increased
ROS levels play a key role in the induction of tumor cell apoptosis by n-3 PUFAs.
Interestingly, it has been reported that there are significant differences in tumor
vs normal cells not only in the uptake and distribution of n-3 PUFAs, but also
in the ability to generate reactive species and oxidative stress from intracellular
n-3 PUFAs. Indeed, as mentioned, tumor cells contain higher levels of oxygen
radicals compared to normal cells and in presence of DHA they increase the
production of cytotoxic lipid hydroperoxydes and other peroxides, undergoing
apoptosis. In contrast to tumor cells, normal cells can use DHA to protect themselves
from oxidative stress-induced apoptosis through a certain number of mechanisms,
including the activation of the survival PI3K/Akt pathway as well as the increased
production of cytoprotective molecules such as resolvins and protectins (see also
Section 3.3) [138–140]. As reported in the next section, several investigators have
shown that, as exogenous n-3 PUFAs are provided to cancer cells, these FAs can
induce apoptosis by augmenting free radical generation and lipid peroxidation,
whereas normal cells are not influenced [36,130,138].
Since ROS have been proposed as common mediators of apoptosis, the majority
of cytotoxic anticancer agents (including ionizing radiations, most chemotherapeutic
agents and some targeted therapies) work through ROS generation [29]. However,
although they initially generate ROS production, most cancer cells following
prolonged treatment with these drugs develop the capability to reduce ROS levels,
resulting in drug-resistance. Evidence exists on the capability of n-3 PUFAs
to increase both the efficacy of conventional anticancer therapies towards drug
resistance and their tolerability towards normal cell damage. Indeed, n-3 PUFAs can
increase the susceptibility of tumor cells to oxidative stress induced by conventional
therapies, by maintaining high ROS levels in cancer cells, thereby precluding drug
resistance [27,29]. Moreover, n-3 PUFAs can increase the tolerability to conventional
therapies, by promoting both the selective induction of letal levels of oxidative stress
in tumor cells and the selective production of protective lipid mediators in normal
cells. Both activities have important therapeutic potential, further supporting the use
of n-3 PUFAs as adjuvant in conventional cancer therapies.
Increased Oxidative Stress in Cancer Cells by n-3 PUFAs and Induction of Apoptosis
Early in vitro studies performed in breast [60] and pancreatic [56] cancer cells
proposed the involvement of oxidative mechanisms in the induction of cancer cell
apoptosis by EPA and n-3 PUFAs, respectively; interestingly, increased oxidative
stress and apoptosis were not observed in human normal cells, such as fibroblasts [60].
Further studies have shown that oxidative stress in cancer cells was generated by
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n-3 PUFAs through both generating lethal ROS levels and decreasing anti-oxidant
activities in tumor cells [38].
In our laboratory, we showed that DHA promoted apoptosis in the human
PaCa-44 pancreatic cell line through the induction of an active extrusion process
of intracellular reduced glutathione (GSH), depleting tumor cells of one of the
endogenous antioxidant defences, and increasing thus tumor cell sensibility to lipid
peroxidation and oxidative stress [57]. This data has important implications for
cancer therapy, since elevated GSH levels in tumors have been associated with
resistance to apoptosis and chemotherapy [29]. Similarly, Ding and co-workers [141]
found downregulation of the antioxidant enzyme superoxide dismutase 1 (SOD1)
expression in the DHL-4 lymphoid cell line undergoing apoptotsis by DHA. Then,
in the same laboratory, it was shown that DHA-mediated cytotoxicity in human
ovarian cancer cell lines was associated to a reduction of glutathione peroxidase
(GPx)-4 protein expression and that DHA-mediated cytotoxicity was reversed by
vitamin E, suggesting that GPx-4 downregulation was due to oxidative stress [142].
Moreover, it was reported that the in vitro and in vivo sensitization of MDA-MB-231
breast cancer cells to anthracyclines (doxorubicin) by DHA was caused by a decrease
of cytosolic GPx-1 activity and a concomitant increase of ROS levels [143].
On the other hand, n-3 PUFAs can also promote apoptosis by increasing
lipid peroxidation and intracellular oxidative stress. It has been shown that DHA
enhanced arsenic-trioxide-induced apoptosis in arsenic-trioxide resistant HL-60
(myeloid leukemia), SH-1 (hairy cell-leukemia), and Daudi (Burkitt lymphoma)
cell lines by an increase of lipid peroxidation and a reduction of the mitochondrial
membrane potential; these effects were reversed by the addition of the antioxidant
vitamin E [144]. Similarly, Lindskog et al. [66] showed that DHA-mediated
neuroblastoma cell death was associated with production of ROS and depolarization
of the mitochondrial membrane potential, whereas vitamin E inhibited both
mitochondrial depolarization and cell death; of note, nontransformed fibroblasts
were not substantially affected by DHA. Moreover, DHA also significantly enhanced
the cytotoxicity of arsenic trioxide, nonsteroidal antiinflammatory drug (diclofenac)
and conventional chemotherapeutic agents (cisplatin, doxorubicin and irinotecan)
both in chemosensitive and in multidrug-resistant neuroblastoma cells. More recently,
similar effects were found in human HT-29 colorectal adenocarcinoma cells treated
with DHA-combined treatment with 5-FU, OX and irinotecan (IRI); the anticancer
action of DHA, observed in presence of low doses of chemotherapeutic drugs
(1 µM 5-FU, 1 µM OX and 10 µM IRI), was carried out by loss of mitochondrial
membrane potential and caspase-9 activation [145]. Increased lipid peroxidation
associated to the activation of the intrinsic apoptotic pathway was confirmed by
other investigators as mechanism underlying DHA- or EPA-mediated apoptosis,
in different human cancer colon (HT-29 and Caco-2) [146] and gastric (MGC and
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SGC) [147] cell lines. In addition, in DHA-induced apoptotic human papillomavirus
(HPV)-infected cancer cells, it was reported that the overproduction of mitochondrial
ROS by DHA promoted the activation of the cellular ubiquitin-proteasome system,
which leads to the degradation of E6/E7 oncoproteins, essential in the maintenance
of HPV-associated malignancies [148].
Furthermore, it has been found that oxidative stress could induce apoptosis
by triggering not only the intrinsic pathway, but also by the extrinsic pathway.
Indeed, Kang et al. [149] found that DHA promoted apoptosis in MCF-7 breast cancer
cells in vitro and in vivo via both ROS formation and caspase-8 activation, in that
antioxidants or knockdown of caspase-8 each effectively abrogated cytotoxicity by
DHA. To explain caspase-8 activation, the authors have hypothesized that ROS
accumulation in plasma membrane lipid rafts might induce the assembly of DISC,
triggering thus the extrinsic pathway. Then, the same investigators [58] also showed
the induction of both ROS accumulation and caspase-8-dependent cell death by EPA
and DHA, in human pancreatic cancer (MIA-PaCa-2 and Capan-2) cells in vitro and
in xenografts athymic nude mice fed with 5% FO.
Recently, Jeong et al. [137] reported that the activation of MAPKs such as
ERK/JNK/p38 was involved in DHA-induced apoptosis and that this activation was
associated with mitochondrial ROS overproduction. Accordingly, Zhang et al. [55]
showed that EPA caused apoptosis in HepG2 cells by evoking ROS formation,
leading to both [Ca2+] accumulation and increased activation of JNK; both events
promoted MOMP, the release of cytochrome C from mitochondria, and the activation
of caspase-9 and caspase-3; to notice, EPA had no significant effect on the viability of
normal liver (L-02) cells.
Finally, while it is well established that excessive ROS can instigate apoptosis,
emerging data have also revealed a signaling role for ROS in the activation
of autophagy. In PC3 and DU145 prostate cancer cells, with mutant p53 and
exposed to DHA, it was found that ROS-mediated apoptosis and autophagy were
caused by the inhibition of Akt-mTOR signaling [132]. According to these results,
Zajdel et al. [150] showed that oxidative stress induced in human A549 lung cancer
cells by EPA and DHA influenced apoptosis as well as tumor cell autophagy; the
inhibition of the autophagic process suppressed cell death and decreased activation
of caspase-3/7, indicating that EPA- and DHA-mediated autophagy could amplify
cancer cell apoptosis.
3.3. Cell Membrane Enrichment in n-3 PUFAs and Changes in the Level and Quality of
Eicosanoid Metabolites
Eicosanoids are generally considered as oxidized derivatives of 20-carbon FAs
in the cell membrane, such as ARA (20:4n-6) and EPA. They include prostaglandins
(PGs), thromboxanes (TXs), leukotrienes (LXs) and lipoxins (LXs). The major n-6
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PUFA ARA, because of its prevalence in the phospholipids of cell membranes,
is generally the major substrate for eicosanoid synthesis. Once released from
membrane phospholipids, free ARA acts as a substrate for cyclooxygenases (COXs),
lipoxygenases (LOXs) and cytochrome P450 enzymes; COX enzymes lead to
2-series PGs (e.g., PGE2) and TXs, and LOX enzymes to 4-series LTs and LXs,
known as pro-inflammatory and pro-tumorigenic mediators. In fact, inflammation
confers to tumor survival and drug resistance. On the other hand, EPA is also a
substrate for COXs, LOXs and cytochrome P450 enzymes, giving rise to 3-series PGs
(e.g., PGE3) and TXs and to 5-series LTs, known as anti-inflammatory and
anti-tumorigenic mediators. These bioproducts bind specific receptors, usually
G protein-coupled receptors, leading to the activation of signaling pathways
involved in the regulation of cancer cell growth and death [9,13]. In addition, EPA
and DHA give rise to anti-inflammatory and inflammation resolving metabolites,
including resolvins produced from EPA (E-series) and DHA (D-series) and protectins
and maresins produced from DHA [113,139,140,151,152]. Anti-inflammatory LXs,
resolvins and protectins inhibit the expression of pro-inflammatory cytokines and
adhesion molecules, thereby inhibiting tumor cell growth and invasion. Moreover, as
mentioned in Section 3.2, it has been proposed that they behave as endogenous
cytoprotective molecules for normal cells against lipid peroxidation-mediated
damage by n-3 PUFAs. Indeed, enrichment of normal cell membranes in EPA and
DHA, both in vitro and in vivo, may allow normal cells to produce enhanced amounts
of resolvins and protectins, protecting themselves against toxic chemicals such as
anti-cancer drugs [81]. Tumor cell membrane enrichment in n-3 PUFAs can induce
changes in the level and quality of eicosanoid products by two main ways: (1) directly,
by increasing specific metabolites derived from their metabolic conversion (e.g.,
PGE3); (2) indirectly, by inhibiting the conversion of ARA to pro-tumorigenic n-6
series eicosanoids (e.g., PGE-2). This second way might be pursued by displacing
ARA from cell membranes (i.e., n-3 PUFAs membrane incorporation partially replace
ARA, reducing its availability), by competing with ARA for enzymes (e.g., EPA
can act as an alternative substrate for COX-2, leading to a reduction in PGE2 in
favour of PGE3), or by inhibiting NF-κB activation, thus decreasing COX-2 enzyme
expression [9,29]. Moreover, DHA can inhibit COX-2 activity by binding the substrate
channel of COX-2 [9].
COX-2 is overexpressed in many types of cancer leading to the formation of
excess of PGE2 [153], and the autocrine COX-2/PGE2 pathway can confer tumor
cell resistance to apoptosis by different ways, including the up-regulation of the
β-catenin and Ras/Raf/MEK/ERK signaling pathways [154].
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Modulation of Eicosanoid Bioproducts by n-3 PUFAs and Induction of Cancer
Cell Apoptosis
Several studies have indicated that the modulation of eicosanoid production by
n-3 PUFAs (mainly EPA) may contribute to the induction of apoptosis in cancer cells.
Some investigations have demonstrated that n-3 PUFAs can inhibit the autocrine
anti-apoptotic COX-2/PGE2 pathway in tumor cells, leading thus to cancer cell
apoptosis. Early in vitro and in vivo studies reported that decreased PGE2 production
was associated with decreased growth of prostate [155,156] and breast [157]
cancer cells. Furthermore, n-3 PUFAs inhibited tumor cell growth in a xenograft
prostate cancer model by decreasing PGE2 as well as COX-2 levels [158]. Later,
Funahashi et al. [159] showed that EPA decreased the growth of COX-2-positive and
COX-2-negative PaCa pancreatic cancer cells and the COX-2-dependent mechanism
was mediated by the binding of PGE3 to EP2 and EP4 receptors. Accordingly,
dietary intake of n-3 PUFAs decreased the pancreatic cancer cell growth in a
xenograft model through increasing PGE3 and decreasing PGE2 in tumor tissues. The
down-regulation of COX-2 by n-3 PUFAs might be a crucial mechanism underlying
their apoptotic effect in other types of tumors, including colon cancer [160,161].
In colorectal cancer cells, it was shown that EPA not only decreased COX-2
expression and PGE2 formation, but also increased the COX-dependent formation
of EPA-derived metabolites [153]. All these results suggest that EPA may act as
a “natural COX inhibitor”. Very recently, Zhang C. et al. [113] found that the
tumoricidal action of n-3 PUFAs on LoVo and RKO colorectal cancer cells in vitro was
associated not only with the decreased production of pro-inflammatory PGE2 and
LTB4, COX-2, arachidonate 5-LOX and microsomal PGE synthase expression, but also
with the increased formation of anti-inflammtory LXA4, supporting the hypothesis
that LXs, resolvins and protectins have a direct growth inhibitory action on tumor
cells; in contrast, 5-FU produced opposite effects on these indices. On the other hand,
concerning DHA metabolites, Gleissman et al. [138] showed that the cytotoxic action
exerted by DHA in neuroblastoma cells was related to its conversion by 15-LOX
and, at much lower degree by autoxidation, to 17-hydroxydocosahexaenoic acid
(17-HDHA), via 17-hydroxyperoxydocosahexaenoic acid (17-HPDHA), a compound
with significant cytotoxicity potency compared to DHA. In normal nervous tissue,
DHA was converted by 5-LOX to anti-inflammatory and cytoprotective resolvins
and protectins. In contrast, although neuroblastoma cells contained both 15-LOX
and 5-LOX enzymes, the complete conversion of DHA into resolvins and protectins
did not take place in cancer cells; thus, 17-HPDHA accumulated and exerted high
cytotoxicity. Moreover, DHA, similarly to EPA, inhibited the secretion of PGE2 and
augmented the cytotoxic potency of the COX-2-inhibitor celecoxib, by competing
with ARA metabolites and by binding to catalytic sites of elongases, desaturases,
and COX-2.
23
3.4. Binding of Nuclear Receptors by n-3 PUFAs and Changes in Gene Expression
Once released from the cell membrane, n-3 PUFAs can bind nuclear receptors
such as peroxisome proliferator activating receptors (PPARs) in tumor cells [26],
which, as ligand-activated transcription factors, regulate the expression of
specific/target genes involved in several biological processes, including lipid
metabolism and cell death. However, many of nuclear receptor-mediated effects of
EPA and DHA are still unexplored.
It was shown that DHA-induced apoptosis in Reh and Ramos cells was
mediated by PPARγ, which in turn up-regulated the p53 protein, leading to
the activation of caspase-9 and caspase-3 [77]. Moreover, in vitro treatment of
breast [162] and prostate [163] cancer cells with DHA activated PPARγ, which in turn
up-regulated SDC-1 expression, inducing thus apoptosis. According to these results,
O’Flaherty [164], Hu [165] and coworkers showed that 15-LOX metabolites of DHA,
such as 17-HPDHA, 17-HDHA, 10,17-dihydroxy- and 7,17-dihydroxy-DHA, while
exerting a more potent cytotoxicity on prostate PC3 cancer cells than DHA, like DHA
induced apoptotic PC3 cells to activate a PPARγ reporter, which up-regulated SDC-1
expression; apoptosis was reduced by pharmacological inhibition or knockdown of
PPARγ or SDC-1. In addition, 15-LOX-1-mediated metabolism of DHA was required
to upregulate SDC-1 and to regulate the PDK/Akt signaling pathway that elicited
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nature of  transcriptional changes  induced by n‐3 PUFAs have been recently  illustrated by studies 
where global gene expression patterns were determined by microarray analysis in vitro and in vivo 
[44,166,167]. Several genes, potentially involved directly or indirectly in cancer cell apoptosis, appear 
to  be  regulated  by  n‐3  PUFAs,  underlining  the  complexity  of  the mechanisms  involved  in  the 
induction of cancer cell apoptosis by these FAs. Therefore, further basic research is needed to show 
which pathways are crucial for the control of tumor cell apoptosis by n‐3 PUFAs. Moreover, a clear 
need  appears  for  further  clinical  studies,  evaluating  the  potential  role  of  DHA  and  EPA 
Figure 1. Multiple apoptotic molecular signals targeted by n-3 PUFAs in cancer
cells. Abbreviations: RTK, prot in tyrosin kinase; SOS-1, son of s venless-1;
Erk, extracellular-signal-regulate kinase; MAPK, mitogen-activated protein
kinase; JNK, Jun N-terminal kinase; AP-1, activator protein-1; SDC-1, syndecan-1;
PTEN, phosphatase and tensin homolog deleted on chromosome ten; PI3K,
phosphatidylinositol-3-kinase; mTOR, mammalian target of rapamycin; IAP,
inhibitor of apoptosis; NF-κB, nuclear factor-κB; FLIP, FLICE-like inhibitory
protein; RIPK-1, receptor-like protein kinase-1; FADD, Fas-associated death domain;
TRADD, TNF receptor-associated death domain; Bcl-2, B-cell lymphoma pr tein-2;
Bim, Cyto C, cytochrome C; GPCR, G-protein coupled receptor; cAMP, cyclic
adenosine monophosphate; PKA, protein kinase A; GSK, glycogen synthase kinase;
TCF, T-cell fac or; LEF, lymphoid enhancer-binding factor; JAK, Janus kinase; STAT,
signal transducer and activator of transcription; ROS, reactive oxygen species;
GSH, glutathione; COX-2, cyclooxygenase-2; PGE2, prostaglandin E2; PPAR-γ,
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transcription;  ROS,  reactive  oxygen  species;  GSH,  lutathione;  COX‐2,  cyclooxygenas ‐2;  PGE2, 
prostaglandin  E2;  PPAR‐γ,  peroxisome  proliferator‐activated  receptor  γ.  arrows,  activation; ┴, 
inhibition; dashed arrows, indirect action; red/blue flash, targeted by n‐3 PUFAs. 





nature of  transcriptional changes  induced by n‐3 PUFAs have been recently  illustrated by studies 
where global gene expression patterns were determined by microarray analysis in vitro and in vivo 
[44,166,167]. Several genes, potentially involved directly or indirectly in cancer cell apoptosis, appear 
to  be  regulated  by  n‐3  PUFAs,  underlining  the  complexity  of  the mechanisms  involved  in  the 
induction of cancer cell apoptosis by these FAs. Therefore, further basic research is needed to show 
which pathways are crucial for the control of tumor cell apoptosis by n‐3 PUFAs. Moreover, a clear 
need  appears  for  further  clinical  studies,  evaluating  the  potential  role  of  DHA  and  EPA 
, inhibition;
dashed arrows, indirect action; red/blue flash, targeted by n-3 PUFAs.
4. Conclusion
The targeting of tumor cell apoptosis has important therapeutic potential. It
is known that essentially all chemotherapeutic drugs and radiotherapy regimens
that are in clinical use induce apoptosis of malignant cells when they work
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properly. However, the resistance to therapy, due to the modulation of the
expression of multiple genes and gene products involved in cell death and survival,
prompt oncologists to believe that, for a more effective apoptosis-based treatment,
combinational therapies are needed to target multitude molecular signals involved in
cancer cell death. Several studies have proposed the potential cability of n-3 PUFAs
DHA and EPA to enhance the efficacy as well as the tolerability of conventional
anticancer therapies. Taken together, the data presented in this review, showing
the ability of n-3 PUFAs, DHA and EPA to induce cytotoxicity via apoptosis in
different tumor cell types in vitro (Table 2) and in vivo (Table 3), indicate that these FAs
potentially target multiple molecular signals involved in tumor cell death (Figure 1).
The use of multiple different pathways by n-3 PUFAs to trigger apoptosis
in tumor cells may be partly related to the diverse activities possibly exerted in
diverse cellular cancer models, but also to the different n-3 PUFAs used (EPA,
DHA or FO), as well as to the different ways of administration, such as doses
and kinetics. The context is complex and it might be even more complex if we
consider that most of the molecular signals converge into the nucleus, altering gene
expression. The pleiotropic nature of transcriptional changes induced by n-3 PUFAs
have been recently illustrated by studies where global gene expression patterns were
determined by microarray analysis in vitro and in vivo [44,166,167]. Several genes,
potentially involved directly or indirectly in cancer cell apoptosis, appear to be
regulated by n-3 PUFAs, underlining the complexity of the mechanisms involved in
the induction of cancer cell apoptosis by these FAs. Therefore, further basic research
is needed to show which pathways are crucial for the control of tumor cell apoptosis
by n-3 PUFAs. Moreover, a clear need appears for further clinical studies, evaluating
the potential role of DHA and EPA supplementation, mainly in combination with
chemo- and radio-therapeutic anticancer regimens, in the improvement of patients’
clinical outcome and survival.
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Cancer Risk and Eicosanoid Production:
Interaction between the Protective Effect of
Long Chain Omega-3 Polyunsaturated Fatty
Acid Intake and Genotype
Georgia Lenihan-Geels, Karen S. Bishop and Lynnette R. Ferguson
Abstract: Dietary inclusion of fish and fish supplements as a means to improve
cancer prognosis and prevent tumour growth is largely controversial. Long chain
omega-3 polyunsaturated fatty acids (LCn-3 PUFA), eicosapentaenoic acid and
docosahexaenoic acid, may modulate the production of inflammatory eicosanoids,
thereby influencing local inflammatory status, which is important in cancer
development. Although in vitro studies have demonstrated inhibition of tumour cell
growth and proliferation by LCn-3 PUFA, results from human studies have been
mainly inconsistent. Genes involved in the desaturation of fatty acids, as well as
the genes encoding enzymes responsible for eicosanoid production, are known to
be implicated in tumour development. This review discusses the current evidence
for an interaction between genetic polymorphisms and dietary LCn-3 PUFA in
the risk for breast, prostate and colorectal cancers, in regards to inflammation and
eicosanoid synthesis.
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1. Introduction
Cancer is a multifactorial, widely spread, variable and largely non-communicable
disease, affecting populations in all parts of the world. Currently, some of the most
significant cancers throughout the Western world include breast, colorectal and
prostate cancers [1]. The role of nutrition in cancer risk and development is becoming
increasingly recognised, particularly in regards to dietary intake of fresh fruit and
vegetables, meat and meat products, and fish or fish oils, which may be related
to their effects on inflammatory processes [2–6]. Intake of animal sources of fat,
saturated and trans-unsaturated fatty acids are associated with all-cause mortality
and death due to colorectal, breast and prostate cancers. On the other hand, plant
based oils and fish oils are associated with a decrease in the risk and death due to the
aforementioned cancers [7–9].
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The predominant omega-6 (n-6) and omega-3 (n-3) fatty acids (FA) in the typical
Western diet are linoleic acid (LA) (18:2n-6) and alpha-linolenic acid (ALA) (18:3n-3),
respectively, known as the essential fatty acids. Through elongation and desaturation,
these FA are converted to longer and more desaturated FAs via the n-6 and n-3
pathways (Figure 1). However, the conversion of LA and ALA to longer-chain FAs is
limited by the enzymatic capacity of the desaturases, as well as dietary levels of LA
and ALA, which compete for the same enzymes. For example, the conversion of ALA
to eicosapentaenoic acid (EPA) (20:5n-3) ranges from between 0.2% and 21% [10].




fatty  acid  elongation  from ALA  and  LA  begins with  desaturation  by  the D6D  enzyme.  Subsequent 
elongation and desaturation by  the corresponding enzymes  (orange) generates  longer chain PUFA 
such as AA and EPA. n‐3 and n‐6 PUFA compete  for  the D6D, E5, D5D and E2 enzymes  [11–15]. 
D5D: Delta 5 desaturase; D6D: Delta 6 desaturase; E: Elongase.*: Rate limiting step. 
Long  chain  (LC)  polyunsaturated  fatty  acids  (PUFA)  play  a  significant  role  in  inflammatory 
processes,  as  they  act  as  precursors  for  inflammatory mediators  called  eicosanoids.  Eicosanoids  are 
potent signaling molecules synthesized during  inflammation and  include  leukotrienes,  thromboxanes 
and prostaglandins [16]. A diverse set of enzymes are responsible for the synthesis of eicosanoids from 
PUFA, some of which are outlined in Figure 2. Cyclooxygenases catalyse the formation of series 2 and 
series 3 prostaglandins and  thromboxanes, while  lipoxygenases  synthesise  lipoxins and  leukotrienes, 
which  are  further  metabolized  by  glutathione  transferases  [16].  Additionally,  dietary  EPA  and 
docosahexaenoic  acid  (DHA)  are  precursors  for  mainly  anti‐inflammatory  eicosanoids,  while 
arachidonic  acid  (AA)  (20:4n‐6)  is  a  precursor  for mainly  pro‐inflammatory  compounds  and  is  in 
competition with EPA for eicosanoid production. Furthermore, the ratio of AA to EPA/DHA  in cell 
membranes  is  thought  to be  informative  in  regards  to  inflammatory  status.  In  fact,  studies  clearly 
show  lower  levels  of  circulating  pro‐inflammatory  compounds  such  as  cytokines  and  adhesion 
molecules with higher levels of membrane‐bound and free EPA and DHA [17–20]. 
 
Figure  2.  Effects  of  eicosanoids  derived  from  AA  and  EPA/DHA.  Cyclooxygenases  and 
lipoxygenases act on AA, EPA and DHA  to synthesise a range of different eicosanoids during an 
inflammatory response. AA‐derived eicosanoids often generate pro‐inflammatory compounds that 
enhance  tumour  growth,  while  EPA/DHA‐derived  eicosanoids  often  have  anti‐inflammatory 
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Figure 1. Synthesis of polyunsaturated fatty acids through the n-3 and n-6 pathways.
Polyunsaturated fatty acid elongatio from ALA and LA begins with desaturation
by the D6D enzyme. Subs quent el gation and d satur tion by the corresponding
enzymes (ora ge) generates longer chain PUFA such as AA and EPA. n-3 and
n-6 PUFA compete for the D6D, E5, D5D and E2 enzymes [11–15]. D5D: Delta
5 desaturase; D6D: Delta 6 desaturase; E: Elongase.*: Rate limiting step.
Long chain (LC) polyunsaturated fatty acids (PUFA) play a significant role
in inflammatory processes, as they act as precursors for inflammatory mediators
called eicosanoids. Eicosanoids are potent signaling molecules synthesized during
inflammation and include leukotrienes, thromboxanes and prostaglandins [16].
A diverse set of enzymes are responsible for the synthesis of eicosanoids from PUFA,
some of which are outlined in Figure 2. Cyclooxygenases catalyse the formation
of series 2 and series 3 prostaglandins and thromboxanes, while lipoxygenases
synthesise lipoxins and leukotrienes, which are further metabolized by glutathione
transferases [16]. Additionally, dietary EPA and docosahexaenoic acid (DHA)
are precursors for mainly anti-inflammatory eicosanoids, while arachidonic acid
(AA) (20:4n-6) is a precursor for mainly pro-inflammatory compounds and is
in competition with EPA for eicosanoid production. Furthermore, the ratio of
AA to EPA/DHA in cell membranes is thought to be informative in regards to
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inflammatory status. In fact, studies clearly show lower levels of circulating
pro-inflammatory compounds such as cytokines and adhesion molecules with higher
levels of membrane-bound and free EPA and DHA [17–20].
Figure 2. Effects of eicosanoids derived from AA and EPA/DHA. Cyclooxygenases
and lipoxygenases act on AA, EPA and DHA to synthesise a range of different
eicosanoids during an inflammatory response. AA-derived eicosanoids often
generate pro-inflammatory compounds that enhance tumour growth, while
EPA/DHA-derived eicosanoids often have anti-inflammatory properties and inhibit
tumour growth [21,22]. FA: fatty acids; AA: arachidonic acid; EPA: eicosapentanoic
acid; DHA: docosahexanoic acid.
Inflammation is a key event in the development of tumours and is known to
promote tumour growth, angiogenesis and metastasis [23]. For example, the
metabolism of AA to pro-inflammatory eicosanoids is characteristic of some
colorectal and breast cancer cells [24–26]. Therefore, dietary LCn-3 PUFA intake
is of great interest in the prevention and treatment of these cancers and as agents in
reducing inflammation, although the topic remains largely controversial [9,27–29].
Discrepancies in both observational and experimental data may arise from multiple
sources including: heterogeneity of cancers; confounding in epidemiological data;
environmental contaminants, particularly from LCn-3 PUFA-rich marine sources;
accuracy of dietary intake data; bioavailability; and/or genetic variation [9,12,30–33].
One challenging aspect in cancer epidemiology is that any factor reducing cancer
risk will usually promote life-expectancy, which in itself is a risk for cancer [34].
It has come to light that efficiency of conversion of LA and ALA to LC
PUFA is partially determined by the genotype of the fatty acid desaturase (FADS)
family of genes, which code for the delta-5 and delta-6 desaturases that catalyse
the rate limiting steps of the n-3 and n-6 pathways, which may therefore impact
downstream eicosanoid production [9,14,35–38]. Interestingly, single nucleotide
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polymorphisms (SNPs) found in other genes, for example cytochrome c oxidase
(COX) and arachidonate lipoxygenase (ALOX), may also influence levels of eicosanoids
produced from EPA and AA [26,39]. COX and ALOX genes code for the
cyclooxygenase and lipoxygenase enzymes, respectively, and are responsible for
generating a range of eicosanoid mediators [16] (Figure 2). Consequently, both levels
of dietary fatty acids and variation at the FADS, COX and ALOX loci may impact
inflammatory processes and carcinogenesis.
There is increasing evidence to support the view that LCn-3 PUFA, specifically
EPA and DHA, inhibit the growth of colorectal, breast and prostate cancer cell
lines [27,40–42] and inhibit tumour growth in animal models [43–45]. Current evidence
in humans is less clear and epidemiological data is largely inconsistent [9,27,28].
As inflammation is a predominant hallmark in many cancers, the relationship
between inflammation and dietary LCn-3 PUFA is of high interest. Furthermore,
the impact of genetic polymorphisms on the production of eicosanoids is important
to consider. In this review, we discuss the interaction between LCn-3 PUFA and
genotype, related to eicosanoid production, which may have an impact on the
development and progression of cancers. The genes or family of genes under
consideration include the FADS genes involved in the desaturation of LCn-3
PUFA [46], the glutathione S-transferase (GST) family of genes involved in oxidative
stress and inflammation [47], and the ALOX and COX genes that generate pro- and
anti-inflammatory mediators [48].
2. Methods
Articles utilised in this review were selected using the PubMed and Google
Scholar databases. Key words used in the searches included: eicosanoid/s;
polymorphism/s; cancer; dietary; polyunsaturated fatty acid; omega-3. One of
these words must have also been present: prostate OR breast OR colorectal OR
colon OR rectal AND FADS/fatty acid desaturase OR COX/cyclooxygenase OR
ALOX/lipoxygenase OR GST/glutathione transferase. Included articles focused on
human studies only. Exclusion criteria were: review articles; articles in any language
other than English; articles older than 1990; articles focused on another disease other
than breast, prostate or colorectal cancer; and articles lacking data on diet specific
to PUFA or fish. Following searches of combinations of the above keywords, a total
number of 417 articles were found. The titles of these 417 articles were read and after
applying the exclusion criteria, 56 articles were selected for the next stage. Adjusting













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3. The Role of Genetic Variation in Fatty Acid Desaturation
The FADS gene cluster is located on a highly polymorphic region of chromosome
11 and includes FADS1 and FADS2, which encode delta 5 desaturase (D5D) and
delta 6 desaturase (D6D), respectively [9]. These polymorphisms create a diverse
set of haplotypes. The first demonstration of a relationship between FADS genotype
and membrane-bound FAs was shown by Schaefer et al. (2006) [54] in serum
phospholipids. Further evidence came from a study on infants, in which Danish
infants carrying the FADS minor allele for locus rs1535 had a higher DHA level than
those with the wild-type allele [55]. In contrast, those carrying the minor alleles of
rs174448 (C) and rs174575 (G) had decreased DHA levels relative to wild-type [55].
Similarly, carriers of the T allele at rs174537 (in strong linkage disequilibrium with
rs174546 and rs3834458) had lower levels of AA than the carriers of the G allele [37].
Additional examples have been presented by Al-Hilal et al. (2013) in which the minor
allele of SNPs rs174537, rs174561 and rs3834458 correlate with higher amounts of
ALA and lower levels of EPA, docosapentaenoic acid (DPA) and DHA, as well as
lower activity of both D5D and D6D [14].
Of particular interest to the interplay with dietary LCn-3 PUFA, a 6-month
intervention of an EPA/DHA supplement in individuals carrying a T allele at locus
rs174537 showed rising activity of D5D with an increasing supplement dose [14].
Additionally, polymorphisms at FADS locus rs174546 correlated with serum
triacylglycerides at baseline and 6 weeks following EPA/DHA supplementation [56].
At locus rs174537, the presence of a T-allele correlated with lower levels of AA,
consistent with a similar study [37], and those carrying the GG genotype had
higher levels of eicosanoids leukotriene B4 (LTB4) and 5-hydroxyeicosatetraenoic acid
(5-HETE) [13]. LTB4 and 5-HETE are pro-inflammatory compounds synthesized from
AA by the leukotriene synthase and 5-LOX enzymes, respectively [39]. Therefore, it
is possible that levels of circulating eicosanoids may be modulated by the interplay
of diet and genotype. If these individuals are at particular risk for cancer, it would be
advisable to increase the intake of LCn-3 PUFA.
Studies on colonic mucosal fatty acid compositions have revealed a
diet-genotype effect. Lower concentrations of AA were observed in subjects carrying
major alleles within the FADS gene cluster (rs174556 and rs174561 in FADS1, rs383445
in FADS2 and rs174537 of the FADS1/2 intragenic region) when consuming a
Mediterranean diet compared to a Healthy Eating diet, due to increases in AA levels
within the Healthy Eating group [53]. The Mediterranean diet has been extensively
studied with regards to its effect on cancers. This diet is traditionally high in fat,
but low in LCn-6 PUFA and trans fatty acids, and is typically high in olive oil, fresh
fruit and vegetables [57,58]. The Mediterranean diet used in an intervention by
Porenta et al. (2013) [53] was also high in fish and flaxseed. Additional studies are
required to confirm these results, as diets were not strictly controlled and sample
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size was relatively small. A summary of the interaction between LCn-3 PUFA on
prostate, breast and colorectal cancers as modified by FADS genotype, is provided in
Table 1, alongside additionally discussed genotypes.
4. Genetic Polymorphisms Modulate Leukotriene Synthesis in Cancer
4.1. Lipoxygenases
Leukotrienes are eicosanoid inflammatory mediators produced by the oxidation
of AA, and are implicated in inflammation and cancer [59]. Leukotriene synthesis
begins with the formation of hydroperoxyeicosatetranoic acid (5-HPETE) and
hydroperoxyeicosapentaenoic acid (5-HPEPE) from AA and EPA, respectively, by
the lipoxygenases [16]. Although not statistically significant, a lower risk for colon
cancer was demonstrated in wild-type homozygous individuals at locus rs11568131
of ALOX15 when consuming high amounts of fish, an association that was absent in
those carrying the variant allele [11]. Carriers of a G minor allele at locus rs11571339
of the ALOX12 gene showed a lower risk for rectal cancer in those with low n-3 PUFA
intake compared to higher intakes [11]. However, G allele carriers with high intakes
showed no increased risk compared to the homozygous major allele reference group.
Despite also demonstrating no statistical significance, this finding is particularly
interesting, as a lower LCn-3 PUFA intake would generate fewer anti-inflammatory
compounds than a higher intake. Furthermore, G allele carriers with lower intakes
of LA and total PUFA showed a similar pattern. Studies investigating the differences
in activity of 12-lipoxygenase due to this polymorphism could help to explain
these findings.
A recent meta-analysis found that polymorphisms in the ALOX12 gene at
the Gln261Arg locus may influence cancer risk in Asian populations but not in
Caucasians [60]. Furthermore, carriers of the variant in homozygous or heterozygous
form had an increased risk for breast cancer, also demonstrating differences across
ethnic populations [61]. The same polymorphism also showed an association
with risk of colorectal adenomas [62]. To our knowledge, the interplay of this
polymorphism with EPA/DHA intake has not been previously explored and is
worthy of further investigation.
4.2. Glutathione S-Transferases
The glutathione S-transferase (GST) enzymes implicated in various types of
cancer are important for the detoxification of environmental pollutants and chemical
carcinogens, and modulate signaling of pathways associated with cell proliferation,
cell differentiation and apoptosis [47]. In addition, GSTs are involved in the synthesis
of leukotrienes from 5-HPETE. Finally, GSTs are also important for the detoxification
of reactive oxygen species [63] and may help protect against DNA damage [64].
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Raised levels of anti-oxidants can help activate GST genes and this in turn
may help to reduce the increased levels of DNA damage that are associated with
prostate cancer [36,64]. GST phenotype (e.g., GSTT1 null genotype) is associated
with risk of prostate cancer in Caucasians but this does not hold true for other
races [47]. Unfortunately, no evidence appears to be available with respect
to the modification of this effect by fatty acids in prostate cancer. However,
van Hemelrijck et al. (2012) [65] identified an association between prostate cancer and
the intake of heterocyclic aromatic amines (HCAs) that was modified by the genotype
of HCA-metabolizing enzymes (e.g., MnSOD rs4880 and GPX4 rs713041). HCAs are
mutagenic and are generated by cooking meat at high temperatures [66]. Meat is a
common source of animal fat and the effect of some monounsaturated fatty acids
(e.g., palmitic and stearic acids) as well as n-6 PUFA (e.g., AA) on prostate cancer
may be confounded by the presence of HCAs. For this reason, we propose that while
the genotype of HCA-metabolizing enzymes may appear to interact with type of
fatty acid intake and prostate cancer risk, in fact it is the presence of HCAs that is
interacting with genotype to influence disease risk.
In contrast, a clear association has been shown between the polymorphic GST
genes, breast cancer and marine FA intake [49]. Women carrying variants resulting in
higher activity of the GST enzymes show a correlation with marine n-3 PUFA intake
and risk of breast cancer, in which lower intake demonstrates a higher risk compared
to those with higher intakes of the same genotypes. These associations were found
in Chinese and Singaporean women [49].
5. Prostaglandin Synthesis
Cyclooxygenase enzymes, also known as prostaglandin endoperoxide synthases,
catalyse the rate-limited formation of inflammatory prostaglandins. Two isozymes
(COX1 and COX2) exist, both of which are associated with injury and inflammation
and demonstrate different tissue expression patterns [12]. Increased expression
of COX2 leads to hyperproliferation of colon epithelial cells, a process which was
decreased following the presence of EPA [67]. Furthermore, the inhibitory effects of
non-steroidal anti-inflammatory drugs (NSAIDs) associated with colorectal cancer
are thought to relate to their inhibitory activity at both COX1 and COX2 [68].
In vitro studies have shown inhibitory actions of LCn-3 PUFA on prostate
cancer cell growth. In different prostate cancer cell models, namely LNCaP and
PacMetUT1, DHA appeared to sensitise the cells by attenuating the NF-κB survival
pathway that promotes cancer cell survival, resulting in decreased cancer cell
survival [69]. On the other hand, NF-κB does not appear to be involved in the
induction of COX2 expression in the prostate cancer cells, PC3, treated with DHA
and EPA [70]. In regards to human studies, five of sixteen SNPs found within
the COX2 region were tested in a Swedish population with and without prostate
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cancer, identifying a relationship between two SNPs and the presence of prostate
cancer [50,71]. Subsequently, the same authors demonstrated that the presence of a
C allele at locus rs5275 was significantly associated with a decreased risk of prostate
cancer in men with a high intake of fatty fish [50]. Similarly, Fradet et al. (2009) [12]
assessed diet alongside nine COX2 SNPs in men diagnosed with aggressive prostate
cancer and found that LCn-3 PUFA intake was strongly associated with a decreased
risk of aggressive prostate cancer. This effect was modified by the rs4648310 SNP,
such that the increased risk of aggressive prostate cancer associated with a low intake
of n-3 PUFA in those with the G allele (odds ratio = 5.49) could be reversed by
increasing n-3 PUFA intake [12]. Therefore, it is reasonable to say that carriers of a G
allele at the rs4648310 locus could benefit from increasing LCn-3 PUFA intake.
COX1 SNPs at the rs10306110 locus may modulate colon cancer risk.
Habermann et al. (2013) [11] demonstrated an association between low LCn-3 PUFA
intake and the variant allele, with an odds ratio of 1.56 and 1.62 for EPA and DHA,
respectively. Total and monounsaturated fatty acid intake was associated with the
variant allele at rs10306122 of PTGS1, the gene encoding COX1, and increased rectal
cancer risk, although marine LC PUFA showed no effect [11].
The P17L polymorphism, leading to sequence changes within the signal peptide
of COX1, was associated with risk of colorectal adenomas, in which higher fish intake
in those homozygous for phenylalanine at position 17 had a modestly lower risk
of adenomas with increasing fish intake [51]. Interestingly, those carrying at least
one leucine at position 17 had a decreased risk of adenomas when consuming less
fish per week [51]. Importantly, these individuals demonstrated a higher risk for
colorectal cancer with increasing fish intake. This is a highly interesting finding
which highlights the occurrence of inconsistencies in studies of cancer and LCn-3
PUFA and the importance of designing and performing studies that will provide
clarity in this regard.
The same authors [51] then analysed the risk of colorectal adenomas between
those in an assumed low risk group (high fish intake + NSAID use) and an assumed
high risk group (low fish intake + no NSAID use) and variable intermediate groups,
to assess the dual implications of both NSAID use and fish intake in the relationship
between P17L polymorphisms and adenoma risk. PP homozygotes benefited from
including more than 2 servings of fish per week as well as regular use of NSAIDs.
However, those with PL and LL genotypes showed no statistically significant
associations [51]. These findings are unexpected and it is necessary to replicate
these investigations in larger studies with more detail on type of fish in the diet, as
well as other dietary information.
Polymorphisms within the gene for prostaglandin E2 synthase-1 (PGES) also
correlate with colorectal adenoma risk. PGES catalyses the formation of PGE2, a
pro-inflammatory prostaglandin associated with increased cell proliferation [72,73].
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Individuals carrying a T allele at rs7873087 had a lower risk for colorectal adenomas
with increasing fish intake, whereas those homozygous for the A allele showed no
significant association with fish intake [52]. Additional relationships were observed
for polymorphisms within the 15-hydroxyprostaglandin dehydrogenase gene and the
EP4 receptor gene, which code for proteins responsible for the breakdown of PGE2
and the corresponding PGE2 receptor, respectively. These studies highlight the
importance of inter individual differences in genes involved in the prostaglandin
synthesis pathways from AA and EPA, and their complex association with colorectal
cancer and fish intake. This relationship warrants further investigation.
Limitations in these studies include recall bias in the FFQ and diet diaries,
which are commonly used in large studies such as cohorts or case-control designs
due to lack of affordable and better alternatives. Furthermore, ethnicity must be
adjusted for in studies, as ethnicity may influence the relationship between dietary
n-3 PUFA, cancer risk and genotype, as highlighted earlier [60,61]. Additional factors
potentially influencing the outcome of the studies reviewed herein, include the
stage of the disease, as LCn-3 PUFA may interact differently with genotypes as the
physiology of the tumour changes, and fish contaminants. Dioxins may increase
cancer risk, which could generate substantial confounding [33]. In addition, it is
important to note that this review highlights the current knowledge of the interplay
between genes involved in eicosanoid synthesis only, and that there are a range of
other genes that are likely to contribute to the relationship between cancer risk and
LCn-3 PUFA intake, such as polymorphisms in DNA repair- and apoptosis-related
genes [74].
6. Conclusions
The effects of LCn-3 PUFA on prostate, breast and colorectal cancer modified
by genotype are presented in Table 1. It is clear that both dietary intake
and polymorphisms of the FADS genes contribute to the concentrations of
membrane-bound fatty acids such as EPA, DHA and AA. Although genetic variation
within the FADS genes have not been directly associated with cancer, the effects on
desaturase activity may influence the production of eicosanoids further downstream.
Dietary LCn-3 PUFA (EPA, DPA and DHA) are inversely associated with aggressive
prostate cancer [12] and prostate cancer risk. This protective effect can be modified
by genotype including rs5275 [50] and rs4648310 [12] in COX2. On the other hand,
the loss of expression of FADS2, in response to a mutation in FAD2, is associated
with a more aggressive breast cancer tumour and reduced survival [9,75]. Breast
cancer risk may also be modulated by dietary LCn-3 PUFA and activity of the GST
enzymes [49]. Interestingly, an association between ALOX12 polymorphisms and
breast cancer, which was modified by ethnicity [60,61] could be further explored in
regards to the relationship with LCn-3 PUFA intake. In regards to colon and rectal
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cancers, certain individuals may benefit largely from including LCn-3 PUFA in their
diets while others do not, as demonstrated by polymorphisms in ALOX12, ALOX15
and PGES genes [11,52]. Furthermore, there exists a positive association between
increased risk of colorectal cancers and increased fish intake in some genotypes of
the COX1 gene, a relationship worthy of further investigation.
Compelling evidence from in vivo and in vitro studies has been presented on the
inhibition of cancer progression. Here, evidence has been presented on the genotypic
modification of response to LCn-3 PUFA and it is clear that we are on the brink of
offering personalised nutritional advice with respect to these FAs. Such advice would
ensure that people are correctly informed with respect to the types and amounts of
LCn-3 PUFA they should consume in order to meet their specific requirements. In
addition, further study could decipher the significance of the role of n-3 PUFA in
cancer and inflammation, for example whether altered PUFA metabolism is a driver
or a passenger in cancer [76].
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Eicosopentaneoic Acid and Other Free
Fatty Acid Receptor Agonists Inhibit
Lysophosphatidic Acid- and Epidermal
Growth Factor-Induced Proliferation of
Human Breast Cancer Cells
Mandi M. Hopkins, Zhihong Zhang, Ze Liu and Kathryn E. Meier
Abstract: Many key actions of ω-3 (n-3) fatty acids have recently been shown to
be mediated by two G protein-coupled receptors (GPCRs) in the free fatty acid
receptor (FFAR) family, FFA1 (GPR40) and FFA4 (GPR120). n-3 Fatty acids inhibit
proliferation of human breast cancer cells in culture and in animals. In the current
study, the roles of FFA1 and FFA4 were investigated. In addition, the role of cross-talk
between GPCRs activated by lysophosphatidic acid (LPA), and the tyrosine kinase
receptor activated by epidermal growth factor (EGF), was examined. In MCF-7
and MDA-MB-231 human breast cancer cell lines, both LPA and EGF stimulated
proliferation, Erk activation, Akt activation, and CCN1 induction. LPA antagonists
blocked effects of LPA and EGF on proliferation in MCF-7 and MDA-MB-231, and on
cell migration in MCF-7. The n-3 fatty acid eicosopentaneoic acid inhibited LPA- and
EGF-induced proliferation in both cell lines. Two synthetic FFAR agonists, GW9508
and TUG-891, likewise inhibited LPA- and EGF-induced proliferation. The data
suggest a major role for FFA1, which was expressed by both cell lines. The results
indicate that n-3 fatty acids inhibit breast cancer cell proliferation via FFARs, and
suggest a mechanism involving negative cross-talk between FFARS, LPA receptors,
and EGF receptor.
Reprinted from J. Clin. Med. Cite as: Hopkins, M.M.; Zhang, Z.; Liu, Z.;
Meier, K.E. Eicosopentaneoic Acid and Other Free Fatty Acid Receptor Agonists
Inhibit Lysophosphatidic Acid- and Epidermal Growth Factor-Induced Proliferation
of Human Breast Cancer Cells. J. Clin. Med. 2016, 5, 16.
1. Introduction
Our group recently demonstrated that the inhibitory effects ofω-3 fatty acids on
prostate cancer cell proliferation are mediated by FFA4, a G protein-coupled receptor
in the free fatty acid receptor (FFAR) family [1]. The purpose of the current study
was to determine whether FFARs mediate similar inhibitory effects in human breast
cancer cells.
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The dietary polyunsaturatedω-3 fatty acids (n-3 FAs) are alpha-linolenic acid
(ALA), docosahexaenoic acid (DHA) and eicosapentaneoic acid (EPA). Although
effects of n-3 FAs in prostate cancer have been debated [2], there is relatively strong
evidence supporting a preventative effect of n-3 FA consumption on many human
cancers [3], including breast cancer [4]. Multiple reports show that n-3 fatty acids
inhibit growth of breast cancer cells, either in cell culture [5,6], or in xenograft
tumors [7–10].
The prevailing mechanistic paradigm has been that n-3 FAs exert
anti-inflammatory and potentially anti-cancer effects by competitively reducing
production of eicosanoids, and/or more directly by generating metabolites with
anti-inflammatory activity (e.g., “resolvins”) [11,12]. However, the direct effects of
n-3 metabolites on cancer cells, as compared to their anti-inflammatory effects, are
under-studied [13]. In one report, resolvin D2, a DHA metabolite, unexpectedly
increased proliferation of MCF-7 breast cancer cells [14].
Alternatively, it was shown in the last decade that n-3 FAs are agonist ligands
for free fatty acid receptors (FFARs) that were formerly “orphan receptors” [15].
Two G-protein-coupled receptors (GPCRs), FFA1 and FFA4, bind long-chain
polyunsaturated fatty acids that include n-3 FAs. The “de-orphanization” discovery
has led to the ongoing characterization of the roles of the FFARs in cellular
regulation, and to the rapid development of selective FFAR agonists with therapeutic
potential [16–19].
Several studies have specifically explored the mechanism of the inhibitory action
of n-3 FAs on breast cancer cells. The pathways implicated in the response include
decreased Akt activation [5], increased neutral sphingomyelinase activity [20],
increased BRCA levels [21], and increased PTEN levels [22]. GPCR-independent
mechanisms have been reviewed [23]. To date, there is little information available
concerning the roles of FFARs in breast cancer. It has however been shown that FFA1
is expressed in MCF-7 cells [24], and that MCF-7 and MDA-MB-231 cells express
both FFA1 and FFA4 [25,26].
One study investigated the role of FFA4 in breast cancer in a mouse model,
focusing on the role of FFA4 in inhibiting inflammation [27]. In this study, n-3 FAs
reduced tumor burden even when FFA4 was knocked out in the host mouse. The
authors suggest that anti-inflammatory effects of n-3 FAs, mediated by FFA4, are not
important for their anti-tumor effects. Using cultured cells derived from their mouse
model, the investigators showed that DHA induced apoptosis in either wild-type
or FFA4 knockdown cells when applied at high doses (40–100 µM). The role of the
alternative n-3 FA receptor, FFA1, has not been examined in breast cancer cell, to
our knowledge.
In this study, we utilized two commonly used human breast cancer cell lines:
MCF-7 and MDA-MB-231, as experimental models. MCF-7 is a luminal A estrogen
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receptor positive cell line, while MDA-MB-231 is a highly metastatic triple negative
cell line. These two cell lines were used to explore the role of FFARs in the mechanism
of action of n-3 FAs in breast cancer.
2. Experimental Section
2.1. Materials
EPA (prepared in ethanol) was from Cayman Chemical (Ann Arbor,
MI, USA). The FFAR agonists TUG-891 (4-[(4-fluoro-41-methyl[1,11-biphenyl]-
2-yl)methoxy]-benzenepropanoic acid; prepared in dimethylsulfoxide (DMSO) and
GW9508 (4-[[(3-phenoxyphenyl)methyl]amino]-benzenepropanoic acid; prepared
in ethanol), were from Millipore (Billerica, MA, USA) and Cayman Chemical,
respectively. AM966 (2-[4-[4-[4-[[(1R)-1-(2-chlorophenyl)ethoxy]carbonylamino]-3-
methyl-1,2-oxazol- 5-yl]phenyl] phenyl]acetic acid) was purchased pre-dissolved
in DMSO from MedChem Express (Monmouth Junction, NJ, USA). Ki16425
(3-[[[4-[4-[[[1-(2-chlorophenyl)ethoxy]carbonyl]amino]-3-methyl-5- isoazoly]phenyl]
methyl]thio]-propanoic acid; prepared in DMSO) was purchased from Cayman
Chemical (Ann Arbor, MI, USA). Vehicle controls were included in all samples not
receiving FFAR agonists or LPA receptor (LPAR) antagonists (final concentrations of
0.03% (v/v) ethanol or 0.01% DMSO). LPA (18:1; oleoyl) was obtained from Avanti
Polar Lipids (Birmingham, UK), and was delivered to cells as a 1000X stock solution
prepared in 4 mg/mL fatty acid-free bovine serum albumin (BSA). The vehicle
control for LPA was a final concentration of 4 µg/mL BSA. EGF was from Sigma
(St. Louis, MO, USA). Antibody recognizing CCN1 (lot # F0509; 1:1000 dilution)
was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-actin,
obtained from BD Transduction Laboratories (Lexington, KY, USA) (lot # 51711), was
used at a 1:5000 dilution. Goat anti-rabbit secondary antibody (lot #083M4752) was
purchased from Sigma (St Louis, MO, USA) and used at 1:20,000 dilution, while goat
anti-mouse secondary antibody (lot #1124907A) was purchased from Invitrogen/Life
Technologies (Grand Island, NE, USA) and used at a 1:5000 dilution.
2.2. Cell Culture
MCF-7 and MDA-MB-231 cells were obtained from the American Type
Culture Collection (Manassas, VA, USA). The cells were grown in RPMI medium
supplemented with 10% FBS (Hyclone/Thermo-Fisher Scientific, Waltham, MA,
USA). Both cell lines were grown in an incubator at 37 ˝C in 5% CO2 on standard
tissue culture plastic.
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2.3. Cell Proliferation Assays
Cells were seeded in 6-well plates at 3 ˆ 105 cells/well in serum-containing
medium. After 1 day, the medium was changed to RPMI 1640 without serum. On
the next day, the medium was changed to RPMI 1640 with 10% FBS, 10 µM LPA, or
10 nM EGF, in the absence or presence of 100 nM AM966, 10 µM Ki16425, 20 µM
EPA or 1 µM TUG-891. Control cells were incubated with the appropriate vehicle
(0.03% ethanol, v/v; 0.01% DMSO, v/v; and/or 4 µg/mL BSA). Duplicate wells were
prepared for each experimental condition. Cell numbers were evaluated after 24,
48, and 72 h by removing medium, incubating cells with trypsin/EDTA for 5 min,
adding trypan blue, and counting the suspended live cells (excluding trypan blue)
using a hemacytometer.
2.4. Cell Migration Assays
MCF-7 cell migration was assessed using a modified Boyden chamber method,
as previously described [28]. Cells were serum starved for 24 h and then seeded
in serum-free medium at 2.5 ˆ 104 cells per insert in the upper chambers of 8-µm
transwell inserts (BD Biosciences, San Jose, CA, USA). Cells were then treated with
10% FBS, 100 nM AM966, 20 µM EPA, 1 µM TUG-891, 10 µM LPA, or 10 nM EGF,
either alone or in combination, with appropriate vehicle controls as described above.
Serum-free medium was added to the lower wells. Following a 6-h migration, the
insert membranes were fixed and stained using methanol and crystal violet. Cells
that invaded the lower chambers were counted by microscopy.
2.5. Cell Incubations for Signal Transduction Assays
Cells were grown in DME medium supplemented with 10% FBS until ~80%
confluent. Cells were serum-starved for 24 h in RPMI 1640 medium, then incubated
with 10 µM LPA, 10 nM EGF, and/or 100 nM AM966 or 10 µM Ki16425 for 10 min.
Cells were rinsed twice with ice-cold phosphate-buffered saline (PBS), harvested by
scraping into 1 mL ice-cold PBS, collected by centrifugation at 10,000ˆ g for 10 min
at 4 ˝C, and resuspended in ice-cold lysis buffer (20 mM HEPES (pH = 7.4)), 1%
Triton X-100, 50 mM NaCl, 2 mM EGTA, 5 mM β-glycerophosphate, 30 mM sodium
pyrophosphate, 100 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl
fluoride, 10 µg/mL aprotinin, 10 µg/mL leupeptin). Insoluble debris was removed
after centrifugation.
2.6. Reverse Transcription Polymerase Chain Reacton (RT-PCR)
For analysis of FFAR expression, total RNA was isolated using an RNeasy
Mini kit (Qiagen, Valencia, Spain). First-strand complementary DNA (cDNA)
was synthesized with SuperScript II Reverse Transcriptase (Invitrogen) following
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the manufacturer’s instructions using 20 µL of reaction mixture containing 2 µg
RNA. PCR was carried out using Platinum Pfx DNA Polymerase (Invitrogen) and
Integrated DNA Technology (San Diego, CA, USA) primers: FFA4 (F: 51-CCTGGA
GAGATCTCGTGGGA-31; and R: 51-AGGAGGTGTTCCGAGGTCTG-31); FFA1
(F: 51-CTCCTTCGGCCTCTATGTGG-31; and R: 51-AGACCAGGCTAGGGGTGA
GA-31); RPLP0 (F: 51-CGCTATCCGCGGTTTCTGAT-31; and R: 51-AGACGA
TGTCACTTCCACGA-31). For each reaction, 5 µg cDNA template was used.
Products were separated by ethidium bromide agarose gel electrophoresis, and
were then imaged using a ChemiDoc with Image Lab software (Bio-Rad, Hercules,
CA, USA). For analysis of LPA receptor expression, total RNA was extracted from
harvested cells using TRIzol solution (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s protocol. Reverse transcription was performed using
iScriptTMcDNA synthesis kit (Bio-Rad, Hercules, CA) in a reaction volume of
20 µL under the conditions recommended by the manufacture. Total RNA (1 µg)
was used as a template for cDNA synthesis. PCR was performed in a 50-µL
reaction volume with a buffer consisting of 10 ˆ iTaq buffer, 50 mM MgCl2,
10 mM dNTP mix, iTaq DNA polymerase;and 0.25 µmol/L each primer. The
primers were: LPA1/Edg-2 (F: 51-TGTCATGGCTGCCATCTC-31; and R: 51-CATCT
CAGTTTCCGTTCTAA-31); LPA2/Edg-4 (F: 51-CCCAACCAACAGGACTGACT-31;
and R: 51-GAGCCCTTATCTCTCCCCAC-31); LPA3/Edg-7 (F: 51-GGACACC
CATGAAGCTAATG-31; and R: 51-TCTGGGTTCTCCTGAGAGAA-31); β-actin
(F: 51-TGACGGGGTCACCCACACTGTGCCCATCTA-31; and R: 51-CTAGA
AGCATTTGCGG TGGACGATGGAGGG-31). RT-PCR products were separated on a
2% agarose gel by electrophoresis and visualized and imaged under UV illumination.
2.7. Immunoblotting
Whole-cell extracts containing equal amounts of protein (30 µg) were separated
by SDS-PAGE on 10% Laemmli gels, transferred to nitrocellulose, and incubated
with primary (overnight at 4 ˝C) and then secondary (one to two hours at room
temperature) antibodies. Blots were developed using enhanced chemiluminescence
(GE Healthcare, Pittsburgh, PA, USA), and imaged using a Gel Doc system (BioRad,
Hercules, CA, USA). Protein expression was quantified by densitometry using
Quantity One software (Bio-Rad). Results were normalized to the actin loading
control, and then to the value obtained for untreated control cells.
2.8. Statistical Analysis
Data were analyzed by two-way ANOVA followed by Tukey’s multiple
comparisons test. The only exceptions were assays in which there was only one
time point (e.g., migration assays); these data were analyzed by one-way ANOVA
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followed by Tukey’s mutliple comparisons test. All analyses were done using Prism
software (Graphpad, San Diego, CA, USA).
3. Results and Discussion
3.1. Effects of Lysophosphatidic Acid (LPA) and Epidermal Growth Factor (EGF) on Breast
Cancer Cell Proliferation
Before testing for effects of FFAR agonists on breast cancer cells, we first established
conditions for using growth factors to stimulate proliferation. Cells were serum-starved
before treatments in order to remove confounding effects of LPA contained in serum,
and to provide a baseline for testing effects of growth factors. The effects of serum,
LPA, and EGF on proliferation of serum-starved MCF-7 and MDA-MB-231 cells are
shown in Figure 1. All growth factors significantly increased cell number as compared
to control. Serum was significantly more effective in inducing proliferation than LPA
or EGF at all time points tested, in both cell lines; this result was expected since serum
contains multiple mitogens including LPA. There was no significant difference between
responses to LPA versus EGF at any time point.
3.2. Signal Transduction Responses to LPA and EGF in Breast Cancer Cells
To further characterize responses to LPA and EGF in the breast cancer cell
lines, we performed immunoblotting experiments to test for Erk and Akt activation
(Figure 2). Both LPA and EGF increase activating phosphorylation of Erk and Akt in
both MCF-7 and MDA-MB-231 cells (Figure 2A). These results are consistent with





















































































































Figure 1. Effects of growth factors on proliferation of human breast cancer
cells. Proliferation assays were conducted using serum-starved MCF-7 (A) or
MDA-MB-231 (B) cells. Cells were incubated with or without 10% FBS (serum),
10 µM LPA, or 10 nM EGF for the indicat d times (growth factors wer added at
time “0”). Each data point represents the mean ˘ SEM (n = 4) f values (number of
live cells per well) from two separate experiments, each done in with two separate
replicate wells of cells for each condition. Data analysis was performed using
two-way ANOVA, followed by Tukey’s multiple comparisons test. All growth
factor values were significantly (p < 0.05) different from the control value at all time
points shown, except for LPA at 24 h in MCF-7. Serum values were significantly
different from lysophosphatidic acid (LPA) or epidermal growth factor (EGF) at all
time points tested.
We also examined a more novel response to growth factors, CCN1 induction,
in MCF-7 cells. CCN1 is an inducible matricellular protein whose expression is
positively correlated with breast cancer progression [31,32]. As shown in Figure 2B,
both LPA and EGF stimulate expression of CCN1 in MCF-7 cells. An increase in
CCN1 protein levels was seen after only 30 min of treatment with either growth
factor. Taken together, the results presented in Figure 2A,B confirm that both LPA
and EGF activate pro-mitogenic signaling pathways in human breast cancer cell lines.
3.3. Effects of LPA Antagonists on Breast Cancer Cell Proliferation
Previous studies have shown that LPA receptors are expressed in breast cancer
cell lines. One group performed a comprehensive analysis of LPA receptor expression
in commonly-used breast cancer cell lines [33]. Their data show that MDA-MB-231
and MCF-7 cells, among other cell lines, express LPA1, LPA2, and LPA3. LPA1 has
been determined to mediate many of the actions of LPA in breast cancer cells [34–37].
RT-PCR experiments conducted in our lab confirmed that LPA1 was expressed in






















































Figure 2. Effects of LPA and EGF on signal transduction events in human breast
cancer cells. ( ) Serum-starved MCF-7 and MDA-MB-231 cells were incubated with
10 µM LPA or 10 nM EGF for 5 min. Whol -cell extracts were immunoblott d using
antibodies re ognizing ph sphorylated active Erk and Akt. An immunoblot for
t tal actin w s performed as a loading control; (B) Serum-starved MCF-7 c lls were
incubated for the indicated times with 10 µM LPA or 10 nM EGF. Whole-cell extr cts
wer immunoblotted using antibody recognizing total CCN1. An immunoblot for
total actin was performed as a loading control. Each experiment is representative
of at least three separate experiments.
Two LPA receptor pharmacologic antagonists were used to further study the role
of LPA1 in breast cancer cells. Ki16425 is a selective inhibitor of LPA1 and LPA3 [38],
while AM966 is an LPA1-selective antagonist [39]. We used a dose-response study
(Figure 3B) to test whether LPA1 inhibitors inhibit LPA-induced proliferation in
MDA-MB-231 breast cancer cells. As expected, based on their relative receptor
affinities, the LPA1-selective antagonist AM966 was more potent (IC50 = 32 nM)
in inhibiting LPA-induced proliferation than was the pan-LPA inhibitor Ki16425
(IC50 = 904 nM). Interestingly, the amount of AM966 needed to completely inhibit
MDA-MB-231 cell proliferation was 100-fold higher than in our previously published
work using DU145 prostate cancer cells [1], although the amount of Ki16425
required was similar in both MDA-MB-231 and DU145. The dose-response curve for
AM966 was very shallow, suggesting the involvement of multiple receptors. These
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results suggest that LPA1 is not the only LPA receptor that mediates LPA-induced














breast  cancer  cells  [34–37]. RT‐PCR  experiments  conducted  in  our  lab  conf rmed  that LPA1 was 
expressed in both MCF‐7 and MDA‐MB‐231 cells under the conditions used herein (Figure 3A). 
 























Figure 3. LPAR expression in breast cancer cell lines, and dose-response for the
effects of LPA1 antagonists on MDA-MB-231 cell proliferation. (A) Total RNA
was extracted from MCF-7 and MDA-MB-231 breast cancer cells. RT-PCR was
performed (s parate gels for each cell line) using the cDNA primers d s ribed
in th Methods. β-actin was amplified as loading control; (B) Serum-starved
MDA-MB-231 cells were incubated for 48 h with and without 10 µM LPA in the
absence and presence of the indicated concentrations of Ki16425 or AM966. The
number of cells achieved in response to LPA alone was defined as 100% response;
the number of cells in the abse ce f LPA was defined as 0% response. Each po t
represents mean ˘ SEM (n ě 4) for values obtained from at l ast two experiments,
each performed with two separate replicate wells of cells for each condition.
In Figure 4, we further tested the effects of LPA antagoni s. We asked 1) whether
the inhibitory effects of LPA antagonists extend to EGF-induced proliferation, and 2)
whether LPA antagonists have similar effects in MCF-7 and MDA-MB-231 cells.
The results of this series of experiments, which are presented in Figure 4, clearly
demonstrate that the LPA receptor antagonists block proliferation in response to both
LPA and EGF. This response was ob erved in both MCF-7 an MDA-MB-231 cells.
Taken together, these results are consistent with a crucial role for LPARs in EGF












values  (number  of  live  cells per well)  from  two  separate  experiments,  each performed with  two 
separate replicate wells of cells for each experimental condition (**** p < 0.0001 compared to control). 















out  for human FFA4, FFA1, or RPLP0  (loading  control)  as described  in Methods. Products were 



































































































































Figure 4. Effects of LPAR antagonists on breast cancer cell proliferation.
Serum-starved MCF-7 (A) or MDA-MB-231 (B) cells were incubated with or without
10 µM LPA or 10 nM EGF in the absence and presence of 10 µM AM966 or 10 µM
Ki16425. Each data point represents the mean ˘ SEM (n = 4) of values (number
of live cells per well) from two separate experiments, each performed with two
separate replicate wells of cells for each experi ental condition (**** p < 0.0001
compared to control). The 48-h time is point shown; similar results were obtained
at 24 and 72 h. Data analysis was performed using two-way ANOVA, followed by
Tukey’s multiple comparisons test.
3.4. Expressi n of Free Fatty Acid Receptors (FFARs) in Breast Cancer Cells
We next turned to the effects of n-3 FAs. We examined whether FFARs are
expressed in MCF-7 and MDA-MB-231 cells. Both receptors have previously been
reported to be present in MCF-7 cells, based on flow cytometry [25]. Using RT-PCR,
we assessed mRNA levels for FFA4 and FFA1, the two receptors for long chain
free fat y acid (Figur 5A). Both PCR products were de ected, alth ugh the PCR
pr du t for FFA4 was present at such low levels that it was difficult to visualize. To
confirm that FFA4 was expressed, we performed immunoblotting using an antibody
previously validated in our laboratory [1], and did detect FFA4 protein (Figure 5B).
We were unable to validate an appropriate antibody for FFA1, but our PCR results
suggest that FFA1 is likely expressed at higher levels than FFA4 in the two breast
cancer cell lines. These results indicate that the roles of both FFA1 and FFA4 need to












values  (number  of  live  cells per well)  from  two  separate  experiments,  each performed with  two 
separate replicate wells of cells for each experimental condition (**** p < 0.0001 compared to control). 
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Figure 5. Expression of FFA1 and FFA4 in breast cancer cell lines. (A) RT-PCR
reactions were carried ut for huma FFA4, FFA1, or RPLP0 (l ading control)
as described in M thods. Products were separated and visualized under UV
light. Results shown are representative of two separate experiments, each done
in triplicate. Faint signals for FFA4 were confirmed in additional experiments;
(B) Whole-cell extracts, from MCF-7 and MDA-MB-231 cells growing in serum,
were separated by SDS-PAGE and then immunoblotted for FFA4 and actin
(loading control).
3.5. Effects of FFAR Agonists on Breast Cancer Cell Proliferation
We next performed a dose-response study (Figure 6) to test whether FFAR
agonists inhibit proliferation of MDA-MB-231 cells. EPA, TUG-891, and GW9503
all inhibited proliferation of these cells. EPA was the least potent compound (IC50
403 nM), which was expected based on results with other cell lines [1]. The IC50
for the FFA4-selective agonist, TUG-891, was 24 nM. However, a 100-fold higher
dose of TUG-891 was required to completely inhibit LPA-induced proliferation in the
breast cancer cell line (Figure 6) as compared to our previously published results with
Du145 prostate cancer cells [1]. In addition, the dose-response curve for TUG-891 was
very shallow, suggesting the involvement of more than one receptor in the inhibitory
response. While TUG-891 is selective for FFA4 over FFA1, neither TUG-891 nor
GW9508 is specific for a single receptor. The FFA1-specific agonist GW9508 was
100-fold more potent (IC50 = 16 nm) in inhibiting LPA-induced proliferation in
MDA-MB-231 (Figure 6) as compared to previous results in DU145 cells where FFA4
response predominates [1]. The published EC50 for GW9508 at FFA1 is ~50 nM. Thus,
our results are consistent with a role for FFA1, and possibly also FFA4, in inhibiting
proliferation of MDA-MB-231 cells.
We next tested the effects of LPA1 inhibitors on both LPA- and EGF-induced
breast cancer cell proliferation (Figure 7). Neither the LPA antagonists AM966 and
Ki16425, nor the FFAR agonists EPA, GW9508, and TUG891, had any significant
effects on cell numbers on their own. However, all agents completely inhibited
LPA- and EGF-induced proliferation in MCF-7 and MDA-MB-231 cells, when added
individually, consistent with the results in Figures 4 and 6. Although EPA appeared
to decrease cell numbers slightly below control values in the presence of LPA or EGF,
the effect was not significant. There was no additional effect (e.g., cytotoxicity) on
cell numbers when LPA antagonists were combined with FFAR agonists GW9508
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or TUG891 (Figure 7). Thus, both LPA antagonists and FFAR agonists can block the










cells  [1].  In  addition,  the  dose‐response  curve  for  TUG‐891  was  very  shallow,  suggesting  the 
involvement of more  than one receptor  in  the  inhibitory response. While TUG‐891  is selective  for 
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of  the  indicated  concentrations of EPA, GW9508,  and TUG‐891. The number of  cells  achieved  in 
response to LPA alone was defined as 100% response; the number of cells present in the absence of 
LPA was defined as 0% response. Each point represents mean ± SEM (n ≥ 4 for values obtained from 
at  least  two  experiments,  each  performed  with  two  separate  replicate  wells  of  cells  for  each 
experimental condition. 








































Figure 6. Dose-response for effects of FFAR agonists on breast cancer cell
proliferation. Serum-starved MDA-MB-231 cells were incubated for 48 h with
and without 10 µM LPA in the absence and presence of the indicated concentrations
of EPA, GW9508, and TUG-891. The number of cells achieved in response to LPA
alone was defined as 100% response; the number of cells present in the absence of
LPA was defined as 0% response. Each point represents mean ˘ SEM (n ě 4 for
values obtained from at least two experiments, each performed with two separate
replicate wells of cells for each experimental condition.
3.6. Effects of FFAR Agonists on Breast Cancer Cell Migration
Finally, we asked whether FFAR agonists inhibit migration of breast cancer cells.
As shown in Figure 8, EPA and GW9508 both block LPA- and EGF-induced migration
of MCF-7 cells. The LPAR antagonist Ki16425 has a similar effect. The combination of
GW9508 and Ki16425 also yields complete inhibition; i.e., there is no additional effect
of the FFAR agonist in the presence of an LPA antagonist. We conclude that either
activation of FFARs, or antagonism of LPARs, can inhibit migration in response to
















two  separate  replicate wells of  cells  for each experimental  condition  (**** p < 0.0001  compared  to 







We  conclude  that  either  activation  of  FFARs,  or  antagonism  of LPARs,  can  inhibit migration  in 
response to either LPA or EGF. 
Figure 7. Effects of FFAR agonists on breast cancer cell proliferation. Serum-starved
MCF-7 or MDA-MB-231 cells were incubated with or without 10 µM LPA or 10 nM
EGF for 48 h in the absence and presence of 1 µM GW9508, 10 µM Ki16425, and/or
10 µM AM966 (Panels A and B), or (Panels C and D), 10 µM LPA or 10 nM EGF in
the absence and presence of 10 µM TUG891, 10 µM Ki16425, and/or 10 µM AM966.
In addition, Panels C and D show the effects of TUG-891 as co pared to that of
25 µM EPA, and controls were included for the LPA antagonists alon . Some of
the data points from Panels C and D were presented earlier in Figur 4, which was
derived from the same series of experiments; panels (A) and (B) are from separate
sets of experiments. Although only the 48-h time point is shown, similar inhibitory
effects were observed at 24 and 72 h. Each value represents the mean ˘ SEM (n = 4)
of values (number of live cells per well) obtained from two separate experiments,
each of which used two separate replicate wells of cells for each experimental
condition (**** p < 0.0001 compared to control). Data were analyzed done using


















LPARs  in  the mechanism of FFAR‐mediated  inhibition of cancer cell proliferation. LPA has multiple 
actions  that  support  breast  cancer  growth,  migration,  invasion,  and  survival  [37,41–44].  An  LPA 
antagonist was shown to induce regression of breast tumors in a mouse model [45]. Others reported that 
either an LPA1 antagonist or LPA1 knockdown decreases MDA‐MB‐231 cell metastasis, but not primary 
















































































































Figure 8. Effects of LPAR agonists on MCF-7 cell migration. Serum-starved MCF-7
cells were treated with 10 µM Ki16425, 20 µM EPA, 1 µM GW9508, 10 µM LPA,
or 10 nM EGF, either alone or in combination. After a 6-h migration period, cells
were analyzed as described in Methods. Each bar epres nts the mea ˘ SEM
(n = 4) of values (total number of migrated cells/well) obtained fr m two separate
experiments, each of which used two separate replicate wells of cells for each
experimental condition (**** p < 0.0001 vs. control). Data were analyzed using
one-way ANOVA, followed by Tukey’s multiple comparisons test.
4. Conclusions
In extending ur ongoing studies of FFAR activation to breast cancer cells, the
intention was to expand our knowledge of the roles of FFARs in cancer. While others
have examined the effects of n-3 FAs on breast cancer, to our knowledge no other
studies have tested the roles of FFARs in human breast cancer cells.
The current study used LPA as one of the growth factors, based on our previous
work implicating LPARs in the mechanism of FFAR-mediated inhibition of cancer
cell proliferation. LPA has multiple actions t at support breast cancer growth,
migration, i vasion, and survival [37,41–44]. An LPA antagonist was shown to
induce regression of br ast tumors in mouse model [45]. Others r ported that either
an LPA1 antagonist or LPA1 knockdown decreases MDA-MB-231 cell metastasis, but
not primary tumor size, in mice [46]. Together, these data have established a potential
role for the LPA axis as a therapeutic target in breast cancer cells, as reviewed by
Panupinthu and colleagues [29]. However, the overall roles of LPA and its receptors
in breast cancer cell proliferation have not been fully delineated.
FFA1/GPR40 was first reported to be present in MCF-7 cells i 2004 [24]. Th s
was later confir ed by another group usi g flow cytometry [25] and also in the
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current study by PCR (Figure 5). Soto-Guzman and colleagues also detected FFA4
expression in MCF-7 cells [25]. Our data demonstrate expression of FFA1 and FFA4
mRNA, and FFAR protein, in both MCF-7 and MDA-MB-231 cells. Interestingly, the
results of dose-response studies using two selective FFAR agonists were consistent
with a major role for FFA1 in MDA-MB-231 cells (Figure 6). While these results do
not exclude a role for FFA4, this is the first demonstration in our lab that FFA1 and
FFA4 may similarly mediate inhibition of cancer cell proliferation.
Figures 4 and 7 demonstrate that LPAR inhibition not only impedes
LPA-induced proliferation, but also EGF-induced proliferation. This result suggests
that, in MCF-7 and MDA-MB-231 cells, EGFR is reliant on one or more LPARs. This
result is similar to those obtained with prostate cancer cells [1,40]. LPARs have been
described as “masters” of EGFR signaling [47], as confirmed by studies in various
cell types [1,48–53]. Further studies will be required to determine whether FFA1
or FFA4 act directly on both LPARs and EGFR to result in inhibition, or indirectly
inhibit EGFR via effects on LPARs.
FFAR activation through EPA, GW9508, or TUG-891 abolishes LPA- and
EGF-induced proliferation and migration in MCF-7 and MDA-MB-231 cells
(Figures 6–8). GW9508 yields a classical dose-response curve with an IC50 consistent
with action at FFA1. At the higher dose of TUG-891 used to achieve complete
inhibition in breast cancer cells (10 µM), it is plausible that it is activating FFA1 in
addition to, FFA4. Our results are consistent with other reports of inhibitory effects
of n-3 FAs in breast cancer cells. In one study, low doses of n-3 FAs were shown to
inhibit proliferation of MCF-7 cells, while high doses induced apoptosis [20]. This is
consistent with our dose-response results for MDA-MB-231 cells, where inhibition of
proliferation was achieved without cytotoxicity (Figure 6). The EPA concentration
(25 µM) used in subsequent experiments was chosen as the dose that maximally
inhibited proliferation but did not decrease viability, since our focus was on inhibition
of growth factor response rather than toxic responses that may occur at high doses.
Although our results suggest that both FFAR agonists and LPAR antagonists
inhibit proliferation in MCF-7 and MDA-MB-231 cells, more work is needed to fully
elucidate the mechanism of action. It remains to be definitively determined which
FFAR is responsible for the inhibition in breast cancer cells. It is also unclear at
this point whether FFAR activation directly influences EGF-mediated signaling, or
whether FFARs act indirectly via interference with LPAR activity as appears to be the
case in prostate cancer cells [40]. Since the synthetic FFAR agonists used in the current
study are not metabolized to resolvins, and are designed to act selectively at GPCRs,
utilization of these agonist drugs is helpful in distinguishing receptor-mediated
effects from effects of n-3 FAs on lipid metabolism. In addition, the emerging
small-molecule FFAR agonists have therapeutic potential for the prevention and/or
treatment of breast cancer. In summary, the results presented herein demonstrate
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for the first time that FFAR activation results in inhibition of breast cancer cell
proliferation and migration. The inhibitory response mediated by FFARs needs to be
taken into account when considering effects of n-3 fatty acids on breast cancer cells.
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Potential Benefits of Omega-3 Fatty Acids in
Non-Melanoma Skin Cancer
Homer S. Black and Lesley E. Rhodes
Abstract: Considerable circumstantial evidence has accrued from both experimental
animal and human clinical studies that support a role for omega-3 fatty acids (FA)
in the prevention of non-melanoma skin cancer (NMSC). Direct evidence from
animal studies has shown that omega-3 FA inhibit ultraviolet radiation (UVR)
induced carcinogenic expression. In contrast, increasing levels of dietary omega-6
FA increase UVR carcinogenic expression, with respect to a shorter tumor latent
period and increased tumor multiplicity. Both omega-6 and omega-3 FA are
essential FA, necessary for normal growth and maintenance of health and although
these two classes of FA exhibit only minor structural differences, these differences
cause them to act significantly differently in the body. Omega-6 and omega-3 FA,
metabolized through the lipoxygenase (LOX) and cyclooxygenase (COX) pathways,
lead to differential metabolites that are influential in inflammatory and immune
responses involved in carcinogenesis. Clinical studies have shown that omega-3
FA ingestion protects against UVR-induced genotoxicity, raises the UVR-mediated
erythema threshold, reduces the level of pro-inflammatory and immunosuppressive
prostaglandin E2 (PGE2) in UVR-irradiated human skin, and appears to protect
human skin from UVR-induced immune-suppression. Thus, there is considerable
evidence that omega-3 FA supplementation might be beneficial in reducing the
occurrence of NMSC, especially in those individuals who are at highest risk.
Reprinted from J. Clin. Med. Cite as: Black, H.S.; Rhodes, L.E. Potential Benefits of
Omega-3 Fatty Acids in Non-Melanoma Skin Cancer. J. Clin. Med. 2016, 5, 23.
1. Introduction
Considerable interest has been focused on the potential health benefits of
omega-3 fatty acids (FA) on a range of human diseases. This interest arose from
a series of reports in which high dietary intake of these unsaturated FA among
Greenlandic West Coast Eskimos was specifically associated with low incidence of
ischemic heart disease, and inflammatory symptoms, in general [1–3]. Whereas
the major focus has been on cardiovascular disease [4–6], studies have been
extended to type II diabetes and the metabolic syndrome, inflammatory bowel
disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and
osteoporosis [7,8].
Dietary lipids have also been implicated in the development of several kinds of
cancer, e.g., breast, lung, bowel, bladder, pancreatic, and prostate [9–12]. Whereas,
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omega-3 FA have generally shown positive effects on cardiovascular disease, studies
are equivocal for human cancers [13,14]. Among 43 risk ratios calculated across
19 cohorts for 11 different types of cancer and 5 different ways to assess omega-3
FA consumption, only four were significant, and it was concluded that omega-3 FA
do not reduce overall cancer risk [14]. A systematic review involving 20 cohorts
and using up to 6 different ways to categorize omega-3 FA consumption similarly
arrived at the conclusion that, overall, there was not a significant association between
omega-3 FA and cancer incidence and that dietary supplementation was unlikely to
prevent cancer [15].
Although women with high intake ratios of marine omega-3 FA, relative to
omega-6 FA have been found to have a reduced risk of breast cancer, not all
case-control and cohort studies are in agreement [16]. In the first meta-analysis
previously referenced [14], five estimates of risk for breast cancer did not show a
significant association, and no effects were found for cancers of the aero-digestive
tract, bladder, colorectum, ovary, pancreas or stomach, or for lymphoma. While
a recent study observed that high levels of serum phospholipid omega-3 FA
(a biomarker) were associated with a large increase in the risk of high-grade prostate
cancer [17], subsequent systematic review and meta-analysis, including 12 studies of
self-reported dietary intake of omega-3 FA and 9 biomarker studies, failed to find
an association between omega-3 FA and prostate cancer [18]. These ambiguities
require clarification and undoubtedly will require randomized, double-blinded
intervention trials.
Inflammatory processes are involved in initiation, promotion, and progression
stages of cancer and herein rests the rationale upon which omega-3 FA might be
expected to reduce cancer risk [19]. In this regard, there has accrued a considerable
body of evidence, albeit circumstantial at this point, that omega-3 FA could reduce
cancer risk for the most common of cancers, i.e., skin cancer. The American Cancer
Society [20] estimates that over 3.5 million cases of skin cancer will occur this year in
the United States alone. The evidence to support a beneficial outcome for omega-3
FA supplementation on non-melanoma skin cancer (NMSC) is presented herein.
2. Essential Fatty Acids
Linoleic acid (LA) and α-linolenic acid (ALA) cannot be synthesized by humans
and are, thus, considered essential and must be supplied in the diet. These essential
fatty acids (EFA) are the precursors of the omega-6 and omega-3 series of FA,
respectively. These FA are often abbreviated by their chemical designation, e.g.,
LA is 18:2n-6 where 18 indicated the length of the carbon chain, the 2 represents
the number of double bonds and the n-6 indicates that the first of the double bonds
begins at the sixth carbon atom from the methyl end of the carbon chain. ALA is
abbreviated as 18:3n-3, the n-3 signifies that the first double bond is at the third
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carbon from the methyl end of the chain. Longer chain polyunsaturated FA (PUFA)
can be synthesized in humans from their respective precursor EFA (LA or ALA)
through a series of elongation (addition of two carbon atoms) and desaturation
(addition of a double bond) enzymatic reactions. The two series of EFA cannot be
inter-converted in humans and thus compete for these enzymes. Because Western
diets may contain 15–20 times more LA than ALA, greater levels of long- chain
omega-6 FA (Arachidonic acid, 20:4n-6) result. Consequently under certain dietary
conditions supplementation with EPA (Eicosapentaenoic acid, 20:5n-3) and DHA











The  first report  that dietary fat could potentiate UVR‐carcinogenesis  came  in 1939  [25]. With 
the advent of World War II, this avenue of research lay fallow for nearly 45 years until this lead was 
followed‐up  in  a  series  of  studies  that  demonstrated  that  an  approximate  linear  relationship 
occurred  between  PUFA  (dietary  corn  oil  that  contained  roughly  50%  omega‐6  FA)  and 
UVR‐carcinogenic expression [26,27]. Increasing dietary levels of omega‐6 FA shortened the tumor 
latent period  and  increased  tumor multiplicity. Partial hydrogenation  of  the PUFA  resulted  in  a 
marked inhibition of carcinogenesis [26]. Reeve et al. [28] found that feeding a totally hydrogenated 
PUFA  completely  abolished  UVR‐carcinogenic  expression  while  those  animals  fed  the  normal 
PUFA  exhibited  100%  tumor  incidence.  Furthermore,  when  the  diet  of  animals  fed  the 
hydrogenated  fat  was  reconstituted with  a  normal mixed  fat,  large  numbers  of  tumors  rapidly 
appeared. The authors suggested that UVR initiation of tumors had not been prevented by lack of 
PUFA,  but  that  the EFA deficiency  held  the appearance  of  tumors  in  abeyance,  probably  at  the 





multiplicity  analysis  provided  confirmation  that  diets  containing  high  levels  of  omega‐6  FA 
enhanced UVR‐carcinogenic expression and that enhancement occurred during the post‐initiation, 
or promotion/progression, stages of carcinogenesis.  Importantly, crossing from a high fat to a low 
Figure 1. Differential eicosanoid metabolism from omega-6 and omega-3 FA sources.
Arachidonic acid, 20:4n-6 (AA), is metabolized via lipoxygenase and cyclooxygenase
pathways. Eicosapentaenoic acid, 20:5n-3 (EPA) acts as a competitive inhibitor to
the cyclooxygenase enzyme complex with AA and produces different leukotriene
and prostaglandin oxidation products. Malondialdehyde (MDA) is a product of
prostaglandin and thromboxane metabolism and is commonly used as a measure of
lipid peroxidation.
Not only do these two series of EFA compete for elongase and desaturase
enzymes, but they also compete with the cyclooxygenase (COX) and lipoxygenase
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(LOX) enzymes and differentially influence the flux of metabolites through these
pathways. These oxidative metabolites differ in hormonal potency. The omega-6
FA derived products are more active than their omega-3 FA counterparts. Some
of these metabolites are known to influence tumor biology. PGE2, derived from
omega-6 FA oxidation via the COX pathway, acts as a tumor promoter and has been
associated with aggressive tumor growth patterns in both basal cell carcinoma (BCC)
and squamous cell carcinoma (SCC) in humans [21]. On the other hand, omega-3 FA
compete with omega-6 FA for binding sites on COX and inhibit the production of
PGE2, resulting in higher levels of the less potent PGE3. Omega-3 FA may also shunt
potential PG precursors through the LOX pathway, resulting in products that inhibit
tumor growth and in products that are involved in immune surveillance [21–23]. A
simplified schema of eicosanoid metabolism is illustrated in Figure 1. Thus, the COX
and LOX pathways, with their bioactive intermediates, provide a strong rational
foundation for the cancer preventive potential of omega-3 FA [24].
3. Evidence for Participation of Dietary PUFA in UVR-Induced Skin Cancer
3.1. Animal Studies
The first report that dietary fat could potentiate UVR-carcinogenesis came in
1939 [25]. With the advent of World War II, this avenue of research lay fallow
for nearly 45 years until this lead was followed-up in a series of studies that
demonstrated that an approximate linear relationship occurred between PUFA
(dietary corn oil that contained roughly 50% omega-6 FA) and UVR-carcinogenic
expression [26,27]. Increasing dietary levels of omega-6 FA shortened the tumor latent
period and increased tumor multiplicity. Partial hydrogenation of the PUFA resulted
in a marked inhibition of carcinogenesis [26]. Reeve et al. [28] found that feeding a
totally hydrogenated PUFA completely abolished UVR-carcinogenic expression while
those animals fed the normal PUFA exhibited 100% tumor incidence. Furthermore,
when the diet of animals fed the hydrogenated fat was reconstituted with a normal
mixed fat, large numbers of tumors rapidly appeared. The authors suggested that
UVR initiation of tumors had not been prevented by lack of PUFA, but that the EFA
deficiency held the appearance of tumors in abeyance, probably at the promotion
stage of carcinogenesis. Confirmation that omega-6 FA exerted their influence
principally at the post-initiation stage of carcinogenesis came from cross-over feeding
studies [29]. Animals were placed on a defined, isocaloric diet containing high
(12% w/w) and low (0.75%, w/w) levels of corn oil. At completion of a regimen of
UVR, and before tumors appeared, some diets were crossed to the contravening diet,
e.g., high to low fat and low to high fat. Incidence curves and tumor multiplicity
analysis provided confirmation that diets containing high levels of omega-6 FA
enhanced UVR-carcinogenic expression and that enhancement occurred during the
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post-initiation, or promotion/progression, stages of carcinogenesis. Importantly,
crossing from a high fat to a low fat diet after a cancer causing dose of UVR had
already been administered, negated the exacerbating influence of high fat diets. This
finding provided the rationale upon which a low-fat dietary intervention might act
to ameliorate cancer expression.
Contrary to the tumor promoting effects of omega-6 FA, animals fed a
diet containing menhaden oil as lipid source exhibited a marked inhibition of
UVR-carcinogenic expression [30]. Menhaden oil is rich in omega-3 FA. Unlike
omega-6 FA, cross-over feeding studies indicated that omega-3 FA exert their
principal anti-cancer effects during the initiation stage of carcinogenesis. Animals
fed with the omega-3 FA diet throughout the study exhibited an increased tumor
latent period and decreased tumor multiplicity compared to animals receiving an
equivalent level of corn oil (rich in omega-6 FA).
As noted previously, omega-3 FA compete with omega-6 FA for active sites
on COX, a major enzyme in the eicosanoid cascade [24,31]. As such, the level of
pro-inflammatory and immune modulating omega-6 FA metabolites is reduced.
As dietary omega-6 FA increase, the plasma PGE2 level increases. Omega-3 FA
intake reduces PGE2 levels approximately 7-fold in comparison to an equivalent
level of omega-6 FA [32]. These data support the thesis that omega-6 and omega-3
PUFA differentially influence not only PGE2 levels, but other pro-inflammatory and
immune-modulating intermediates of the COX and LOX pathways.
Supporting evidence for a role of omega-3 FA in carcinogenesis has recently
been acquired from studies with a transgenic mouse model designated fat-1 [33]. The
fat-1 transgenic mice are capable of producing omega-3 FA from omega-6 FA, i.e., the
transgenic has received a gene encoding an omega-3 FA desaturase that converts
omega-6 FA to omega-3 FA. This results in abundant omega-3 FA and reduced
omega-6 FA in the animals’ tissues without the need for omega-3 FA supplementation
and eliminates many of the confounding variables encountered in dietary studies.
With regard to skin tumorigenesis, Xia et al. [34] showed that there was a dramatic
reduction of melanoma formation and growth when fat-1 mice were injected with
B16 melanoma cells, compared to their non-transgenic littermates. The levels of
omega-3 FA and metabolite PGE3 were much higher in the transgenic animals
and the omega-6/omega-3 FA ratio much lower. This transgenic model should be
invaluable in future studies to elucidate the role and mechanism(s) of effects of
omega-3 FA in NMSC.
As alluded to earlier, previous studies had indicated that carcinogenesis might
be modulated immunologically and that this influence might occur at the promotion
stage [32]. Notably, the systemic alteration induced by UVR that suppresses an
animal’s ability to reject highly antigenic UVR-induced allergens occurs during the
chemical promotion stage of carcinogenesis [35]. Reeve et al. [28] had already shown
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that feeding mice an EFA (omega-6 FA) deficient diet inhibited the appearance
of UVR-induced tumors and suggested that this inhibition might be due to the
lack of eicosanoid precursors that, in turn, might prevent UVR induction of the
immune state. In the case of omega-6 FA, this would be deficient levels of PGE2, the
gate-keeper for other eicosanoids. This would account for protection observed from
UVR-initiated tumor outgrowth. Chung et al. [36] had shown that T-cell function
was PGE2 dependent and that UVR-induced suppression of contact hypersensitivity
(CHS) was abrogated by treatment with an inhibitor of PG synthesis.
It was subsequently shown that plasma PGE2 levels were directly related to
omega-6 FA dietary intake, i.e., the highest level of PGE2 occurring with the highest
level of omega-6 FA intake [32]. This, in turn, induced the greatest exacerbation of
UVR carcinogenic expression. Importantly, omega-3 FA provided striking protection
against UVR-induced immunosuppression. This observation was subsequently
confirmed [37]. Delayed type hypersensitivity (DTH) and CHS are both regulated by
T-cell function and share common pathways with immunological tumor rejection.
DTH in UVR-irradiated animals is dramatically suppressed in animals fed high
levels of omega-6 FA when compared to those receiving low levels of the FA or those
receiving omega-3 FA [32,38].The ability of an animal to reject a transplanted tumor
was related to the level of omega-6 FA intake. Moreover, the tumor rejection time
for animals fed high levels of omega-6 FA was three times longer than animals fed
low levels of the omega-6 FA and occurred at a time when high omega-6 FA had
been shown to exacerbate primary tumor expression [38].These studies suggest that
one potential mechanism of omega-3 FA inhibition of carcinogenic expression is via
immune modulation [31].
In summary, the following sequence of observations support the thesis that
omega-6, -3 PUFA metabolism, through the LOX and COX pathways, leads to
differential metabolites that influence inflammatory and immune responses involved
in UVR-carcinogenesis:
1. Increasing levels of dietary omega-6 FA exacerbate UVR carcinogenic
expression, with respect to both shortened tumor latent period and increased
tumor multiplicity.
2. Dietary omega-3 FA inhibit UVR carcinogenic expression.
3. Omega-6 FA exert their principal effect upon the post-initiation, or
promotion/progression stages of UVR carcinogenesis.
4. Omega-3 FA appear to exert their principal effects during the initiation stage of
the carcinogenic continuum.
5. Pro-inflammatory and immunosuppressive PGE2 levels are increased linearly
as dietary omega-6 FA levels increase.
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6. Pro-inflammatory and immunosuppressive PGE2 levels are dramatically
reduced by dietary omega-3 FA intake.
7. Dietary omega-6 FA suppress the immunologic responses involved in tumor
transplant rejection and the immunologic pathways involved in DTH and CHS.
8. Dietary omega-3 FA inhibit UVR-induced suppression of DTH and CHS.
3.2. Clinical Studies
The experimental studies employing a high-fat diet to low-fat diet cross-over,
even after a cancer causing dose of UVR had been administered, negated the
exacerbating influence of the high-fat diet and provided a rationale for undertaking
a clinical intervention trial. This trial, involving 133 skin cancer patients, of whom
115 completed the two year study, clearly demonstrated that a low-fat intervention
reduced the occurrence of NMSC [39,40]. The cumulative rate of occurrence of
NMSC (cumulative NMSC/patient/time period) was 0.21 and 0.19 during the first
8-month period of the study and 0.26 and 0.02 (p ď 0.02) during the last 8-month
period for control and intervention arms, respectively. The dietary parameters
involved only a reduction in the calories consumed as fat, while maintaining total
calorie intake and body weight. Efforts were made to maintain the P/S ratio
(polyunsaturated/saturated fat ratio) of patients’ diets going into the trial and
there were no increases in omega-3 FA intake. Thus, the influence of fat on MNSC
occurrence was primarily that resulting from lowering fat intake, primarily omega-6
FA. Furthermore, the influence of this low-fat intervention was observed early in the
study as a significant difference in the number of actinic keratoses (pre-malignant
lesions) between control and low-fat diets occurred [41]. Patients in the control arm
of the study (no dietary modifications introduced) were found to be at 4.7 times
greater risk of having one or more actinic keratoses during the two-year study period
than patients in the low-fat intervention arm.
Whereas lower intake of omega-6 FA reduces the risk of NMSC occurrence in
skin cancer patients, a population based case-control study showed a consistent
tendency toward a lower risk of SCC with higher intakes of omega-3 FA [42].
Their data also suggested a tendency for a lower risk of SCC with diets containing
high omega-3/omega-6 FA ratios. Although this study was suggestive that
omega-3 FA could influence NMSC risk, a number of human studies have provided
a physiological rationale to support such a hypothesis. Encouraged by the
experimental animal results, a short term supplementation study of mixed omega-3
FA was conducted in humans [43]. The patients received oral capsules of either
4 g/day of mixed omega-3 FA (2.8 g EPA + 1.2 g DHA) or a gelatin placebo. After
four weeks there was a statistically significant increase in the minimal erythema
dose (MED) to UVB in the active group. Serum triglyceride levels decreased by
40 mg/dL. A second study examined the effects of omega-3 FA supplementation
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on UVB-induced erythema and lipid peroxidation [44]. This study employed a
supplement of 3 g/day of mixed omega-3 FA (1.8 g EPA + 1.2 g DHA) administered
over a 3–6 month period. The MED rose progressively with increasing time of
omega-3 FA supplementation, and had more than doubled at six months. This
increase in MED was accompanied by an increase in epidermal omega-3 FA
composition and increased susceptibility to lipid peroxidation. The MED had
returned to baseline two and a half months after omega-3 FA supplementation
was halted.
As noted earlier, a number of cytokines and PG have been shown to be
modulated by omega-3 FA. When human keratinocytes were cultured in the presence
of omega-3 FA, TNF-α and IL-1α secretion was induced and PGE2 and IL-6 level
reduced [45]. Subsequently, further in vitro keratinocyte studies showed that EPA
and DHA each inhibited basal and UVR-induced IL-8, a chemokine pivotal to
UVR- induced skin inflammation and which exhibits pro-carcinogenic activity [46].
However, a double- blind, randomized trial of 28 patients supplemented with
4 g/day of 95% of ethyl esters of EPA or oleic acid for three months found no
evidence that the MED response evoked by omega-3 FA was mediated by the
pro-inflammatory cytokines IL-8, TNF-α, IL-6 or IL-1β. In contrast, there was a
notable and significant reduction in cutaneous PGE2, the pro-inflammatory and
immune-suppressor mediator [47]. Further, lipidomic analysis was performed
in a human intervention trial of EPA-rich omega-3 FA, quantifying impact of
supplement on eicosanoid levels in skin blister fluid [48]. This showed a significant
reduction in the ratio of PGE2: PGE3 in UVR-exposed skin, accompanied by
a reduction in the ratio of the pro-inflammatory and tumor promoting 12-LOX
product 12-hydroxyeicosatetraenoic acid (12-HETE): 12-hydroxyeicosapentaenoic
acid (12-HEPE), EPA-derived homologue of 12-HETE [48].
A double-blind, randomized intervention examined the impact of oral omega-3
FA on UVR suppression of cell-mediated immunity, assessed through the nickel CHS
response [49]. Seventy-nine nickel-sensitive adult females consumed encapsulated
omega-3 FA (3.5 g EPA + 1.5 g DHA) or control lipid daily for 3 months,
with compliance and skin bioavailability of omega-3 FA assessed by blood [49]
and skin [48] assay, respectively. This indicated apparent abrogation of the
photo-immunosuppression induced by low level solar simulated ultraviolet radiation
(SSR; 95% UVA, 5% UVB) exposure. Following SSR exposure equivalent to ~15 min
of midday summer sunlight in Manchester, UK (latitude 53.5˝ N), on 3 consecutive
days, the UVR-suppression of the CHS response was 50% lower in the subjects taking
omega-3 FA compared to those taking control.
Previous discussion provides clear evidence that omega-3 FA protect against
the clinical sunburn response. Yet, there was no evidence of an EPA effect on direct
UVR-induced DNA damage to DNA, i.e., cyclobutane pyrimidine dimer formation
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in skin [50]. There was, however, protection against UVR induction of cutaneous p53,
considered to be a biomarker of DNA damage and which acts as a tumor suppressor
gene. In addition, in ex vivo UVR-treated peripheral blood lymphocytes, omega-3 FA
protected against DNA single-strand breaks [50].
Thus, human studies (and cell culture studies employing human cells)
have shown:
1. Omega-3 FA supplementation significantly increases the erythema threshold
to UVR.
2. Omega-3 FA modulate a number of cytokines (in human cells in vitro only) and
eicosanoids that mediate inflammatory and immune responses.
3. Omega-3 FA inhibit certain genotoxic markers of UVR-induced DNA damage,
e.g., UVR- induced cutaneous p53.
4. Omega-3 FA abrogate UVR-induced immunosuppression of cell mediated
immunity assessed as nickel CHS
4. Conclusions
In Toto, the results of experimental studies, and the influence of omega-3 FA
on UVR-induced erythema, early genotoxic markers and immune-suppression in
human trials, suggest that supplementation of these photoprotective nutrients [51]
could result, in the longer term, in a reduction in NMSC in humans. Based upon
age-adjusted cancer incidence/UVR exposure plots, an omega-3 FA enhanced sun
protection factor (SPF), even of the low reported magnitude could reduce incidence of
NMSC by as much as 30% [50–52]. Neither have observational studies, case-control
or prospective cohort studies, provided clear evidence that dietary omega-6 FA or
omega-3 FA reduces the risk of NMSC. A recent meta-analysis has been suggestive,
but lacked adequate data due to scarcity of trials in this area, to support the
hypothesis that omega-3 FA protect against NMSC [53]. For the most part, both
case-control and prospective cohort studies have failed to find a relationship between
skin cancer incidence with dietary fat intake. Indeed these types of studies are
fraught with methodological difficulties resulting from: (1) the complexity of the
human diet in a free living population; (2) the difficulties in measuring food intake
and analyzing dietary information; (3) the epidemiologist requires assess of dietary
patterns that are stable over long periods, i.e., usually years if cancer induction is
under study [54].
The authors have previously proposed that the most direct evidence for the
preventive potential of omega-3 FA would be achieved through intervention trials
in populations with high, and known, risk for NMSC—much in the manner that
reduction in the percentage of calories consumed as fat was shown to influence
NMSC occurrence in skin cancer patients [24,39–41,55]. Caveats to the design of
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such a study will include consideration of baseline omega-3 FA nutrition at study
inclusion [56] and careful monitoring of the diets of study patients to assure that any
potential benefits of omega-3 FA supplementation is not diminished by increasing
omega-6 FA intake. The relative omega-6/omega-3 FA ratios will determine response
and could be monitored by an easily determined parameter such as red blood cell
membrane omega-6/omega-3 FA ratios [48,56]. This parameter could also be used to
determine adherence to the supplement protocol. It is also important that an adequate
level of omega-3 FA supplementation be employed. Omega-3 FA have a high safety
profile and a daily intake of circa 4 g/day as employed in previous photoprotection
studies is envisaged to be adequate. Because of the promising evidence from animal
and clinical studies, it is imperative that the potential of omega-3 FA as a preventive
agent for NMSC be fully explored.
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Supplementation with Omega-3 Fatty
Acids in Psychiatric Disorders: A Review
of Literature Data
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Abstract: A new application for omega-3 fatty acids has recently emerged, concerning
the treatment of several mental disorders. This indication is supported by data
of neurobiological research, as highly unsaturated fatty acids (HUFAs) are highly
concentrated in neural phospholipids and are important components of the neuronal
cell membrane. They modulate the mechanisms of brain cell signaling, including
the dopaminergic and serotonergic pathways. The aim of this review is to provide a
complete and updated account of the empirical evidence of the efficacy and safety
that are currently available for omega-3 fatty acids in the treatment of psychiatric
disorders. The main evidence for the effectiveness of eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA) has been obtained in mood disorders, in particular
in the treatment of depressive symptoms in unipolar and bipolar depression. There
is some evidence to support the use of omega-3 fatty acids in the treatment of
conditions characterized by a high level of impulsivity and aggression and borderline
personality disorders. In patients with attention deficit hyperactivity disorder,
small-to-modest effects of omega-3 HUFAs have been found. The most promising
results have been reported by studies using high doses of EPA or the association of
omega-3 and omega-6 fatty acids. In schizophrenia, current data are not conclusive
and do not allow us either to refuse or support the indication of omega-3 fatty acids.
For the remaining psychiatric disturbances, including autism spectrum disorders,
anxiety disorders, obsessive-compulsive disorder, eating disorders and substance
use disorder, the data are too scarce to draw any conclusion. Concerning tolerability,
several studies concluded that omega-3 can be considered safe and well tolerated at
doses up to 5 g/day.
Reprinted from J. Clin. Med. Cite as: Bozzatello, P.; Brignolo, E.; De Grandi, E.;
Bellino, S. Supplementation with Omega-3 Fatty Acids in Psychiatric Disorders:
A Review of Literature Data. J. Clin. Med. 2016, 5, 67.
1. Introduction
The role of omega-3 highly unsaturated fatty acids (HUFAs) in human mental
health has been widely studied in the last two decades.
Omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) are derived from alpha-linolenic acid (ALA) and are dietary essential fatty
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acids. They cannot be synthetized de novo by mammals and are provided by
supplementation, such as fish oil.
EPA and DHA act as competitive inhibitors of omega-6 fatty acids causing a
reduction in the synthesis of pro-inflammatory mediators [1]. In fact, the omega-6
family of fatty acids is converted to arachidonic acid and then into prostaglandins and
leukotrienes, which are responsible of the pro-inflammatory effects. Therefore, a diet
rich in fish oil has been shown to decrease the incidence of inflammatory diseases.
In addition, HUFAs slow coronary atherosclerosis by optimizing cholesterol
concentrations and lowering plasma triglyceride levels. HUFAs also have
antithrombotic, antiarrhythmic and vasodilatory properties, providing the protection
of the cardiovascular system and significantly diminishing cardiovascular mortality.
These effects of omega-3 fatty acids have supported indications in the secondary
prevention of hypertension, coronary heart disease, type 2 diabetes and in some
cases of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, chronic obstructive
pulmonary disease and renal disease [2,3].
EPA and DHA are important for fetal development, including neuronal, retinal
and immune functions [4].
In recent years, the interest of omega-3 fatty acids has grown in psychiatry,
and their role in the treatment of several mental diseases has been investigated.
HUFAs are important components of phospholipids and cholesterol esters of
the neuronal cell membrane, especially of dendritic and synaptic membranes.
The rationale for the use of these new agents in psychiatric disorders stemmed
from their primary action in producing modification of the synaptic membrane [5].
Indeed, they modulate and are involved in brain cell signaling, including monoamine
regulation [6–10], modification of receptor properties or the activation of signal
transduction by receptors.
Among psychiatric diseases, long-chain omega-3 fatty acids have been tested
in the treatment of schizophrenia, unipolar and bipolar mood disorders, anxiety
disorders, obsessive-compulsive disorder, attention deficit hyperactivity disorder
(ADHD), autism, aggression, hostility and impulsivity, borderline personality
disorder, substance abuse and anorexia nervosa. The aim of this review is to provide
an updated account of the empirical evidence of the efficacy and safety that are
currently available for omega-3 fatty acids in the treatment of mental disorders. In
particular, we focused on the data of efficacy and the adverse effects of different
doses of HUFAs in the treatment of mental disorders, to determine which dose levels
of single or combined fatty acids are related to a good clinical response of specific
mental disorders with a low risk of significant adverse effects.
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2. Methods
This review presents and critically evaluates data from clinical trials, systematic
reviews and meta-analyses published from 1980 to September 2015, after a systematic
research on the Medline database provided by the U.S. National Library of
Medicine (http://www.ncbi.nlm.nih.gov/pubmed?otool=iitutolib). The search
terms were: omega-3 fatty acids; HUFAs; eicosapentaenoic acid; docosahexaenoic
acid; ethyl-eicosapentaenoic acid; α-lipoic acid; α-linoleic acid; psychiatric
disorders; psychotic disorders; schizophrenia; mood disorders; anxiety disorders;
obsessive-compulsive disorder; attention deficit hyperactivity disorder; autism
spectrum disorders; aggression, hostility, impulsivity; personality disorders;
borderline personality disorder; substance dependence; anorexia nervosa; adverse
effects; dose.
2.1. Schizophrenia
Studies of post mortem samples have shown that patients with schizophrenia
have often low levels of EPA and DHA in their brain cells. The level of fatty acids is
considered important to maintain the correct nerve cell-membrane metabolism [11].
The evidence is strong enough to have led to a ‘membrane phospholipid hypothesis’
of schizophrenia [12,13]. Based on findings that in individuals with schizophrenia
or related psychotic disorders, certain omega-3 and omega-6 HUFA levels are
reduced compared to healthy control samples, the idea that restoration of HUFA
resources could be used as a treatment option in psychotic disorders has been widely
discussed [14].
To date, there are 13 RCTs available concerning the role of omega-3 fatty acids
supplementation in schizophrenia or related disorders. For ethical and clinical
reasons, most trials used the add-on strategy, including patients who already received
neuroleptics or atypical antipsychotics. Two exceptions are the studies published
by Amminger [15] and Markulev [16], which considered patients at high risk for
developing psychosis. Peet et al. [17] and Emsley et al. [18] designed trials with
omega-3 HUFAs as a monotherapy, but in both cases, almost all patients needed
to be treated also with an antipsychotic drug during the course of the trial. Only
six RCTs [15,17,19–22] reported that HUFAs had a benefit on positive or negative
symptoms. The sample size of all of the reviewed studies was small, and the
population investigated suffered from a considerable degree of heterogeneity. In fact,
not only patients with a diagnosis of schizophrenia were included, but also subjects
with schizoaffective disorder [23], first episode of psychosis [21,24] and resistant
schizophrenia [19]. The omega-3 supplementation has been administered in a dosage
ranging from 1–4 g/day. The duration of the trials has been limited to 8–16 weeks in
the majority of the studies. The main issue is that no conclusions could be drawn
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regarding the medium- to long-term effects of HUFAs in schizophrenia, according to
the findings of the four meta-analysis available on this topic [25–28] (Table 1).
Table 1. Double-blind controlled trials of highly unsaturated fatty acids (HUFAs)
as an add-on strategy in the treatment of schizophrenia. PANSS, Positive and
Negative Syndrome Scale; E-EPA, ethyl-EPA.
Study Drug and Dose Sample TreatmentDuration Results
Peet et al.,
2001 [17]
EPA or DHA 2
g/day 45 patients 12 weeks
Ó psychotic symptoms measured with
PANSS in the group treated with EPA
Peet et al.,




E-EPA 1–4 g/day 115 patients 12 weeks Ó positive symptoms measured with PANSS,
Ó depressive symptoms
Jamilian et al.,
2014 [20] 1 g/day 60 patients 8 weeks
Ó psychotic symptoms measured
with PANSS
Fenton et al.,
2001 [23] ethyl-EPA 3 g/day 87 patients 16 weeks
no significant differences in positive,
negative symptoms, mood or cognition
Berger et al.,
2007 [24] ethyl-EPA 2 g/day 69 patients 12 weeks no efficacy on specific psychotic symptoms
Amminger et al.,
2010 [15]











with FEP 26 weeks
Ó psychotic symptoms measured with
PANSS Ó depressive symptoms Ò
level of functioning
Bentsen et al.,
2013 [22] ethyl-EPA 2 g/day 99 patients 16 weeks Ó impairment of the course of psychosis
Emsley et al.,
2014 [18]
EPA 2 g/day +
DHA 1 g/day +
α-LA 300 mg/day
33 patients 2 years relapse prevention of psychotic symptoms
Emsley et al.,
2002 [29] ethyl-EPA 3 g/day 40 patients 12 weeks
Ó positive symptoms and negative symptoms
measured with PANSS
Abbreviations: EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid;
ethyl-EPA = ethyl-eicosapentaenoic acid; α-LA = α-lipoic acid; UHR = ultra-high-risk;
FEP = first episode of psychosis; Ó = decrease of; Ò = increase of.
Peet and colleagues [17] performed a 12-week placebo-controlled trial in
30 males and 15 females on stable antipsychotic medication who were still
symptomatic. Only 35 patients completed the trial. The authors found that EPA
was more effective at the reduction of symptoms as assessed with the Positive and
Negative Syndrome Scale (PANSS) in comparison to DHA and placebo. In the
same year, Peet and colleagues [17] conducted a second RCT to test EPA (dose:
2 g/day) as a monotherapy for schizophrenia. Thirty patients who never assumed
an antipsychotic agent with a recent diagnosis of schizophrenia were recruited.
For ethical reasons, antipsychotic medications were permitted, so at the end of the
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study, only two patients remained without an antipsychotic treatment. The results
indicated that patients treated with EPA, but also antipsychotics, improved more than
placebo-treated subjects in psychopathology measured with the PANSS. In 2002, Peet
and Horrobin [19] administered ethyl-EPA to patients with resistant schizophrenia
for 12 weeks. One hundred and fifteen subjects, who were already in treatment
with clozapine, olanzapine, risperidone, quetiapine or a neuroleptic, were randomly
assigned to placebo or 1, 2 or 4 g/day of ethyl-EPA arm in addition to antipsychotic
drugs. Authors reported a significant improvement of the PANSS total score and
subscales scores in the 2 g/day EPA-treated group, but there was also a large effect
of placebo in patients receiving only typical or new generation antipsychotics. In
contrast, in patients on clozapine, there was little placebo response, but a significant
effect of augmentation with ethyl-EPA on all rating scales, PANSS, PANSS subscales
and the Montgomery-Asberg Depression Rating Scale (MADRS).
More recently, Jamilian and colleagues [20] compared 1 g/day of non-specified
omega-3 with placebo in 60 patients with schizophrenia who already assumed a
standard antipsychotic medication. Omega-3 outperformed placebo significantly,
based on the PANSS score.
Less encouraging findings were presented by Fenton and colleagues [23] who
designed a 16-week study to evaluate the efficacy of ethyl-EPA (3 g/day) vs. placebo
in 87 patients with schizophrenia or schizoaffective disorder with residual symptoms
in treatment with conventional antipsychotics. The results indicated no significant
differences in positive or negative symptoms, mood and cognition. Similar results
were reported by Berger and colleagues [24], who performed an RCT including
69 patients with first-episode psychosis who were treated for 12 weeks with a
flexible dose of antipsychotic medication (risperidone, olanzapine or quetiapine)
plus ethyl-EPA (E-EPA) (2 g/day) or placebo. The authors suggested that E-EPA may
accelerate treatment response and ameliorate the tolerability of antipsychotics, but
they remained skeptical about the specific efficacy of EPA in early psychosis.
Early treatment of the prodromal period of psychotic disorders has been linked
to more favorable outcomes. The term ‘ultra-high-risk’ (UHR) identifies individuals
who are at increased risk of developing full blown psychotic symptoms. Treatment
with omega-3 HUFAs may be an interesting treatment option for UHR subjects due
to the low incidence of adverse effects.
Amminger and colleagues [15] performed an RCT on 76 individuals with high
risk for developing psychosis comparing omega-3 HUFAs (1.2 g/day) to placebo
during a period of 12 weeks. This phase was followed by a further 40-week
monitoring period. This study showed that fatty acids may prevent the progression
in psychosis in young UHR patients. Recently, in a multicenter double-blind
randomized study, 304 participants meeting the ‘at-risk’ criteria were allocated to
treatment with either omega-3 plus cognitive-behavioral case management (CBCM)
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or placebo plus CBCM. The total length of treatment was six months. The data
collected are still under evaluation [16].
Another recent RCT was designed by Pawelczyk et al. [21] to compare the
efficacy of 2.2 g/day of HUFAs or olive oil placebo added on to an antipsychotic
medication with regard to symptom severity in patients suffering from first-episode
schizophrenia. An improvement in psychopathology and the level of functioning
was observed.
In the last few years, the first placebo-controlled trial on the association of
omega-3 fatty acid and redox regulators for treating schizophrenia was conducted
for 16 weeks by Bentsen and colleagues [22]. The participants were 99 patients
with a diagnosis of schizophrenia or related psychoses who were divided in four
groups (double placebo, active vitamins, active EPA or double active). The psychotic
symptoms were assessed with PANSS. The results showed that adding E-EPA 2 g/day
or vitamin E 364 mg¨ day/1 plus vitamin C 1000 mg/day to antipsychotic drugs
prevented the course of psychosis, but only among patients with low levels of
erythrocyte HUFAs. On the contrary, combining EPA and the vitamins neutralized
this detrimental effect. Emsley and colleagues [18] tested a combination of omega-3
polyunsaturated fatty acids (EPA 2 g/day and DHA 1 g/day) and a metabolic
antioxidant, alpha-lipoic acid (α-LA 300 mg/day), as prevention treatment of
relapse after antipsychotic discontinuation in subjects who were successfully treated
for 2–3 years after a first-episode of schizophrenia or schizoaffective disorder.
Unfortunately, this study was affected by a small sample size and by premature
termination of recruitment due to the high relapse rates and the severity of the relapse
episodes. Finally, the results failed to support evidence that HUFAs + α-LA could be
a worthwhile tool to maintenance antipsychotic treatment in relapse prevention.
Emsley et al. [29,30] also investigated the efficacy of long-chain fatty acids in
reducing side effects due to conventional antipsychotic treatment in two randomized
controlled trials. In particular, they verified the effects of omega-3 fatty acids
supplementation on extrapyramidal symptoms. The first study [29] found some
beneficial effects of E-EPA (3 g/day) as add-on treatment in 40 patients with
chronic schizophrenia, who had received a stable antipsychotic medication for at
least six months on extrapyramidal symptoms assessed with the Extrapyramidal
Symptoms Rating Scale. Moreover, the authors in this study also found a significant
improvement of positive and negative symptoms measured with the PANSS.
Unfortunately, the second study [30], disconfirmed these results in a larger sample
of 77 patients with schizophrenia or schizoaffective disorders and tardive dyskinesia.
In this trial, patients received E-EPA (2 g/day) or placebo for 12 weeks. The E-EPA
arm had an initial improvement in dyskinesia, but this result was not stable beyond
six weeks.
100
Four meta-analyses [25–28] of RCTs were conducted in order to establish if
the available data support the use of omega-3 fatty acids in patients affected by
schizophrenia or other psychotic disorders. The authors concluded that the evidence
in favor of omega-3s as psychotropic agents in schizophrenia is preliminary, and the
findings remain yet inconclusive.
2.2. Major Depressive Disorder
In 1998, Hibbeln [31] discovered a direct and powerful inverse association
between fish consumption and the prevalence of major depression in a study aimed
to test the hypothesis that a high consumption of fish could be correlated with a
lower annual prevalence of major depression. One year later, it was established that
depression often co-occurs with cardiovascular disease, which is associated with
elevated cholesterol and lower fatty acids plasma levels [32]. After this discovery,
abnormal fatty acid compositions in the peripheral tissues (e.g., plasma, serum and
red blood cells) of patients with depression have been reported extensively [33,34].
Twenty randomized controlled trials were conducted in order to evaluate the
effectiveness of omega-3, EPA and DHA, in the treatment of mild or moderate
depressive disorder. Fatty acids were administered both as a monotherapy and as
supplementation to ongoing pharmacotherapy or psychotherapy. Doses ranged
from 0.4–4.4 g/day of EPA and from 0.2–2.4 g/day of DHA. Ten RCTs investigated
the efficacy of omega-3 fatty acids as an individual treatment strategy, but only
seven of them reported that EPA and/or DHA had a positive effect on core
depressive symptoms. Seven RCTs aimed to determine whether administering
omega-3 fatty acids provides any additional benefit to conventional patient treatment
(e.g., fluoxetine, citalopram or sertraline) for major depression. Five of these studies
obtained a significant improvement of depressive symptoms [35–39]. However,
the validity of these findings is limited by the heterogeneity of methods among
different studies, including the use of unstandardized assessment instruments of
depressive symptoms, as well as considerable differences in doses and ratios of
omega-3 fatty acids, the duration of the trials and the demographic and clinical
characteristics of the samples. Further studies are needed to better understand the
mechanisms of the antidepressant effects of HUFAs and to explain the reason for the
discordant results published until now.
Peet and Horrobin [35] conducted a 12-week study that showed improvement
in patients treated with 1 g/day of ethyl-EPA (E-EPA) and who were refractory to
selective serotonin uptake inhibitor monotherapy for major depression. Findings
showed that only 1 g/day of omega-3, but not 2 or 4 g/day, was effective in reducing
depressive symptoms measured with the Hamilton Depression Rating Scale (HDRS),
the MADRS and the Back Depression Inventory (BDI) (effect size: 0.92) in adults
with ongoing depression. Nemets et al. [40] designed a four-week placebo-controlled
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study on 20 subjects already undergoing antidepressant therapy and found better
outcome results in the treatment group with E-EPA at the dosage of 2 g/day.
The effect of omega-3 was significant from the second week of treatment, similarly
to the time of response to antidepressants and resulting in an improvement of
core depressive symptoms on the HDRS. The same authors [41] suggested that
omega-3 may have a therapeutic benefit in 6–12-year-old children with major
depression. Of the 20 patients who entered data analysis, 10 received placebo
and 10 received omega-3 (0.4 g/day of EPA plus 0.2 g/day of DHA) for 16 weeks.
Depression symptoms were assessed with the Childhood Depression Rating Scale,
the Childhood Depression Inventory and the Clinical Global Impression (CGI). Su
and colleagues [36] conducted an eight-week RCT comparing EPA (at the dose
of 4.4 g/day) plus DHA (at the dose of 2.2 g/day) with placebo in augmentation
to antidepressant in 22 patients with major depression. They found encouraging
results: participants who were treated with omega-3 fatty acids had a significantly
lower score of the HDRS. An interesting study on 36 pregnant women with major
depressive disorder [42] compared omega-3 HUFAs monotherapy (2.2 g/day of
EPA plus 1.2 g/day of DHA) with placebo. Twenty-four patients who finished
the trial showed significantly lower depressive symptoms’ ratings on the HDRS,
the Edinburgh Postnatal Depression Scale (EPDS), and the BDI. The findings of this
study are remarkable because omega-3s are preferentially transported to the growing
fetus during pregnancy, which can deplete fatty acid levels in mothers.
The beneficial effect of omega-3 fatty acids supplementation on depressive
symptoms was also confirmed in elderly women (aged 66–95 years) residents in a
nursing home [43,44]. Within a context of an eight-week double-blind RCT, 46 women
who received a diagnosis of depression were randomly assigned to the intervention
group (1.67 g/day of EPA plus 0.83 g/day of DHA) or the placebo group. Depressive
symptoms, assessed with the Geriatric Depression Scale, quality of life assessed
with the Short-Form 36-Item Health Survey and phospholipids fatty acids’ profile
improved. Nevertheless, the same authors in another study [45] measured some
immunological parameters and cytokines in the same sample, but they did not find a
significant amelioration of the immunological function in the intervention group.
Currently, there is not a general consensus concerning the efficacy of omega-3s
in the treatment of depression. Rees and colleagues [46] found that omega-3 fatty
acids were not superior over placebo in treating perinatal depressive symptoms.
They administered 0.4 g/day of EPA plus 1.6 g/day of DHA as a monotherapy
to 26 pregnant women for six weeks. Similar results were collected by Freeman
and colleagues [47], who did not detect significant differences between omega-3
HUFAs (EPA 1.1 g/day plus DHA at the dose of 0.8 g/day) and placebo on perinatal
depressive symptoms measured with the HDRS and the EPDS. All 59 women
enrolled in this trial received also a supportive psychotherapy for eight weeks.
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In a similar way, omega-3s were not found superior to placebo in treating
depressive symptoms in three other studies. Marangell et al. [48], Silvers et al. [49]
and Grenyer et al. [50] obtained no significant improvement in the symptoms of
depression in patients who were treated with similar doses of EPA and/or DHA
(ranging 2–3 g/day) as sole therapy or in addition to antidepressive drug. These
studies were different for sample size, duration and instruments to assess depressive
symptoms, but they drew the same conclusions.
Lespérance et al. (2011) [37] conducted an inclusive, double-blind, randomized
controlled trial on 432 patients with a major depressive episode. They administered
EPA (1.050 g/day) and DHA (150 mg/day) for eight weeks to a sample with a
heterogeneous therapy (40.3% of the patients already received an antidepressant at
the baseline). Omega-3 supplementation resulted in being superior over placebo
only for the patients without comorbid anxiety disorders.
Two studies investigated the effectiveness of omega-3s on depression and on
cognitive functions. Rogers et al. [51] in a 12-week trial tested the efficacy of EPA plus
DHA (0.6 g/day + 0.85 g/day) on mood and cognition in 218 patients with mild to
moderate depression. More recently, Antypa and colleagues [52] treated 71 depressed
patients with omega-3 fatty acids or placebo for four weeks. They evaluated cognitive
reactivity with the Leiden Index of Depression Sensitivity-Revised (LEIDS-R) and
the Profile of Mood States (POMS), and depressive symptoms were measured with
the BDI. Both studies have not obtained favorable results on mood and cognition
using omega-3s.
Two trials compared the effectiveness of different doses of EPA or DHA in the
treatment of depressive disorders. Mischoulon and colleagues in 2008 [53] enrolled
35 depressed outpatients that were randomized into one of three double-blind dosing
arms for 12 weeks: 1 g/day DHA; 2 g/day DHA; 4 g/day DHA. In this study,
subjects who received 2 g/day or more DHA had a lower response rate (on the
HDRS) compared to those who received 1 g/day. It is interesting to note that these
findings are similar to Peet and Horrobin’s results [35]: E-EPA, as well as DHA appear
more effective at lower doses. In the same year (2008), Jazayeri and colleagues [38]
compared EPA at the low dosage of 1 g/day with fluoxetine (20 mg/day) in
60 patients with major depressive disorder for eight weeks. The results showed
that a low dose of EPA may have similar therapeutic effects as fluoxetine.
A recent and larger eight-week RCT [54] compared the potential therapeutic
effects of three differing doses, (i) EPA (1 g/day), (ii) DHA (1 g/day) or (iii) placebo
(containing 980 mg of soybean oil per cap; four capsules/day), in 196 depressed
patients. The authors reported a significant improvement in depressive symptoms in
all three groups; neither EPA nor DHA were superior to placebo.
Interesting results were obtained from one study that explored the association
of omega-3 fatty acids and antidepressants in treating depressed patients [39].
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The authors investigated the efficacy of combination therapy with citalopram
plus omega-3 fatty acids (1.8 g/day of EPA + 0.4 g/day of DHA + 0.2 g/day of
other omega-3s) vs. citalopram plus placebo in 42 patients with initial depression.
Combined therapy showed grater improvements in depression symptoms assessed
with HDRS, but did not enhance the speed of antidepressant response.
The effects of fish oil supplementation were also investigated in patients with
major depression associated with coronary heart disease [55]. Carney and colleagues
(2009) obtained negative results testing omega-3 in cardiopathic patients. They
performed a 10-week RCT to evaluate the effects of ethyl-EPA (0.93 g/day) plus DHA
(0.75 g/day) in addition to sertraline on symptoms of depression in 122 patients with
major depressive disorder and coronary heart disease. The authors did not find any
superiority of treatment over placebo.
In conclusion, supplementation with HUFA in patients with major depression
seems useful in improving depressive symptoms, but the findings are not univocal.
Systematic reviews and meta-analyses also provided controversial conclusions.
Appleton and colleagues [56] reviewed 35 RCTs that included 329 adults and
concluded that trials investigating the effects of HUFAs on depression are increasing,
but it is difficult to evaluate their results because of data heterogeneity. Bloch and
Hannestad [57] outlined the methodological limits of available studies that affect the
validity of results. On the contrary, other meta-analyses [58–60] indicated a more
encouraging prospective in this field and concluded that omega-3 fatty acids produce
a significant antidepressant effect. In particular, EPA seems to be more efficacious
than DHA in treating depression. A more recent comprehensive meta-analysis [61]
of RCTs confirmed that the use of omega-3s as therapeutic agents was effective
in patients with the diagnosis of major depression or depressive symptoms and
suggested that patients with greater depressive severity and those meeting full
criteria for a diagnosis of depressive disorder demonstrated greater treatment gains
(Table 2).
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Table 2. Double-blind controlled trials of HUFAs in the treatment of depressive
disorders. HDRS, Hamilton Depression Rating Scale; MADRS, Montgomery-Åsberg
Depression Rating Scale.




ethyl-EPA 1, 2 or 4 g/day
add-on standard
antidepressant treatment




Ó depressive symptoms measured
with HDRS, MADRS and BDI in
the group treated with
1 g/day of HUFAs
Nemets et al.,
2002 [40] ethyl-EPA 2 g/day 20 patients 4 weeks
Ó depressive symptoms measured








Ó depressive symptoms measured
with CDRS, CDI and CGI
Su et al.,
2003 [36]
ethyl-EPA 4.4 g/day + DHA
2.2 g/day add-on existing
antidepressant treatment
22 patients 8 weeks Ó depressive symptomsmeasured with HDRS
Su et al.,
2008 [42]
ethyl-EPA 2.2 g/day +
DHA 1.2 g/day 36 pregnant patients 8 weeks
Ó depressive symptoms measured
with HDRS, EPDS and BDI
Rondanelli et al.,
2010, 2011 [43,44]
EPA 1.67 g/day + DHA
0.83 g/day add-on existing
antidepressant treatment
46 elderly female
residents in a nursing
home
8 weeks
Ó depressive symptoms assessed
with GDS, improvement of
phospholipids fatty acids’ profile
Rees et al.,
2008 [46]
ethyl-EPA 0.4 g/day +





EPA 1.1 g/day +
DHA 0.8 g/day 59 women 8 weeks




EPA 1.050 g/day +
DHA 150 mg/day




Ó depressive symptoms only for
the patients without comorbid
anxiety disorders
Mischoulon et al.,
2008 [53] DHA 1, 2, or 4 g/day 35 patients 12 weeks
measured in the group in
treatment with 1 g/day of HUFAs
Jazayeri et al.,
2008 [38]
EPA 1 g/day vs. fluoxetine





EPA 1 g/day or DHA
1 g/day 196 patients 8 weeks




EPA 1.8 g/day + DHA
0.4 g/day + other omega-3
fatty acids 0.2 g/day +
citalopram vs.
placebo + citalopram
42 patients 9 weeks Ó depressive symptomsmeasured with HDRS
Carney et al.,
2009 [55]
E-EPA (0.93 g/day) plus







10 weeks EPA and DHA were notsuperior to placebo
Abbreviations: EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid;
ethyl-EPA = ethyl-eicosapentaenoic acid; CDRS = Childhood Depression Rating Scale;
CDI = Childhood Depression Inventory; EPDS = Edinburgh Postnatal Depression Scale;
GDS = Geriatric Depression Scale; Ó = decrease of; Ò = increase of.
2.3. Bipolar Disorders
In patients with a diagnosis of bipolar disorder, lower erythrocyte membrane
levels of omega-3 fatty acids have been observed [62]. Based on this consideration,
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several investigators performed clinical trials to evaluate whether the implementation
of these agents may impact the clinical features of this disorder. To date, only seven
RCTs on omega-3 treatment for bipolar disorders have been published. Except
for the first pioneering trial, they were all augmentation studies. Intervention
length ranged from 6–16 weeks. Three of these [63–65] used EPA in addition to
stable psychotropic medication. Two studies [66,67] explored the combination
of EPA and DHA in addition to mood stabilizers or other usual treatments. In
one trial [68], alpha-linolenic acid was administered in association with stable
psychotropic medications. Finally, in one add-on RCT [69], omega-3 was associated
with cytidine or not as augmentation to a stable medication. Doses ranged from
0.3–6.2 g/day of EPA and from 0.2–3.4 g/day of DHA. The dose of alpha-linolenic
acid was 6.6 g/day.
In the first trial, Stoll and colleagues [66] administered a combination of EPA
(6.2 g/day) and DHA (3.4 g/day) as a monotherapy to 14 patients, while 16 patients
received placebo for 16 weeks. This study was affected by a large number (13 subjects)
of drop-outs because of depression, mania, hypomania and mixed state. Outcomes
revealed the efficacy of omega-3 in terms of the reduction and remission of depressive
symptoms (HDRS), whereas no significant effects were registered on mania (Young
Mania Rating Scale (YMRS)). These findings were replicated by Frangou and
colleagues [63] in a 12-week controlled study including 75 patients treated with
ethyl-EPA (1 or 2 g/day) as adjunctive treatment to stable psychotropic medications.
The same authors [64] reported increased brain levels of N-acetyl-aspartate (NAA),
a presumed marker of neuronal integrity, with 2 g/day of ethyl-EPA in 14 female
patients with type I bipolar disorder that were treated with a stable dose of lithium.
The study was controlled with placebo. The rise in NAA level provided the first
evidence for a neurotrophic role of E-EPA treatment in bipolar disorder.
Concerning the manic phase, less encouraging findings were presented by
Chiu et al. [67], who designed a four-week study to evaluate the efficacy of 4.4 g/day
of EPA plus 2.4 g/day of DHA vs. placebo in addition to a fixed dose of valproate
(20 mg/kg/day) in 15 patients with acute mania. The authors found a reduction
in both groups of the YMRS scores from baseline, with no significant differences
between omega-3 and placebo. Similar results were obtained in a larger RCT [65],
which involved 121 patients with bipolar depression or rapid cycling bipolar disorder.
The adjunction of 6 g/day of EPA to at least one mood stabilizer did not produce
meaningful differences in reducing the severity of depressive or manic symptoms,
assessed respectively with the Inventory for Depressive Symptomology total and
the YMRS.
Gracious and colleagues [68] conducted a double-blind RCT of alpha-linoleic
acid (ALA) as flax seed oil in children and adolescents with bipolar I or II disorder,
assuming a stable psychotropic medication. In this study, there was a high rate of
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noncompliance with taking supplements because of the large number of capsules
required (up to 12 per day). Those who were treated with an adequate amount
of ALA, demonstrated a significant improvement of overall symptom severity in
comparison with the placebo group. Nevertheless, depression and mania measures
did not show significant differences between treatment and placebo groups. More
recently, therapeutic properties of omega-3 fatty acids in bipolar disorder were
further denied by Murphy et al. [69] in a four-month RCT. Forty-five patients
with a diagnosis of type I bipolar disorder, who were already treated with a mood
stabilizer, were randomly assigned to three different groups consisting of omega-3
fatty acids plus cytidine, omega-3 fatty acid plus placebo or only placebo. In this
study, supplementation with omega-3 did not produce a significant improvement in
affective symptoms over an extended period of treatment.
Overall, a moderate antidepressant effect was observed for adjunctive omega-3
agents compared to conventional therapy alone in the treatment of bipolar
depression [66,67]. The small number of studies, the heterogeneity of HUFA doses
and ratios and the small sample sizes were important limitations to obtain reliable
data on this topic.
In summary, some beneficial effects of omega-3 HUFAs in bipolar disorders were
observed. The conclusions of systematic reviews and meta-analyses [70–73] provided
initial evidence that bipolar depressive symptoms, but not manic symptoms, may be
improved by adjunctive administration of omega-3 fatty acids (Table 3).
2.4. Anxiety Disorders
The hypothesis that omega-3s may have anxiolytic properties was formulated in
the light of the frequent comorbidity between mood disorders and anxiety disorders
and the effectiveness of some conventional pharmacotherapy on both disorders.
Furthermore, low omega-3 erythrocyte membrane levels have been observed in
patients with anxiety disorders [74–76]. Unfortunately, to our knowledge, there
are no RCTs that have systematically investigated the effect of omega-3 PUFA
in anxiety disorders. Only a small trial [77] showed a reduction in the levels of
anxiety and tension in 24 substance abusers. Participants received 2.2 g of EPA/day
plus 0.5 g of DHA/day vs. placebo (vegetable oil) for three months. Anxiety
continued to be significantly decreased in the active treatment group after three
months’ discontinuation. In each case, the evidence supporting the use of omega-3
PUFAs as an anxiolytic is currently insufficient [78].
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Table 3. Double-blind controlled trials of HUFAs in the treatment of bipolar
disorders (depressive and maniac phases).
Study Dose and Method Sample TreatmentDuration Results
Stoll et al.,
1999 [66]
EPA 6.2 g/day +





ethyl-EPA 1 or 2 g/day
add-on to stable psychotropic
medications
75 patients 12 weeks Ó depressive symptomsmeasured with HDRS
Chiu et al.,
2003 [67]
EPA 4.4 g/day + DHA 2.4
g/day vs. placebo in addition
to valproate 20 mg/kg/day
15 patients with
acute mania 4 weeks
no significant differences




EPA 6 g/day in addition to at





4 months no significant differences
Gracious et al.,
2010 [68]




bipolar I or II disorder
16 weeks
significant improvement of





omega-3 fatty acids plus
cytidine, omega-3 fatty acid
plus placebo or only placebo in
addition to a mood stabilizer
45 patients with type I
bipolar disorder 4 months
no benefits of omega-3 fatty
acids on affective symptoms
Abbreviations: EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid;
ethyl-EPA = ethyl-eicosapentaenoic acid; ALA = α-linoleic acid; Ó = decrease of;
Ò = increase of.
2.5. Obsessive-Compulsive Disorder
Only one RCT about obsessive-compulsive disorder was published by Fux and
colleagues [79], who administered 2 g/day of EPA or placebo in augmentation of
a stable dose of SSRIs to 11 patients (four of these received 40 mg; two received
30 mg; and two received 60 mg of paroxetine daily; one patient was on 250 mg
of fluvoxamine daily; and two were on 40 mg of fluoxetine daily) for six weeks.
The augmentation with HUFAs was not associated with significant improvement of
anxious, obsessive-compulsive and depressive symptoms compared to placebo.
2.6. Attention Deficit Hyperactivity Disorder
Increasing attention has been given to the role of HUFAs in childhood
developmental disorders. Since the 1980s, reduced HUFA levels have been reported
in blood analysis of hyperactive children compared to healthy controls [80–83].
Recently, several double-blind placebo controlled trials have been conducted to assess
the efficacy of omega-3 fatty acid in the treatment of children with ADHD [84–95], but
results are still discordant and disputable. Due to the considerable heterogeneity of
published investigations, additional large-cohort studies and well-designed clinical
trials of ADHD patients are required. In particular, studies should be conducted with
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strict criteria concerning methodological issues, such as an accurate DSM-5 diagnosis
of ADHD, a double-blind controlled design, the choice of reliable assessment
instruments of symptoms and functioning, a clear definition of the doses and ratios
of omega-3 fatty acids and of the possible association with conventional medications.
If we examine the available data, seven [84,85,87–90] of thirteen RCTs
investigating the efficacy of omega-3 fatty acids had a positive effect on
ADHD-related symptoms. The remaining studies did not obtain significant
improvement in ADHD symptoms [81,91–95]. Only two of these thirteen RCTs
aimed to determine whether taking omega-3 fatty acids confers any additional
benefit to conventional patient treatment (stimulant and non-stimulant medications):
one found negative results [91] and one positive [90].
In particular, not very encouraging findings have been presented by six
RCTs comparing the association of EPA and DHA to placebo. In a double-blind
study performed by Stevens and colleagues [81], fifty patients with ADHD-like
symptoms received either placebo (olive oil) or HUFA supplementation (480 mg of
DHA, 80 mg of EPA, 40 mg of arachidonic acid and 96 mg of gamma-linolenic
acid/day) for four months. At baseline and at the end of the intervention
period, both parents and teachers completed the Conners’ Abbreviated Symptom
Questionnaires (ASQ) and the Disruptive Behavior Disorders (DBD) Rating
Scale. Other additional neuropsychological tests were administered: the Conners’
Continuous Performance Test (CPT) and eight tests of cognitive ability of the
Woodcock-Johnson Psycho-Educational Battery-Revised (WJ-R). No significant
difference between active group and placebo was observed for any rating scale
comparing patients who completed the trial. HUFAs supplementation led to a
significant behavioral improvement over placebo on only two of the 16 outcome
measures that were used (DBD-Conduct for Parents and the DBD-Attention for
Teachers) and by intention-to-treat analysis only.
In 2004, Hirayama and colleagues [92] also reported no evidence of efficacy
of omega-3 fatty acids compared to placebo in treating ADHD symptoms. In this
double-blind placebo controlled trial, the majority of the 40 children did not receive
ADHD medications (only six of them had been under conventional medications).
They administered both DHA and EPA through fish oil-enriched food (the daily
dose was approximately 100 mg of EPA and 500 mg of DHA) to twenty children
with ADHD for two months. The control group (n = 20) took indistinguishable food
without fish oil. The authors measured ADHD related symptoms according to the
DSM-IV criteria, aggression, impatience and some cognitive features, but they did
not find any significant changes in outcome measures.
In another study (Johnson and colleagues) [93], seventy-five children and
adolescents 8–18 years old with ADHD were included and treated with 558 mg
EPA, 174 mg DHA and 60 mg gamma linoleic acid daily, compared to placebo.
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Only one of the patients had been previously treated with a conventional
drug for ADHD (methylphenidate). Investigators found that only a subgroup
of patients characterized by the inattentive subtype of ADHD and associated
neurodevelopmental disorders showed a meaningful clinical response to omega-3
and omega-6 treatment. They concluded the study results were essentially negative
and did not support the superiority of HUFAs over placebo.
Milte [94] performed a double-blind RCT, including 90 children 7–12 years old
with ADHD treated with EPA-rich oil (providing 1109 mg of EPA and 108 mg of
DHA), DHA-rich oil (providing 264 mg of EPA and 1032 mg of DHA) vs. an omega-6
HUFA oil during a period of four months. Children were taking no other medication.
Despite that this study demonstrated no statistically-significant differences between
the two groups, the authors found that increased levels of erythrocyte DHA seemed
associated with improved word reading and lower parent ratings of oppositional
behavior. Interestingly, a subgroup of 17 patients with learning difficulties exhibited
superior benefits from the supplementation with omega-3 fatty acids.
A more recent randomized, double-blind controlled trial
(Widenhorn-Müller et al.) [95] was conducted in 95 ADHD patients aged
between six and 12 years who received omega-3 fatty acids or placebo for 16 weeks,
not treated with medications for ADHD. The authors found less negative results
than those from previous studies, but not yet satisfactory. Supplementation with EPA
and DHA (600 mg of EPA and 120 mg of DHA daily) improved working memory
function, but had no effect on other cognitive measures or behavioral symptoms in
the study population.
Only one study concerning the use of DHA has been reported: using a
randomized, double-blind design, Voigt and colleagues [91] tested the effect of
345 mg/day of DHA for four months upon 63 children (6–12 years old) with
ADHD, all receiving maintenance therapy with stimulant medication. Despite blood
phospholipid DHA content being increased in the active treatment group, there
was no statistically-significant improvement in any ADHD symptoms compared
to placebo.
On the other hand, some investigations have provided more promising findings.
In particular, interesting results have been obtained by the seven RCTs in which EPA
and DHA were administered to ADHD patients and compared to placebo.
Richardson and colleagues [84] published a pilot double-blind RCT investigating
the efficacy of the combination of omega-3 and omega-6 fatty acids (daily dose of
186 mg of EPA, 480 mg of DHA, 864 mg of linolenic acid and 42 mg of arachidonic
acid) vs. placebo in 41 children with ADHD-related symptoms and specific learning
disabilities. ADHD-type symptoms were assessed using the Conners’s Teacher
Rating Scale. After 12 weeks of treatment, mean scores for cognitive problems and
general behavior improved more in the group treated with HUFAs than placebo.
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More recently, these findings were replicated by the same authors [85]. They
conducted a larger double-blind placebo controlled RCT, including 117 children
diagnosed with Developmental Coordination Disorder (DCD), which is characterized
by deficit of motor functions and shows substantial overlap with ADHD in terms of
difficulties with organizational skills and attention. The active treatment provided a
high ratio of omega-3 and omega-6 fatty acids for three months. Despite no effects
being reported on motor skills, HUFAs dietary supplementation led to improvement
of reading, spelling and behavior in the treatment group compared to placebo.
Subsequently, a one-way, uncontrolled crossover to active supplement followed for a
further three months: similar changes were observed in the placebo-active group,
while the original treatment group’s scores continued to improve.
Sinn and Bryan (2008) on a large sample included 132 children aged 7–12 years
with a diagnosis of ADHD [86]. Participants were enrolled in a 15-week double-blind
controlled trial and were treated with 93 mg of EPA, 29 mg of DHA and 10 mg of
gamma-linolenic acid daily, with or without a micronutrient supplement, and were
compared to placebo. Children were not treated with ADHD medications. The results
outlined that both groups treated with HUFAs improved more than placebo subjects
in some core ADHD symptoms, such as inattention, hyperactivity and impulsivity.
These results were confirmed by the same authors (Sinn and Bryan) [87] in a 15-week
crossover study.
Bélanger et al. (2009), in a Canadian double-blind, one-way, crossover
randomized trial [88], measured the impact on ADHD of omega-3 HUFAs, using
equivalent quantities of omega-6 HUFAs (sunflower oil) as the control condition.
Thirty seven subjects were enrolled, but only 26 children succeeded in completing the
study. Participants did not receive any other medication. They were divided into two
groups (A and B) and participated in a 16-week, double-blind, one-way, crossover
randomized study. In the first phase, Group A received the n-3 HUFA supplement,
and Group B received placebo. During the second phase, Group B received the
active n-3 HUFA supplement that was continued in Group A. In the first phase of
the study (Weeks 0–15), a meaningful improvement in inattention and global ADHD
symptoms emerged in patients who received omega-3 treatment (20 mg/kg/day–25
mg/kg/day of EPA and 8.5 mg/kg/day–10.5 mg/kg/day of DHA). These positive
results were maintained during the second phase (the treatment crossover, Weeks
16–30) but did not reach in this phase statistical significance.
Kirby et al. [89] have assessed the effects of the administration of 0.8 g/day
fish oil (including 400 mg of DHA and 56 mg of EPA/day) on 450 healthy
school-children. After a period of 16 weeks, the plasma ratio omega-6/omega-3
was measured, and patients were submitted to a series of cognitive tests to assess IQ,
reading, language and writing skills, attention, working memory, impulsivity and
hyperactivity. This RCT showed a significant improvement in impulsivity, evaluated
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with the Matching Familiar Figures Task (MFFT), handwriting and attentional
capacity, evaluated with the Computerized Penmanship Evaluation Tool (COCOM)
and a possible protective effect of omega-3s on behavioral dysregulation, compared
to placebo.
In accordance with these findings, a six-month randomized double-blind
controlled trial by Perera [90] indicated the efficacy of supplementation with a
combined omega-3 and omega-6 preparation vs. placebo in 98 children with
ADHD, refractory to methylphenidate treatment (all participants continued taking
immediate-release methylphenidate during the study). In particular, omega-3
(600 mg/day) combined with omega-6 (360 mg/day) improved behavior and
learning in restlessness, aggressiveness, completing work and academic performance,
but not in inattention, impulsiveness and cooperation with parents and teachers.
A comprehensive meta-analysis conducted by Bloch et al. [96] of omega-3
fatty acids supplementation in children with ADHD found a small to modest
effect size for EPA at high doses. Another recent meta-analysis conducted by
Sonuga-Barke et al. [97] concluded that free fatty acids (omega-3 supplements,
omega-6 supplements and both omega-3 and omega-6 supplements) produce small,
but significant reductions in ADHD symptoms. Besides, it provides evidence
to justify the use of omega-3 fatty acids for ADHD as a supplement to other
empirically-supported therapies. Gillies et al. [98] suggested that the efficacy
of omega-3 fatty acids is supported only in combination with omega-6 fatty
acids. A recent review [99] found that randomized clinical trials with omega-3
HUFAs have reported small-to-modest effects in reducing symptoms of ADHD in
children and that available findings need to be replicated in future investigations of
nonpharmacological interventions in clinical practice (Table 4).
2.7. Autism Spectrum Disorders
The efficacy of HUFAs as a treatment consideration has also been taken
into account in other developmental disorders, such as autism spectrum
disorder [100,101]. There is some evidence to suggest that autism may involve
a cellular functional deficiency or imbalance of omega-3 [100–102]. Studies focused
on the deficit in the concentration of HUFAs complexed to membrane phospholipids
in children with autism showed controversial results. Vancassel and colleagues [102]
examined the concentration of fatty acids in plasma in a population of children
with autism and in another group of children with learning disabilities. This study
reported a 23% reduction of DHA levels in the group with autism compared to the
control group, a reduction in the erythrocytes membrane concentration of omega-3
and a concomitant increase in the levels of saturated fatty acids [100,101].
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Table 4. Double-blind controlled trials of HUFAs in the treatment of ADHD.
Study Dose and Method Sample TreatmentDuration Results
Voigt et al.,
2001 [91]








improvement in any ADHD
symptoms compared to placebo
Richardson et al.,
2002 [84]
EPA 186 mg¨g/day +
DHA 480 mg/die +
linolenic acid 864 mg/die






mean scores for cognitive
problems and general behavior
improved more in the group
treated with HUFAs than placebo
Stevens et al.,
2003 [81]
DHA 480 mg/day + EPA
80 mg/day + arachidonic
acid 40 mg/day +
gamma-linolenic acid 96






no significant difference between
active group and placebo was





EPA 100 mg/die + DHA
500 mg/die vs. placebo;
mostly without ADHD
medications (only six




no evidence of the efficacy of




EPA 558 mg/die + DHA
174 mg/die + gamma
linoleic acid 60 mg/die vs.







no evidence of the efficacy of




EPA 20–25 mg/kg/die +
DHA 8.5–10.5 mg/kg/day
vs. placebo; no ADHD
medications
26 children 16-week
improvement in inattention and
global ADHD symptoms only in





EPA 1109 mg and DHA
108 mg), DHA-rich oil
(providing EPA 264 mg
and DHA 1032 mg) vs. an







differences between the two
groups
Widenhorn-Müller
et al., 2014 [95]
EPA 600 mg/die + DHA







function, but no effect on other
cognitive measures or behavioral




EPA 93 mg/day + DHA 29
mg/day +
gamma-linolenic acid 10






hyperactivity and impulsivity in
most ADHD scales in parents’
reports; no improvement in





Study Dose and Method Sample TreatmentDuration Results
Perera et al.,
2012 [90]







improved behavior and learning
in restlessness, aggressiveness,
completing work and academic




Kirby et al. [89]
DHA 400 mg/day + EPA






attentional capacity and a possible
protective effect of omega-3 on
behavioral dysregulation,
compared to placebo
Abbreviations: EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid.
In addition, some evidence showed that omega-3 may improve the course
of chronic inflammatory diseases [103], frequently associated with autism and
potentially related to its pathophysiology [104].
Considering that data collected from uncontrolled studies are affected by
severe limitations and that only three RCTs are available, evidence is insufficient
at the moment to determine whether HUFAs are effective for autism spectrum
disorder. Actually, only one study [105] supported HUFAs supplementation to
treat autism-related symptoms, while the remaining did not find any positive
effects [106,107].
The first RCT is a double-blind, randomized, placebo-controlled, pilot study,
performed by Amminger in 13 children (aged 5–17 years) with autistic disorder [105].
After six weeks, the group treated with EPA (840 mg/day) and DHA (700 mg/day)
showed an improvement of hyperactivity and stereotyped behaviors.
The second double-blind, placebo-controlled trial was conducted by Voigt [106]
and presented different conclusions. In particular, the authors did not show any
improvement in core symptoms of autism after a dietary DHA supplementation of
200 mg/day for six months in a group of 48 children with autism.
The third randomized, double-blind, placebo-controlled trial was conducted
by Mankad et al. [107]. They designed a six-month trial of omega-3 fatty acid
supplementation (1.5 g of EPA and DHA/day) in comparison with placebo in
38 children (2–5 years old) with autism. This study did not support the hypothesis
that high dose supplementation of HUFAs in children with autism provides any
efficacy in terms of improvement of core symptom domains or adaptive function.
Considering the scarcity of data in this field, we also reported the results from
one case-report and one open-label study performed in patients with autism. The case
report study [108] showed an improvement of symptoms in a child suffering from
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autism following treatment with EPA in the first time administered at a dose of
1 g/day, then at a dose of 3 g/day, for a period of four weeks. During the eight-month
follow-up phase, the improvements were maintained. The open-label study [109]
carried out on 20 autistic children reported a significant improvement of the disease
after three months of treatment with omega-3, omega-6 and omega-9 at a dose of
1 g/day (1 g/day).
To date, one systematic review [110] about the efficacy of HUFAs in the
treatment of autism spectrum disorders is available. The conclusions showed that
the omega-6/omega-3 fatty acid ratio’s alteration during early life can affect major
processes in brain development and induces aberrant behavior. Thus, changes in
dietary omega-6/omega-3 supplies may contribute to reducing the incidence of
symptoms related to autism. So far, the studies are still few and provided limited
results; therefore, further investigations on a larger population are required to draw
conclusions in this field.
2.8. Aggression, Hostility and Impulsivity
In the last two decades, growing attention has been given to the potential role
of omega-3 in clinical conditions characterized by high impulsivity, hostility and
aggressive behaviors [5]. The discovery of low levels of EPA and DHA in the central
nervous system of patients with impulsive-aggressive, self-harm and parasuicidal
behaviors [111,112] has encouraged the investigators to perform trials on omega-3
implementation in this clinical population characterized by a high level of impulsivity
and aggression with favorable results in terms of mood symptoms and control of
impulsivity [113,114].
Two randomized, double-blind, placebo-controlled trials have been performed
to analyze the effects of HUFA supplementation in populations without psychiatric
diagnosis on aggression and impulsivity. Both showed positive results, but available
data are limited by the heterogeneity of the study criteria. The first RCT [113]
was conducted by Hamazaki in a group of 41 healthy controls (21–30 years old)
monitoring the episodes of aggressive behaviors and cognitive functions during
three months. Participants daily received 1.5–1.8 g of DHA or placebo. Aggression
toward others significantly increased in the control group, while it decreased in the
DHA supplement group. No significant differences were observed on cognitive
functions. Another trial was conducted by Itomura et al. (2005) in 166 healthy school
children 9–12 years old in order to investigate whether fatty acid nutrition may
affect physical aggression [114]. Eighty-three children received a fish oil-fortified
diet, providing a daily intake of 3.6 g of DHA and 0.84 of EPA for three months.
Aggression against others and impulsivity were significantly decreased in the fish oil
group, especially in girls.
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In a six-week RCT, Bradbury and colleagues (2004) [115] investigated the
possible role of DHA in improving adaptation to perceived stress in a group of
47 healthy controls (18–60 years). They found a significant reduction in stress for
both the fish oil (1.5 g/day of DHA) and the placebo groups, but the stress reduction
for the fish oil group was significantly superior to that in the no-treatment controls.
The fish oil group obtained a more substantial stress reduction than the olive oil
group, but the differences between treatments did not reach statistical significance.
2.9. Borderline Personality Disorder
The effects of omega-3 fatty acids supplementation has been studied in patients
with personality disorders, who often show high levels of impulsive-behavioral
dyscontrol and aggressiveness. Only two RCTs with a double-blind, randomized,
placebo-controlled design have been conducted [116,117]. Both indicated the efficacy
of HUFAs on borderline personality disorder (BPD) core symptoms, although they
were different in diagnostic criteria, contemporary administration of conventional
medications and the doses and ratios of omega-3 fatty acids.
Zanarini and Frankenburg [116] performed the first RCT in a group of 30 female
patients with a diagnosis of BPD who were treated for eight weeks with 1 g/day
of E-EPA or placebo and without any other psychotropic medication. The results
showed a significant effect of E-EPA on aggressive behaviors measured with the
Modified Overt Aggression Scale (MOAS) and on depressive symptoms assessed
with the Montgomery-Åsberg Depression Rating Scale (MADRS) compared to
placebo. In another study, published by Hallahan and colleagues [117], 49 patients
with self-defeating behaviors (39 patients had received a diagnosis of BPD) were
enrolled. Twenty-seven patients were randomly assigned to placebo, and 22 were
treated with EPA at the dose of 1.2 g/day and DHA at the dose of 0.9 g/day for
12 weeks. Omega-3s were added to the standard psychiatric therapies. This RCT
showed a significant improvement of affect (measured with the Beck Depression
Inventory and the Hamilton for Depression Rating Scale (HDRS)), parasuicidal
behaviors and stress reactivity in the treatment group. Aggressiveness, measured
with the MOAS score, and impulsive behaviors, assessed with the Memory Delay
Task, did not obtain a significant difference in the two groups.
On the basis of this background, our research group performed a RCT in order
to assess the efficacy and tolerability of omega-3 fatty acids in combination with
valproic acid in a group of 43 BPD patients [118] who were randomly assigned to
two treatments for twelve weeks: (1) valproic acid (800–1300 mg/day) (plasma range:
50–100 µg/mL); (2) EPA (1.2 g/day) and DHA (0.6 g/day) in combination with
the same dose of valproic acid. Results indicated that the association of omega-3
fatty acids and valproate was effective in reducing the severity of characteristic
BPD symptoms, measured with the Borderline Personality Disorder Severity Index
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(BPDSI), impulsive behavioral dyscontrol, assessed with the Barratt Impulsiveness
Scale (BIS-11), outbursts of anger, evaluated with the item “outburst of anger” of the
BPDSI, and self-mutilating conduct, measured with the Self-Harm Inventory (SHI)
(Table 5).
Table 5. Double-blind controlled trials of HUFAs in the treatment of impulsivity
and borderline personality disorder.
Study Drug and Dose Sample TreatmentDuration Results
Hamazaki et al.,
1996 [113] DHA 1.5–1.8 g/day
41 healthy controls
(21–30 years) 3 months Ó aggression
Bradbury et al.
(2004) [115] DHA 1.5 g/day
47 healthy controls
(18–60 years) 6 weeks Ó level of stress
Itomura et al.
(2005) [114] DHA 3.6 g/day + EPA 0.84 g/day
166 healthy controls






EPA 1 g/day (with no standard





EPA 1.2 g/day + DHA 0.9 g/day












EPA (1.2 g/day) + DHA
(0.6 g/day) in combination with




43 BPD patients 12 weeks





Abbreviations: EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; ethyl-EPA =
ethyl-eicosapentaenoic acid; BPDSI = Borderline Personality Disorder Severity Index; Ó =
decrease of; Ò = increase of.
2.10. Substance Dependence
According to research, proinflammatory cytokines are responsible for the
physical and psychological symptoms concomitant to craving, and EPA can
neutralize these molecules’ toxic effects in the brain [75,119]. The neuroprotective
effect of omega-3s on the production of serotonin and its action on the prefrontal
cortex may also help with maintaining executive ability, both compromised during
withdrawal and craving. Only two studies have been conducted to assess the
efficacy of omega-3 fatty acid in the treatment of substance dependence [75,120].
The first study [75] evaluated the efficacy of EPA + DHA (3 g/day) for a period of
three months on anxiety symptoms in addicted patients. The group treated with
omega-3s showed a significant reduction in anxiety when compared to placebo.
These results were replicated and confirmed by the following study performed by
the same authors [120].
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2.11. Anorexia Nervosa
Two studies, focused on the deficit in the concentration of HUFAs complexed
to membrane phospholipids in patients with anorexia nervosa, showed similar
results. Holman and colleagues [121] examined the concentration of fatty acids
in plasma in a population of eight hospitalized anorexia nervosa fasting females
compared to 19 healthy female adults <25 years old. Subjects with anorexia nervosa
had deficiencies of essential fatty acids and showed decreased concentrations of
total omega-6 and omega-3 acids, compared to the control group; this indicates
compensatory changes in non-essential fatty acids and can lead to a consequent
problem in terms of membrane structure and fluidity. Furthermore, Langan and
Farrell [122] reported a concomitant significantly reduction of omega-3 and omega-6
in plasma phospholipids’ concentration in a group of 17 patients (16 females, one
male) hospitalized for anorexia nervosa compared to 11 normal females.
Only two trials have been conducted to assess the efficacy of omega-3 fatty acid
in the treatment of anorexia nervosa. In the first pilot open label study, conducted
by Ayton [123], seven patients between 13 and 22 years old with anorexia nervosa,
restrictive subtype, received 1 g/day EPA in addition to standard treatment for three
months. This small study showed a general improvement in sleep, mood, dry skin
and constipation (measured with Weight 4 Height software, the Eating Disorder
Inventory (EDI-2), the Morgan-Russell Average Outcome Scale (MRAOS), BDI-2,
the Children’s Global Assessment Scale (CGA-S) and CGI-S.
Negative results in this clinical population were reported by Barbarich and
collaborators [124]. Twenty six subjects with anorexia nervosa (10 subjects were
restricting-type; six subjects were restricting and purging only-type; and 10 subjects
were binge eating/purging-type) participated in a six-month trial of fluoxetine
(20–60 mg/die). Using a randomized, double-blind design, subjects were assigned to
either nutritional supplements (600 mg of DHA and 180 mg of arachidonic acid daily,
tryptophan, vitamins, minerals) or placebo. Patients were evaluated with: the Frost
Multidimensional Perfectionism Scale (FMPS), the State-Trait Anxiety Inventory
(STAI-Y) and Yale-Brown Obsessive Compulsive Scale (Y-BOCS). They were also
weighed at weekly intervals for the first eight weeks, at two-week intervals for the
following six weeks and at 4-week intervals for a further 12 weeks. There were
no significant differences in weight gain per week between subjects treated with
fluoxetine plus nutritional supplements vs. fluoxetine plus placebo. Moreover,
there were no significant differences between groups in mean changes of anxiety or
obsessive and compulsive symptoms.
3. Adverse Effects
Omega-3 fatty acids did not induce serious adverse effects and were generally
well tolerated: most common side effects reported in clinical trials were nausea and
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a fishy aftertaste, but they were mild and rarely induced discontinuation [125].
The Panel of The European Food Safety Authority (EFSA) concluded that the
available data are insufficient to establish a tolerable daily intake (UL) of DHA, EPA
and DPA individually or in combination, but the supplementation with EPA and
DHA up to 5 g/day is not dangerous for the general population [126]. In particular,
EPA and DHA are generally recognized as safe and well tolerated at dose up to
5 g/day in terms of bleeding risk, as pointed out by Yokoyama et al. [127] and
Tanaka et al. [128]. In addition, doses up to 5 g/day, consumed for a maximum
period of 12–16 weeks, do not significantly affect glucose regulation in both healthy
and diabetic subjects [119,129–131] and do not increase infection risk by the activation
of inappropriate inflammatory responses [132]. The intake of EPA and DHA at the
same dose and up to 16 weeks does not induce alteration of lipid peroxidation and
does not increase cardiovascular risk [133]. Combined intake of EPA and DHA at
the dose of 2–6 g/day and intake of DHA at the dose of 2–4 g/die are responsible
for an LDL concentration increase (3%), but do not affect cardiovascular risk. At last,
an intake of EPA at the maximum dose of 4 g/day does not induce significant changes
in LDL plasma levels [134].
4. Conclusions
In the last decade, the role of long-chain HUFAs in the treatment of several
psychiatric diseases has gradually increased, as confirmed by the growing number
of randomized controlled trials testing the efficacy of essential fatty acid, especially
omega-3 HUFA, supplementation. Nevertheless, an overall consensus about their
efficacy is still lacking, and the findings of most of trials are controversial and
inconclusive. Differences in methods, including sample size, selection criteria, choice
and dosage of fatty acids (i.e., EPA, or DHA, or a combination of the two, or the
addition of omega-6 HUFAs) and the duration of supplementation often make results
not comparable.
The main evidence for the efficacy of EPA and DHA has been obtained in
mood disorders. In particular, omega-3 fatty acids seem to be useful in preventing
and improving depressive symptoms at a low dose of 1 g/day; EPA seems to be
more efficacious than DHA; patients with more severe depression showed greater
treatment gains. However, due to the considerable heterogeneity of the investigations,
additional large cohort studies and well-designed clinical trials are warranted.
Concerning bipolar disorder, the results of systematic reviews and meta-analyses
suggested a potential beneficial role of omega-3 fatty acids in addition to stable
medications in treating depressive symptom at the approximate dose of 1–2 g/day,
but did not support their use in attenuating mania. Furthermore, studies using a
combination of EPA and DHA reported a statistically-significant improvement in
symptoms of bipolar depression, whereas trials using a single compound did not. In
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schizophrenia, little evidence of a meaningful clinical effect was reported, and current
data do not allow us either to refuse or support the use of omega-3 fatty acids in
psychotic patients. However, adverse effects of antipsychotics, in particular metabolic
abnormalities and extrapyramidal symptoms, may benefit from the addition of EPA
or a combination of EPA and DHA. In ADHD disorder, several RCTs have been
performed, but the main findings have reported small-to-modest effects of omega-3
HUFAs in reducing ADHD symptoms in children. Most promising results in this field
have been reached by studies using EPA at high doses or the association of omega-3
and omega-6 fatty acids. Anyway, the relative efficacy of these agents was modest
compared to the currently available pharmacotherapies. To date, a small number
of clinical trials have explored the impact of HUFAs on impulsive and aggressive
behaviors and a growing number of studies has been conducted in order to test the
efficacy of these agents in borderline personality disorder. Results are encouraging,
although this area of psychopathology needs to be explored in depth by future
investigations. In autism spectrum disorders, only two RCTs with opposite results
are available, whereas there is a substantial lack of data about the use of omega-3
fatty acids in anxiety disorders and obsessive-compulsive disorder. The majority of
trials assessing patients with mood disorders did not investigate changes in anxiety
symptoms, although anxiety is frequently associated with depression or mania.
HUFAs were not found efficacious in treating eating disorders and substance use
disorders. Concerning tolerability, RCTs considered in this review share a common
finding: omega-3 fatty acids did not induce serious adverse effects. A survey of
studies concluded that omega-3 are generally recognized as safe and well tolerated
at doses up to 5 g/day for a maximum period of 12–16 weeks. Several authors
have assessed the effects of omega-3 HUFA administration in terms of bleeding risk,
glucose metabolism, lipid profile, infection risk and cardiovascular function with a
general consensus about their harmlessness.
In summary, preliminary findings on omega-3 fatty acids in psychiatric
populations allow us to consider these naturally-derived and well-tolerated
psychotropic agents as a promising therapeutic tool. However, their efficacy
in treating specific mental disorders or clusters of psychiatric symptoms is not
sufficiently proven, as the findings from studies and reviews are too divergent to
draw any conclusion.
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Paola Bozzatello et al. [1] have done a comprehensive qualitative review of
the potential use of long-chain polyunsaturated fatty acids in the prevention and
treatment of mental disorders. The number of placebo-controlled trials across a range
of mental disorders has surged substantially over the last two decades; however,
only very few well-designed large scale trials have been performed. Therefore, even
in conditions like schizophrenia, depression or attention deficit and hyperactivity
disorders (ADHD) where most omega-3 fatty acid RCTs have been performed, no
final conclusions regarding the use of omega-3 fatty acids can be drawn yet. One of
the key problems of systematic reviews investigating the use of omega-3 fatty acids
in mental disorders is that they have integrated quite diverse phenotypic groups,
e.g., the use of omega-3 fatty acids in controlled treatment trials that also assessed
depressive symptoms included the following different conditions:
Primary diagnosis of adult major depressive disorders (MDD) [2–16]
Depressive episodes in bipolar affective disorders [17–23]
Depression during or post pregnancy (postpartum depression) [24–26]
Depression in non-MDD mood disorders (e.g., premenstrual syndrome,
dysthymia) [27–32]
Depression in other psychiatric conditions (e.g., borderline PD, self-harm,
OCD) [33–37]
Depression in established schizophrenia [2,38]
Depression in Alzheimer’s dementia/mild cognitive impairment [13,39,40]
Depression in Parkinson disease [41]
Depression in medical conditions (cerebro-vascular and metabolic diseases or
cancer) [42–46]
Depressive symptoms in healthy individuals [47–52]
Several meta-analytic reviews have tried to integrate the above-mentioned very
heterogeneous controlled treatment trials investigating the effects of omega-3 fatty
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acids on mood symptoms [53–59]. Most meta-analysis including RCTs investigating
depressive syndromes confirmed a statistical significant effect in favour of omega-3
fatty acids with minimal to moderate effect sizes depending on the selection of studies
(except of one meta-analysis [57]). Effect sizes in favour of omega-3 fatty acids [60] are
larger if RCTs are selected based on (1) a EPA/DHA ratio >60% of the overall omega-3
fatty acid content [54,56] and (2) only RCTs with a primary diagnosis of MDD are
included [54,59]. To our knowledge, only one pilot RCT (n = 20) in children with
a mean age of 10 was performed [61]. Martins et al.’s [54] meta-analysis including
RCTs with primary and secondary MDD found a significant overall SMD = ´0.291
in favour of omega-3 fatty acids, but also detected a marked study heterogeneity and
evidence for publication bias. A more recent meta-analysis by Sublette et al. [56] only
including primary MDD RCTs dichotomized according to a EPA/DHA ratio >60%
of the overall omega-3 fatty acids content found a moderate effect size (SMD = 0.558)
with negligible contribution of random effects or heteroscedasticity. Bloch and
Hannestadl’s meta-analysis [57] including studies with mildly depressed individuals
not meeting criteria for clinical depression could not replicate previous meta-analyses;
however, a sub-analysis restricted to moderate to marked depression confirmed an
SMD of 0.42 in favour of omega-3 fatty acid treatment. It is likely that a single
study by Rogers et al. [27] investigating the effects of omega-3 fatty acids on mild
depressive symptoms in a large non-clinical population was responsible for the
negative overall outcome as the Rogers study accounted for 31.7% of the overall
weight in this particular meta-analysis [62]. Grosso et al. [59] found a SMD = 0.56 for
primary MDD, an SMD = 0.22 for non-primary MDD, and an overall SMD = 0.38 in
favour of omega-3 fatty acid compared to placebo treatment. The above mentioned
meta-analyses suggest that mainly the use of EPA rather than DHA rich formulations
are responsible for the clinical efficacy of omega-3 fatty acids. Unexpected is the
finding that the use of purified or DHA-enriched oils is not successful in treating
depression, postnatal depression or OCD [4,63,64]. This finding is in contrast to the
greater face validity of DHA, which is the major brain omega-3 fatty acids and which
is lower in brain tissue of depressed suicide victims [65].
Two RCTs encompassing a large proportion of patients with refractory
depression highlight the potential use of EPA-enriched omega-3 fatty acids as an
augmentation treatment of antidepressants (potentially via an increase in membrane
fluidity) [2,3]. Two RCTs in populations without a primary MDD provide evidence
of an association between inflammation and omega-3 fatty acids response: (1) A
placebo-controlled trial investigating the positive effects of omega-3 fatty acids on
depressive symptoms and chronic inflammation in haemodialysis patients [66]; and
(2) a study [67] that found a preventive effect of EPA against the development of
depressive symptoms in IFN-alpha-treated hepatitis C virus carriers (associated with
a very high risk of drug-induced depressive symptoms). The latter two studies
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suggest that omega-3 fatty acids rich in EPA may modulate its antidepressant
properties via immune-modulatory strategies, which is of interest in the light of more
recent models of the underlying pathophysiology of a range of mental disorders [68].
A whole range of RCTs have also been performed in schizophrenia and related
disorders. A study in first episode psychosis adolescents demonstrates that omega-3
fatty acids augmentation treatment of antipsychotic medication may result in a better
tolerability (less EPS, less sexual side effects) and faster response to antipsychotic
medication; however, at the end of the three month treatment period, there was
no difference in treatment effects on all primary outcome measures between active
and placebo [69]. The final outcome of this study is in line with a meta-analysis of
Dr. Fusar-Poli and the author of this commentary coming to the conclusion that
omega-3 fatty acids in established (but not prodromal) schizophrenia have no or only
minor additional efficacy compared to currently available treatments (also not on
depressive symptoms in schizophrenia) [70], but may have some beneficial effects in
tertiary prevention.
The use of omega-3 fatty acids in primary (indicated) prevention of mental
disorders in general may be a separate important area of omega-3 fatty acid research
that goes beyond the schizophrenia prodrome, and is an avenue yet to be further
explored. A pilot RCT in 81 adolescents at ultra-high risk (UHR) for developing
a psychotic disorder (mean age 16.4) compared 1.2 g of an EPA-enriched omega-3
fatty acids oil as a sole agent with a placebo oil in a double blind fashion [71]. A
total of 27.5% in the placebo group progressed towards a first psychotic episode
compared to only 4.9% in the omega-3 fatty acids group. A recent multinational
multicentre study (the NEURAPRO study [72]) including over 300 UHR adolescents
tried to replicate this promising pilot study. However, the key problem of the
replication study is that the overall transition rate of the study after one year was
as low as 10.5% and the compliance rate of 43% was very poor so that a reasonable
conclusion at this stage of data analysis is not really appropriate [73]. Another
multinational multi-centre omega-3 RCT in prodromal schizophrenia will start in
the near future (the PURPOSE trial). Bozzatello et al. [1] discussed the latter studies
in the schizophrenia section. However, as only 10% to 20% of URH adolescents
will progress to a first psychotic episode within one year and only about half these
first episode cases actually meet criteria for core schizophrenia, it is probably not
correct to discuss URH studies within the schizophrenia section. It may be much
more appropriate to investigate neuroprotective interventions like omega-3 fatty
acids not solely within a schizophrenia concept, but much more in the light of brain
developmental factors and biological relevant markers, such as the inflammatory
markers, the omega-3 index or markers of neuronal damage (e.g., TNF-beta).
The above mentioned small pilot omega-3 RCT in prepubertal children with
childhood-onset depression shows a very large effect size (SMD = 1.2) [61]. Also the
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pilot study in UHR adolescents for psychosis [71] with a mean age of 16.1 showed
large effect sizes. Furthermore, most omega-3 fatty acids RCTs in children were done
in ADHD and show a beneficial effect. Bloch et al.’s meta-analysis [74] including
699 ADHD children of ten RCTs between 7 and 12 years found a beneficial effect in
favour of omega-3 fatty acids with a SMD of 0.31 with no evidence of publication
bias and a significant dose dependency; RCTs using a daily dose of 500 to 750mg EPA
were the most effective ones [75]. Even so, the effect size of stimulant treatment with
methylphenidate, dexamphetamines or atomotexine is still two to four times stronger
compared to omega-3 fatty acids alone, the positive findings of omega-3 fatty acid
studies in children is suggestive that in particular the developing brain may benefit
from omega-3 fatty acids. Future research has to address the question if subgroups
of children with mental disorders may benefit more from benign interventions like
omega-3 fatty acids compared to adults with established (end stage) mental disorders.
For all other mental disorders and associated conditions only limited evidence
exists to promote or refute the use of Omega-3 fatty acids in daily clinical care. As
outlined by Bozzatello et al. [1], there is some evidence that omega-3 fatty acids
augmentation may have some beneficial effects in bipolar affective disorders [17],
in particular against depressive symptoms [19,76]. Furthermore, EPA-enriched
omega-3 fatty acids may also attenuate impulsivity in patients with Borderline
Personality Disorder [35,77] and incarcerated young males [78]. The latter findings
may be of particular importance for male pediatric MDD individuals that sometimes
present with impulsive and aggressive behaviour rather than sadness [25]. A recently
published trial in adolescents with conduct disorders highlights the importance to
implement long study durations (e.g., one year) to be able to demonstrate potential
positive effects of omega-3 fatty acids on difficult to treat behavioural traits [79].
Worth mentioning is a recent RCT in premenstrual syndrome (PMS) showing
some beneficial effects on depression, nervousness, anxiety, lack of concentration
and a reduction of somatic symptoms such as bloating, headaches and breast
tenderness [32]. These studies need replication, but point towards important
phenotypic features that may benefit from omega-3 fatty acids, such as impulsivity.
We may consider more complex trial designs to address the questions if omega-3 fatty
acids may be of importance across a whole range of mental disorders, in particular
in childhood and adolescents and for certain phenotypic features.
The underlying mechanisms of the potential preventive and therapeutic actions
of omega-3 fatty acids against mental disorder are still unclear. Preclinical and
clinical data point towards several mechanisms most likely acting in concert [80].
Some of them might be more responsible for short-term, other for postulated
long-term effects of omega-3 fatty acids. There is some preclinical evidence that
Omega-3 fatty acids may modulate the HPA-axis that is suggested to play a role
in a range of mental disorders [81]. Omega-3 fatty acids have shown to attenuate
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stress-related changes in animal models with depressive features [82–85] as well as in
humans [86–88]. Furthermore, Omega-3 fatty acids may influence myelination and
synaptic pruning, important processes for normal pubertal brain development. The
regulation of PUFA metabolism is crucial for both processes [89,90]. Of particular
interest is a preclinical study investigating cognition and behaviour across different
developmental stages. Omega-3 fatty acids deficient diets across consecutive
generations produced a modality-selective and task-dependent impairment in
cognitive and motivated behaviour in adolescence distinct from the deficits observed
in adults [91,92]. Omega-3 fatty acids attenuate such depression-like animal
behaviours during critical periods of brain development [93]. Furthermore, the FADS
haplotype determining LC-PUFAs availability and concentrations in white matter
(WM) showed age-related WM differences in humans (significant age ˆ genotype
interactions, p(corrected) < 0.05). PUFA metabolism is therefore likely to play a
role in disorders of neurodevelopmental origin [94]. Animal models with structural
hippocampal alterations with depression-like and anxiety-like behaviours [95,96]
provide evidence that omega-3 fatty acids have a preventive and neurotrophic effect
against hippocampal changes [97,98]. Omega-3 fatty acids enhance hippocampal cell
viability and are able to protect hippocampal cells from stress-related damage [99].
Monoaminergic transmitter systems are proposed to be involved in the pathogenesis
of many mental disorders. Animal experiments of omega-3 fatty acids deprived
rats provide evidence for an increase in serotonin 2 (5-HT2) and a decrease in
dopamine 2 (D2) receptor density in the frontal cortex, as well as an increased
serotonin turnover in the prefrontal cortex and decreased midbrain tryptophan
hydroxylase-2 expression [100–106]. In humans, omege-3 intake is associated with
an increase in cerebrospinal fluid 5-HIAA release [107,108]. Several lines of evidence
support that Omega-3 fatty acids have immune-modulatory, anti-inflammatory
and pro-resolving properties [109], e.g., via the modulation of pro-inflammatory
omega-6, the promotion of proresolvins, neuroprotectins and anti-inflammatory
mediators [110–112]. Omega-3 fatty acids seem to induce protective in vivo brain
mechanisms against oxidative stress. Ethyl-EPA supplementation is associated with
a marked increase of glutathione, a strong intracellular antioxidant using proton
magnetic resonance spectroscopy in patients with a first-episode psychosis [113].
Another group found similar effects in older patients at risk for depression [114].
Some evidence regarding the measurement of glutathione in peripheral blood is also
suggestive that omega-3 fatty acids may support the antioxidative defence system in
individuals at ultra-high risk for psychosis [115]. Finally, a decrease in membrane
fluidity can affect the rotation and diffusion of proteins and other bio-molecules
within the membrane, thereby affecting the functions of these molecules and
processes. An increase in membrane fluidity results in a more flexible membrane and
facilitates transmission (e.g., in the retina) [116]. In vivo imaging techniques such
136
as diffusion tensor imaging could demonstrate that omega-3 fatty acids are closely
linked to PUFA metabolism [94]. The effect of omega-3 fatty acids on membrane
structure [117] may contribute to its clinical effects, in particular in augmentation
studies. T2-relaxation time normalizes under the influence omega-3 fatty acids
potentially being a signifier of normalization in membrane structure [118]. Future
studies should therefore address if particular markers, such as low baseline levels of
omega-3 fatty acids, increased inflammatory mediators, markers of intact myelination
(e.g., measured with DTI), or a functional glia-neuronal interface (e.g., measured
with MRS) may serve as predictors of omega-3 fatty acid response, in particular in
children and adolescents in the early course of disorders [119]. Bozzatello et al.’s [1]
qualitative and comprehensive review is a contribution to this endeavour and highly
recommended to interested readers.
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Omega-3 Fatty Acids in Modern Parenteral
Nutrition: A Review of the Current Evidence
Stanislaw Klek
Abstract: Intravenous lipid emulsions are an essential component of parenteral
nutrition regimens. Originally employed as an efficient non-glucose energy source to
reduce the adverse effects of high glucose intake and provide essential fatty acids,
lipid emulsions have assumed a larger therapeutic role due to research demonstrating
the effects of omega-3 and omega-6 polyunsaturated fatty acids (PUFA) on key
metabolic functions, including inflammatory and immune response, coagulation,
and cell signaling. Indeed, emerging evidence suggests that the effects of omega-3
PUFA on inflammation and immune response result in meaningful therapeutic
benefits in surgical, cancer, and critically ill patients as well as patients requiring
long-term parenteral nutrition. The present review provides an overview of the
mechanisms of action through which omega-3 and omega-6 PUFA modulate the
immune-inflammatory response and summarizes the current body of evidence
regarding the clinical and pharmacoeconomic benefits of intravenous n-3 fatty
acid-containing lipid emulsions in patients requiring parenteral nutrition.
Reprinted from J. Clin. Med. Cite as: Klek, S. Omega-3 Fatty Acids in Modern
Parenteral Nutrition: A Review of the Current Evidence. J. Clin. Med. 2016, 5, 34.
1. Introduction
Intravenous (IV) lipid emulsions (LE) are an integral component of parenteral
nutrition (PN) regimens. The earliest LE, subsequently referred to as “first generation”
LE, were derived from soybean or cottonseed oil. Soybean oil is rich in omega-6
(n-6) polyunsaturated fatty acids (PUFA) and provides high amounts of linoleic
acid (LA) and moderate amounts of α-linolenic acid (ALA), with an n-6/n-3 ratio of
approximately 7:1 [1–5]. These early emulsions, which were primarily used as an
efficient non-glucose energy source to reduce the adverse effects of high dextrose
intake, have two main functions: to provide a source of energy and supply essential
fatty acids [6].
While the cottonseed oil-based LE (Lipomul, USA) has been permanently
removed from the market [6], the soybean oil-based LE Intralipid® (Fresenius Kabi,
Germany) has been used worldwide since its introduction in 1962 and has been
proven to be a safe and well tolerated emulsion [3,7–10]. However, a potential
disadvantage with existing soybean oil emulsions is their relatively high content of
n-6 PUFA (polyunsaturated fatty acids), in particular LA [2,11,12]. The emergence of
evidence suggesting that n-6 polyunsaturated fatty acids might be pro-inflammatory
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and immunosuppressive led to the development of more complex lipid emulsions
consisting of a mixture of different oils [13]. As a result, the latest generation of n-3
fatty acid-containing LE provide a more balanced combination of n-6 and n-3 fatty
acids, with an n-6/n-3 ratio in the range of 2:1–4:1 [14,15]. For this reason, second and
third generation IVLE contain not only soybean oil but alternative lipid sources such
as medium-chain triglycerides (MCT), olive oil and/or fish oil/n-3 fatty acids [2,5].
In particular, n-3 fatty acid-containing IVLE have received considerable attention
due to their ability to modulate key metabolic functions, including inflammatory
response, coagulation, and cell signaling [5].
The present review provides a brief overview of the mechanisms of action and
the role of n-6 and n-3 PUFA in modulating the immune-inflammatory response. The
subsequent sections summarize the health benefits associated with n-3 long-chain
(LC)-PUFA as well as the available evidence regarding the clinical and economic
advantages of PN with n-3 fatty acids.
2. Classification and Mechanisms of Action
Fatty acids are classified according to their structure, carbon chain length (short,
medium, or long), degree of saturation (number of double bonds), and the location of
double bonds (counted from the methyl carbon of the hydrocarbon chain) [2–6]. As
a common structural feature of all n-3 PUFAs, the double bond closest to the methyl
terminus of the acyl chain of the fatty acid is located on carbon 3 [16]. The parent fatty
acid of the n-3 family is ALA. The active ingredients in fish oil are the n-3 LC-PUFAs,
eicosapentaenoic acid (EPA, C20:5 n-3) and docosahexaenoic acid (DHA, C22:6 n-3),
as well as the n-6 LC-PUFA arachidonic acid (AA, C20:4 n-6). All are involved in
the generation of pro- and anti-inflammatory lipid mediators. While AA exerts a
pro-inflammatory effect, EPA and DHA have the ability to reduce inflammation
through anti-inflammatory and immunomodulatory mechanisms [13,17–19].
The oil obtained from the flesh of oily fish or livers of lean fish is commonly
referred to as “fish oil” and it has the distinctive characteristic of being rich
in n-3 LC-PUFAs [1]. The effects of emulsions described as “fish oil rich” or
“n-3-rich/containing” are attributable to the LC-PUFAs EPA, DHA, and in some
cases ALA. Various oily fish contain different amounts of n-3 fatty acids, as do
the various fish oils. This also applies to the content of EPA and DHA in enteral
and parenteral products; hence, it is important to analyze the ingredients of PN
admixtures to ensure they provide the appropriate amount of EPA and DHA.
In Europe there are currently three available IVLE products containing n-3
LC-PUFAs: Omegaven® (Fresenius Kabi, Germany), Lipoplus®/Lipidem® (B. Braun,
Germany), and SMOFlipid® (Fresenius Kabi, Germany). Omegaven® is a 10% fish
oil emulsion supplement. Lipoplus® contains a mix of 50% MCT, 40% soybean oil,
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and 10% fish oil, and SMOFlipid® is a 4-oil mixture of 30% soybean oil, 30% MCT,
25% olive oil, and 15% fish oil.
3. Fatty Acids: An Overview of Clinical Impact
Fatty acids represent not only a significant energy source and a human body
energy store, but they are also necessary for proper biologic function. Fatty acids are
key structural components of cell membranes (phospholipids), assuring membrane
integrity and fluidity. They also serve as precursors of bioactive mediators such as
eicosanoids (prostaglandins, leukotrienes, and thromboxanes) and steroid hormones
(cholesterol) [1]. Finally, lipids regulate the expression of a variety of genes and
modulate cell signaling pathways (apoptosis, inflammation, and cell-mediated
immune responses). Therefore, lipids can modulate metabolic processes at local,
regional, and distant sites [1].
3.1. Fatty Acids and Immune-Inflammatory Response
Inflammation is part of the complex physiological response to harmful stimuli
such as pathogens, damaged cells, toxins, and irritants [19]. The primary functions of
inflammation are to eliminate the initial cause of injury, launch defense mechanisms,
remove necrotic cells and tissues, and initiate tissue repair [1,19]. Properly regulated
inflammation represents an efficient physiological mechanism that protects the
host from infection and other insults and is thus essential to health. Conversely,
excessive pathological inflammation may cause irreparable damage to host tissues
and ultimately lead to sepsis—the complex systemic inflammatory host response to
an infection [20].
Inflammation can be classified as either acute or chronic according to the
duration of the response. It can also be categorized according to the intensity of
the process. In 1992, the American College of Chest Physicians and the Society of
Critical Care Medicine introduced definitions for systemic inflammatory response
syndrome (SIRS), sepsis, severe sepsis, septic shock, and multiple organ dysfunction
syndrome [21]. SIRS is nonspecific and can be caused by ischemia, inflammation,
trauma, infection, or multiple combined insults. It is defined as two or more of the
following: temperature >38 ˝C (100.4 ˝F) or <36 ˝C (96.8 ˝F), heart rate >90 beats per
minute and/or respiratory rate >20 breaths per minute or arterial carbon dioxide
tension (PaCO2) <32 mm Hg [21]. It is important to recognize that SIRS is not always
related to infection; accordingly, it cannot be treated the same way. Sepsis, by contrast,
always stems from infection; indeed, it is defined as the presence of harmful bacteria
and bacterial toxins in blood and tissues (sepsis = SIRS + infection). Severe sepsis
is a condition in which there is organ dysfunction, hypotension, or hypoperfusion.
If it progresses, septic shock may develop, potentially leading to multiple organ
dysfunction syndrome (formerly known as multiple organ failure) and death.
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During critical illness, increased production of reactive oxygen species and
inflammatory mediators occurs along with a reduction in antioxidant activity, which
is partly due to preexisting nutritional deficiencies and/or suboptimal provision
of clinical nutrition [6]. This state of imbalance can cause tissue damage and may
play an important role in the development of sepsis and multiple organ failure [6].
Therefore, the primary goals of treatment in critically ill patients should be to decrease
the pro-inflammatory response during the catabolic phase of illness and enhance
immune defense mechanisms. PN should always be considered as part of any such
intervention if enteral intervention is impossible or insufficient [22]. The n-3 fatty
acids EPA and DHA exhibit strong anti-hyperinflammatory and immunomodulatory
effects via direct and indirect mechanisms and may thus be of benefit in patients at
risk of hyperinflammation and sepsis [2,13,16].
The incorporation of PUFA into the phospholipids of cell membranes ensures
the maintenance of membrane fluidity and the adequate function of membrane
proteins. Through the formation of membrane rafts, n-3 PUFA are also involved in
the inhibition of tumor growth [23,24]. The ratio of n-6/n-3 PUFA released from
the hydrolysis of membrane phospholipids influences the synthesis of eicosanoid
mediators such as prostaglandins (PGs), thromboxanes (TXs), and leukotrienes (LTs).
The n-6 PUFA AA gives rise to 2-series PGs, TXs, 5-hydroxy-eicosatetraenoic acid
(HETE), and 4-series LTs, thereby contributing to the inflammatory process and
suppressing cell-mediated immunity [25–28]. Conversely, enzymatic conversion of
the n-3 fatty acid EPA results in the production of 3-series PGs and TXs and 5-series
LTs, all of which are less potent than the AA-derived mediators [16,24,28].
The recent discovery of families of novel pro-resolving lipid mediators such
as resolvins, protectins, maresins, and lipoxins has shed new light on the role of
n-3 PUFAs in the inflammatory process [29–32]. Pro-resolving lipid mediators
derived from EPA are designated resolvins of the E series (RvE), while those
derived from DHA are designated resolvins of the D series (RvD) [33]. The latter
include the neuroprotectins/protectins (NPD1/PD1) and the maresins (MaR).
These mediators have been shown to limit neutrophilic infiltration and enhance
macrophage resolution responses, thus playing a role in diseases characterized by
excessive uncontrolled inflammation [34–41]. Notably, their generation is linked to
the fatty acid composition of cellular membranes and can therefore be effectively
increased with n-3 fatty acid supplementation [37].
Exposure of inflammatory cells to n-3 PUFA in vitro attenuates chemotaxis of
human neutrophils and monocytes and decreases expression of certain adhesion
molecules on the surface of monocytes, macrophages, lymphocytes, and endothelial
cells [20]. By coupling with surface or intracellular “fatty acid receptors”, the
LC-PUFA or their oxidized derivatives can regulate gene expression via the activation
of transcription factors such as peroxisome proliferator-activated receptor (PPAR)-γ
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and nuclear factor-kappa B (NF-κB). N-3 LC-PUFA also modulate the inflammatory
processes by inhibiting the production of pro-inflammatory cytokines and other
pro-inflammatory proteins induced via activation of NF-κB in response to exogenous
inflammatory stimuli. It appears that this effect is at least partly mediated by
G-protein coupled cell surface receptors [20,24]. Consequently, the use of EPA
and DHA leads to a more balanced immune response, which may result in faster
resolution of inflammation [4,13,17,18].
4. Physiological Effects and Associated Health Benefits of n-3 LC-PUFA
4.1. Cardioprotective, Antihypertensive, and Antithrombotic Effects
In animal models of atherogenesis, n-3 fatty acids inhibit the hepatic synthesis
of triglycerides [1]. EPA and DHA partly replace AA in membrane phospholipids;
therefore, n-3 fatty acids may improve membrane structure, ligand/receptor binding,
enzyme secretion, antigen presentation, and activation of intracellular signaling
pathways [1]. By reducing the availability of AA-derived fatty acids as a substrate
for eicosanoid synthesis by cyclooxygenase and lipoxygenase in platelets, monocytes,
and macrophages, EPA and DHA delay platelet aggregation and progression of
atherogenesis [10].
Consuming n-3 PUFA from fish oil is beneficial in the prevention of
cardiovascular disease (CVD) and associated complications, as demonstrated by
randomized control trials (RCTs) investigating secondary prevention in heart
disease patients as well as epidemiological studies in populations that traditionally
consume large quantities of sea fish as a part of their daily diet (e.g., Inuit) [42,43].
Potential underlying mechanisms include the inhibition of thrombogenesis and
cytokine-dependent inflammation [42]. At total doses >3 g/day, EPA + DHA
reduces CVD risk factors by decreasing plasma triglycerides, blood pressure, platelet
aggregation, and inflammation and improving vascular reactivity [43].
4.2. Anticancer and Anti-Cachectic Effects and Inhibition of Tumor Growth
N-3 PUFA have been shown to attenuate cell growth and induce apoptosis in a
variety of human cancer cell lines such as colonic, pancreatic, prostate, and breast
cancer [44]. Through their effects on eicosanoid metabolism, n-3 PUFA may also
decrease “sprouting angiogenesis”, suppress endothelial cell proliferation, decrease
tumor micro-vessel density, and even decrease tumor growth [45–49]. Research
indicates that n-3 fatty acids act synergistically with chemotherapeutic agents and
may also be used to enhance tumor radiosensitivity [50–52]. In patients with
cancer-related cachexia, the pro-inflammatory state can be modulated by suppressing
the inflammatory milieu and the release of pro-inflammatory mediators such as
cytokines and prostaglandins by means of fish oil-based preparations, thus allowing
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nutrition to have an anabolic effect [53]. The underlying mechanisms for these effects
include the incorporation of n-3 fatty acids into biological membranes as well as
the modulation of the expression of proteins involved in the regulation of cell cycle
and apoptosis, such as Bcl-2, Bax, and c-Myc [23,45,54]. More studies are needed,
however, to fully assess the effects of n-3 PUFA in cancer treatment and prevention.
4.3. Visual and Cognitive Development
N-3 PUFA may reduce the risk of neurological disorders by influencing
neuronal membranes and the activities of membrane-bound enzymes, receptors, and
transporters [55]. Moreover, EPA and DHA can affect neurotransmission, including
dopaminergic, noradrenergic, serotoninergic, and GABAergic neurotransmission
in specific brain regions [56,57]. DHA, together with AA, is crucial for the
development and maintenance of normal structure and function of the central
nervous system (CNS). During fetal development DHA is taken up via the placenta
and accumulates in the brain where it is required for the proper function of
cholinergic neurotransmission [57–60]. Additionally, DHA may protect the brain
from free radical and reactive oxygen species by enhancing the activity of cerebral
catalase and glutathione peroxidase [61]. DHA may also be important for the efficient
regeneration of axons and dendrites following neuronal injury [55].
The putative effects of n-3 PUFA on CNS function are mediated not only through
an effect on the physicochemical properties of neural membranes but also through
activation of transcription factors such as PPAR-γ [62]. AA, EPA, and DHA play a
major role in protecting neuronal cells in the brain via inhibition of tumor necrosis
factor (TNF)-α synthesis, thereby augmenting acetylcholine and endothelial nitric
oxide (NO) formation and enhancing glucose uptake by neuronal cells, resulting in
improved memory [53]. Epidemiological data suggest that a low dietary intake of
n-3 LC-PUFA is a risk factor for Alzheimer disease [63]. Notably, studies have shown
that the intake of fish oil lowers the risk of dementia by reducing the synthesis of
proinflammatory cytokines and inhibiting the activities of phospholipase A2 and
caspase A1 [64,65].
The effects of EPA and ethyl-EPA intake in schizophrenic patients have been
investigated in a number of RCTs [63]. Overall, the results suggest a potential
benefit; however, due to the limited size and duration of the studies it remains
unknown whether the benefit is clinically meaningful. Research also suggests
that n-3 LC-PUFA may confer a benefit in certain cases of depression; however,
the routine use of n-3 LC-PUFA for the treatment of major depression cannot yet be
recommended. Further research is necessary to establish the efficacy, appropriate
dosing, and active components (EPA, DHA, or both) of n-3 LC-PUFA in patients with
major depression [55].
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4.4. Lipid Metabolism and Insulin Sensitivity
Fish oil supplementation has been shown to produce a clinically significant,
dose-dependent reduction in fasting blood triglycerides and normalize serum
lipid concentrations, including high density lipoproteins (HDL) and low density
lipoproteins (LDL), in patients with hyperlipidemia [66]. Fish oil may also be
beneficial in individuals with diabetes mellitus. In patients with type 2 diabetes,
fish oil lowers triglycerides and raises LDL cholesterol [67]. However, additional
studies are needed to gain a more comprehensive understanding of the role of fish
oil supplementation in type 2 diabetes.
4.5. Inflammatory Disease
Due to their ability to regulate inflammatory processes and cellular responses,
n-3 fatty acids have the potential to affect the development and progression
of a multitude of diseases associated with an inflammatory state, including
rheumatoid arthritis, Crohn’s disease, ulcerative colitis, type-1 diabetes, cystic
fibrosis, asthma, allergic disease, chronic obstructive pulmonary disease, psoriasis,
and multiple sclerosis (reviewed in [20,68,69]). In a rat model of experimental
colitis [70], administration of an n-3 PUFA-enriched parenteral LE decreased colonic
concentrations of pro-inflammatory mediators and attenuated the morphological
and inflammatory consequences of colitis. Although the current state of knowledge
is insufficient to support a clear recommendation for the use of n-3 PUFA in patients
with inflammatory bowel disease, emerging evidence suggests a potential benefit.
Clinical decisions regarding the use of fish oil in such patients should be informed
by due consideration of the available evidence.
4.6. Immune Function
Among other effects, n-3 fatty acids inhibit immune and inflammatory functions
by decreasing lymphocyte proliferation, cytokine production, natural killer (NK)
cell cytotoxicity, and antibody production [71]. Additionally, n-3 fatty acids
suppress neutrophil chemotactic responsiveness to leukotriene B4 [71,72], reduce
antigen-presenting capability, and decrease expression of major histocompatibility
complex II (MHC II) molecules of mononuclear phagocytes [73]. DHA has
been shown to partly restore the oxygen-dependent bactericidal mechanisms of
monocytes [74], and neutrophils treated with EPA and DHA showed enhanced
antiparasitic activity against Plasmodium falciparum [75].
Reports on the effects of different n-3 fatty acids on cytokine secretion and
immune cell activity are somewhat inconsistent. In mice fed a diet rich in EPA, plasma
concentrations of TNF-α were increased [76], whereas others have demonstrated
decreased TNF-α secretion by neutrophils in DHA-fed human volunteers [77].
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Purasiri et al. [78] observed decreased production of interleukin-1 (IL)-1, IL-2,
TNF-α, and interferon-γ by human neutrophils treated with n-3 fatty acids, while
Chavali et al. [76] reported decreased expression of IL-6 and IL-10 by endothelial cells
and monocytes in mice fed an EPA-enriched diet [76]. Diets rich in n-3 fatty acids
have been shown to inhibit lymphocyte activation and modulate antibody production
by B-lymphocytes [71]. Conversely, the proliferative response to T-cell mitogens
was increased by n-3 fatty acids in an animal model of autoimmune disease [79]. In
a rat model of antibody-mediated autoimmune disease, diets low in fat, deficient
in essential fatty acids, or rich in fish omega-3 fatty acids were associated with a
better prognosis and higher survival [80]. In general, n-3 PUFA inhibit NK cell and
lymphokine-activated killer cell activities. DHA feeding inhibited NK cell activity
in healthy men [77]; however, a diet rich in n-3 fatty acids augmented NK cell
cytotoxicity in healthy rats [81].
N-3 and n-6 PUFA differentially influence the plasma free fatty acid profile, with
consequent effects on neutrophil functions [82]. In an open-label randomized study
of septic patients with markedly reduced neutrophil function, patients receiving n-6
lipid infusions experienced persistent or worsening abnormalities in plasma free fatty
acids and impaired neutrophil function, while patients receiving n-3 lipid infusions
showed a rapid switch in the plasma free fatty acid fraction to a predominance of
EPA and DHA over AA, with rapid incorporation of n-3 fatty acids into mononuclear
leukocyte membranes and subsequent suppression of pro-inflammatory cytokine
generation. Additionally, neutrophil function was significantly improved following
administration of n-3 LE [82].
Collectively, these findings suggest that n-3 PUFA have a favorable effect on
immunocompetence and inflammation and may therefore reduce the risk of clinical
sequelae in critically ill septic patients.
5. N-3 Fatty Acids in Parenteral Nutrition—Clinical Benefits
5.1. Preservation of Hepatocellular Integrity During Long-Term PN in Adults and Children
Patients with critical illness, compromised gastrointestinal tract, sepsis, or
recurrent infection who require prolonged PN therapy are at high risk of developing
hepatic complications [83–85]. The long-term use of IVLE, especially at doses
exceeding 1g/kg of body weight per day, is thought to play a role in the etiology
of intestinal failure-associated liver disease (IFALD) [7,86]. Emerging evidence
suggests that reducing the amount of n-6 fatty acids from soybean oil by partial
replacement with n-3 PUFA from fish oil may improve parameters of liver function in
parenterally fed adult and pediatric patients [87–93]. Thus, replacing a pure soybean
oil emulsion by an LE containing soybean oil, MCT, olive oil, and fish oil (resulting
in a lower n-6/n-3 fatty acid ratio of ~2.5:1) appears to be a promising approach [7].
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Indeed, the available evidence supports the use of n-3 PUFA in PN, infused either
as a part of the basic LE or added separately (as a fish oil emulsion supplement).
Studies evaluating both short- and long-term use of n-3 PUFA-containing LE have
demonstrated preserved hepatic integrity and improvements in parameters of liver
function in adult and pediatric patients [7,89,90,94]. Klek et al. investigated the
safety and tolerability of a soybean/MCT/olive oil/fish oil emulsion in patients
with intestinal failure receiving long-term PN. After four weeks of treatment,
measures of liver function (alanine transaminase [ALT], aspartate transaminase [AST],
and total bilirubin) were significantly improved in patients who received the
soybean/MCT/olive oil/fish oil emulsion compared with controls who received a
conventional soybean oil emulsion [7]. Parenteral infusion of n-3 PUFA from fish oil
has also been repeatedly shown to be effective in reversing PN-associated cholestasis
in children when administered alone or in combination with a soybean oil-based
lipid emulsion [95–99].
5.2. Critical Illness
According to the European Society for Clinical Nutrition and Metabolism
(ESPEN) definition, a critically ill patient is a patient developing an intensive
inflammatory response with failure of at least one organ (Sequential Organ Failure
Assessment (SOFA) score >4) necessitating support of organ function during an
ICU episode expected to be longer than three days [100]. Patients admitted to
the intensive care unit (ICU) only for monitoring (typical ICU stay <3 days) are
therefore not representative ICU patients. The aforementioned acute inflammatory
conditions, SIRS, sepsis, and septic shock represent the range of abnormalities during
critical illness.
Numerous studies in ICU patients confirm the clinical value of n-3 PUFA in
critically ill patients. In a multicenter study in 661 critically ill patients with a
Simplified Acute Physiology II Score (SAPS II) >32, Heller et al. demonstrated
that IV fish oil improved survival compared with that predicted by the SAPS II
score and reduced infection rates, antibiotic requirements, and length of stay in a
dose-dependent manner [101]. Consistent with these findings, Mayer et al. concluded,
based on a review of the available evidence, that inclusion of n-3 fatty acids in PN
improves immunologic parameters and length of stay in surgical patients [102].
Finally, in a recent comprehensive meta-analysis of studies evaluating the use of
n-3 PUFA in ICU patients, Manzanares et al. analyzed data from 10 RCTs involving
733 patients and showed that the use of fish oil-containing LE was associated with
significantly fewer infectious complications (RR 0.64; 95% CI, 0.44–0.92; p = 0.02) [103].
Trends toward a reduction in the number of days on mechanical ventilation (weighted
mean difference [WMD] ´1.14; 95% CI, ´2.67 to 0.38; p = 0.14; heterogeneity I2 = 0%)
and the length of hospital stay (WMD ´3.71; 95% CI, ´9.31 to 1.88; p = 0.19) were
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also reported. However, there was no significant effect on ICU length of stay (WMD
´1.42; 95% CI, ´4.53 to 1.69; p = 0.37) or mortality (RR 0.90; 95% CI, 0.67–1.20;
p = 0.46; heterogeneity I2 = 0%). In a subgroup analysis of trials including patients
who received IV n-3 PUFA in combination with enteral nutrition (EN) [104–107],
a trend toward a reduction in mortality was observed (RR 0.69; 95% CI, 0.40–1.18;
p = 0.18; heterogeneity I2 = 35%) [103].
According to the ESPEN Guidelines on Parenteral Nutrition in Intensive
Care, the addition of EPA and DHA to lipid emulsions has demonstrable effects
on cell membranes and inflammatory processes, and fish oil-enriched LEs likely
decrease the length of hospital stay in critically ill patients (grade B) [100].
Canadian recommendations endorse the use of second generation LE when PN
is indicated [108].
5.3. Oncology
Preclinical studies have demonstrated that n-3 PUFA can be effective in
preventing the initiation and progression of cancer cells [45]. In the clinical
setting, it was recently shown that fish oil-supplemented PN may help to reduce
inflammation and stabilize energy expenditure in patients with pancreatic cancer [49].
In the same study, fish oil also improved patients’ quality of life (QOL) by
reducing cachexia, increasing appetite, and increasing performance status. In a
separate study, fish oil-containing LE combined with gemcitabine improved the
effectiveness of anti-cancer therapy in patients with advanced pancreatic cancer by
decreasing gemcitabine resistance and improving QOL [49]. However, referring to
a systematic review of the published studies evaluating EPA in cancer patients by
Dewey et al. [109], ESPEN concluded that there was no benefit associated with the
oral administration of EPA in patients with consolidated cachexia [110].
In recent years several well-designed clinical studies assessing the effect of
nutritional intervention with EPA/fish oil in conjunction with antineoplastic therapy
have been published. Positive results have be shown with regard to increased
energy/protein intake and gain/maintenance of body weight/lean body mass
(LBM) [111–113], with evidence to suggest a potential effect on several domains
of health-related quality of life (HRQOL) [113]. Ma et al. recently published a
systematic review examining the effects of n-3 fatty acids in patients with unresectable
pancreatic cancer and reported a significant increase in body weight and LBM
as well as a significant decrease in resting energy expenditure and improved
overall survival (130–259 days vs. 63–130 days) in patients who consumed an oral
nutrition supplement enriched with n-3 fatty acids compared to those who consumed
conventional nutrition [114]. The review concluded that n-3 fatty acids are safe and




Recent studies have shown that the use of LE containing an increased dosage
of n-3 PUFA may improve outcomes in surgical patients [115–120]. Among the
clinical benefits observed in these studies were improvements in liver function
tests [115,116], improvements in measures of immunologic function and inflammatory
response [117,118], decreased length of hospitalization [116,119,120], and a reduced
risk of clinical complications [116]. Moreover, the benefits of n-3 PUFA were
observed when administered preoperatively (three days) [118], postoperatively
(seven days) [116,117,119], or during the entire perioperative period [121]. Based on
these findings, n-3 PUFA-enriched LE administered as a part of PN appear to confer
benefits to selected groups of surgical patients, including those with major trauma
or undergoing extended digestive tract resections or liver transplantation [122].
A summary of recent studies evaluating various IVLE formulations in surgical
patients is presented in Table 1.
Table 1. Latest studies/meta-analyses evaluating the benefits of n-3 PUFA
(polyunsaturated fatty acids) in parenteral nutrition in surgical populations *.
Author Year Population Intervention Duration Result
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fish oil less toxic to liver
when compared to
LCT or olive oil
* Adapted from Klek et al. 2015 [122]. Abbreviations: ICU = intensive care unit;
LCT = long-chain triglycerides; LOS = length of stay; MCT = medium-chain triglycerides;
PN = parenteral nutrition; RCT = randomized clinical trial; SIRS = systemic inflammatory
response syndrome.
Several recent meta-analyses evaluating the clinical benefit of n-3
PUFA-enriched PN in surgical patients showed significant reductions in infectious
complications [123–127], with three of these meta-analyses reporting a significant
reduction in the length of hospital stay in surgical patients who received n-3 fatty
acid-containing LE compared with controls [125–127].
5.5. Safety and Tolerability during Long-Term Use
Data from available studies confirm the safety and tolerability of n-3
PUFA-containing LE during long-term use, regardless of indication [7,91]. In adult
patients with stable intestinal failure requiring long-term PN, beneficial effects
were observed on parameters of liver function and Vitamin E profile following
the administration of a mixed-type LE containing 15% fish oil for four weeks [7].
Safety and tolerability were also demonstrated in 28 children (age, five months
to 11 years) with short bowel syndrome, chronic intestinal pseudo-obstruction, or
congenital disease of the intestinal mucosa who required home PN for at least four
weeks [91]. Finally, a meta-analysis of 23 trials involving 1503 patients found no
evidence of deleterious effects or symptoms of intolerance during long-term use of
fish oil-containing LE during ICU stay or surgical hospitalization [126].
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5.6. Recommended Dosage and Duration of Intervention
According to ESPEN Guidelines on Parenteral Nutrition in Intensive Care,
lipids should be an integral part of the regimen to provide energy and essential fatty
acids in all patients requiring PN [100]. IVLE (LCT, MCT, or mixed emulsions)
can be administered safely at a rate of 0.7–1.5 g/kg over 12 to 24 h [100]. In
the previously mentioned multicenter trial by Heller et al., IV fish oil was safe
and conferred significant clinical benefits when administered to critically ill adults
in doses between 0.1 and 0.2 g/kg/day [101]. Therefore, it seems reasonable
to recommend the administration of fish oil in doses higher than 0.1 g/kg/day.
Studies in surgical patients showed that while short-term (<5 days) administration
of n-3 PUFA influences immune parameters and liver function, postoperative
administration also reduces complication rates and length of stay [118,119]. While
it takes several days for n-3 PUFA to be incorporated in host tissues and influence
the generation of inflammatory mediators, impairment of host defense mechanisms
occurs immediately after surgery. Braga et al. [128] thus concluded based on a
literature review that n-3 PUFA should be given prior to surgery to achieve an
optimum effect. In premature infants, a mixed LE with 15% fish oil administered for
seven to 14 days showed a potential beneficial effect on cholestasis, n-3 fatty acids,
and Vitamin E status [90,92,129].
5.7. Cost-Effectiveness
The cost-effectiveness of omega-3 PUFA-enriched LE is an important
consideration, as acquisition costs for fish oil-containing LE are comparatively higher
than those for pure soybean or MCT/LCT-based emulsions [130]. Nonetheless,
pharmacoeconomic analyses support the supplementation of LE with n-3 PUFA.
Wu et al. demonstrated that fish oil-based LE improves clinical outcomes and
decreases the overall costs of ICU stay compared with standard LE in Chinese
ICU patients (mean savings, ¥10,000) [131]. Additionally, in the most comprehensive
analysis of the cost-effectiveness of LE published to date, Pradelli et al. analyzed
patient outcomes and hospital economic data from Italian, French, German, and UK
hospitals using a discrete event simulation scheme and demonstrated that treatment
costs were entirely offset by reductions in antibiotic use and the length of hospital
stay [132]. Cost savings ranged from €3972 to €4897 per ICU patient and from €561
to €1762 per non-ICU patient [126].
6. Conclusions
Lipids are not only an important energy source, but they also modulate
metabolic processes at local, regional, and distant sites. IVLE are undoubtedly an
indispensable element of PN regimens. Indeed, there is a strong scientific rationale
163
for n-3 PUFA in PN; they improve clinical outcomes in pediatric, surgical, cancer, and
critically ill patients as well as patients requiring long-term PN. Finally, LE-containing
fish oils have a proven safety and tolerability profile and represent a cost-effective
component of PN regimens.
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Is There A Role for Alpha-Linolenic Acid in
the Fetal Programming of Health?
Alicia I. Leikin-Frenkel
Abstract: The role of ω3 alpha linolenic acid (ALA) in the maternal diet during
pregnancy and lactation, and its effect on the prevention of disease and programming
of health in offspring, is largely unknown. Compared to ALA,ω3 docosahexaenoic
(DHA) and eicosapentaenoic (EPA) acids have been more widely researched due
to their direct implication in fetal neural development. In this literature search
we found that ALA, the essential ω3 fatty acid and metabolic precursor of DHA
and EPA has been, paradoxically, almost unexplored. In light of new and evolving
findings, this review proposes that ALA may have an intrinsic role, beyond the role
as metabolic parent of DHA and EPA, during fetal development as a regulator of
gene programming for the prevention of metabolic disease and promotion of health
in offspring.
Reprinted from J. Clin. Med. Cite as: Leikin-Frenkel, A.I. Is There A Role for
Alpha-Linolenic Acid in the Fetal Programming of Health?. J. Clin. Med. 2016,
5, 40.
1. Introduction
More than 80 years ago, Burr et al. [1] described the essential fatty acids (EFA)
linoleic acid (ω6 LA) and alpha linolenic acid (ω3 ALA) in animals. Their research
contributed to the knowledge and concept that normal growth, development and
health in mammals depends on EFA nutritional supply. Both EFA share enzymes like
the ∆6 desaturase and elongases, and, thus, compete as substrates in this metabolic
pathway (Figure 1). The genetic variants of desaturases determine the nutritional
requirements for the supply of fatty acids and consequently, health and/or disease,
as previously reviewed [2,3].
During the course of mammalian development, fatty acids (FA) are transferred
to the fetus through the placenta [4] and their composition depends, to a great
extent, on the maternal diet [5]. Maternal nutrition during pregnancy-lactation can
induce significant changes in body composition, physiology and metabolism in
offspring. Thus, the Fetal Origins Hypothesis was inspired by evidence showing
that adult cardiovascular disease begins through developmental activation of a set
of genes and metabolic pathways in the offspring in response to in utero under- or
over-nutrition [6]. FAs play a primary role in growth and development and it is now
accepted that imbalances in their intake during pregnancy and lactation may result in
permanent changes that affect appetite control, neuroendocrine function and energy
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metabolism in the fetus; thus, influencing the metabolic programming [7]. However,
the roles of EFAs and the mechanisms by which they impact the long-term health of
the offspring remains to be determined [8]. The importance of the FA composition
in the diet and the significant differences between ALA and its metabolic products
DHA and EPA has been spotted both in adults [9] and in maternal diets during
pregnancy [10]. Some recent reviews even reinforce the importance of maternal





morphological placental developments  are  conserved between  species. Therefore, animal models 
can be considered suitable when researching the impact of nutritional FAs on development and their 
long‐term influence on the offspring’s susceptibility to metabolic diseases, including obesity, insulin 





DHA  and  EPA  are  its  downstream  metabolic  products.  The  benefits  of  consumption  or 
supplementation  of  ω3  polyunsaturated  fatty  acids  (PUFAs)  by  adults  on  the  prevention  and 
treatment  of  obesity,  metabolic  syndrome  (MS),  and  cardiovascular  disease  (CVD)  have  been 
reported  [16,17]. Most  of  the  reviewed  studies  were  randomized‐controlled  intervention  trials 
suggesting that supplementation with ω3 PUFA might improve some obesity‐associated metabolic 
syndrome features such as insulin resistance, hypertension and dyslipidemia by decreasing plasma 
triglycerides  [18].  Similarly,  they  also  confer  cardio  protection  by  lowering  blood  pressure  and 
Figure 1. Linoleic (C18:2n-6) and α-Linolenic (C18:3n-3) acid metabolism
and elongation.
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Beyond the existing differences between human and animals, the basic tissue,
physiological and morphological placental developments are conserved between
species. Therefore, animal models can be considered suitable when researching
the impact of nutritional FAs on development and their long-term influence on the
offspring’s susceptibility to metabolic diseases, including obesity, insulin resistance
(IR), and cardiovascular risk [13]. Importantly, when looking for a comprehensive
understanding of the role of nutritional FAs on development for the prevention of
adult disease, a nutrigenetics approach is recommended [14,15].
2. Dietaryω3 Fatty Acids and Health
DHA and EPA: As defined by Burr [1], ALA is the only ω3 essential FA for
mammals, while DHA and EPA are its downstream metabolic products. The
benefits of consumption or supplementation of ω3 polyunsaturated fatty acids
(PUFAs) by adults on the prevention and treatment of obesity, metabolic syndrome
(MS), and cardiovascular disease (CVD) have been reported [16,17]. Most of the
reviewed studies were randomized-controlled intervention trials suggesting that
supplementation withω3 PUFA might improve some obesity-associated metabolic
syndrome features such as insulin resistance, hypertension and dyslipidemia
by decreasing plasma triglycerides [18]. Similarly, they also confer cardio
protection by lowering blood pressure and through their benefits on vascular
and anti-inflammatory properties [19]. The efficacy of ω3 PUFA on reducing
myocardial infarction, arrhythmia, cardiac and sudden death, or stroke is, however,
controversial [20]. Although it is now widely accepted that DHA and EPA have
beneficial effects on CVD, it is not yet clear if these benefits are directly or exclusively
related to DHA and EPA [21,22]. Other benefits of DHA and EPA, such as reversion
of neuropathies, have also been described [23,24] for both plant and marine ω-3 FAs.
ALA: The relationship between ALA and chronic disease is unclear. As
supported by human studies [22–24], high intake of ALA is protective against fatal
ischemic heart disease. In later years, the use of ALA-rich oils deserved attention in
the search for nutritional ways of preventing or ameliorating cardiovascular disease
and metabolic syndrome. Rodriguez-Leyva et al. reported that epidemiological
randomized studies using flaxseed oil as a preventive intervention in a healthy
population or in subjects identified as "at risk" for CVD are missing [25].
Baxheinrich et al. reported the beneficial effects of ALA rich rapeseed oil on
body weight, systemic inflammation and endothelial function in patients with MS
traits [26,27]. These past works showed that providing ALA significantly contributed
to reductions in systolic blood pressure, total cholesterol, LDL-cholesterol and insulin
levels after six months. Moreover, ALA was shown to significantly decrease body fat
mass, as well as improve both vascular function and inflammation.
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The effects of ALA, as well as those of EPA and DHA, on the metabolic syndrome
have been further reviewed by Poudyal et al. [28]. They addressed ALA, DHA and
EPA as individual entities, and provided evidence of potentially independent effects
for each of theω3 FAs on cardiovascular health. These same authors also reported
that the three ω3 FA could each reduce inflammation in cardiac fibrosis and hepatic
steatosis in a high-fat diet induced model of metabolic syndrome in rats. Those
effects were associated to a complete suppression of Stearoyl CoA desaturase (SCD1)
function. In those studies, ALA induced comparatively different FA redistribution
of retroperitoneal fat, skeletal muscle and liver. Furthermore, it was suggested
that the accumulation of theω3 FA in adipose tissue, as well as in skeletal muscle,
may account for their crucial role in the reduction of abdominal fat, inflammation,
dyslipidemia and IR [28]. Conversely, recommendations for ALA intake in pregnant
women for the prevention of metabolic diseases in offspring are limited [29–33].
3. How Efficient Is ALA Conversion to EPA and DHA in Humans?
Dietary ALA is metabolically converted into acetate or CO2 through β-oxidation,
or desaturated and elongated into EPA,ω3 DPA and DHA [34]. ALA conversion to
longer products in tracer studies has been observed in nearly all humans studied
from birth through late middle-aged men and women [34,35].
It is clear that the metabolism of ω3 FA depends on other nutrients, in
particular ω6 FAs, due to their competition for the same enzymes and transport
systems [2]. They also compete for incorporation into more complex lipids that
comprise mammalian tissues, where high levels ofω6 PUFA replace and reduceω3
PUFA levels. Early studies of rat liver microsomes showed that the ∆-6 desaturase
activity measured in vitro was subject to competitive inhibition by other substrates. In
particular, desaturation of ALA toω3 eicosatrienoic acid was shown to be inhibited
by LA and, conversely, LA conversion to ω6 gamma linolenic acid was inhibited by
ALA [36,37].
When studying the impact of ALA on the improvement of the metabolic
syndrome, the following question arises: is the conversion of ALA into EPA and
DHA responsible for the observed effects? This question was addressed by Truong
et al. [32] in relation to genetic variants in the ∆6 desaturase gene (Fads2). Adipose
tissue was used as a biomarker of ALA intake in adult humans, and the authors
showed that high concentrations of ALA in adipose tissue were associated with
lower prevalence ratios of the metabolic syndrome compared to low ALA. Although
an interaction between ALA and Fads2 genotype (T-del) was borderline significant, it
nevertheless suggested that genetic variation may play an important role along with
diet in the development of metabolic syndrome, at least in the studied population.
A variety of models have confirmed that ALA accumulates significantly and is
converted into longer ω3 FA in humans [34]. According to the ISSFAL official
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statement #5, studies in healthy adults showed that supplementing ALA to Western
diets containing LA raises DHA and EPA levels in blood and breast milk [38].
In addition, these and other studies have provided evidence indicating that FA
accumulation is tissue-dependent [38] suggesting that metabolism may be based
upon a tissue-selective need for longerω3 FA, such as DHA.
As claimed by Anderson et al. [39], clarification of ALA’s involvement in health
and disease is essential. Indeed, it is insufficient to assume that ALA exerts its
beneficial effects through conversion to EPA and DHA. More thorough research is
required to identify the differential effects of ALA on metabolic disease like IR and
CVD and to differentiate the possible heterogeneous effects of ALA versus DHA and
EPA. The use of developed animal models such as the ∆6 knockout mouse [40] that
inhibits the conversion of ALA into EPA, and EPA into DHA, could be highly useful
in this regard. No such work has been performed to date.
4. Adults
It has been observed that humans of all ages, from preterm and even fetuses
to adults, convert ALA to DHA. However, the efficiency of conversion seems to
decrease as infants mature [35]. ALA is partitioned to β-oxidation as energy source,
for metabolic conversion to longer PUFA and for incorporation into tissues [39,41,42].
Importantly, studies were also reported in which a significant increase in plasma
DHA levels was achieved by altering the oils in the diet and changing both ALA and
LA content [43].
There seems to be an agreement that the partitioning of ALA towards
β-oxidation in humans is lower in women than in men [44,45], an effect attributed to
estrogen [34], which may explain the higher conversion of ALA to longer-chain PUFA
in women [32,41]. The explanation for the preferred use of ALA for β-oxidation
seems to be the greater affinity of carnitine palmitoyl transferase-1, the rate limiting
enzyme in mitochondrial β-oxidation, for this EFA compared to other PUFA [41].
Most studies examining ALA have been performed in young men. The few studies
focused specifically on women of reproductive age showed that conversion of ALA
to EPA and DHA is 2.5ˆ greater in women compared to age-matched men [43–45].
This is ascribed not only to the differential partitioning towards β-oxidation, but also
to an up-regulation of the translocation of very long metabolic products towards the
peroxisome in women [34]. It has been suggested that ALA conversion increases in
pregnancy, which is supported by data in pregnant rats [44–46].
Clearly, gender differences exist and are of importance when recommending
ω3 FA to men or women and, in this case of the latter, whether they are pregnant
or not [41]. Work performed by Childs and others [46,47] have provided further
support for this concept. The examination of whether there are sex differences in the
long-chainω3 FA response to increased ALA intake in humans showed that women
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have a higher increase than men in the EPA content of plasma phospholipids after six
months. The gender differences in ALA use, metabolism and destination, warrant
further investigation.
5. Fatty Acids Quality and Early Life
Pregnancy is supposed to be a period of high requirement for DHA in humans
due to the fetus’ need for rapid growth and neural development [34]. FA levels in
the embryo and newborn babies are directly associated with maternal FA levels and
composition; therefore, any variation in the maternal intake of FAs susceptible to
genetic variability is pivotal for fetal growth, development and health [47]. There is
some evidence suggesting that the influence of genetic variation in FADS genes on
both circulating and tissue FA profiles, which can influence disease risk, may have
a trans-generational effect [48,49]. Moreover, it has been shown that breastfeeding
also exposes babies to the maternal genetic Fads variations through their effects
on milk quality and quantity of fatty acids that, in turn, affect the baby health and
intelligence quotient [50]. Consequently, these studies show that the influence of
FADS2 polymorphisms in the mother is of uttermost importance for the array of
FAs transferred from mother to child during uterine development and breastfeeding.
This knowledge reinforces the importance of a nutritional adjustment during the
critical perinatal period.
DHA and EPA: The effects of different qualities of dietary FAs during pregnancy
and/or lactation on fetal development and offspring metabolism have been recently
reviewed [7]. Maternal consumption of diets rich inω3 PUFA in particular showed
benefits for the development of offspring and it was even suggested that they
exert epigenetic regulation for the prevention of obesity, insulin resistance and
cardiovascular diseases [51,52]. The consumption of DHA and EPA during crucial
periods of fetal development has beneficial physiologic and metabolic effects on the
health of offspring by protecting them from the onset of metabolic diseases [7,11].
Nevertheless, results in the field are controversial, and the independent effects of
ALA have not been studied enough.
ALA: During pregnancy there is a reduction of DHA in maternal serum
while, at the same time, an increased requirement of DHA and EPA for fetal brain
development [38,49]. The solution to compensate for this supposed imbalance can
be to either provide ALA, the precursor for DHA and EPA, or these end products
directly. Not enough scientific information exists comparing for the benefits of either
supplementation. From the clinical aspect, criticism is raised regarding the claim of
support for fetal cognitive health and brain function improvement associated with
DHA and EPA supplementation [53].
Larque et al. [12] reported a somewhat positive relationship between maternal or
cord serum DHA percentages and cognitive skills in young children. Unfortunately,
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valuable information was missing from this study: ALA is not mentioned amongst
ω3 FAs and the blood FA composition of mothers and/or children was not described.
During the literature search described here, only one study was found indicating
a negative effect of maternal over-consumption of ω3 FAs on life span and auditory
brainstem response in older adult offspring. As in several papers, the term ω3
FA was broadly used, without specifying the dietary FA composition and without
mentioning the specific effects of ALA [54].
6. Perinatal Manipulation of ALA
In relation to perinatal metabolism, significant FA desaturase activities have
been detected in fetuses and preterm infants, indicating the existence of the molecular
pathways at early stages of life [55,56].
Published research regarding the positive effects of DHA and EPA has
been reviewed showing that they are essential for proper fetal development [57].
Supplementation of ω3 PUFA during pregnancy has been linked to decreased
incidence of allergies [58]. An interesting study using flaxseed oil in mice
questions whether ALA provision during gestation and lactation could induce
epigenetic changes in maternal and offspring livers [58]. In this study, the authors
described an interaction between ALA dietary content and the FA metabolism,
through down-regulation of the expression of enzymes involved in the elongation
(Elovl2) and desaturation (Fads1) of FAs in maternal livers. A positive correlation
between Fads2 promoter methylation in maternal livers and offspring livers with
changes in the expression of DNA methyltransferases at day 19 of pregnancy was
described. Even though the work was inconclusive, the authors suggested that the
maternal availability of ALA during gestation-lactation could differentially alter the
metabolism ofω3 andω6 FAs, as well as the epigenetic status of Fads2 in maternal
and offspring’ livers.
Research focusing on ALA content in the maternal diet and the long-term
side effects on metabolic syndrome in the offspring is scarce. Our laboratory has
begun focusing on those effects and showed that maternal dietary enrichment of
ALA, compared to SFA, led to lower body weight gain, liver fat accumulation,
and homeostasis model assessment (HOMA) index, as well as reduced SCD1 in
the adult offspring exposed to a high fat diet [59]. Those results suggested that
the relative increase in dietary ALA during pregnancy and lactation may have the
potential to prevent obesity and insulin resistance in the offspring. Furthermore,
Shomonov-Wagner et al. [60] compared the effects of dietary enrichment in ω3 ALA,
DHA or EPA, compared to saturated fatty acids (SFA). That work showed that SFA,
independent of total fat amount or calories, induced liver lipid accumulation and
IR in offspring at weaning, while ALA was the most efficientω3 FA to prevent the
induced metabolic alterations. That work proposed that not only ALA and SFA have
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divergent effects on IR and liver lipid levels, but also that each of ALA, DHA and
EPA behaved differently. Furthermore, ALA preventive effects were, apparently,
unrelated to its conversion into DHA and EPA. Consequently, we conclude that
ω3 ALA, DHA and EPA should be studied and referred to individually and not
as a group.
Recently published results seem to indicate that ALA, as opposed to SFA,
up-regulates the expression of genes involved in lipid oxidation and in the circadian
rhythm [61].
7. Regulatory Mechanisms
The ω3 FA family seems to have distinct abilities to modulate metabolic
functions and gene expression [62]. Deckelman et al. [63] mentioned that the longer
chain length and higher number of double bonds give these FAs unique properties
and suggested that they relate to modulation of enzymes associated with signaling
pathways/incorporation of EPA and DHA into membrane phospholipids and direct
effects on gene expression, amongst others. However, ALA has not been studied enough,
and the molecular interactions between ALA and genes, are only now beginning to be
described [61].
Maternal dietary enrichment with ALA and the long terms effects on offspring
susceptibility to obesity and metabolic syndrome are an important and urgent subject
waiting to be investigated. Also important to consider are FA-gene interactions.
Based on the literature found, we may assume that ALA has beneficial effects
during gestation, presumably on the prevention of obesity-associated disease in
offspring [61]. Ahmed [64] described a proteomics approach to examine the
regulatory roles of ω3 FAs. By using mice fed high or low ω3 FA containing
diets, some affected proteins were identified related to lipid, glucose and protein
metabolism. Unfortunately their work excluded ALA, but their information hints
at the interaction between FAs and protein targets for the regulation of metabolic
pathways. These results, together with preliminary evolving information, warrant
more studies that would benefit from testing ALA, DHA and EPA separately.
8. Epigenetics
Environmental factors such as diet during fetal development can induce
long-term modifications in the genes of the fetus. Human epidemiological data
and controlled animal studies corroborate the impact of diet in the perinatal period
and its lasting effect on gene expression and metabolism [65]. The question, “how do
FAs influence the establishment of an epigenotype” [66], is intriguing and stimulating.
It is proposed that the peroxisome proliferator-activated receptor alpha (PPARa), an
abundant nuclear receptor transcription factor, may be a candidate to be regulated by
maternal dietary FAs in embryonic life. Wang et al. [67] described the way maternal
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and, possibly, paternal imbalanced over- and under-nutrition may induce epigenetic
modifications. Thus, DNA methylation, histone modification and miRNAs, may
regulate genome activity and gene expression leading to proteins that affect fetal
programming and organ physiology with lifelong consequences, sex-dependent in
some cases. The developmental adaptations that permanently change structure,
physiology and metabolism in offspring would thereby predispose for metabolic
and cardiovascular risk later in adult life. Vickers’s [68] analyzed not only the
in utero, but also the trans-generational, possibilities for epigenetic modifications
and its consequences. Niculescu et al. [58] showed epigenetic modifications induced
specifically by ALA in an in vitro study. ALA was shown to alter the distribution
of cells by influencing cell cycle phases, apoptosis and gene and protein expression
of DNA methyl transferases 1 and 3. However, no modifications in global DNA
methylation were found.
Burdge et al. [69] reviewed the interaction between FAs and the epigenome to
conclude that it is not known, at present, how FAs modify the epigenome. Some of
the existing limitations include the lack of definition of the experimental diets and
the susceptibility of histone deacetylases to inhibition by short chain FAs present in
most experimental diets. Nevertheless, the mechanisms underpinning transmission
of developmental programming urgently require further research.
9. Final Thoughts and Recommendations
The importance ofω3 FAs for the development and long-term health of offspring
is widely recognized. The importance of ALA, specifically, is only now beginning
to be recognized; however, more thorough research is necessary in order to better
understand its independent role in developmental programming.
Based on ongoing research [28,61] we propose here the concept that ALA may
have a role in the programming of health. Specifically, it may have intrinsic regulatory
properties on gene expression during fetal development that extend beyond its simple
metabolic conversion to DHA and EPA.
Although the human conversion of ALA to DHA and EPA is gender-related
and relatively low (up to 4%) [41], a higher consumption of ALA related to LA may
increase it. Besides, individual DHA and EPA are not easily available and expensive.
Moreover, DHA- and EPA-rich fish oil has some health disadvantages [22] due to
contaminating factors such as heavy metals, teratogens, and others.
Due to the widespread use of the general term “ω3 FA”, that is sometimes
misleading, we propose that scientific publications apply a more precise nomenclature
to identify the specific FAs tested (i.e., ALA, DHA, and EPA).
In order to enlarge the understanding of ALA’s role in fetal development and
programming, we recommend to analyze the effects of a maternal diet enriched in
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each of the individualω3 FAs, in simple nutritional animal models that examine the
tissue distribution, as well as gene expression and metabolic outcomes, in offspring.
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Abbreviations
ALA ω3 alpha linolenic acid
FA fatty acid
CVD cardiovascular risk disease
DHA docosahexenoic acid
DPA docosapentenoic acid
EFA essential fatty acid
EPA eicosapentenoic acid
Fads2 gene of ∆6 desaturase enzyme
IR insulin resistance
LA linoleic acid
LDL low density lipoproteins
Ppargc1a/Ppargc1a peroxisome proliferative activated receptor gamma
coactivator1a enzyle and gene, respectively
PUFA polyunsaturated fatty acid
SCD1/Scd1 stearoyl-CoA desaturase 1 enzyme and gene, respectively
SFA saturated fatty acid
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Abstract: Pork is the most widely eaten meat in the world, but typical feeding
practices give it a high omega-6 (n-6) to omega-3 (n-3) fatty acid ratio and make
it a poor source of n-3 fatty acids. Feeding pigs n-3 fatty acids can increase their
contents in pork, and in countries where label claims are permitted, claims can be
met with limited feeding of n-3 fatty acid enrich feedstuffs, provided contributions
of both fat and muscle are included in pork servings. Pork enriched with n-3 fatty
acids is, however, not widely available. Producing and marketing n-3 fatty acid
enriched pork requires regulatory approval, development costs, quality control costs,
may increase production costs, and enriched pork has to be tracked to retail and
sold for a premium. Mandatory labelling of the n-6/n-3 ratio and the n-3 fatty acid
content of pork may help drive production of n-3 fatty acid enriched pork, and open
the door to population-based disease prevention polices (i.e., food tax to provide
incentives to improve production practices). A shift from the status-quo, however,
will require stronger signals along the value chain indicating production of n-3 fatty
acid enriched pork is an industry priority.
Reprinted from J. Clin. Med. Cite as: Dugan, M.E.R.; Vahmani, P.; Turner, T.D.;
Mapiye, C.; Juárez, M.; Prieto, N.; Beaulieu, A.D.; Zijlstra, R.T.; Patience, J.F.;
Aalhus, J.L. Pork as a Source of Omega-3 (n-3) Fatty Acids. J. Clin. Med. 2015,
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1. Introduction
Over the last century, changes in agricultural production and patterns of food
consumption have led to an increase in the omega-6 (n-6) to omega-3 (n-3) fatty
acid ratio in human diets. The imbalance in the n-6 to n-3 ratio has been associated
with numerous diseases, from cardiovascular and inflammatory diseases to diabetes
and autoimmune disorders, and led to calls for rebalancing the ratio in the food
supply [1]. Pork is the most widely eaten meat world-wide, accounting for 38%
of meat production and over 36% of meat intake in the world [2]. Enriching pork
among other meats represents a viable means to increase n-3 fatty acid consumption
in humans, while leading to concomitant reductions in fatty acids associated with
adverse health outcomes (e.g., saturated fatty acids (SFA)). This may be of particular
importance in populations that do not consume fish or marine products, where red
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meat may contribute up to 30% of dietary long chain n-3 fatty acids [3]. The objectives
of the present review are to examine where pork fits in the human diet, the fatty
acid composition of pork, efforts to enrich pork with n-3 fatty acids when feeding
flaxseed, and examination of practical barriers and possible strategies to help drive
n-3 pork development and entry into the food supply.
2. Pork in Human Diets
The apparent link between plasma cholesterol and cardiovascular disease, and
its association with SFA intake, led to recommendations to reduce the intake of SFA
rich foods including red meat [4]. In response, swine industries in several countries
adopted feeding and breeding strategies to reduce the fat content of pork. Results of
these efforts were dramatic, leading to as little as 0.8%–1% intramuscular (marbling)
fat, and increasing to a minimum of 1.5% marbling fat has since been recommended to
ensure palatability [5]. Even at 2% marbling fat, lean pork contains 120–130 calories
per 100 g serving, and only 15% of the calories are from fat. It would take pork
marbling levels of 3%–6% to fall into the maximum recommended range of fat intakes
for humans (20%–35% of dietary energy, Figure 1) [6]. In addition, if retail pork
contains 2% intramuscular fat, the fat typically contains ~35%–40% SFA, equaling
5%–6% of total energy, which is again less than the maximum recommendation of
10% [6]. In light of these facts, and results of a meta-analyses of observational and
epidemiological studies indicating SFA intake is not associated with cardiovascular
disease risk [7,8], recommendations to substitute other protein sources for lean red
meat in the human diet have been questioned [9,10]. On the other hand, even though
the low fat and high protein contents of lean pork make it an excellent whole food
for inclusion in human diets, complete pork carcasses contain ~47% fat [11], and this
fat enters the food supply in the form of sausages, bacon, processed meats, and as
lard in baked goods.
Common indicators of the healthfulness of fatty acid profiles (polyunsaturated
fatty acid (PUFA)/SFA, and n-6/n-3 ratios) indicate there may be existing
opportunities for their rebalancing in pork. In a survey of retail pork in England, the
PUFA/SFA ratio of lean pork was 0.58 [12], which is greater than the 0.4 minimum
recommended by the UK Department of Health [13], but an n-6/n-3 ratio of 7.2:1 was
found, exceeding the recommended ratio of 4:1 [13]. Swine diets used in commercial
intensive production are typically grain based, with the type of grain fed dependent
on local availability and economics. Swine in the US and Canada are typically
fed diets based on corn or small grains (barley/wheat). Juárez et al. [14] fed pigs
on a barley/wheat/soybean based diet for 11 weeks prior to market and found a
longissimus muscle (i.e., the largest steak/chop muscle running the length of the spine)
PUFA/SFA ratio of 0.32 and a n-6/n-3 ratio of 4.5:1. Romans et al. [15] finished pigs
using a typical corn/soybean based diet and found a longissimus muscle PUFA/SFA
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ratio of 0.24 and an n-6/n-3 ratio of 14.3:1. Thus, although lean pork has a desirable
nutrient profile with high protein and low fat, there may still be some health benefit
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Figure 1. Calories in pork fat relative to recommendations for fat consumption.
3. Pork Fatty Acid Composition
Lean pork contains a fairly constant proportion of cell membrane phospholipids,
which are relatively rich in PUFA [16]. Lean pork also contains variable amounts of
neutral lipid, composed mainly of SFA-rich triacyglycerol. The fatty acid composition
of pork can thus be improved by reducing its total fat content, but if the fat content
is too low, it can lead to palatability issues [17]. The composition of pork can
also be influenced by diet, and diet adjustments can be used to improve pork fatty
acid profiles without reducing total fat content [18,19]. Opportunities to use diet to
change the fatty acid composition of meat are species specific, with major differences
found between monogastric and ruminant livestock [20]. Pigs are monogastrics and
categorized as homolipoid organisms [21], meaning their fatty acid composition
closely reflects the fatty acid composition of their diet. In contrast to ruminant
animals, in pigs, fatty acids are not metabolized to any great extent by microbes in
the digestive tract prior to lipid digestion and absorption [20]. This makes pork a
good candidate for enrichment with n-3 fatty acids.
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Contrary to popular assumption, fat in red meats, including pork, is not solely
composed of SFA (Table 1). When Juárez et al. [14] and Turner et al. [22] fed
pigs a barley/wheat/soybean meal based diet, the longissimus muscle (denuded
of epimysium and closely associated adipose tissue) was found to contain 2.9% total
fat, and the fat contained 39% SFA, 47% monounsaturated fatty acids (MUFA), 11.5%
PUFA, and the PUFA were comprised of 9.4% n-6 and 2.0% n-3 fatty acids. Within
the n-3 fatty acids, α-linolenic acid (LNA, C18:3n-3) was the most concentrated at
22.7 mg/100 g of fresh tissue, and the most abundant long chain (LC) n-3 fatty
acid was docosapentaenoic acid (DPA, C22:5n-3) at 11 mg/100g of fresh tissue.
The LC n-3 fatty acids most widely studied for their health promoting properties
include eicosapentaenoic acid (EPA, C20:5n-3) and docosahexaenoic acid (DHA,
C22:6n-3) [23,24], and are concentrated in oily fish and marine products (e.g.,
microalgae). On the other hand, DPA is an intermediate in the pathway during
DHA synthesis from EPA (Figure 2), and it is the most abundant LC n-3 fatty acid in
meat and adipose tissue of terrestrial animals [25]. Docosapentaenoic acid which is
freely converted between EPA and DHA, may have beneficial health effects on its
own [26]. Consequently, when considering n-3 fatty acid nutrition, particularly in
populations where oily fish or other LC n-3 fatty acid enriched marine products are
not consumed, contributions of DPA made by terrestrial animals should be taken
into consideration [27].
Table 1. Typical fatty acid composition of longissimus muscle and associated tissues
in pork from pigs fed a barley/wheat/soybean meal diet.
Fatty
Acid
mg/100 g Tissue % of Fatty Acids
LM AM + E AM +E + SF
AM +E +
SF + SCF SEM LM AM + E
AM +
E + SF
AM + E +
SF + SCF SEM
C16:0 718 d 1523 c 3033 b 5782 a 227 24.3 24.8 25.6 25.6 0.5
C18:0 378 d 822 c 1740 b 3438 a 128 12.8 c 13.3 bc 14.6 ab 15.2 a 0.5
ΣSFA 1147 d 2458 c 5001 b 9659 a 371 38.8 b 39.9 ab 42.2 a 42.6 a 0.9
C16:1-9c 101 d 191 c 313 b 519 a 25.8 3.39 a 3.09 a 2.66 b 2.29 c 0.12
C18:1-9c 1148 d 2430 c 4627 b 9006 a 357 38.6 39.4 39.2 39.9 0.8
C18:1-11c 116 d 295 c 420 b 667 a 24.0 3.96 b 4.82 a 3.59 c 2.97 d 0.06
ΣMUFA 1409 d 3017 c 5610 b 10652 a 415 47.4 49.0 47.5 47.2 0.9
C18:2n-6 189 d 422 c 822 b 1656 a 51.4 7.07 7.00 7.09 7.39 0.47
C18:3n-6 8.08 c 13.8 c 29.8 b 66.5 a 2.55 0.284ab 0.220 c 0.258 bc 0.295 a 0.012
C20:2n-6 5.54 d 15.5 c 37.2 b 85.9 a 2.28 0.205 d 0.262 c 0.322 b 0.385 a 0.019
C20:3n-6 6.92 d 10.1 c 13.4 b 21.5 a 0.761 0.263 a 0.166 b 0.115 bc 0.095 c 0.020
C20:4n-6 46.0 d 59.7 c 65.8 b 75.4 a 2.03 1.77 a 1.00 b 0.580 c 0.342 c 0.120
C22:4n-6 1.35 d 8.66 c 11.8 b 17.1 a 0.59 0.048 d 0.145 a 0.102 b 0.076 c 0.005
Σn-6 249 d 516 c 950 b 1856 a 55.0 9.36 8.57 8.21 8.29 0.61
C18:3n-3 22.7 c 41.3 c 89.5 b 186 a 8.22 0.818 0.669 0.758 0.824 0.067
C20:3n-3 3.01 c 5.75 c 15.6 b 36.7 a 1.22 0.104 c 0.092 c 0.131 b 0.162 a 0.008
C20:5n-3 6.35 5.26 5.72 7.87 0.68 0.235 a 0.0854 b 0.0484 bc 0.0349 c 0.016
C22:3n-3 5.40 a 0.918 c 1.79 bc 2.52 b 0.50 0.204 a 0.0134 b 0.0141 b 0.0108 b 0.011
C22:5n-3 11.0 d 15.4 c 20.8 b 30.4 a 1.1 0.422 a 0.257 b 0.181 bc 0.137 c 0.029





mg/100 g Tissue % of Fatty Acids
LM AM + E AM +E + SF
AM +E +
SF + SCF SEM LM AM + E
AM +
E + SF
AM + E +
SF + SCF SEM
Σn-3 54.0 c 75.1 c 142 b 276 a 10.8 1.99 a 1.22 b 1.21 b 1.22 b 0.13
ΣPUFA 306 d 596 c 1104 b 2158 a 66 11.5 9.88 9.52 9.63 0.7
TOTAL 2922 d 6140 c 11,795b 22,577 a 821 100 100 100 100 0
n-6/n-3 4.77 b 7.00 a 6.81 a 6.76 a 0.26
PUFA/SFA 0.301 0.250 0.228 0.228 0.025
LM, longissimus muscle; AM + E, all muscles in loin + epimysium; AM + E + SF, AM +
E + seam fat; AM + E + SF + SCF, AM + E + S + subcutaneous fat; SEM, standard error
of the mean. SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA,
polyunsaturated fatty acids. a,b,c For mg/100 g and % data, means within a row with
different superscripts are significantly different at p < 0.05.
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C18:3n‐3  22.7 c  41.3 c  89.5 b  186 a  8.22  0.818  0.669  0.758  0.824  0.067 
C20:3n‐3  3.01 c  5.75 c  15.6 b  36.7 a  1.22  0.104 c  0.092 c  0.131 b  0.162 a  0.008 
C20:5n‐3  6.35  5.26  5.72  7.87  0.68  0.235 a  0.0854 b  0.0484 bc  0.0349 c  0.016 
C22:3n‐3  5.40 a  0.918 c  1.79 bc  2.52 b  0.50  0.204 a  0.0134 b  0.0141 b  0.0108 b  0.011 
C22:5n‐3  11.0 d  15.4 c  20.8 b  30.4 a  1.1  0.422 a  0.257 b  0.181 bc  0.137 c  0.029 
C22:6n‐3  5.45 c  6.42 bc  8.71 b  12.7 a  0.88  0.209 a  0.109 b  0.0773 b  0.0581 b  0.024 
Σn‐3  54.0 c  75.1 c  142 b  276 a  10.8  1.99 a  1.22 b  1.21 b  1.22 b  0.13 
ΣPUFA  306 d  596 c  1104 b  2158 a  66  11.5  9.88  9.52  9.63  0.7 
TOTAL  2922 d  6140 c  11,795 b  22,577 a  821  100  100  100  100  0 
n‐6/n‐3  4.77 b  7.00 a  6.81 a  6.76 a  .26           
PUFA/SFA  0.301  0.250  0.228  0.228  0.025           
LM, longissimus muscle; AM + E, all muscles in loin + epimysium; AM + E + SF, AM + E + seam fat; 
AM + E + SF + SCF, AM + E + S + subcutaneous fat; SEM, standard error of the mean. SFA, saturated 
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Figure 2. Pathways for n-3 fatty acid synthesis. LNA, alpha-linolenic acid; EPA,
eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, docosahexaenoic acid.
The fatty acid composition of pig longissimus is the muscle most reported in
the literature. Scientifically it is expedient to report fatty acid compositions on
pure muscle, but when examining servings of pork, it is important to consider
contributions made by various tissues. When Juárez et al. [14] and Turner et al. [22]
combined longissimus and other muscles in the primal loin cut, including epimysium
and closely associated adipose tissues, the fat content was 6.1% (i.e., increased from
2.9% fat in pure longissimus muscle). When intermuscular (seam) fat was further
included, the fat content of pork increased to 11.8%, and when 5 mm of overlying
backfat was added to complete a commercially trimmed pork chop, the total fat
content increased to 22.6%. The addition of fatty tissues to pure muscle also increased
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the percentage of SFA in total fat, and increased the n-6/n-3 ratio. In addition, when
fatty tissues were included with pure muscle, LNA remained as the most abundant
n-3 fatty acid, but the second most abundant n-3 fatty acid changed from DPA to
eicosatrienoic acid (ETA, C20:3n-3). Despite the reduction in the %PUFA in the fat
because the total fat increased, the actual amount of PUFA on a mg/100 g of fresh
tissue basis increased from 306 mg to 2158 mg, and the n-3 fatty acids increase from
54 to 276 mg per 100g. Knowing the content of n-3 fatty acids in various cuts of
pork is therefore of considerable importance as these help define the pig feeding
practices required to meet label (enrichment) claims for n-3 fatty acids. For example,
in Canada to make a retail label claim for n-3 fatty acid enrichment, a serving of
food must contain at least 300 mg n-3 fatty acids [28]. If the serving only contains
longissimus muscle, the n-3 fatty acid content would need to be increased 5–6 fold
to reach enrichment status. On the other hand, a commercial loin chop (all muscles,
seam and 5 mm of back fat) would likely need limited n-3 fatty acid supplementation
in pig diets to reach 300 mg n-3 fatty acids per serving. Similarly, other higher
fat cuts such as back or side ribs and bacon could also meet this label claim with
limited supplementation.
As previously mentioned, reducing the marbling fat content of lean pork
improves the fatty acid composition by increasing the proportion of PUFA and
the PUFA/SFA ratio. If extra-muscular fatty tissues are then added to pork cuts,
the proportion of SFA goes up (Table 1). As illustrated in Figure 3, however, when
extra-muscular sources of fatty tissue are included in pork cuts, changes in fatty
acid composition are not striking. This is because, even when as little as 2.9%
intramuscular fat is present, the content of SFA rich triacylglycerols are still enough
to overwhelm the contribution made by PUFA rich phospholipids. In practical terms,
the fatty acid profile of pork with enough intramuscular fat to ensure palatability is
not very different from higher fat products such as pork sausage. The difference in
healthfulness is more related to the total fat content rather than the fatty acid profile.
It is also worth re-emphasizing that the most abundant class of fatty acids in pork
are MUFA, and these are the main fatty acids in the heart healthy Mediterranean
diet [29]. Moreover, approximately ~25% of the SFA in pork is stearic acid (C18:0),
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to weaned  pigs  for  8 weeks  and  found  several  fold  increases  in  LNA  and  its  elongation  and 
desaturation  products  in  a  number  of  tissues.  Since  this  time,  a  number  of  studies  have  been 
conducted feeding flaxseed, flaxseed oil or sources of LC n‐3 fatty acids (i.e., fish meal, fish oil, and 
marine algae) and results have been extensively reviewed [16,18,19,35,36]. Cherian et al. [37], Romans 
Figure 3. The percentage of saturated fatty acid (SFA), monounsaturated fatty acid
(MUFA), and polyunsaturated fatty acid (PUFA) in total fatty acids in cuts of pork
loin (LM, longissimus muscle; AM+E all loin muscles + epimysium; AM + E + seam
fat; AM + E + SF + subcutaneous fat).
4. Enriching Pork with n-3 Fatty Acids
4.1. Initial Efforts to Improve Pork Fatty Acid Composition
The idea of modifying the fatty acid composition of pork to make it mor
healthful is not ew. To improve the healthfulness of pork fatty acid profiles,
Koch et al. [31] fed pigs s fflow r oil and achieved larg increases in pork PUFA in
the form of linoleic acid (LA, C18:2n-6). Stewart et al. [32] als fed a diet rich in LA,
and achi v increased PUFA levels in pork and lard. When the LA enriched pork
and foods made with LA enriched lard were fed to young women (aged 19–24) they
significantly lowered total plasma and low- nsity lipoprotein (LDL) cholesterol,
and increased PUFA and red ced SFA and MUFA in plasma lipids and erythrocytes.
The pig diet, however, had n-6/n-3 fatty acid ratios of ~10:1, and with today’s
understanding that lower ratios may impart even further benefits, there have been a
number of studies conducted attempting to increase pork PUFA by increasing the
n-3 fatty acid content.
4.2. Efforts to Increase n-3 Fatty Acids in Pork
The ability o substa ially alte the n-3 fatty acid content of pork was
demonstrated in 1972 by Anderson et al. [33] when studying LNA turnover. Feedi g
20% flaxseed oil for two mo ths to six month old p gs incre sed fat depot
concentrations of LNA from 1% to 15%. Giv n the understanding that increasing
the n-3 fatty cid content of p rk may benefit consumers, and that feeding flaxseed
instead of xtracted flaxs ed oil may reduc input costs, Cunnane et al. [34] fed 5%
ground flaxseed to weaned pigs for 8 weeks and found several fold increases in
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LNA and its elongation and desaturation products in a number of tissues. Since
this time, a number of studies have been conducted feeding flaxseed, flaxseed oil or
sources of LC n-3 fatty acids (i.e., fish meal, fish oil, and marine algae) and results
have been extensively reviewed [16,18,19,35,36]. Cherian et al. [37], Romans et al. [15],
Riley et al. [38] and Ahn et al. [39] conducted intensive studies on the effects of feeding
0 to ~15% flaxseed on pork quality and fatty acid composition, Romans et al. [40]
and Juárez et al. [41] investigated feeding flaxseed for different durations, and
Fontanillas et al. [42] and Huang et al. [43] investigated the evolution of n-3 fatty
acids in pig tissues over the feeding period. Maximum levels of n-3 fatty acid
deposition were comparable with enrichments achieved by Anderson et al. [33]
when feeding flaxseed oil. To date, most studies feeding higher levels of flaxseed
or flaxseed oil have found increased tissue contents of LNA, EPA and DPA, but not
DHA. For example, Martínez-Ramírez et al. [44] found no increase in DHA when
feeding pigs diets containing 7%–10% flaxseed, but interestingly, the amounts of
other LC n-3 fatty acids deposited in pork were independent of whether the flaxseed
was fed early or late in the feeding period. When feeding a limited amount of
flaxseed (~2%), however, Enser et al. [45] found a reduction in the n-6/n-3 ratio
from 9:1 to 5:1 and an increase in DHA. The pathway for n-3 fatty acid synthesis
from LNA to DHA requires delta-6 desaturation in two places (Figure 2), and the
increase in DHA was attributed to the low level of flaxseed supplementation. This
means enough LNA was supplied to provide substrate for delta-6 desaturation to
C18:4n-3, but not enough to out complete for delta-6 desaturase activity later in
the pathway (i.e., conversion of C24:5n-3 to C24:6n-3). Overall, feeding sources
of n-3 fatty acids to pigs increased their content in pork, but results have been
variable, and the differences attributed to the source, amount and type of n-3
fatty acids fed, the duration of feeding, the type of feed processing, the weight
or age of pigs fed and their gender. Nevertheless, Nguyen et al. [46] found the
mathematical relationship between the amount of LNA fed and deposited in pork
was strong within a study (R2 = 0.98), but lower when data from several studies
are incorporated into a regression (R2 = 0.68). Consequently, producers seeking
to develop a strategy to produce n-3 enriched pork will likely be able to achieve
consistency, but a standardized feeding program will be required based on in-house
development rather than solely on strategies reported in the literature.
4.3. An Example of n-3 Enriched Pork and Post-Production Considerations
Results from Juárez et al. [14] and Turner et al. [22] provide an example of
n-3 fatty acid enrichments in pork that might be attained when feeding optimally
processed flaxseed to pigs, and factors that need to be considered when developing
feeding strategies to meet n-3 fatty acid enrichment goals (Table 2). Pigs were fed
a diet containing 10% flaxseed co-extruded 50:50 with field peas to optimize LNA
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digestibility [47]. The diet was fed from 48 to 121 kg body weight over an 11 week
period resulting in increased LNA and total n-3 fatty acids from 0.82 and 1.99% of
total longissimus muscle fatty acids to 5.76 and 8.94% respectively. This translated into
an increase of LNA and total n-3 fatty acids from 22.7 and 54.0 mg per 100 g serving
of pork to 145 and 217 mg respectively. These amounts of n-3 fatty acids would,
however, not qualify for a source claim in a number of countries including Canada
and the European Union, but may have potential in the United States. As mentioned
previously, to be labelled as a source of n-3 fatty acids in Canada, a serving of food
serving has to have 300 mg of total n-3 fatty acids [28]. In the USA, food servings
with ě160 mg or ě320 mg LNA can be referred to as a “source” or “rich” in LNA
respectively, and claims cannot be made for EPA and DHA [48]. In the European
Union, foods with 300 mg LNA or 40 mg combined EPA and DHA per serving
can be labeled as a source of n-3 fatty acids, and foods with 600 mg LNA or 80 mg
combined EPA and DHA can be labeled as rich in n-3 fatty acids [49]. Source claims
in all countries would, however, be possible when all muscles and fatty tissues were
included in a retail pork chop. In fact, the amount of n-3 fatty acids in commercially
trimmed pork chops was 10 times more than required for a source claim in Canada
(3360 mg per 100 g serving) [22]. A source claim for combined EPA and DHA could
also be made in the European Union (71.5 mg), but could only be considered a rich
source if DPA was included in LC n-3 fatty acids (174 mg). The ability to make
a source claim is, therefore, dependent on the country, what tissues are included
in a serving of pork, the type of cut and the n-3 fatty acids considered to be LC.
Consideration should, however, also be given to what consumers actually eat, as
often some external fat may be trimmed before consumption. Therefore, ensuring
consistent n-3 fatty acid enrichment and consumption might be most easily attained
through development of further processed n-3 enriched pork products (e.g., sausages)
and secondary products prepared with enriched lard (e.g., baked goods). Notably,
when fatty tissues are added to pure muscle, the second most abundant n-3 fatty acid
in pork changes from DPA to ETA (up to 381 mg per 100 g serving), and ETA has
been shown to have a photo-protective effect in human skin [50]. There is also some
limited evidence for delta-8 desaturase activity [51], converting ETA to C20:4n-3 in
liver, which may gain importance in LC n-3 fatty acid synthesis as ETA concentrations
increase (Figure 2).
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Table 2. The fatty acid composition of longissimus muscle and associated tissues in
pork from pigs fed a diet supplemented with 10% flaxseed.
Fatty
Acid
mg/100 g Tissue % of Fatty Acids
LM AM + E AM +E + SF
AM +
E + SF +
SCF
SEM LM AM + E AM +E + SF
AM +
E + SF +
SCF
SEM
C16:0 571 d 1180 c 2227 b 4169 a 152 22.1 a 20.1 b 20.5 b 19.8 b 0.3
C18:0 318 d 678 c 1326 b 2545 a 102 12.4 11.7 12.2 12.1 0.3
ΣSFA 931 d 1953 c 3731 b 7040 a 265 36.0 a 33.4 b 34.3 b 33.5 b 0.6
C16:1-9c 66.6 d 113 c 177 b 295 a 12.0 2.59 a 1.94 b 1.68 bc 1.41 c 0.10
C18:1-9c 873 d 1871 c 3380 b 6727 a 218 33.8 a 32.2 b 31.7 b 32.2 b 0.5
C18:1-11c 76.7 d 196 c 265 b 419 a 14.3 3.06 b 3.39 a 2.53 c 2.01 d 0.08
ΣMUFA 1045 d 2259 c 3991 b 7724 a 256 40.7 a 38.9 ab 37.4 bc 36.9 c 0.6
C18:2n-6 225 d 652 c 1207 b 2470 a 55.0 9.68 b 11.4 a 11.5 a 11.9 a 0.34
C18:3n-6 6.38 d 12.8 c 25.1 b 53.0 a 1.54 0.26 0.223 0.236 0.253 0.011
C20:2n-6 6.40 d 24.7 c 47.1 b 106 a 2.75 0.27 b 0.437 a 0.454 a 0.509 a 0.025
C20:3n-6 5.86 c 7.83 bc 10.0 b 15.9 a 0.79 0.26 a 0.141 b 0.099 c 0.076 c 0.012
C20:4n-6 28.2 c 34.3 b 36.6 b 42.3 a 1.9 1.35 a 0.626 b 0.372 c 0.205 c 0.06
C22:4n-6 1.23 c 3.87 b 5.27 b 7.95 a 0.56 0.05ab 0.067 a 0.049 ab 0.037 b 0.007
Σn-6 266 d 723 c 1306 b 2643 a 59 11.6 12.7 12.5 12.7 0.4
C18:3n-3 145 d 614 c 1290 b 2800 a 71 5.76 d 10.6 c 12.1 b 13.4 a 0.30
C20:3n-3 21.5 d 82.2 c 166 b 381 a 11.6 0.85 c 1.42 b 1.55 b 1.82 a 0.053
C20:5n-3 23.3 d 31.9 c 38.8 b 55.3 a 1.7 1.08 a 0.573 b 0.385 c 0.268 c 0.05
C22:3n-3 2.48 b 2.27 b 3.06 b 4.75 a 0.40 0.10 a 0.038 b 0.029 b 0.023 b 0.005
C22:5n-3 21.1 d 39.5 c 59.7 b 102 a 3.0 0.95 a 0.705 b 0.575 c 0.491 c 0.038
C22:6n-3 3.85 d 8.13 c 10.6 b 16.2 a 0.77 0.18 a 0.146 b 0.105 c 0.079 c 0.011
Σn-3 217 d 778 c 1569 b 3360 a 85 8.94 d 13.5 c 14.7 b 16.1 a 0.39
ΣPUFA 486 d 1506 c 2883 b 6018 a 143 20.6 c 26.3 b 27.4 ab 28.9 a 0.7
TOTAL 2519 d 5788 c 10,683 b 20,881 a 627 100 100 100 100 0
n-6/n-3 1.28 a 0.935 b 0.850 c 0.788 c
PUFA/SFA 0.581 b 0.796 a 0.807 a 0.869 a
LM, longissimus muscle; AM+E, all muscles in loin + epimysium; AM + E + SF, AM + E +
seam fat; AM + E + SF + SCF, AM + E + S + subcutaneous fat; SEM, standard error
of the mean. SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA,
polyunsaturated fatty acids. a,b,c For mg/100 g and % data, means within a row with
different superscripts are significantly different at p < 0.05.
Currently, production of pork enriched with n-3 fatty acids is possible, but it
is not clear which n-3 fatty acid should be enriched, to what extent they should
be enriched and in what tissues. Feeding pigs a limited amount of flaxseed can
rebalance the n-6/n-3 ratio in pork [45], but a healthier n-6/n-3 ratio is not something
that can be advertised or put on a label in most countries. Feeding increased amounts
of flaxseed can yield pork that can be labelled as a source, or rich source of n-3 fatty
acids, but if consumers trim visible fat or the fat is lost during cooking, purchased
pork may differ from pork consumed. Even when pork is enriched with enough
n-3 fatty acids to allow for a source claim, beneficial effects of consuming such pork
have not been extensively investigated. Coats et al. [52] found regular consumption
of pork enriched with LC n-3 fatty acids by feeding fish meal increased erythrocyte
DHA by 15%, and compared to a control group, serum triacylglycerol decreased
to a greater extent and thromboxane production increased to a lesser extent. Using
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a rabbit model, Vossen et al. [53] fed pork enriched with LNA or LNA plus LC n-3,
and found only pork enriched with LNA plus LC n-3 fatty acids reduced the total
plasma cholesterol to high-density lipoprotein cholesterol (HDL-C) ratio. Clearly, it
would be of benefit to conduct additional clinical trials to establish the health effects
of consuming commercial pork compared to pork enriched with n-3 fatty acids, and
factors considered should include the n-6/n-3 ratio, the amount and composition of
n-3 fatty acids and the overall fat content of the pork in different meat cuts.
5. Practical Barriers Limiting n-3 Pork Development and Entry into
the Food Supply
5.1. The Call for n-3 Enriched Meat Unfulfilled to Date
Simopoulos [54] indicated that it is essential in the process of returning the
n-3 fatty acids into the food supply, that the balance of n-6/n-3 fatty acids in the
diet that existed during human evolution is maintained. To date fish-meal, flaxseed,
and marine algae in poultry feeds have increased the n-3 fatty acid content of egg
yolks and led to the supply of n-3 fatty acid-enriched eggs in the marketplace [55].
Simopoulos [54] noted research on the production of n-3 fatty acid-enriched products
from poultry, beef, lamb, pork, milk and bakery products was ongoing. Taking
advancements in the ability to enrich animal products with n-3 fatty acids into
account, Givens and Gibbs [56] estimated potential dietary intakes of EPA+DHA from
foods derived from animals fed enriched diets would be ~231 mg/day, which would
double current intakes in the UK, and help meet the recommend intake of 450 mg/day.
Currently, however, in most countries, despite the technological capability to do so,
the availability of n-3 enriched meats, including pork, is not widespread.
5.2. Why Production of n-3 Enriched Pork Has Not Been Adopted
5.2.1. Visibility
When the SFA content of red meat was associated with increased plasma
cholesterol and cardiovascular disease in the 1960s, consumers could visually identify
and select meats with lower fat contents, and animal producers selected and fed
animals to meet consumer demands for leaner meat. In developed countries,
sweeping changes in pork production took place within a value chain geared to
produce commodity pork for mass markets. The cost of pork production and the
retail price of pork were not increased due to changes in production strategies.
Currently, even though the production of n-3 fatty acid enriched meats, including
pork, has been encouraged, changing fat composition in retail pork has not been as
successful as previous efforts to reduce the total fat content of pork. As opposed to the
total fat content, the fatty acid composition of retail pork is not visible to consumers.
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5.2.2. Challenges along the Value Chain
There are several challenges to producing n-3 enriched pork along the value
chain. Increasing the n-3 fatty acid content of pork can lead to increased input costs
depending on feedstuffs available and requirements for processing. Entry into the
n-3 pork market may also have lagged because feeding high levels of n-3 fatty acids
can lead to fat softness and palatability problems [14]. Effects on freshly cooked
pork chops have, however, been limited [14,39,57] and most negative effects have
been found in cooked/reheated pork chops and freshly cooked ground pork with
excessive n-3 fatty acid enrichments. Once n-3 fatty acid enriched pork is produced,
it also requires vertical integration from production to retail, along with differentiated
marketing and higher prices to cover input costs, distribution costs and profits for
producers. Producing n-3 fatty acid enriched pork to meet source claims also requires
regulatory approval for package labelling, defining what will be included in portions,
what production strategies are needed to meet enrichment requirements, and also
added costs for fatty acid analysis of feeds and pork during product development
and for quality control. Strategies to drive an industry-wide shift towards n-3 fatty
acid enriched pork must, therefore, be developed if a clear goal for producers is
widespread production and marketing of n-3 enriched pork.
6. Strategies to Encourage Production and Market Availability of n-3 Fatty
Acid Enriched Pork
Strategies to encourage production and market availability of n-3 fatty acid
enriched pork will likely require concerted efforts along the value chain. Producer
entry into the n-3 fatty acid enriched pork market may be enhanced with the
understanding that only limited supplementation of n-3 fatty acids in diets is required
to meet label claims when contributions of all tissues in a serving are included [22].
This also opens possibilities for feeding oils or oilseeds that may not be as highly
enriched with LNA as flaxseed (e.g., whole canola or canola oil). An industry-wide
shift in pork production practices might also be driven by mandatory labelling of
n-3 fatty acids and the n-6/n-3 ratio in meat, making these visible to consumers.
When consumers know the n-3 fatty acid and n-6/n-3 ratio in foods, it provides
the opportunity to select more healthful foods, and impetus to the industry to find
lower cost production strategies. In this way, pork may not have to reach specified
amounts of n-3 fatty acids to meet regulatory approval as a source of n-3 fatty acids,
but could contribute a greater quantity of n-3 fatty acids to the human diet, and at
the very least, not further imbalance in the n-6/n-3 ratio. Analyzing the fatty acid
composition of pork in the packing house or at retail by traditional means (i.e., gas
chromatography) would not be cost effective or practical, but newer non-invasive
technologies including near infra-red reflectance spectrophotometry (NIRS), NIRS
hyperspectral imaging, or Raman spectroscopy [58–61] may hold promise to deliver
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analyses in seconds versus days, and coupled to new tracking systems, such as radio
frequency identifier tags, may be able to deliver this information to the consumer at
retail. Mandatory labelling of n-3 fatty acids and the n-6/n-3 ratio might also open
the door to population-based prevention policies (i.e., food tax to drive nutritional
improvements through changes in production practices), which could generate
health gains while paying for themselves through future reductions of health-care
expenditures [62], or by providing incentives to producers with specified amounts
and types of n-3 fatty acids in their pig feed. Market pull could also be generated
through inclusion of healthier sources of fatty acids (i.e., n-3 enriched lard) in baked
goods, and further processed products that already qualify for nutritional labels, and
this might in turn result in healthier pork meat as a byproduct. For all the strategies,
however, it is clear that there needs to be more defined incentives provided to
producers, and a stronger signal that changes are required along the value chain.
7. Conclusions
Currently retail pork is not considered a source of n-3 fatty acids, and in
fact suffers from an imbalanced n-6/n-3 fatty acid ratio related to modern feeding
practices. Pork is the most consumed meat in the world, and its fatty acid content
and composition is directly influenced by diet. There have been calls to correct
the imbalanced n-6/n-3 ratio in foods, including pork, and although this correction
would seem to be a simple fix by modifying pig diets, adoption of such practices
is not widespread. Producing n-3 enriched pork may increase production costs,
enriched pork has to be tracked to retail, and the pork must be sold at a premium to
recover added costs and provide profit for the effort. Labelling pork as a source of
n-3 fatty acids also requires regulatory approval, development costs and costs for
quality control to maintain enrichment status. As a result, n-3 enriched pork will
likely continue to command a limited market share, and only be available to those
willing to pay a premium. Several strategies to drive an industry wide shift towards
n-3 fatty acid enriched pork production are possible including mandatory labelling
of the n-3 fatty acid content and n-6/n-3 ratio, and development of population based
prevention polices. This would allow consumers to make choices based on valued
attributes, and provide for natural market segmentation without having to reach
specific amounts of n-3 fatty acids per serving. When coupled with improvements in
the speed of non-invasive fatty acid analyses and tracking technologies, we could be
on the verge of meeting health conscious consumers growing demand for nutritional
information, while providing impetus to pork value chain to make producing pork
with a higher n-3 fatty acid content and lower n-6/n-3 ratio an industry wide priority.
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Mechanisms Involved in the Improvement
of Lipotoxicity and Impaired Lipid
Metabolism by Dietary α-Linolenic Acid
Rich Salvia hispanica L (Salba) Seed in the
Heart of Dyslipemic Insulin-Resistant Rats
Agustina Creus, María R. Ferreira, María E. Oliva and Yolanda B. Lombardo
Abstract: This study explores the mechanisms underlying the altered lipid
metabolism in the heart of dyslipemic insulin-resistant (IR) rats fed a sucrose-rich
diet (SRD) and investigates if chia seeds (rich in α-linolenic acid 18:3, n-3 ALA)
improve/reverse cardiac lipotoxicity. Wistar rats received an SRD-diet for three
months. Half of the animals continued with the SRD up to month 6. The
other half was fed an SRD in which the fat source, corn oil (CO), was replaced
by chia seeds from month 3 to 6 (SRD+chia). A reference group consumed a
control diet (CD) all the time. Triglyceride, long-chain acyl CoA (LC ACoA)
and diacylglycerol (DAG) contents, pyruvate dehydrogenase complex (PDHc)
and muscle-type carnitine palmitoyltransferase 1 (M-CPT1) activities and protein
mass levels of M-CPT1, membrane fatty acid transporter (FAT/CD36), peroxisome
proliferator activated receptor α (PPARα) and uncoupling protein 2 (UCP2) were
analyzed. Results show that: (a) the hearts of SRD-fed rats display lipotoxicity
suggesting impaired myocardial lipid utilization; (b) Compared with the SRD group,
dietary chia normalizes blood pressure; reverses/improves heart lipotoxicity, glucose
oxidation, the increased protein mass level of FAT/CD36, and the impaired insulin
stimulated FAT/CD36 translocation to the plasma membrane. The enhanced M-CPT1
activity is markedly reduced without similar changes in protein mass. PPARα
slightly decreases, while the UCP2 protein level remains unchanged in all groups.
Normalization of dyslipidemia and IR by chia reduces plasma fatty acids (FAs)
availability, suggesting that a different milieu prevents the robust translocation of
FAT/CD36. This could reduce the influx of FAs, decreasing the elevated M-CPT1
activity and lipid storage and improving glucose oxidation in cardiac muscles of
SRD-fed rats.
Reprinted from J. Clin. Med. Cite as: Creus, A.; Ferreira, M.R.; Oliva, M.E.;
Lombardo, Y.B. Mechanisms Involved in the Improvement of Lipotoxicity and
Impaired Lipid Metabolism by Dietary α-Linolenic Acid Rich Salvia hispanica L




Metabolic syndrome (MS) is a complex metabolic disorder influenced by genetic
and environmental factors [1]. In Western societies, the high increase of MS, including
cardiovascular disease (CVD), seems to be due to changes in lifestyle (e.g., increased
consumption of food high in refined sugar and decreased physical activities). CVD
represents a major cause of premature death in Western countries [2]. Therefore,
there is growing interest in identifying novel therapeutic approaches including a
particular focus on nutrition and dietary interventions.
Cardiac energy metabolic shifts occur as a normal response to diverse
physiological and dietary conditions and as a component of the pathophysiological
processes that accompany heart disease. It is well established that insulin and
fatty acids (FAs) are important modulators of cardiac substrate utilization [3]. In
the heart, there is a fine-tuning of high rates of myocellular FAs uptake and of
mitochondrial fatty acid oxidation. When the rate of FA delivery to the heart
increases (e.g., diabetes, high fat feeding) it may cause a mismatch between FA
uptake and oxidation leading to excessive intracellular storage of the bio-active lipid
intermediates within the cardiomyocytes that could subsequently lead to cardiac
dysfunction [4,5]. Accordingly, several studies have shown that lipids accumulate
in the heart of diabetic animals [6,7]. Myocardial FA uptake is largely regulated by
the membrane fatty acid transporter (FAT/CD36) [8]. Chiu et al. [9] showed that a
myocardial lipid accretion due to an increase of fat uptake leads to myocyte apoptosis
and cardiomyopathy. An enhanced long-chain acyl CoA (LC ACoA) uptake and
channeling into triglycerides was observed in the heart of obese Zucker rats [10]. The
accumulation of triglyceride is likely toxic to the myocardium and has been linked
with insulin resistance (IR) and cardiac dysfunction [6,11]. Besides, it is generally
acknowledged that dietary factors, among them FAs, up-regulated the transcription
of genes encoding for proteins involved in cardiac FA transport and metabolism, most
likely through the activation of peroxisome proliferator activated receptor α (PPARα)
(e.g., expression of muscle-type carnitine palmitoyltransferase 1 (M-CPT1) [12,13].
On the other hand, high sucrose, high fructose and/or high fat diets have
been used to induce metabolic and physiological alterations in rodents, mimicking
several aspects of the MS in humans such as dyslipidemia, IR and adiposity [14].
Furthermore, we have previously demonstrated that the cardiac muscle of rats
chronically fed a sucrose-rich diet (SRD) showed a significant increase of lipid
storage accompanied by a significant reduction of basal and insulin stimulated
glucose uptake and metabolism (isolated perfusion according to Langendorff’s
recirculating mode), as well as in the activities of key enzymes involved in glucose
metabolism [15,16].
Epidemiological data show that a high intake of n-3 polyunsaturated fatty
acids (n-3 PUFAs) from fish is associated with a lower incidence of heart failure
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and cardio protective function [17]. Moreover, different epidemiological and clinical
studies have suggested that a high concentration of dietary α-linolenic acid 18:3
n-3, (ALA) is associated with a decreased risk of CVD [18,19]. Recent studies
carried out in rats by Folino et al. [20] showed that ALA protects against cardiac
injury and remodeling induced by beta-adrenergic over stimulation, and that a
protective role is played by β2 adrenergic receptors which mediate the activation of
the Src kinase-phosphatidylinositol-3-kinase protective pathway. The seeds of Salvia
hispanica L, commonly known as chia seeds, contain the richest botanical oil source
of ALA and high amounts of fiber and minerals. Poudyal et al. [21,22] have recently
shown that the administration of chia oil improved heart left ventricular dimensions,
contractility, volume and stiffness as well as hypertension, glucose tolerance and
insulin sensitivity in rats fed a high fat-high fructose diet. In this line, recent studies
of our group have demonstrated that the administration of chia seeds as a dietary
source of fat in rats fed an SRD reversed dyslipidemia and IR, improved adipose
tissue dysfunction and glucose and lipid metabolism in the skeletal muscle [23–25].
However, the effect of chia seeds on myocardial substrate utilization has been only
partially investigated in this experimental model [21,22].
Thus, the aims of the present study were the following: (i) to further explore
the mechanisms underlying the impaired lipid metabolism in the heart muscle of
dyslipidemic insulin-resistant rats fed an SRD; (ii) to investigate if chia seeds as a
dietary intervention could improve or even revert cardiac lipotoxicity. To achieve
these goals: (a) we analyzed the protein mass levels of FAT/CD36 both at basal
conditions and under insulin stimulation and the mitochondrial oxidation of LC
ACoA by the activity and protein mass levels of the enzyme M-CPT1; (b) since the
effect of FAs or FA derivatives in cardiac myocytes are considered to be PPARα
mediated, we measured the protein mass level of this receptor; (c) we evaluated the
protein mass levels of uncoupling protein 2 (UCP2), which plays a major role in the
mitochondrial FAs flux. Additionally, the activities of the pyruvate dehydrogenase
complex (PDHc) and lipid storage were assessed. The study was conducted in rats
fed an SRD during 6 months, during which permanent dyslipidemia, IR, abnormal
glucose homeostasis and visceral adiposity were present before the source of dietary
fat, corn oil (CO), was replaced by an isocaloric amount of chia seeds for the last
three months of the experimental period in half of the animals.
2. Materials and Methods
2.1. Animals
Male Wistar rats initially weighing 180–190 g purchased from the National
Institute of Pharmacology (Buenos Aires, Argentina) were housed in an animal
room under controlled temperature (22 ˘ 1 ˝C), humidity and airflow, with a
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fixed (12 h) light–dark cycle (lights on from 07:00 to 19:00 h) and with free access
to water and food. Adequate measures were taken to minimize the pain or
discomfort of the rats and we used the smallest number of animals as possible.
The animal protocols were evaluated and approved by the Human and Animal
Research Investigation Committee of the School of Biochemistry, University of Litoral,
Argentina (FONCyT-PICT #945/2012).
2.2. Experimental Design
The rats (n = 60) were initially fed with a standard non-purified diet (Ralston
Purina, St Louis, MO, USA). After one week of acclimation, the rats were randomly
divided into two separate groups and were fed a semi-synthetic diet. The control
group (n = 20) received a control diet (CD) containing corn starch (60% energy),
protein (17% energy) and CO as sources of fat (23% energy) throughout the
experimental period (6 months). The other group (n = 40) received the same
semi-synthetic diet with the sucrose as the carbohydrate source (SRD). After 3 months,
the animals in the SRD group were randomly divided into two subgroups. The rats
in the first subgroup continued with the SRD diet for up to 6 months of feeding.
The second subgroup received the Salba seed (chia) as the source of dietary fat
(SRD + chia) for the next 3 months. The carbohydrates, proteins, fibers, vitamins and
mineral contents in the chia seed of SRD + chia group were balanced with the CD and
SRD groups, according to the amount of these nutrients present in the chia seeds. A
detailed composition of each diet is described in Table 1. The fatty acid composition of
each experimental diet is shown in Table 2. The preparation and handling of diets have
been reported elsewhere [23,24]. All diets provided approximately 17 kJ/g of food.
Table 1. Composition of experimental diets 1.





% w/w % Energy % w/w % Energy % w/w % Energy
Carbohydrates
Corn starch 58.0 60.0 2.5 2.6 – –
Sucrose – – 55.5 57.4 55.5 57.4
Chia seed 2 – – – – 2.5 2.6
Fat
Corn oil 10.5 23.0 10.5 23.0 0.1 0.2
Chia seed – – – – 10.4 22.8
Protein
Casein (vitamin free) 16.3 17.0 16.3 17.0 8.6 9.0
Chia seed – – – – 7.7 8.0
1 The compositions of experimental diets are based on the AIN-93M diet. All diets contain
by weight: salt mix 3.5% (AIN-93Mx); vitamin mix 1% (AIN-93Vx); choline chloride 0.2%;
methionine 0.3%; fiber 10%–11%; 2 Chia seed (variety Salba; Salvia hispánica L.): 362 g/Kg
diet. Chia composition (g/100 g chia seed): carbohydrate 37.45; insoluble fiber 81% of
total of carbohydrates; fat 30.23; protein 21.19. Mineral composition (mg/100 g chia seed):
Na 103.15; K 826.15; Ca 589.60; Fe 11.90; Mg 77.0; P 604.0; Zn 5.32; Cu 1.66; Mn 1.36.
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Table 2. Total fatty acid composition of experimental diets (g/kg diet).
Fatty Acids 1 CD and SRD SRD+chia Seed
16:0 10.92 6.96
18:0 2.73 2.42
18:1 n-9 33.71 7.39
18:2 n-6 54.10 19.85
18:3 n-3 0.80 67.26
20:1 n-9 0.47 0.36






1 Other minor fatty acids have been excluded.
The body weight and energy intake of each animal were recorded twice per
week throughout the experimental period in all groups and subgroups of rats. In a
separate experiment, the individual caloric intake and weight gain of eight animals in
each group and subgroup were assessed twice a week. At the end of the experimental
period, food was removed at 07:00 h (end of the dark period) and unless otherwise
indicated, experiments were performed under feed conditions.
2.3. Analytical Methods
Rats from the three dietary groups were anaesthetized with intraperitoneal
sodium pentobarbital (60 mg/kg body weight). Blood samples were obtained from
the jugular vein, collected in tubes containing sodium EDTA as anticoagulant and
rapidly centrifuged. Plasma was either immediately assayed or stored at ´20 ˝C.
Plasma triglycerides, cholesterol, glucose and free fatty acids and immunoreactive
insulin were determined as previously described [25]. Epididymal, retroperitoneal
and omental adipose tissues were removed and weighed. The visceral adiposity
index (%) was calculated as shown elsewhere [25]. The heart muscle was totally
removed; then, it was weighed and the left ventricle was separated. The heart tissue
was immediately frozen and stored at temperature of liquid N2. Heart weight was
normalized relative to the tibia length at the time of removal. The homogenate of
frozen muscle powder was used to determine triglyceride [26], LC ACoA [27] and
diacylglycerol (DAG) content [28].
2.4. Determination of Blood Pressure
Blood pressure was measured in the three dietary groups in conscious animals
maintained at 28 ˝C in a restraining tube, at the beginning, at 3 months and at the end
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of the experimental period using a CODA™ Monitor of tail-cuff non-invasive blood
pressure system (Kent Scientific Corporation, Torrington, CT, USA). The values are
reported as the average of 8 individual measurements.
2.5. Enzymatic Activity Assays of CPT and PDHc
Heart M-CPT1 enzyme activities were measured as reported by Ling et al. [29]
with some modifications. Frozen tissue was homogenized in buffer (20 mM
HEPES pH 7.4, 140 mM KCl, 10 mM EDTA and 5 mM MgCl2) and after
centrifugation; the mitochondrial pellet was resuspended in a homogenization
buffer. Protein concentration was measured by the Bradford assay (Bio-Rad reagent).
To determine the total CPT activity, 100 µg of protein were added in a reaction
buffer (20 mM HEPES pH 7.4, 220 mM sucrose, 40 mM KCl, 1 mM EGTA, 0.1 mM
5,5´-dithio-bis(2-nitrobenzoic acid) (DTNB) and 40 µM palmitoyl CoA). In addition,
1 mM of L-carnitine was added to start the reaction. The rate of appearance of
CoASH-DTNB was monitored at 412 nm at 37 ˝C. CPT2 activity was measured under
the same conditions in the presence of 10 µM of malonyl CoA (M-CPT1 inhibitor).
The M-CPT1 activity was calculated as the difference between total CPT and CPT2
activities. The M-CPT1 activity was expressed as the amount of CoASH released per
min per mg of protein. The extract and assay of the PDHc activity from the heart
muscle were measured as previously described [15].
2.6. Determination of FAT/CD36 Protein Mass Level (Euglycemic-Hyperinsulinemic
Clamp Studies)
The heart muscles of six rats from the CD, SRD and SRD+chia groups were
rapidly removed (time 0 of clamp study) and stored at ´80 ˝C for the determination
of the FAT/CD36 protein levels. Immediately, in the other six rats from each
dietary group, an infusion of highly purified porcine neutral insulin (Actrapid,
Novo Nordisk,) was administered at 0.8 units/(kg ˆ h) for 120 min. Glycemia was
maintained at a euglycemic level by infusing glucose at a variable rate. The glucose
infusion rate (GIR) during the second hour of the clamp study was taken as the
net steady state of the whole body glucose. At the end of the clamp period, the
heart muscle of each dietary group was rapidly removed for determination of the
FAT/CD36 protein mass levels (for details see ref. [30]). Plasma membrane fractions
from heart muscle were prepared according to the method of Rodnick et al. [31].
Briefly, the muscle was homogenized in ice-cold buffer (20 mM HEPES pH 7.4,
1 mM EDTA, 250 mM sucrose and 5 µL/mL protease inhibitor cocktail (Sigma, St.
Louis, MO, USA)) and the homogenate was centrifuged at 3000ˆ g at 4 ˝C. The
supernatant was centrifuged at 184,000ˆ g at 4 ˝C. The resulting pellet (membrane
fraction) was resuspended in buffer and stored at ´80 ˝C until the assay. Protein
concentrations were quantified by the Bradford assay (Bio-Rad reagent). Proteins
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were separated by SDS-PAGE and transferred to PVDF membranes. The membranes
were probed with a specific antibody (rabbit polyclonal anti-CD36 from Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA). The blot was incubated with horseradish
peroxidase-linked secondary antibody (Santa Cruz Biotechnology) followed by
chemiluminescence detection according to the manufacturer’s instruction (Pierce
Biotechnology, Rockford, IL, USA). The protein levels were normalized to actin. The
intensity of the bands was quantified by National Institutes of Health (NIH) imaging
software (Bethesda, MD, USA). The relationship between the amount of the sample
subjected to immunoblotting and the signal intensity observed was linear under the
conditions described above.
2.7. Determination of M-CPT1 and PPARα Protein Mass Levels
Frozen heart powder was homogenized in a lysis buffer (10 mM Tris-HCl
pH 7.4, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100 and 5 µL/mL
protease inhibitor cocktail (Sigma)) as described by Bogazzi et al. [32]. After 30 min
incubation on ice, the lysates were centrifuged at 4 ˝C and supernatants were
stored at ´80 ˝C. The protein content was quantified by the Bradford assay. Total
protein samples (100 µg/lane) were resolved on SDS-PAGE, transferred to PVDF
membranes and probed with specific antibodies (rabbit polyclonal anti M-CPT1
or rabbit polyclonal anti-PPARα from Santa Cruz Biotechnology, Inc.). The blots
were incubated with horseradish peroxidase-linked secondary antibody (Santa Cruz
Biotechnology) followed by chemiluminescence detection as described above. The
protein levels were normalized to actin.
2.8. Determination of UCP2 Protein Mass Level
The mitochondrial fraction from the heart muscle was carried out according to
the method described by Pecqueur et al. [33]. Briefly, the tissue was homogenized
at 4 ˝C in a TES buffer (10 mM Tris pH 7.5, 1 mM EDTA, 250 mM sucrose and
5 µL/mL protease inhibitor cocktail (Sigma)). After centrifugation, the mitochondrial
pellet was resuspended in TES buffer and stored at ´80 ˝C. The protein content was
quantified by the Bradford assay. Protein samples (50 µg protein/lane) were resolved
by SDS-PAGE and transferred to PVDF membranes. The membranes were probed
with a specific antibody (goat polyclonal anti-UCP2 from Santa Cruz Biotechnology,
Inc.). The blot was incubated with horseradish peroxidase-linked secondary antibody
(Santa Cruz Biotechnology) followed by chemiluminescence detection as described
above. The protein levels were normalized to actin.
2.9. Statistical Analysis
Sample sizes were calculated on the basis of measurements previously made
with rats fed either a CD or SRD [16,25,30] considering an 80% power as described
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by Glantz [34]. Results were expressed as mean with their standard errors. The
homogeneity of variances were tested using Barlett’s test. The statistical significance
between groups was determined by one way analysis of variance (ANOVA) with one
factor (diet) followed by the Newman Keul‘s multiple comparison post hoc test [35].
Differences having p values lower than 0.05 were considered to be statistically
significant. Statistical analyses were performed using GraphPad Prism version
5.00 for Windows (San Diego, CA, USA). All reported p values are 2-sided.
3. Results
3.1. Body Weight, Energy Intake and Visceral Adiposity Index
Body weight and energy intake were carefully monitored in all groups of rats
through the experimental period. As previously shown [25], a significant increase
in body weight and energy intake occurred in rats fed an SRD from month 3 to
6 compared to those fed a CD (Table 3). A similar energy intake was recorded in both
SRD and SRD+chia groups during the last three months of the experimental period
while body weight at month 6 was slightly lower without statistical differences in
the latter group. As in our previous report [24], SRD-fed rats showed a significant
increase of the visceral adiposity index compared to the CD group. The chia seed
enriched diet significantly reduced the aforementioned index, which reached values
similar to those of the CD group.
Table 3. Body weight, energy intake and adiposity index of rats fed a control diet
(CD), sucrose-rich diet (SRD) or SRD + chia seed (SRD + chia) 1.
Diet









Initial 3 Months Initial to 3Months 6 Months
3 to 6
Months 6 Months
CD (8) 184.3 ˘ 2.6 414.5 ˘ 5.5 294.5 ˘ 12.5 CD (8) 476.3 ˘ 7.6 b 292.0 ˘ 7.2 b 4.1 ˘ 0.3 b
SRD (16) 186.0 ˘ 1.6 428.0 ˘ 6.0 292.0 ˘ 7.2 SRD (8) 545.0 ˘ 10.0 a 374.0 ˘ 9.5 a 6.2 ˘ 0.4 a
SRD+chia (8) 524.0 ˘ 7.3 a 356.5 ˘ 13.0 a 4.5 ˘ 0.2 b
1 Values are expressed as mean ˘ SEM, () number of rats. Values in a column that do
not share the same superscript letter (a, b) are significantly different p < 0.05 when one
variable at a time was compared by the Newman Keul‘s test.
3.2. Total and Relative Heart Weight and Systolic Blood Pressure
Total heart weights recorded at the end of experimental period in each dietary
group showed a significant increase in SRD-fed rats compared with the CD-fed
rats. SRD + chia did not modify heart weight. Conversely, relative heart weights
as g/100 g body weight or by the length of the tibia (mg/mm) were similar in all
dietary groups (Table 4). SRD feeding increased systolic blood pressure throughout
the six-month feeding protocol with values at three and six months significantly
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higher compared to those observed in the CD-fed group. Chia seeds in the SRD
group normalized systolic blood pressure after three months of treatment reaching
values similar to those of the CD group (Table 4).
Table 4. Total and relative heart weight at the end of the experimental period and
systolic blood pressure of rats fed a control diet (CD), sucrose-rich diet (SRD) or
SRD + chia seed (SRD + chia) 1.
CD SRD SRD+chia
Heart tissue
Total wet weight, g 1.24 ˘ 0.01 b (8) 1.31 ˘ 0.03 a (8) 1.28 ˘ 0.02 a (8)
g wet weight/100 g body weight 0.260 ˘ 0.003 (8) 0.250 ˘ 0.004 (8) 0.250 ˘ 0.005 (8)
mg wet weight/mm tibia length 27.2 ˘ 1.0 (8) 30.1 ˘ 1.3 (8) 28.3 ˘ 1.0 (8)
Systolic blood pressure, mmHg
Initial 115.0 ˘ 4.6 (8) 116.0 ˘ 2.4 (16)
3 months 123.3 ˘ 1.0 b (8) 130.9 ˘ 1.2 a (16)
6 months 120.2 ˘ 4.8 b (8) 138.4 ˘ 1.6 a (8) 118.8 ˘ 1.6 b (8)
1 Values are expressed as mean ˘ SEM, () number of rats. Values in a line that do not share
the same superscript letter (a, b) are significantly different p < 0.05 when one variable at a
time was compared by the Newman Keul‘s test.
3.3. Plasma Metabolites, Insulin Levels and GIR
Confirming previous studies [25], the changes observed after three or six months
of SRD on plasma triglyceride, free fatty acids and glucose concentration were similar
and both significantly different from those of the CD groups to which the data from
SRD + chia were similar (Table 5). No statistical differences in plasma insulin levels
were observed at the end of the experimental period between the three dietary
groups. Furthermore, the significant decrease of the GIR recorded in the SRD-fed
group returned to values similar to those obtained in the CD-fed rats in the SRD +
chia group (Figure 1).
Table 5. Plasma metabolites of rats fed a control diet (CD), sucrose-rich diet (SRD)
or SRD + chia seed (SRD+chia) 1.











CD 3 0.69 ˘ 0.04 b 300.1 ˘ 16.0 b 1.85 ˘ 0.10 b 6.5 ˘ 0.2 b 64.1 ˘ 3.2
SRD 3 1.98 ˘ 0.08 a 716.0 ˘ 8.1 a 3.21 ˘ 0.14 a 7.9 ˘ 0.1 a 60.1 ˘ 4.2
CD 6 0.72 ˘ 0.03 b 335.0 ˘ 13.0 b 1.92 ˘ 0.11 b 6.6 ˘ 0.1 b 62.0 ˘ 2.9
SRD 6 2.06 ˘ 0.17 a 760.4 ˘ 16.3 a 3.60 ˘ 0.04 a 8.3 ˘ 0.1 a 65.0 ˘ 3.2
SRD+chia 3 to 6 0.72 ˘ 0.05 b 363.0 ˘ 35.4 b 1.75 ˘ 0.21 b 6.9 ˘ 0.1 b 67.4 ˘ 6.5
1 Values are expressed as mean ˘ SEM, n = 6. Values in a column that do not share the
same superscript letter (a, b) are significantly different p < 0.05 when one variable at a




Table 4. Total and  relative heart weight at  the end of  the experimental period and systolic blood 
pressure of rats fed a control diet (CD), sucrose‐rich diet (SRD) or SRD + chia seed (SRD + chia) 1. 
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mg wet weight/mm tibia length  27.2 ± 1.0 (8)  30.1 ± 1.3 (8)  28.3 ± 1.0 (8) 
Systolic blood pressure, mmHg       
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CD  3  0.69 ± 0.04 b  300.1 ± 16.0 b  1.85 ± 0.10 b  6.5 ± 0.2 b  64.1 ± 3.2 
SRD  3  1.98 ± 0.08 a  716.0 ± 8.1 a  3.21 ± 0.14 a  7.9 ± 0.1 a  60.1 ± 4.2 
CD  6  0.72 ± 0.03 b  335.0 ± 13.0 b  1.92 ± 0.11 b  6.6 ± 0.1 b  62.0 ± 2.9 
SRD  6  2.06 ± 0.17 a  760.4 ± 16.3 a  3.60 ± 0.04 a  8.3 ± 0.1 a  65.0 ± 3.2 
SRD+chia  3 to 6  0.72 ± 0.05 b  363.0 ± 35.4 b  1.75 ± 0.21 b  6.9 ± 0.1 b  67.4 ± 6.5 








Values are mean, with their standard errors depicted by vertical bars (six animals
per group).* p < 0.05 SRD vs. CD and SRD + chia.
Figure 1. GIR during euglycemic-hyperinsulinemic clamp in rats fed a control
diet (CD), sucrose-rich diet (SRD) or SRD + chia seed (SRD + chia).
3.4. Heart Muscle Metabolites Concentrations and PDHc Activity
Table 6 depicts significant increases of lipid storage (triglycerides, LC ACoA and
DAG) levels within the cardiac muscle of SRD-fed rats. The present data show that
in the SRD + chia seed group, neither parameter differed from those of the CD group
at the end of the experimental period. Moreover, the administration of chia seed
(SRD+chia) was able to revert the reduced active form of PDHc (PDHa) observed
in the SRD-fed group reaching values similar to those of the control group (CD).
The total PDHc activity expressed per gram of wet tissue did not differ between the
groups (data not shown).
Table 6. Intramyocardial lipid accumulation and PDHc activity of rats fed a control
diet (CD), sucrose-rich diet (SRD) or SRD + chia seed (SRD + chia) at the end of the
experimental period 1.
CD SRD SRD+chia
Triglyceride (µmol/g wet tissue) 3.60 ˘ 0.22 b 6.03 ˘ 0.34 a 4.44 ˘ 0.60 b
LC ACoA (nmol/g wet tissue) 31.4 ˘ 5.5 b 68.0 ˘ 4.0 a 45.8 ˘ 5.5 b
DAG (nmol/g wet tissue) 250.8 ˘ 19.5 b 355.3 ˘ 15.4 a 276.6 ˘ 24.0 b
PDHa (% of total PDHc) 59.7 ˘ 5.8 a 26.6 ˘ 4.6 b 45.1 ˘ 4.9 a
1 Values are expressed as mean ˘ SEM, n = 6. Values in a line that do not share the same
superscript letter (a, b) are significantly different p < 0.05 when one variable at a time was
compared by the Newman Keul‘s test.
216
3.5. FAT/CD36 Protein Mass Level in Heart Muscle at the Beginning and at the End of the
Euglycemic-Hyperinsulinemic Clamp Studies
Figure 2 shows the protein mass level of FAT/CD36 at the beginning (0 min)
and at the end of the clamp. The immunoblottting of the heart muscle revealed
a single 90 KDa band consistent with FAT/CD36. Each gel contained an equal
number of samples from rats fed a CD, SRD and SRD + chia at 0 min and 120 min of
euglycemic hyperinsulinemic clamp (Figure 2, top panel). After the densitometry
of immunoblots, FAT/CD36 at the beginning of the clamp was normalized to 100%,
and both the SRD and SRD + chia groups at the beginning as well as the three dietary
groups at the end of the study were expressed relative to this. At the beginning of
the clamp, the qualitative and quantitative analysis of the Western blot showed a
significant increase (p < 0.05) in the relative abundance of FAT/CD36 in the SRD-fed
rats compared to the CD and SRD+chia groups. The latter reached values similar
to those of the CD group. At the end of the clamp study, insulin stimulated the
translocation of FAT/CD36 to the sarcolemma in the CD-fed rats that showed a
significant (p < 0.05) increase of their protein mass level, while in the heart of SRD-fed
rats, insulin did not further recruit FAT/CD36 to the sarcolemma under the same
experimental conditions. Moreover, changes induced by the SRD were reverted by
the chia seed enriched diet (Figure 2 bottom panel).
3.6. M-CPT1 Activity and Protein Mass Level
Figure 3a shows the cardiac muscle activity of the M-CPT1 in the three dietary
groups. Compared with the CD-fed group, a three-fold increase of the mitochondrial
M-CPT1 activity was observed in the heart of rats fed an SRD. The M-CPT1 activity
was significantly reduced under the administration of chia seed. However, values
were still higher than those recorded in the CD-fed rats. The CPT2 activity remained
similar in the three dietary groups. Immunoblotting of cardiac muscle M-CPT1
revealed a single 75 KDa band consistent with M-CPT1. Each gel contained an
equal number of samples from rats fed a CD, SRD and SRD+chia (Figure 3b top
panel). After densitometry of immunoblots the M-CPT1 of the CD group was
normalized to 100%, and both the SRD and SRD+chia groups were expressed relative
to this. The qualitative and quantitative abundance of the Western blot showed that
M-CPT1 protein mass level significantly increased (p < 0.05) in the heart muscle
of the SRD group when compared with rats fed a CD (Figure 3b bottom panel).
Interestingly, although the enzymatic activity of M-CPT1 decreased when chia seed













Table  6.  Intramyocardial  lipid  accumulation  and  PDHc  activity  of  rats  fed  a  control  diet  (CD), 
sucrose‐rich diet (SRD) or SRD + chia seed (SRD + chia) at the end of the experimental period 1. 





















at  0 min  and  120 min  of  euglycemic  hyperinsulinemic  clamp  (Figure  2,  top  panel).  After  the 
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Figure  2. Heart protein mass  levels of FAT/CD36 at  the beginning  (0 min) and under  the  insulin 
stimulation at the end (120 min) of the clamp studies in rats fed a control diet (CD), a sucrose‐rich 







Figure  3a  shows  the  cardiac  muscle  activity  of  the M‐CPT1  in  the  three  dietary  groups. 
Compared with the CD‐fed group, a three‐fold increase of the mitochondrial M‐CPT1 activity was 
observed in the heart of rats fed an SRD. The M‐CPT1 activity was significantly reduced under the 
administration of chia seed. However, values were still higher  than  those recorded  in  the CD‐fed 
rats. The CPT2  activity  remained  similar  in  the  three dietary groups.  Immunoblotting of  cardiac 
muscle M‐CPT1 revealed a single 75 KDa band consistent with M‐CPT1. Each gel contained an equal 
number of samples from rats fed a CD, SRD and SRD+chia (Figure 3b top panel). After densitometry 








Values are mean, with their standard errors depicted by vertical bars (six nimals per
group) and expr ssed as percentage relative o the c ntrol diet at 0 min of the cl mp.
* p < 0.05 SRD at 0 min vs. CD and SRD+chia at 0 min of the cla p. † p < 0.05 CD
and SRD+chia at 120 min vs. CD and SRD+chia at 0 min of the clamp.
Figure 2. Heart protein mass levels of FAT/CD36 at the beginning (0 min) and
under the insulin sti ulation at the end (120 min) of the clamp studies in rats fed a
control diet (CD), a sucrose-rich diet (SRD) or SRD + chia seed (SRD + chia). Top
panel: representative immunoblot of heart FAT/CD36 of rats fed CD, SRD d
SRD + chia. Molecular marker is shown on the right. Lane 1, CD 0 min; lane 2, CD
120 in; lane 3, SRD 0 min; lan 4, SRD 120 min; lane 5, SRD + chia 0 min; lane 6,
SRD + chia 120 min. Bottom panel: densitometric immunoblot a alysis of heart
FAT/CD36 protein mass level of rats fed CD, SRD or SRD + chia at the beginning








Figure  2. Heart protein mass  levels of FAT/CD36 at  the beginning  (0 min) and under  the  insulin 
stimulation at the end (120 min) of the clamp studies in rats fed a control diet (CD), a sucrose‐rich 
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rats. The CPT2  activity  remained  similar  in  the  three dietary groups.  Immunoblotting of  cardiac 
muscle M‐CPT1 revealed a single 75 KDa band consistent with M‐CPT1. Each gel contained an equal 
number of samples from rats fed a CD, SRD and SRD+chia (Figure 3b top panel). After densitometry 















diet  (SRD)  or  SRD+chia  seed  (SRD+chia). Values  are  expressed  as mean  ±  SEM  (six  animals per 
group). Values in a line that do not share the same superscript letter (a, b, c) are significantly different 






We  examined  the  protein mass  level  of  PPARα,  since  this  receptor  is  considered  a master 
regulator  of  FAs metabolism  in  several  organs  including  the  heart.  The  immunoblotting  of  the 
cardiac muscle revealed a single 55KDa band consistent with PPARα. Each gel contained an equal 
number  of  samples  from  the  CD,  SRD  and  SRD  +  chia  groups  (Figure  4  top  panel). After  the 
densitometry of immunoblots, the PPARα of the CD group was normalized to 100%, and both the 
SRD  and  SRD  +  chia  groups  were  expressed  relative  to  this.  The  qualitative  and  quantitative 
abundance of the Western blot showed that the relative abundance of the PPARα protein mass level 
significantly increased (p < 0.05) in the hearts of both the SRD and SRD + chia groups, although the 
protein mass  level was  slightly  lower without  statistical differences  in  the  latter group  (Figure 4 







Values ar mean, with their standa d errors depicted by vertical bars (six animals per
group) and express d as percentage relative to the control diet. * p < 0.05 SRD and
SRD + chia vs. CD.
Figure 3. (a) Heart enzyme activities of M-CPT1 and CPT2 in r ts fed a control diet
(CD), sucrose-rich diet (SRD) or SRD+chia seed (SRD+chi ). Values are expressed
as mean ˘ SEM (six animals per group). Values in a line that do not share the same
superscript letter (a, b, c) are significantly different (p < 0.05) when one variable
at time was compared by the Newman Keul‘s test; (b) Top panel: a representative
immunoblot of heart M-CPT1 protein mass level of rats fed CD, SRD and SRD +
chia. Molecular marker is shown on the right. Lane 1, CD; lane 2, SRD; lane 3,
SRD + chia. Bottom panel: densitometric immunoblot analysis of heart M-CPT1
protein mass level of rats fed CD, SRD or SRD + chia.
3.7. PPARα Protein Mass Level
We examined the protein mass level of PPARα, since this receptor is considered
a master regulator of FAs metabolism in several organs including the heart. The
immunoblotting of the cardiac muscle revealed a single 55KDa band consistent with
PPARα. Each gel contained an equal number of samples from the CD, SRD and
SRD + chia groups (Figure 4 top panel). After the densitometry of immunoblots, the
PPARα of the CD group was normalized to 100%, and both the SRD and SRD + chia
groups were expressed relative to this. The qualitative a d quantitative abundance of
the Western blot showed th t the rela ive abundance of the PPARα protein m ss level
significantly increas d (p < 0.05) in the hearts of bot the SRD and SRD + chia groups,
although the protein mass level was slightly lower without statistical differences in
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the latter group (Figure 4 bottom panel). On the other hand, we measured the protein
mass levels of UCP2 since this uncoupling protein could be regulated by increased FA
concentration through PPARα activation. The qualitative and quantitative analysis
of the Western blots showed that the relative abundance of mitochondrial UCP2
protein mass level was similar in the hearts of the three dietary groups. Values were
as follows: (mean ˘ SEM, n = 6); CD 100 ˘ 3.2; SRD 103.8 ˘ 2.5 and SRD + chia







diet  (SRD)  or  SRD+chia  seed  (SRD+chia). Values  are  expressed  as mean  ±  SEM  (six  animals per 
group). Values in a line that do not share the same superscript letter (a, b, c) are significantly different 






We  examined  the  protein mass  level  of  PPARα,  since  this  receptor  is  considered  a master 
regulator  of  FAs metabolism  in  several  organs  including  the  heart.  The  immunoblotting  of  the 
cardiac muscle revealed a single 55KDa band consistent with PPARα. Each gel contained an equal 
number  of  samples  from  the  CD,  SRD  and  SRD  +  chia  groups  (Figure  4  top  panel). After  the 
densitometry of immunoblots, the PPARα of the CD group was normalized to 100%, and both the 
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abundance of the Western blot showed that the relative abundance of the PPARα protein mass level 
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The  present  study  provides  new  information  on  the mechanisms  involved  in  heart muscle 
lipotoxicity  in  dyslipemic  insulin  resistant  rats  fed  an  SRD  and  explores  the  possible  beneficial 
effects of dietary chia supplementation on reversed or improved pre‐exiting impaired cardiac lipid 
metabolism. Disruption of the sensitive balance between FAs and glucose in the heart and increased 




of  FAT/CD36  in  the  plasma membrane,  suggesting  that  the  enhanced  amount  of  FAT/CD36  on 
sarcolemma elicits an increased rate of FAs uptake. In this regard, an increased availability of plasma 











FAT/CD36  to  the sarcolemma  in  the heart of SRD‐fed  rats  that was completely  insensitive  to  the 
stimulus of  the hormone. Similarly,  in cardiac myocytes  from obese Zucker  rats, Coort et al.  [10] 
reported that insulin failed to alter the sub cellular localization of FAT/CD36 and the rate of LCFA 
uptake and triglyceride esterification. Besides, in cardiamyocytes of Wistar rats in which a high‐fat 
diet  induced  cardiac  contractile  dysfunction, Ouwens  et  al.  [5]  demonstrated  that  a  permanent 
Figure 4. Heart protein mass level of PPARα in rats fed a contr l diet (CD),
sucrose-rich diet (SRD) r SRD + chia se d (SRD + chia). T p panel: a epresentative
immunoblot of heart PPARα of rats fed a CD, SRD and SRD + chia. Molecu r
marker is show on th ight. La e 1 CD; lane 2 SRD; lane 3 SRD + chia. Bottom
panel: densitometric immunoblot analysis of hear PPARα p tein mass level of rats
fed CD, SRD or SRD + chi .. Values are mean, with their standard errors depicted
by vertical bars (6 animals per group) and expressed as percentage relative to the
control diet. * p < 0.05 SRD and SRD + chia vs. CD.
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4. Discussion
The present study provides new information on the mechanisms involved
in heart muscle lipotoxicity in dyslipemic insulin resistant rats fed an SRD and
explores the possible beneficial effects of dietary chia supplementation on reversed or
improved pre-exiting impaired cardiac lipid metabolism. Disruption of the sensitive
balance between FAs and glucose in the heart and increased intramyocellular
fat contents and fatty acid metabolites are likely to play a pivotal role in the
development of insulin resistance, cardiac lipotoxicity and heart dysfunction [36].
FAT/CD36 plays a pivotal role in governing myocardial FAs uptake [8]. In the
present work, the increased intracellular LC ACoA in the heart of SRD-fed rats
is accompanied by a significant increase of protein mass level of FAT/CD36 in
the plasma membrane, suggesting that the enhanced amount of FAT/CD36 on
sarcolemma elicits an increased rate of FAs uptake. In this regard, an increased
availability of plasma free fatty acids and triglyceride levels is recorded in the
SRD-fed group. Moreover, despite a significant increase of both the M-CPT1 activity
and its protein mass level, triglyceride accumulates in the heart of this dietary group.
It is possible that the increased flux of FAs to the heart exceeds the mitochondrial
oxidative capacity leading to an increase of FAs storage into the triglyceride pool.
The dynamic equilibrium between triglyceride stores and their metabolites cause
accumulation of DAG and ceramide during prolonged long-chain fatty acid (LCFA)
influx. Although in the present study we did not measure the level of ceramide, our
previous results [16] and the present data show an increase of DAG concentration in
the heart of rats fed an SRD. Both metabolites are implicated in counteracting insulin
signaling, reducing insulin responsiveness and altering its ability to regulate substrate
handling [4]. In this regard, the present data show that insulin stimulated the cell
surface recruitment of FAT/CD36 in the heart of CD-fed rats. However, insulin
was unable to further recruit FAT/CD36 to the sarcolemma in the heart of SRD-fed
rats that was completely insensitive to the stimulus of the hormone. Similarly, in
cardiac myocytes from obese Zucker rats, Coort et al. [10] reported that insulin failed
to alter the sub cellular localization of FAT/CD36 and the rate of LCFA uptake
and triglyceride esterification. Besides, in cardiamyocytes of Wistar rats in which a
high-fat diet induced cardiac contractile dysfunction, Ouwens et al. [5] demonstrated
that a permanent presence of FAT/CD36 in the sarcolemma membrane resulted in
the enhancement of LCFA uptake and myocardial triglyceride accumulation.
PPARα and its co-activator PPARγ co-activator 1 alpha (PGC-1α) play an
important role in the transcriptional regulation of cardiac energy metabolism, and
the effect of FAs in cardiac myocytes is considered to be PPARα mediated [37].
Several lines of evidence suggested that LCFAs that induce the gene expression of
M-CPT1 and other enzymes in the cellular fatty acid utilization pathway are namely
mediated by PPARα transcriptional control [13]. LCFAs: linoleic acid 18:2 n-6, ALA
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and docosahexaenoic acid 22:6, n-3 (DHA) among them, and a variety of related
compounds serve as PPARα ligands [38]. In this context, the present study shows
a significant increase of the relative abundance of the protein mass level of PPARα
and the mitochondrial M-CPT1 activity in the heart of SRD-fed rats. These results
suggest that a chronic high exposure to Fas, which enhances their uptake, induces the
activation of PPARα protein expression that, in turn, encodes the proteins responsible
for FAs oxidation, M-CPT1 among others. Since an increase of intramyocardial lipids
is observed in the SRD heart, it is possible that a disruption of the balance between
lipid oxidation-storage occurs in the heart muscle of this dyslipemic insulin-resistant
model. In this vein, Buchanam et al. [39] have documented an increased PPARα and
PGC-1α expression in murine insulin-resistant hearts. A high fat diet also activates
PPARα in the heart and stimulates expression of key proteins involved in fatty acid
oxidation [40].
It is well known that dietary n-3 PUFAs, mainly eicosapentaenoic acid 20:5, n-3
(EPA) and DHA, improve cardiac function [17]. ALA could be a valuable source of n-3
long-chain FAs via elongase/desaturase activities. Dietary ALA exerts a protective
effect on the CVD [18]. In this regard, and confirming previous results, the present
work demonstrates a reversion of dyslipidemia, abnormal glucose homeostasis and
whole body peripheral insulin insensitivity when dietary chia seed replaced CO
in the SRD-fed rats. The reverse of dyslipidemia by chia seed led to a significant
reduction of lipid storage in the heart of SRD-fed rats, reaching values similar to
those observed in the heart of CD-fed rats. Moreover, at basal conditions (beginning
of the clamp study) a decrease of FAT/CD36 protein mass level suggests that a
different milieu (decreased plasma lipids levels) prevented the robust relocations of
fatty acid translocase to the sarcolemma, which was otherwise seen in the cardiac
muscle of SRD-fed rats and, therefore, reduced the influx of FAs. Furthermore, the
heart of dietary chia-fed rats was sensitive to the stimulus of insulin. As in the
CD-fed group, the hormone significantly induced the translocation of FAT/CD36
to the plasma membrane. Recently, in isolated rat cardiomyocytes incubated under
insulin resistance evoking conditions, Franekova et al. [41] demonstrated that the
inclusion of EPA and DHA to the medium prevented the persistent translocation of
CD36 to the sarcolemma and protected the metabolic and functional properties of the
cardiomyocytes. In this regard, we previously demonstrated that the administration
of dietary fish oil to SRD-fed rats was able to reverse heart muscle lipotoxicity and
benefit key enzyme activities involved in the glucose metabolism [16]. At present,
we are unaware of other studies concerning the effect of the long-term consumption
of dietary chia and/or ALA on lipid metabolism in the cardiac muscle of SRD-fed
rats. However, the reversion of the impaired glucose oxidation, as well as the
accretion of triglyceride and fatty acid derivatives, the normalization of the enhanced
sarcolemmal FAT/CD36 and the significantly reduced mitochondrial oxidative flux
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suggests that dietary chia seeds could improve the altered balance of heart fuel
utilization. Interestingly, compared with CD-fed rats the protein mass level of the
nuclear receptor PPARα and the activity of its target enzyme M-CPT1 were still
higher in the heart of the SRD + chia group. Our results do not provide data on the
mechanisms underlying the effect of chia seed on this nuclear receptor but it was
shown that ALA and DHA, among others, are natural occurring ligands of PPARα
in the heart [38]. In this regard, it has been demonstrated by our group [23] and
others [21,42] that chia seeds change the plasma fatty acid profile increasing ALA,
EPA, docosapentaenoic acid 22:5, n-3 (DPA) and DHA levels as well as the n-3/n-6
FAs ratio in rats fed an SRD, a control diet, or a high fat, high fructose diet. Thus, we
do not discard the possibility that the different plasma FA profiles to which the heart
was exposed could contribute to this finding.
On the other hand, an increase of FAs could induce UCP2 expression through
PPARα activation in adult rat cardiomyocytes [43]. Besides, an increase of UCP2 and
PPARαwas recorded in the heart of ob/ob mice [39]. However, under the present
experimental protocol, our results showed that the mitochondrial protein mass levels
of UCP2 were similar in the three experimental groups. Besides, we are unaware of
any other studies that evaluated the potential role of UCP2 in altering myocardial
substrate in the heart muscle of SRD rats, and the effect of either chia seeds or oil
upon UCP2. Further studies will be needed to evaluate this matter.
Chia seeds were able to decrease the systolic blood pressure that developed in
the SRD-fed rats. In this regard, Poudyal et al. [21], in rats fed a high fructose-high
fat diet, recorded that chia seed normalized systolic blood pressure increasing DPA
and DHA contents in FAs of the heart, and Rousseau et al. [44] showed a decrease
in blood pressure and increased DHA and EPA in cardiac phospholipids in rats
fed a high fructose diet supplemented with either DHA or EPA. Interestingly, we
observed an increase of DHA and ALA in the FA phospholipids of cardiac membrane
in the SRD + chia group (data not shown). Moreover, Vuksan et al. [45] showed
that a long-term supplementation with Salba (S. hispanica L) attenuates systolic
blood pressure and emerging cardiovascular risk factors, safely beyond conventional
therapy, while maintaining good glycemic and lipid control in well-controlled type-2
diabetic patients.
5. Conclusions
In brief, this study demonstrated that the lipotoxicity present in the heart
of SRD-fed rats, an experimental model of dyslipidemia and insulin resistance,
is accompanied by changes involving lipid metabolism suggesting an impaired
myocardial lipid utilization. In this scenario, and for the first time, this work
also provides new information concerning the possible mechanisms underlying
the beneficial effects of dietary chia seeds on lipid cardiac metabolism and glucose
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oxidation. Although caution is warranted before extrapolating results from rodents
to humans, chia seeds may serve as an alternative dietary strategy in the management
of these metabolic alterations susceptible to dietary manipulation.
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Lipidomics to Assess Omega 3 Bioactivity
Francesco Visioli
Abstract: How can we resolve the conflict between the strong epidemiological
evidence pointing to the usefulness of fish—and, thus, omega 3—consumption
with the debacle of supplementation trials? One potential explanation is that the
null results obtained thus far are the consequences of ill-contrived investigations
that do not allow us to conclude on the effects (or lack thereof) of omega 3 fatty acid
supplementation. One potential solution is through the use of lipidomics, which
should prove very useful to screen suitable patients and to correlate plasma (or red
blood cells, or whole blood, or phospholipid) fatty acid profile with outcomes. This
has never been done in omega 3 trials. The wise use of lipidomics should be essential
part of future omega 3 trials and would help in untangling this current riddle.
Reprinted from J. Clin. Med. Cite as: Visioli, F. Lipidomics to Assess Omega
3 Bioactivity. J. Clin. Med. 2015, 4, 1753–1760.
1. Introduction
Fish consumption is directly associated with better cardiovascular prognosis [1].
From the first observations made in Greenland to the latest randomized controlled
trials (RCT), long-chain omega 3 fatty acids, namely docosahexaenoic (DHA) and
eicosapentaenoic (EPA) fatty acids have been held responsible for the health effects of
fish [1]. One notable example is that of the omega 3 index, which is influenced
by omega 3 consumption and is a strong predictor of cardiovascular risk [2].
Consequently, much research has been devoted to elucidating, in vitro and in vivo,
the protective activities of EPA and DHA; indeed, the general perception is that
supplementary intake of these fatty acids would protect from cardiovascular disease
and other degenerative pathologies. Suggesting consumption of adequate amounts
of omega 3 fatty acids actually makes biological sense; these fatty acids are important
in that mammals cannot efficiently synthesize them and they are indispensable to a
number of biological processes, especially those that involve excitable cells such as
cardiomyocytes, neurons, retinal cells, etc. [1]. In addition, nearly every randomized
clinical trial reported that omega 3 fatty acids positively modulate surrogate markers
of cardiovascular disease and in vitro studies explored a wide range of mechanisms
underlying the purported beneficial activities of EPA and DHA. The sad truth
is that, when given as supplements, long chain omega 3 fatty acids are—very
likely—ineffective in affording better health [3]. The big question is why [4]? What is
wrong [5]? Indeed, this is probably the major current conundrum in pharma-nutrition
research, with fish oils threatening to join the vitamin E, beta-carotene, resveratrol,
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etc. in the dustbin of promising nutritional therapies that failed to show benefit in
RCTs [6–8].
2. Omega 3 Fatty Acids in Cardiovascular Therapy
How can we reconcile this apparent failure with strong epidemiological evidence
pointing to the usefulness of fish—and, thus, omega 3—consumption? One potential
explanation is that the null results obtained thus far are the consequences of
ill-contrived trials that do not allow one to draw firm conclusions on the effects
(or lack thereof) of omega 3 fatty acid supplementation [9].
In this respect, one paradigmatic example is that of folate in stroke prevention.
In a well-designed trial recently published by Huo et al. [10], the highest risk of stroke
and the greatest benefit of folic acid therapy were seen in patients with the lowest
baseline folate levels. In addition, Huo et al. [10] suggest that individuals with the TT
genotype may require a higher dosage of folic acid supplementation to overcome
biologically-insufficient levels (as reflected in the relatively greater folate requirement
for subjects with the TT genotype).
Unfortunately, neither basal plasma concentrations nor genotype/nutrigenomics
issues have ever been taken into consideration in omega 3 supplementation studies [9].
The natural consequence is that the near totality of omega 3 trials could not really
conclude that modulation of omega 3 status is ineffective. This situation is unheard of
in classic drug research, where surrogate markers, e.g., blood pressure of cholesterol
concentrations, are mandatorily assessed before and after interventions on these
risk factors.
In this respect, the use of lipidomics in RCTs should prove very useful to
screen patients first and to correlate plasma (or red blood cells, or whole blood, or
phospholipid) fatty acid profile with outcomes.
3. Lipidomics
From a technical viewpoint, lipidomics can be conveniently classified into as two
distinct approaches: A “shotgun”, i.e., electrospray ionization coupled with single
stage or tandem mass spectrometry approach and a liquid chromatography-mass
spectrometry (LC-MS)-based one. The shotgun approach does not require separation
prior to MS analyses. The shotgun approach is being considered as the best method
for analysis of lipid extracts. Its major advantage over other methods is that mixtures
of lipids are directly infused and sprayed into the mass spectrometer, therefore
analyzing all the molecules collectively [11]. In this way, shotgun lipidomics,
when applied to whole tissue lipid extracts, generates molecular ions without
extensive fragmentation of the molecules. This type of lipidomics allows the
identification and quantitation of the lipids in complex mixtures and provides helpful
global information about cellular and tissue lipidomes. The procedures generate
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quasi-molecular ions in high yields. The major limitation of shotgun lipidomics is
that the most abundant or most efficiently ionized molecules “quench” the signal
of other ones, in turn causing ion suppression and hampering detection of lipids
that are present in lower concentrations [12]. Therefore, intra-source separation
is often employed to overcome this limitation. Mostly, the analytical setting
of lipidomics involves a triple-quadrupole mass spectrometer with electrospray
ionization (ESI, primarily negative mode) in selective reaction monitoring (SRM)
or multiple reaction monitoring (MRM) to maximize sensitivity [12]. Whereas
reversed-phase chromatography, i.e., C18, is the first separation choice, hydrophilic
interaction liquid chromatography (HILIC) is best for phospholipids, sphingolipids,
and phosphatidylcholines [12]. In summary, the most appropriate methodological
approach should be based on the goals of the analysis and, in the future, we might
witness a combination of techniques that would match ease of use with accuracy.
When mass spectral equipment is available in clinical laboratories, lipidomics
can be applied to clinical studies. Current bottlenecks include sample handling
methods and data reduction and analysis of the enormous volume of data generated
by contemporary mass spectrometric analysis. However, this rapidly evolving
field can rapidly elucidate the lipidome in medical samples of small size. Of note,
current techniques can identify thousands of distinct lipid molecular species, of
which the most biologically important ones are fatty acyls, glycerolipids (neutral),
glycerophospholipids (polar), sphingolipids, sterols, and prenols [13,14].
4. Lipidomics Applied to Fatty Acid Research
As mentioned, the lipidome provides useful information on the basal omega
3 status of patients or healthy volunteers and can greatly help resolve the current
omega 3 conundrum in cardiovascular research/clinic. To date, lipidomics have been
applied to observational and preclinical models of cardiovascular disease, including
mice, hamsters, rabbits, and pigs, and nonhuman primates.
Example of observational research include the use of lipid profiling in diabetes
mellitus [15,16], cardiovascular disease [17,18], metabolic disorders [19], dietary
habits, and obesity [20], as well as in determining response to drug therapy
(elegantly reviewed by Hinterwirth et al. [13]). These techniques can provides useful
information on the lipid composition and profile of whole blood or of tissues e.g.,
the retina [21], atherosclerotic plaques [22], muscles [23], or adipose tissue [24].
In terms of cardiovascular disease and lipid profiling, some examples are worth
our attention. The use of olive oil as a predominant source of fat has been consistently
associated with better cardiovascular prognosis. Most researchers are still attributing
the purported healthful properties of olive oil to its relatively high monounsaturated
fatty acids (MUFAs) content [25]. The theory behind this is that MUFAs,
namely oleic acid, favorably modifies the high-density lipoprotein/low-density
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lipoprotein (HDL/LDL) ratio and, therefore, afford cardiovascular protection [25].
Yet, accumulated evidence clearly indicates that MUFAs only mildly modify the
HDL/LDL ratio, to an extent that should minimally influence cardiovascular risk [26].
Moreover, at least two lipidomic studies [27,28] show that the proportion of MUFAs
is higher in red blood cells and whole blood, respectively, of myocardial infarct
patients as compared with controls, confirming findings from the large dataset of
Stegeman et al. [17]. In summary, the hypothesis that MUFAs are cardioprotective and
that increasing their intake would benefit the cardiovascular system is still unproven.
Lipidomics have also been employed in pharmaceutical research [11], namely to
assess the effects of selected drugs on hypertension [29] and cardiovascular disease,
in particular when recombinant HDL [16] and statins [30] were employed.
Within the context of this paper, it is worth reiterating that lipidomics have
never been applied to omega 3 intervention trials and that precisely this improper
approach is leading to pallid conclusions on their therapeutic roles.
5. Examples of Lipidomics Applied to Omega 3 Research
As mentioned, the near totality of omega 3 trials did not include baseline or
post-treatment evaluations of omega 3 status in patients of healthy volunteers. In
rats, lipidomics have been successfully employed by Lamaziere and coworkers
to assess the effects of omega 3 supplementation on hepatic lipogenesis [31] and
brain composition [32]. Additionally, this technique allowed the identification of the
in vitro concentrations to be employed in cardiac biochemistry studies [33]. It is worth
noting that, even though rats are given identical feed, their tissutal omega 3 status
varies greatly [31–33]. One can only speculate that these differences are enhanced in
humans who consume varied diets. Additionally, omega 3 supplementation reduces
such inter-individual variations (Figure 1) and renders the omega 3 composition of
organs and tissues more homogeneous [31–33].
Another mechanistic application of lipidomics to omega 3 research concerns the
differential distribution of DHA and EPA in the various lipid classes. As an example,
the former mostly accumulates into phospholipids whereas the latter contributes to
cholesterol esters [34]. Likely, the biological importance of phospholipids is higher
than that of cholesterol esters because they originate from important lipid mediators;
their compositional modulation by diet or supplement should result into more
relevant biological actions.
Finally, we should not forget that the in vivo effects of omega 3 fatty acids
likely depend on capsules’ formulation, i.e., tryacylglycerols vs. ethyl esters vs.
phospholipids [35] and on whether they are taken as supplements or as part of
food items (either food as such [36] or functional food such as milk [37,38]). It is
conceivable that omega 3 fatty acids’ bioavailability and subsequent distribution in
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the body might be different depending on the matrix [35]. This can be explored by
proper lipidomic approaches.
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Figure 1. Example of lipidomics applied to omega 3 research: dendrogram
resulting from the hierarchical cluster analysis of atrial rat cardiomyocytes
isolated from control and docosahexaenoic (DHA)-treated rats. Unpublished data.
Methodological details can be found in Lamaziere et al. [33].
In recent years, much investigation has been dedicated to bioactive small
molecules that activate the resolution of acute inflammation [39]. These molecules
are autacoids that include resolvins, protectins, and maresins, which are formed
from EPA and DHA during acute inflammation. Interestingly, resolvins and
protectins can currently be synthesized [40], which paves the way to their future
use in therapy. Lipid-mediator lipidomic profiling of self-resolving exudates (after
solid-phase extraction) allowed framing the time course of inflammation resolution
and elucidating the roles played by these important omega 3-derived molecules [40].
Alas, the lipidomic methods that have been successfully employed to clarify the lipid
mediator profiles of phagocytes and inflammatory exudates [41] have never been
employed in omega 3 clinical trials, thus preventing drawing firm conclusions on
their real contribution to the resolution of inflammation in humans.
6. Conclusions
While the assessment of relevant biomarkers, e.g., blood pressure, glycaemia,
or cholesterol is habitual in pharmacological research, research in the omega 3 area
has been hampered by the lack of baseline and post-treatment measurements of fatty
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acid levels. This prevents drawing solid conclusions on the true healthful role of
these essential fatty acids. While it is tempting—based on cumulated evidence—to
state that the omega 3 myth has been debunked, we need much more focused
research before solid conclusions be reached and before we can educe evidence-based
recommendations for or against using omega 3 supplements. This is even more
relevant for cardiovascular patients who, as reviewed elsewhere [9], are treated
with effective and potent drugs and might enjoy additional benefits from omega
3 supplementation only if their basal concentrations are low, i.e., with an omega
3 index <4%.
The wise use of lipidomics should be essential part of future omega 3 trials and
would help untangle this current riddle.
Conflicts of Interest: The author declares no conflict of interest.
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Using Caenorhabditis elegans to Uncover
Conserved Functions of Omega-3 and
Omega-6 Fatty Acids
Jennifer L. Watts
Abstract: The nematode Caenorhabditis elegans is a powerful model organism to study
functions of polyunsaturated fatty acids. The ability to alter fatty acid composition
with genetic manipulation and dietary supplementation permits the dissection of
the roles of omega-3 and omega-6 fatty acids in many biological process including
reproduction, aging and neurobiology. Studies in C. elegans to date have mostly
identified overlapping functions of 20-carbon omega-6 and omega-3 fatty acids in
reproduction and in neurons, however, specific roles for either omega-3 or omega-6
fatty acids are beginning to emerge. Recent findings with importance to human health
include the identification of a conserved Cox-independent prostaglandin synthesis
pathway, critical functions for cytochrome P450 derivatives of polyunsaturated fatty
acids, the requirements for omega-6 and omega-3 fatty acids in sensory neurons, and
the importance of fatty acid desaturation for long lifespan. Furthermore, the ability
of C. elegans to interconvert omega-6 to omega-3 fatty acids using the FAT-1 omega-3
desaturase has been exploited in mammalian studies and biotechnology approaches
to generate mammals capable of exogenous generation of omega-3 fatty acids.
Reprinted from J. Clin. Med. Cite as: Watts, J.L. Using Caenorhabditis elegans to
Uncover Conserved Functions of Omega-3 and Omega-6 Fatty Acids. J. Clin. Med.
2016, 5, 19.
1. Introduction
The adage “you are what you eat” is especially true regarding fat. Specific
types of fat in the human diet have important biological consequences on health and
wellness. Long chain polyunsaturated fatty acids (PUFAs) are dietary requirements
for humans and other mammals. Essential fatty acids can be classified as omega-6,
or omega-3, depending on the position of the terminal double bond relative to
the methyl end of the fatty acids. For example, the omega-6 fatty acid linoleic
acid (LA, 18:2) is an 18-carbon fatty acid with double bonds at carbons 9 and 12,
while the omega-3 fatty acid alpha-linolenic acid (ALA, 18:3) is an 18-carbon fatty
acid with double bonds at carbons 9, 12, and 15. The essential fatty acids can be
elongated and further desaturated to generate a range of 20- and 22-carbon omega-6
and omega-3 fatty acids [1]. Omega-6 fatty acids are prevalent in vegetable oils,
especially corn, safflower, and soybean oil, while omega-3 fatty acids are found in
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fishes such as salmon and tuna. Because humans cannot interconvert omega-6 and
omega-3 fatty acids, the ratio of omega-6 to omega-3 fatty acids is determined by
dietary intake [2]. This is important because, in spite of their structural similarity, the
biological functions of omega-6 and omega-3 fatty acids can be quite divergent [3].
Long chain fatty acids from the omega-3 and omega-6 families play crucial
roles in membrane structure and function [4]. For example, the cis double bonds
influence lipid packing, membrane fluidity [5], and membrane protein activity [6].
Omega-3 and omega-6 fatty acids are precursors for potent signaling molecules, and
signals produced from omega-3 versus omega-6 PUFAs can sometimes have opposing
effects [3]. Upon stimulation, long chain omega-6 and omega-3 fatty acids are cleaved
from membrane lipids by phospholipases and oxygenated by cyclooxygenase,
lipoxygenase, or cytochrome P450 enzymes to form a wide range of prostaglandins,
leukotrienes, lipoxins, as well as hydroxy-, epoxy-, and hydroperoxy-derivatives [7,8].
These molecules, collectively termed “eicosanoids” act as powerful short range
hormones affecting inflammation, immune responses, and reproductive processes [9].
PUFAs are important components of endocannabinoids, which are ethanolamide
derivatives of phospholipids that bind to endocannabinoid receptors to regulate
memory, appetite, mood, and pain sensation [10,11]. Finally, both omega-3 and
omega-6 PUFAs and their eicosanoid derivatives are ligands for transcription
factors, and therefore they influence gene expression. In addition to known
receptors for eicosanoid and ethanolamide derivatives, an omega-3 fatty acid
receptor, GPR120, has recently been identified [12,13]. Substantial evidence exists
for opposing functions of omega-3 and omega-6 fatty acids in the regulation of
inflammation, primarily that eicosanoids derived from most omega-6 fatty acids
have pro-inflammatory effects, while those derived from omega-3 fatty acids do not
(reviewed in [3]). However, opposing functions for omega-3 and omega-6 fatty acids
in non-inflammatory processes are not well defined.
2. Why Study Fatty Acid Functions Using C. elegans?
An attractive animal model for studies of fatty acid function is the roundworm
C. elegans. This popular model organism is easy and inexpensive to maintain in
the lab, and its well-understood developmental programs, simple anatomy, short
lifespan, well-annotated genome, and ease of genetic analysis allow for studies
of diverse biological processes, including those related to human nutrition and
disease [14]. In the lab, the nematodes grow on petri plates on lawns of Escherichia
coli bacteria, which provide dietary nutrients, including proteins, carbohydrates, and
saturated and mono-unsaturated fatty acids derived from digestion of bacterial
membranes [15]. However, C. elegans are capable of synthesizing all necessary
fatty acids de novo, and the core enzymes of fatty acid biosynthesis are conserved,
including acetyl CoA carboxylase, fatty acid synthase, and a range of fatty acid
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desaturase and elongase activities, enabling C. elegans to synthesize long chain PUFAs
including arachidonic acid (AA, 20:4) and eicosapentaenoic acid (EPA, 20:5) [16]
(Figure 1A). Unlike most other animal species, the C. elegans genome encodes an
omega-3 desaturase enzyme that can convert 18-carbon and 20-carbon omega-6 fatty
acids into omega-3 fatty acids [17], along with a ∆12 desaturase, which catalyzes the
formation of LA from oleic acid (OA, 18:1) [18]. Thus, C. elegans does not have any
dietary fatty acid requirements. Like most other animals, C. elegans also possesses ∆6
and ∆5 desaturase enzymes, which act, in conjunction with fatty acid elongases, on
similar substrates used by mammals and other animals to form 20-carbon PUFAs [19].
However, C. elegans lacks the specific elongase activity to produce 22-carbon PUFAs.
Strains containing mutations in genes of the fatty acid desaturation pathway facilitate
functional studies of PUFAs, because fatty acid composition can be manipulated




Figure  1.  (A)  Biosynthesis  of  omega‐6  and  omega‐3  fatty  acids  in  C.  elegans. Unlike most  other 
animals, C. elegans possesses  ∆12 desaturase  and  ω3 desaturase  enzymes,  and  therefore does not 
require essential dietary  fatty acids  to synthesize a range of omega‐6 and omega‐3  fatty acids;  (B) 
Mutant strains lacking functional desaturase enzymes are depleted in specific polyunsaturated fatty 
acids. The area of each  circle  represents  the  ratio of  specific  fatty acids  relative  to  total  fatty acid 
content. Data shown are representative examples of multiple GC/MS measurements. Abbreviations: 
ELO, elongase; SA, stearic acid; OA, oleic acid; LA,  linoleic acid; ALA, alpha‐linolenic acid; GLA, 







acids  (MUFAs). One  ∆9  desaturase,  FAT‐5,  uses  palmitic  acid  (16:0)  as  a  substrate  to  produce 
palmitoleic  acid  (16:1), while  the other  two  ∆9 desaturases, FAT‐6  and FAT‐7 use both  16:0  and 




and omega‐3 PUFAs can be  studied  independently of  their  inflammatory  functions. As might be 
expected, strains carrying mutations in the desaturase genes acting early in the pathway, such as ∆9 
desaturases  (fat‐6;fat‐7  double mutants),  ∆12  desaturase  (fat‐2 mutants),  and  ∆6  desaturase  (fat‐3 
mutants)  have  more  severe  lipid  composition  changes,  as  well  as  more  severe  phenotypic 
consequences, such as growth, movement, and reproductive defects, than strains carrying mutations 
in desaturases acting later in the pathway, such as the ∆5 desaturase [20,21,25] (Figure 1B). C. elegans 
has  been  a  powerful  model  for  unraveling  mechanisms  of  development,  neurobiology,  and 
longevity, and the studies reviewed below demonstrate how fatty acid function is involved in these 
fundamental biological processes. 
Figure 1. (A) Biosynthesis of omega-6 and omega-3 fatty acids in C. elegans.
Unlike most other animals, C. elega s possesses ∆12 desaturase andω3 desaturase
enzymes, and therefore does not require essential dietary fatty acids to synthesize a
range of omega-6 and omega-3 fatty acids; (B) Mutant strains lacking functional
desaturase enzymes are epleted in specific polyunsaturated fatty acids. The
area of each circle represents the ratio of specific fatty acids relative to total
fatty acid content. Data shown are representative examples of multiple GC/MS
measurements. Abbreviations: ELO, elongase; SA, stearic acid; OA, oleic acid;
LA, linoleic acid; ALA, alpha-linolenic acid; GLA, gamma-linolenic acid; STA,
stearidonic acid; DGLA, dihommo gamma-linolenic acid; ETA, eicosatrienoic acid;
AA, arachidonic acid; EPA, eicosapentaenoic acid. Figure is modified from [23].
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3. C. elegans Mutants Lacking Fatty Acid Desaturase Activity Are Useful for
Studies of Conserved Functions of Omega-6 and Omega-3 Fatty Acids
The C. elegans genome contains single genes encoding the ∆12, ∆5, ∆6, and
omega-3 desaturase enzymes necessary for the biosynthesis of a range of omega-6
and omega-3 PUFAs. There are three genes encoding the ∆9 desaturases, which
convert saturated fatty acids into monounsaturated fatty acids (MUFAs). One ∆9
desaturase, FAT-5, uses palmitic acid (16:0) as a substrate to produce palmitoleic acid
(16:1), while the other two ∆9 desaturases, FAT-6 and FAT-7 use both 16:0 and stearic
acid (18:0) as substrates to produce (16:1) and oleic acid (18:1) [24]. Mutant strains
lacking functional desaturase enzymes have been isolated and used for many studies
of functions of specific fatty acids in reproduction, longevity and neurobiology.
Because roundworms do not have blood vessels, nor do they express inflammatory
markers such as TNFα and NFκβ, the roles of omega-6 and omega-3 PUFAs can
be studied independently of their inflammatory functions. As might be expected,
strains carrying mutations in the desaturase genes acting early in the pathway, such
as ∆9 desaturases (fat-6;fat-7 double mutants), ∆12 desaturase (fat-2 mutants), and
∆6 desaturase (fat-3 mutants) have more severe lipid composition changes, as well as
more severe phenotypic consequences, such as growth, movement, and reproductive
defects, than strains carrying mutations in desaturases acting later in the pathway,
such as the ∆5 desaturase [20,21,25] (Figure 1B). C. elegans has been a powerful model
for unraveling mechanisms of development, neurobiology, and longevity, and the
studies reviewed below demonstrate how fatty acid function is involved in these
fundamental biological processes.
4. Functions of Omega-6 and Omega-3 Fatty Acids in C. elegans Reproduction:
Sperm Guidance and Germ Cell Maintenance
PUFAs are required for efficient reproduction in many animal species, although
specific mechanisms in invertebrates are just starting to be elucidated [26]. Initial
characterization of fat-2, fat-3 and fat-6;fat-7 mutants lacking 20-carbon PUFAs
revealed slow growth and greatly reduced reproductive capacity in the mutant
strains [20,21,25]. It is likely that PUFAs are required for multiple processes to
ensure optimum reproductive output. One process characterized by the Miller lab
involves signaling molecules derived from PUFAs that are required in the female
germ line for sperm guidance toward oocytes [27]. When wild-type males were
mated to fat-2 mutants, which are unable to synthesize PUFAs, the sperm failed
to migrate toward the spermatheca, the region of the uterus where fertilization
occurs. However, when fat-2 mutants were provided dietary 20-carbon PUFAs, either
omega-3 or omega-6 species, sperm migration greatly improved [27]. It is likely that
the signaling is mediated by prostaglandin derivatives of omega-3 and omega-6
PUFAs, because directly injecting nanomolar concentrations of human F-series
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prostaglandins promoted sperm movement [28]. A range of F-series prostaglandins
are synthesized in the C. elegans germ line, including those derived from both
omega-3 and omega-6 PUFAs [29]. Interestingly, C. elegans does not encode a clear
homolog of the mammalian cyclooxygenase enzyme that is the rate-limiting step
of prostaglandin synthesis. Instead, metabolite analysis revealed an alternative
prostaglandin synthesis pathway that does not involve prostaglandin-D or -E
intermediates [29,30]. The Miller lab took full advantage of whole-organism genetic
approaches to discover that the synthesis of F-series prostaglandins is regulated by
both insulin signaling in the intestine and TGF-β signaling in sensory neurons in
order to finely control reproductive output [28,31]. Both of these signaling pathways
respond to food availability, thus, during food scarcity, prostaglandin biosynthesis
is reduced, leading to reduced efficiency of sperm locating the fertilization site,
ultimately resulting in a lower fertilization rate. Interestingly, the alternative
Cox-independent prostaglandin pathway may be conserved in mammals, because
F-class prostaglandins have been detected in Cox double knockout mice [31].
While 20-carbon omega-6 and omega-3 PUFAs are redundant in their ability
to promote proper sperm migration to oocytes, a role for divergent activities of
omega-6 and omega-3 PUFAs in reproduction is suggested by dietary studies.
Watts and Browse discovered that dietary supplementation of the omega-6 PUFA
dihomogamma linolenic acid (DGLA, 20:3n-6) resulted in sterility due to the
destruction of germ cells [32]. Supplementation of arachidonic acid (AA, 20:4n-6)
also led to germ cell death, although at a much higher concentration than DGLA. On
the contrary, supplementation with omega-3 fatty acids, such as eicosapentaenoic
acid (EPA, 20:5n-3) had no adverse effects on the nematodes [32]. Genetic analyses
revealed a large number of gene mutations that altered the sensitivity to DGLA.
For example, the fat-1 mutant strain, which cannot convert omega-6 fatty acids
to omega-3 fatty acids, was more sensitive to dietary DGLA than wild type [32].
On the other hand, stress resistant strains, such as the insulin-like growth factor
receptor daf-2 mutants, did not become sterile when exposed to DGLA [33]. The
daf-2 mutants showed increased transcription of genes involved in detoxification
and stress resistance, suggesting that the negative effects of DGLA may be due to a
toxic product derived from DGLA [33,34]. A recent study from the Watts lab showed
that the negative effects of DGLA in the C. elegans germ line are likely due to the
production of specific epoxide derivatives of DGLA, the synthesis of which depend
on the cytochrome P450 (CYP) enzyme CYP-33E2 [35]. Direct injection of specific
epoxides derived from DGLA, but not those derived from EPA, triggered germ cell
abnormalities resembling cell fusion or failed cytokinesis, which ultimately lead to
apoptosis and germ cell death. Interestingly, even though knockdown of CYP-33E2
in C. elegans led to reduced germ cell death and higher reproductive outputs during
DGLA feeding, the CYP-33E2 knock-down worms had a lower brood size when fed a
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normal diet [35]. This suggests that CYP-33E2 may be producing beneficial epoxides
from other PUFAs, such as EPA, that could be required for optimal reproduction.
5. Functions of Omega-6 and Omega-3 Fatty Acids in Longevity: Critical Roles
for ∆9 Desaturases
Because of its small size, short lifespan, and ease of genetic manipulation,
C. elegans has been a premier organism for discoveries of genetic and physiological
mechanisms regulating aging and longevity [36,37]. Recent lipidomics and genetic
studies suggest roles for specific fatty acids in promoting longevity in C. elegans [38].
PUFAs contain more double bonds than saturated or MUFAs, therefore they are
more likely to undergo peroxidation, which in turn leads to propagation of reactive
oxygen species (ROS), which cause further damage to proteins and nucleic acids.
In many organisms the degree of membrane unsaturation negatively correlates
with lifespan [39]. This concept is supported by a C. elegans study showing a
correlation between long-lived mutants in the insulin signaling pathway and changes
in unsaturated fatty acid composition [40]. The mutants examined had increased
(MUFAs) with decreased PUFAs. Additionally, high concentrations of dietary fish
oil was shown to lead to higher levels of lipid peroxidation products and shorter
lifespan [40,41]. In contrast, another study showed that supplementation of omega-6
PUFAs activates autophagy and promotes long lifespan [42]. Furthermore, several
long-lived mutant strains express higher levels of ∆9 desaturases than wild type [34].
The ∆9 desaturases synthesize MUFAs in mammals, but are the first step in the
synthesis of PUFAs in C. elegans. Thus, the roles of PUFAs in aging are still not clear.
Importantly, the oxidative damage theory of aging, which states that the
accumulation of molecular damage due to ROS is a key contributor to aging, is
currently undergoing a paradigm shift based on experiments in C. elegans [43].
Studies in which worms were grown under oxygen levels ranging from 2%–40%
did not show significant changes in lifespan [44]. In addition, growth of m in
the presence of antioxidants did not always increase lifespan [43], and specific
mutations in antioxidant genes did not always lead to reduced lifespan [43,45,46].
Furthermore, treatment with low levels of chemicals that induce ROS actually
produced increased resistance to oxidative stress and increased lifespan through
the process of stress-induced hormesis [47,48]. Thus, while it is clear that high
levels of ROS cause cellular damage, regulated ROS release and fluctuations in ROS
are important for inducing both signaling and protection pathways [49–52]. This
might explain why lower concentrations of dietary fish oil led to slightly longer
lifespans [41]. It is also crucial to consider that membranes undergo constant
remodeling and turnover. A recent study demonstrated that PUFAs in C. elegans
membranes turn over very rapidly, such that the majority of PUFAs and other
membrane lipids are replaced each day, suggesting that oxidized fatty acids are
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rapidly removed [53]. Knock-down of ∆9 desaturase activity reduces membrane
turn-over, which might lead to increased lipid peroxidation in spite of lower PUFA
production [53]. It appears that the beneficial functions of omega-6 and omage-3
PUFAs might outweigh the potential for oxidative damage conferred by the high
degree of unsaturation.
In animals, dietary resources must be allocated between reproduction and
somatic maintenance, thus reproduction and life span are metabolically linked.
In C. elegans, removal of the germ line results in worms with increased fat stores
and longer lifespan (reviewed in [54,55]). Several recent studies implicate fatty
acid metabolism in long lifespan in germ-line ablated animals. Two nuclear
hormone receptor homologs, NHR-80 and NHR-49, regulate the expression of ∆9
desaturases [56,57], and these two nuclear receptor proteins, as well as the FAT-6
and FAT-7 ∆9 desaturases are required for long lifespan in animals lacking a germ
line [58,59]. Additionally, the lysosomal lipase LIPL-4 and intact autophagy pathways
are required for extended longevity in germ-line less nematodes [60,61]. A recent
metabolomic analysis revealed that a specific lipid species, oleoylethanolamide,
accumulates in worms over-expressing the lipase LIPL-4. This ethanolamide
derivative of oleic acid then directly binds to the lysosomal lipid chaperone LPB-8,
which is then translocated to the nucleus. Oleoylethanolamide also binds to and
activates the nuclear receptor NHR-80, activating transcription of ∆9 desaturases
and promoting longevity [62]. Thus, lipid signaling from the lysosome to the nucleus
has long lasting physiological effects, including lifespan extension.
In humans, diets high in sugars lead to excess lipid storage and ultimately
cause adverse health effects, including obesity, diabetes, and cardiovascular coronary
heart disease [63,64]. In C. elegans, dietary glucose causes shortened lifespan [65,66].
Two transcriptional regulators of ∆9 desaturases, MDT-15 and SBP-1 were recently
shown to protect C. elegans from glucose-induced accelerated aging by preventing
the accumulation of saturated fat [67]. Glucose feeding increases the saturated fatty
acid composition of C. elegans, and MDT-15 and SBP-1 activate ∆9 and other fatty
acid desaturases to prevent saturated fatty acid-induced lipotoxicity by converting
saturated fatty acids into MUFAs and PUFAs [67–70].
A key transcription factor required for increased longevity in germ-line ablated
worms is SKN-1/Nrf. This transcription factor is most studied for its roles in stress
responses, especially to oxidative stress [71]. Interestingly, SKN-1 also regulates the
transcription of lipid metabolism genes that are up-regulated in germ-line deficient
animals, including fatty acid desaturases [71]. When SKN-1 is over-expressed, lipids
are depleted from somatic, but not germ-line tissues [72]. This phenotype is similar
to that seen in wild type worms upon nutrient depletion or exposure to pro-oxidants,
and is also seen in fat-6;fat-7 double mutants lacking 20-carbon PUFAs, as well as in
fat-1;fat-4 double mutants, which accumulate DGLA, but cannot synthesize EPA or
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AA. Supplementation with OA, AA, and EPA, but not other fatty acids, suppressed
the somatic depletion of lipids, suggesting that specific fatty acid species may be
involved in the allocation of germline versus somatic lipids, thereby influencing both
reproduction and longevity [72].
6. Functions of Omega-6 and Omega-3 Fatty Acids in C. elegans Neurons:
Synaptic Vesicle Formation, Signal Transduction in Sensory Neurons, and
Complex Behavioral Responses to Alcohol and Oxygen
Other than adipose tissue, human brain tissue contains the highest proportion
of lipids, with brain phospholipids containing high levels of both omega-6 and
omega-3 PUFAs. Diets deficient in omega-3 and other PUFAs lead to defective
neural function (reviewed in [73,74]). C. elegans has a simplified nervous system
consisting of 302 neurons, and the network of neurons and their connections has been
thoroughly mapped [75]. The fat-3 mutant strain, which lacks 20-carbon omega-6 and
omega-3 PUFAs, shows uncoordinated movement and defective egg laying behavior,
phenotypes which are controlled by motor neurons and hermaphrodite-specific
serotonergic vulva neurons [21,76]. Lesa et al. showed that fat-3 mutants display
defects in neurotransmitter release, and that synaptic vesicles were depleted in
neuronal termini at the neuromuscular junction, indicating that 20-carbon PUFAs are
required for synaptic vesicle formation and accumulation [76].
Sensory neurons are also affected in fat-3 and fat-1;fat-4 double mutants, which
exhibit defects in olfactory chemotaxis behavior to volatile odorants sensed by
AWC neurons, but less or no defective chemotaxis behavior to odorants sensed
by AWA neurons [23]. This genetic evidence implicates PUFAs in specific neuronal
signal transduction pathways. The AWA neurons possess TRPV type channels to
respond to stimulatory signals, whereas the AWC neurons, which are not affected by
PUFA deficiency, use cyclic nucleotide gated channels. Similarly, the ASH sensory
neurons use TRPV channels to respond to noxious stimuli, and stimulate rapid escape
behavior to heavy metals, high osmolarity, and nose touch. The fat-3 and fat-1;fat-4
double mutants showed behavioral defects upon exposure to these stimuli, and
were rescued by dietary supplementation of both omega-6 and omega-3 fatty acids,
indicating that PUFAs are also necessary for function in ASH neurons [23]. Direct
calcium imaging of ASH neuronal response in fat-3 mutants showed diminished
calcium responses, while exogenous EPA elicited calcium responses and avoidance
responses in fat-3 mutants, bypassing the PUFA biosynthesis defects, and providing
evidence for 20-carbon omega-6 and omega-3 PUFAs as regulators of in vivo TRPV
channel activity [23].
Olfactory adaptation is the process where sensory neurons reduce their response
to prolonged stimulation. Even though sensory response to volatile odorants sensed
by AWC neurons was nearly normal in PUFA-deficient mutants, adaptation to
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volatile odorants mediated by AWC neurons was abnormal in fat-3 and fat-1;fat-4
mutant strains, and this defect was rescued by dietary PUFAs [77]. Similar to the
findings described above for AWA neurons, this study linked the roles of PUFAs in
olfactory adaptation in AWC neurons to TRPV channels, which in AWC neurons
function downstream of the nuclear accumulation of the cGMP-dependent protein
kinase EGL-4 [77].
In the research described above, omega-6 and omega-3 fatty acids play
redundant roles in their ability to rescue the neuronal defects, indicating that
both omega-6 and omega-3 fatty acids perform the required cellular functions.
Several recent studies suggest specific roles for omega-6 and omega-3 fatty acids
in neuronal processes. A C. elegans mutant in fatty acid amide hydrolase activity
(faah-1) is defective in the regeneration of axons after laser surgery [78]. Fatty acid
amide hydrolase breaks down endocannabinoids, such as arachidonyl ethanolamide
(AEA). In C. elegans, AEA appears to inhibit axon regeneration via the Goα subunit
GOA-1 [78]. Surprisingly, eicosapentaenoyl ethanolamide (EPEA), derived from
EPA, shows less inhibitory activity, even though EPEA is much more abundant
in C. elegans tissues than AEA [79]. On the other hand, omega-3 fatty acids are
specifically required for the process of alcohol tolerance [80], a neuroadaptive process
that compensates for the effects of alcohol in humans and in C. elegans [81]. This
study showed that unlike wild type nematodes, fat-3, fat-4, and fat-1 mutants did not
recover movement after exposure to ethanol. EPA, but not AA supplementation was
necessary and sufficient for the neuroplasticity required to compensate for the effects
of alcohol intoxication in C. elegans [80]. Finally, AA in phospholipids, but not EPA, is
required for neurons responding to light touch [82]. The Goodman lab found that fat-3
and fat-4 mutants, neither of which can synthesize AA, showed reduced response
to touch. AA, but not EPA, rescued touch sensitivity in fat-3 and fat-4 mutants.
Interestingly, eicosatetraynoic acid (EYTA), a non-metabolizable structural analog of
AA, also rescued the touch response phenotype. The ability of EYTA to rescue touch
response indicates that AA is not required to be oxidized into an eicosanoid for its
activity. In addition to mutant and dietary supplementation analysis, the researchers
used dynamic force spectroscopy to reveal that AA in phospholipids modulates
biophysical properties of touch receptor neuron membranes to allow for optimal
function [82]. Taken together, these recent studies reveal that omega-6 and omega-3
PUFAs can have distinct roles in neurological processes.
In addition to the alternative prostaglandin synthesis pathway described above,
recent studies demonstrate that in C. elegans, omega-3 and omega-6 fatty acids are
modified into eicosanoid-like molecules by the actions of CYP enzymes, and that
these CYP-derived eicosanoids have important biological functions. Studies from
Menzel’s group revealed that CYP-33E2, which is most closely related to human
CYP2J2, prefers EPA over AA as a substrate, and produces epoxyeicosatetraenoic
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acid (17,18-EEQ) as its main product [83]. CYP-29A3 is most closely related to
human CYP4, and it uses AA to produce the hydroxyl derivative 20-HETE [84].
These eicosanoids have opposing effects on pharyngeal pumping and food uptake,
with 17,18-EEQ mimicking the effects of the neurohormone serotonin on fasted
worms, where both the eicosanoid and serotonin stimulate pharyngeal pumping.
In contrast, 20-HETE and octopamine reduced pharyngeal pumping and food
intact in well-fed worms [85]. Furthermore, 17,18-EEQ synthesis is increased upon
serotonin supplementation, while 20-HETE synthesis increases upon application of
octopamine [85], implicating eicosanoids as mediators of neurohormones affecting
food intake. Another CYP enzyme, CYP-13A12, acts on PUFAs to respond oxygen
levels [86]. In humans, reoxygenzation after oxygen deprivation causes tissue damage
due to inflammation [87]. The C. elegans study showed that CYP-13A12 responds
to the oxygen-dependent enzyme EGL-9 and hypoxia-inducible factor (HIF-1) to
facilitate a movement response to reoxygenation after oxygen deprivation [86].
CYP-13A12 generates epoxy and hydroxyl eicosanoids from AA and EPA, including
14,15-epoxyeicosatrienoic acid (14,15-EET) from AA and 17,18-EEQ from EPA [88].
This research implicates conserved roles for omega-6 and omega-3 PUFAs and
eicosanoid formation in ischemia and reperfusion.
7. Using the C. elegans Fat-1 Gene for Studies in Mammals: Endogenous
Omega-3 Functions and Biotechnology Applications
The discovery of the first animal omega-3 desaturase, the C. elegans FAT-1
desaturase [17], enabled Kang to construct the fat-1 transgenic mouse, which
expresses the C. elegans omega-3 desaturase and permits the conversion endogenous
omega-6 to omega-3 fatty acids in mammalian tissues [89]. Lipidomic analysis
revealed hundreds of specific lipid species that are altered between wild type and the
fat-1 mouse, including EPA and DHA-containing phospholipids and cholesterol
esters, as well as many species of EPA-derived epoxides and diols formed via
CYP enzymes [90]. Studies using the fat-1 mouse model now appear in numerous
publications in which researchers examined the effects of endogenously synthesized,
as opposed to dietary, omega-3 fatty acids on a range of processes in a mammalian
model. This research provides evidence that increased production of omega-3
PUFAs, coupled with a reduction in omega-6 PUFAs, protects mammals from a
range of diseases, including cancer, diabetes and inflammatory diseases (reviewed
in [91–95]). Recent studies reveal new insights into molecular mechanisms in which
omega-3 PUFAs protect against various disease outcomes as diverse as diabetic
neuropathy [96], fatty liver disease [97], pancreatic beta cell death [98], and vascular
inflammation [99]. Thus, the fat-1 mouse model promises to be central to unraveling
the mechanisms of omega-3 and omega-6 fatty acids in health and disease.
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The success of expressing the C. elegans fat-1 omega-3 desaturase gene in mice
led the way for expression of fat-1 in other mammals. Because modern diets are
thought to be deficient in omega-3 fatty acids, increasing omega-3 fatty acids in
human food is desirable [100]. Concerns regarding heavy metal contamination
of marine fish [101], as well as depletion of ocean fish stocks due to overfishing,
lead to a desire for alternative sources of omega-3 fatty acids in human diets. The
creation of transgenic farm animals, such as pigs [102–104] and cattle [105,106], set
the stage for using nematode fat-1 genes to someday provide milk and meat with
higher omega-3 content to human consumers. However, more studies are needed to
ensure the safety of food produced from transgenic animals. In addition, altering
the omega-3/omega-6 ratio in farm animals might have adverse effects on their
reproduction, as lower brood size was observed in mice expressing fat-1 in their
mammary glands [107].
8. Conclusions and Future Studies
Discoveries made using model organisms have had significant impact on
human medicine. For example, C. elegans research has been crucial for the
elucidation of genetic pathways underlying programmed cell death, longevity,
and signal transduction pathways that occur during development as well as
during carcinogenesis (reviewed in [14]). This research has led to the discovery
of drug targets and novel therapeutics in humans. Studies in C. elegans regarding
non-inflammatory functions of PUFAs clearly demonstrate that 20-carbon PUFAs
play key roles in reproduction and in the nervous system. While it appears that many
functions of 20-carbon omega-6 and omega-3 fatty acids are redundant, examples of
specific functions for DGLA, AA and EPA are beginning to emerge [35,42,80,82,85].
Genetic analysis and simple physiology render the C. elegans model especially
useful for studies of PUFA functions in reproduction, development, and longevity,
because vertebrate models are much more difficult, time consuming, and expensive
to manipulate. Roles of PUFAs in longevity are just starting to be examined, and
several studies suggest that ∆9 desaturase is a pro-longevity factor. Future studies are
needed to determine if PUFA activity depends on being metabolized into eicosanoids
or other signaling molecules, or whether their functions are derived from membrane
biophysical properties or direct interactions with membrane proteins. Similarly,
the identification of C. elegans receptors for PUFAs and eicosanoids, as well as the
identification of specific signal transduction pathways that are affected by PUFA
composition, will allow for more mechanistic studies. It is likely that mammalian
studies using the fat-1 transgenic mouse will continue to be fruitful because the
transgene can be crossed into numerous genetic models of disease, thereby examining
the effects of endogenous omega-3 fatty acid production on many different disease
outcomes. In summary, C. elegans is a powerful model for the integration of dietary
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and genetic studies for PUFA function in reproduction, development, neuroscience
and aging.
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Nutritional-Preconditioning by Long Chain
n-3 Polyunsaturated Fatty Acids in the Rat
Grace G. Abdukeyum, Alice J. Owen, Theresa A. Larkin and Peter L. McLennan
Abstract: Reactive oxygen species paradoxically underpin both ischaemia/
reperfusion (I/R) damage and ischaemic preconditioning (IPC) cardioprotection.
Long-chain omega-3 polyunsaturated fatty acids (LCn-3 PUFA) are highly susceptible
to peroxidation, but are paradoxically cardioprotective. This study tested the
hypothesis that LCn-3 PUFA cardioprotection is underpinned by peroxidation,
upregulating antioxidant activity to reduce I/R-induced lipid oxidation, and the
mechanisms of this nutritional preconditioning contrast to mechanisms of IPC. Rats
were fed: fish oil (LCn-3 PUFA); sunflower seed oil (n-6 PUFA); or beef tallow
(saturated fat, SF) enriched diets for six weeks. Isolated hearts were subject to:
180 min normoxic perfusion; a 30 min coronary occlusion ischaemia protocol then
120 min normoxic reperfusion; or a 3 ˆ 5 min global IPC protocol, 30 min ischaemia,
then reperfusion. Dietary LCn-3 PUFA raised basal: membrane docosahexaenoic acid
(22:6n-3 DHA); fatty acid peroxidisability index; concentrations of lipid oxidation
products; and superoxide dismutase (MnSOD) activity (but not CuZnSOD or
glutathione peroxidase). Infarct size correlated inversely with basal MnSOD activity
(r2 = 0.85) in the ischaemia protocol and positively with I/R-induced lipid oxidation
(lipid hydroperoxides (LPO), r2 = 0.475; malondialdehyde (MDA), r2 = 0.583) across
ischaemia and IPC protocols. While both dietary fish oil and IPC infarct-reduction
were associated with reduced I/R-induced lipid oxidation, fish oil produced
nutritional preconditioning by prior LCn-3 PUFA incorporation and increased
peroxidisability leading to up-regulated mitochondrial SOD antioxidant activity.
Reprinted from J. Clin. Med. Cite as: Abdukeyum, G.G.; Owen, A.J.; Larkin, T.A.;
McLennan, P.L. Up-Regulation of Mitochondrial Antioxidant Superoxide Dismutase
Underpins Persistent Cardiac Nutritional-Preconditioning by Long Chain n-3
Polyunsaturated Fatty Acids in the Rat. J. Clin. Med. 2016, 5, 32.
1. Introduction
Regular consumption of fish or fish oil reduces cardiovascular mortality [1],
often without modifying classical risk factors. For example, sudden death is reduced
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in high-risk post-MI patients, without significant reductions in blood pressure, blood
lipids or prevention of new cardiac events [2]. This cardioprotection, associated
with omega-3 long-chain polyunsaturated fatty acid (LCn-3 PUFA) consumption,
is observed independently of the prevention of ischaemic events [3], and therefore
supports a cardiac origin related to incorporation of the fatty acids into myocardial
membranes [4]. Ischaemic preconditioning (IPC) is a powerful cardioprotective
process, wherein brief periods of ischaemia, insufficient to produce cellular damage,
can protect the myocardium from the damaging effects of a subsequent more
prolonged ischaemic insult. The protective envelope of IPC is twofold, categorised as:
classical or early preconditioning, which provides cardioprotection for several hours
after the IPC stimulus; with a second phase called late or delayed preconditioning
which occurs 24–7 h after the stimulus. Experimentally, the LCn-3 PUFA confer their
cardioprotection in part through nutritional preconditioning of the myocardium
that in rat heart is at least as effective in reducing infarct size [5,6] and promoting
post-ischaemic contractile recovery [5], and more effective in preventing ischaemia
or reperfusion induced cardiac arrhythmias [5], as early ischaemic preconditioning
(IPC). Classical, early IPC cardioprotection disappears within several hours of the
initial preconditioning stimulus and repeated brief preconditioning episodes become
ineffective in providing this early protection [7]. In contrast, the cardioprotection
derived from dietary LCn-3 PUFA is obtained only after they are incorporated
into and continuously present in the myocardium for at least seven days and it
persists over weeks or months, for however long elevated membrane content is
sustained [5,8,9]. There is no desensitisation apparent, with acute ischaemia or
reperfusion arrhythmias prevented after five weeks [8] to 52 weeks [10] of continuous
exposure to dietary LCn-3 PUFA. Therefore, the cardioprotective benefit of fish oil
appears to mimic the more sustained, repeatable protection of late IPC and other
persistent preconditioning stimuli [11–13]. Moreover, the LCn-3 PUFA [5] share with
late IPC [14] the capacity to protect against both infarction and myocardial stunning.
Myocardial ischaemia and reperfusion (I/R) stimulates production of reactive
oxygen species (ROS) and depletes antioxidants in the heart, creating oxidative stress,
oxidation of biomolecules and cell damage. Paradoxically, these free radicals also
act as triggers of IPC [15,16]. The highly unsaturated LCn-3 PUFA found in fish oil:
20:5n-3 eicosapentaenoic acid (EPA) and 22:6n-3 docosahexaenoic acid (DHA) with
their numerous bisallylic carbon atoms, are more susceptible to peroxidation and
generation of damaging reactive oxygen species than are shorter, less unsaturated
fatty acids such as 18:2n-6 linoleic acid and 20:4n-6 arachidonic acid [17], which
raises the prospect of adverse effects of fish oil supplementation. However, there
is no clinical evidence to suggest that fish oil supplementation or high fish diets
promote oxidative stress-related cardiovascular disease. In contrast, production of
ROS is a mechanism invoked to explain the paradoxical effects of late IPC in the
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heart, which works by inducing upregulation of endogenous antioxidant protective
mechanisms [16,18]. That protection occurs in lieu of the extreme oxidation of
biomolecules and cell damage that usually occurs with I/R-induced oxidative stress
and antioxidant depletion.
The current study tested the hypothesis that incorporation of LCn-3 PUFA into
myocardial membranes increases their peroxidation potential and basal fatty acid
oxidation, which by their constant presence, in turn increases endogenous antioxidant
enzymes to confer physiological cardioprotective actions against I/R-stimulated
oxidative stress. We propose that this will contrast to the mechanism of early
IPC cardioprotection.
2. Experimental Section
2.1. Animals and Diets
Fifty-four male Wistar rats were randomly assigned to three experimental
dietary groups. For six weeks they were fed one of three iso-energetic diets
containing either predominantly saturated animal fat, n-6 PUFA or LCn-3 PUFA
as the source of fat. The diets were based on the American Institute of Nutrition
AIN93 rat diet, containing all essential vitamins and minerals with gelatine as a
component of the protein source. The diet was prepared with 10% (dry wt) fat (23%
metabolisable energy as fat) consisting of: 7% beef tallow plus 3% olive oil (SF diet);
5% sunflower seed oil plus 5% olive oil (n-6 PUFA diet); or 7% fish oil (Nu-Mega high
DHA tuna fish oil) plus 3% olive oil (LCn-3 PUFA diet). In addition to delivering
diets rich in saturated fat, n-6 PUFA or n-3 PUFA, the oil blends in the LCn-3 PUFA
diet and the n-6 PUFA diet were designed to deliver similar total PUFA, and the oil
blends in the LCn-3 PUFA diet and the SF diet were designed to deliver similar total
n-6 PUFA, as previously described [5]. All diets contained sufficient PUFA to prevent
essential fatty acid deficiency [5].
Animal care and experiments were conducted with the approval of the University
of Wollongong, Animal Care and Ethics Committee according to the guidelines of
the National Health and Medical Research Council, Australia, Australian Code of
Practice for the Care and Use of Animals for Scientific Purposes [19].
2.2. Heart Preparation
After six weeks of feeding, rats were anaesthetised (pentobarbital sodium,
60 mg¨ kg´1 i.p.), the thorax was opened, the heart was rapidly excised, submerged
in ice-cold perfusate to arrest beating, and immediately perfused by an aortic cannula
in the Langendorff mode at a constant pressure of 75 mmHg delivering warm (37 ˝C)
Krebs–Henseleit bicarbonate buffer gassed with 5% CO2 in O2 [5]. The left atrium
was opened and a thin-walled balloon catheter was introduced into the left ventricle,
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with balloon volume adjusted to maintain end diastolic pressure of 6–8 mmHg. 6–0
silk suture was passed through the myocardium closely underlying the left anterior
descending coronary artery near its origin.
2.3. Index Ischaemia and Ischaemic Preconditioning
Each dietary group (n = 18) was separated into groups of n = 6 and randomly
assigned to one of three perfusion protocols for 180 min after initial 30 min
equilibration perfusion (Figure 1).
1. Control normoxia protocol (n = 6 per diet): Hearts were perfused throughout
with oxygenated Krebs–Henseleit solution.
2. Ischaemia protocol (n = 6 per diet): Hearts were normoxically perfused
for 30 min followed by 30 min index-ischaemia and 120 min normoxic
reperfusion. Index-ischaemia was induced by occluding the left anterior
descending coronary artery.
3. Ischaemic preconditioning (IPC) protocol (n = 6 per diet): Hearts were subjected
to three cycles of five minutes global ischaemia (zero perfusion), each followed
by five minutes normoxic reperfusion, prior to the 30 min index-ischaemia then
120 min normoxic reperfusion [5].
On completion of 120 min reperfusion in the ischaemia and IPC protocols,
the coronary artery was re-occluded to reveal the ischaemic zone at risk (I-z/r).
Hearts were then cut into 2 mm slices. The central slice was incubated in a buffer
containing triphenyl-tetrazolium chloride and sodium phosphate (pH 7.4), then
stored in 10% formalin until photographed and analysed for infarct size. Infarct size
was reported as a percentage of the zone at risk. The remaining slices were separated
into non-ischaemic (non-I) and ischaemic (ISCH) segments (Figure 1). Samples of
fresh ISCH and non-I tissue were used immediately for lipid hydroperoxide (LPO)
analysis, with the remainder rapidly frozen and stored at´80 ˝C for analysis of other
markers of oxidation and antioxidant status. Samples of control normoxic heart were
always taken from the left ventricle anterior free wall, supplied by the left anterior
descending coronary artery, that would have been subject to ischaemia in the other
protocols. It represents the basal state of the ischaemic zone at risk.
2.4. Measurement of Oxidative Stress Biomarkers
Concentrations of LPO were measured by modification of the ferric thiocyanate
assay using a colorimetric assay kit (Lipid Hydroperoxide Assay, Cayman
Chemical Company, Ann Arbor, MI, USA) and were expressed per mg of protein.
Concentrations of malondialdehyde (MDA) were measured in thawed tissue
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protocol and  IPC protocol hearts were dissected  into non‐ischaemic  (non‐I) and  ischaemic  (ISCH) 
tissue for biochemical analysis. IPC: ischaemic preconditioning. 
Figure 1. Flow chart illustrating the distribution of dietary groups into: Control
normoxic; Ischaemia; and IPC perfusion protocols. In each protocol, isolated hearts
were perfused for 180 min. Ischaemia protocol and IPC protocol hearts were
dissected into non-ischaemic (non-I) and ischaemic (ISCH) tissue for biochemical
analysis. IPC: ischaemic preconditioning.
2.5. Measurement of Antioxidants
Endogenous: Total superoxide dismutase (SOD) activity and CuZnSOD activity
were measured in ventricle sections of: ISCH tissue; and non-I tissue using a
BIOXYTECH®-SOD-525™ assay kit (Oxis Research™, Portland, OR, USA). The
activity of mitochondrial SOD activated by manganese (MnSOD) was calculated as
the difference between total SOD and CuZnSOD. The activity of SOD was expressed
per mg of tissue protein. Glutathione peroxidase (GPX) activity was measured in
ventricle sections of: ISCH; and non-I ventricle using BIOXYTECH®GPx-340TM
assay kit (OxisResearch™, Portland OR, USA) and was expressed per mg of tissue
protein. Exogenous: Myocardial vitamin E (alpha-tocopherol) was measured by HPLC
with electrochemical detection, using a modification of the method described by
Yang [21].
2.6. Myocardial Fatty Acid Analyses
Total lipids were extracted from 100 to 200 mg samples of ventricular
myocardium using a modification of the Folch method [22]. Phospholipids were
isolated from the total muscle lipid by solid phase extraction using silica Sep-pak™
cartridges (Waters, Rydalmere, NSW, Australia). Fatty acid methyl esters were
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prepared by direct transesterification of the phospholipid fraction [23] and analysed
by gas chromatography using a Shimadzu GC-17A with flame ionization detection
using a 30 m ˆ 0.25 mm, 0.25 µm FAMEWAX column (J and W Scientific, Santa
Clara CA, USA) with hydrogen as carrier gas and a step temperature program rising
from 150 ˝C to 260 ˝C, over 27 min and held for 6 min. Individual fatty acids
were identified by their retention times with reference to authentic fatty acid methyl
ester standards (Sigma-Aldrich, Rydalmere, NSW, Australia) and expressed as a
percentage of total phospholipid fatty acids.
2.7. Statistical Analyses
Results were expressed as mean ˘ SEM. Data were analysed by two-way
analysis of variance (ANOVA) for diet and treatment main effects (normoxic
perfusion, ischaemia, IPC + ischaemia) and by multi-way ANOVA for diet, treatment
and ISCH versus non-I tissue main effects. Tukey’s HSD test was used for post-hoc
pairwise comparison of individual means and interactions. Within dietary groups,
ISCH and non-I sections of the same hearts were compared using repeated measures
ANOVA. Statistical analyses were performed using Statistix software, version
10 (Analytical Software, Tallahassee, FL, USA). Linear regression analysis with
Pearson’s correlation was performed to determine linear associations between lipid
oxidation products, antioxidants and infarct size using Prism for Windows, version 6
(GraphPad Software, La Jolla, CA, USA). Statistical significance was accepted at
p < 0.05.
3. Results
Neither the starting body weight, the final body weight nor the change in body
weight over six weeks differed between dietary groups (Start: SF 348˘ 6 g; n-6 PUFA
351 ˘ 5 g; LCn-3 PUFA 352 ˘ 6 g. Six weeks: SF 460 ˘ 11 g; n-6 PUFA 457 ˘ 8 g;
LCn-3 PUFA 480 ˘ 9 g. Change: SF 112 ˘ 7 g; n-6 PUFA 109 ˘ 9 g; LCn-3 PUFA
128 ˘ 7 g. n = 18 per diet).
3.1. Myocardial Membrane Phospholipid Fatty Acid Composition
The relative concentration of DHA (22:6n-3) was greater in phospholipid of
LCn-3 PUFA hearts than in either n-6 PUFA or SF hearts (p < 0.05) (Table 1). The
LCn-3 PUFA hearts contained significantly lower concentrations of linoleic (18:2n-6)
and arachidonic acids (20:4n-6) compared with n-6 PUFA or SF hearts. Total n-3
PUFA was greater in LCn-3 PUFA hearts compared with either n-6 PUFA or SF hearts,
and lower in n-6 PUFA than SF hearts (p < 0.05). The total concentration of n-6 PUFA
was lower in LCn-3 PUFA hearts than in either n-6 PUFA or SF hearts and greater in
n-6 PUFA than SF hearts (p < 0.05).
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Table 1. Influence of dietary fat (six weeks) on phospholipid fatty acid composition
as percentage of total phospholipid fatty acids of rat heart ventricle.
DIET
Fatty Acid SF n-6 PUFA LCn-3 PUFA
16:0 9.7 ˘ 0.1 10.2 ˘ 0.2 10.8 ˘ 0.1
18:0 23.7 ˘ 0.2 23.8 ˘ 0.1 22.4 ˘ 0.2
18:1n-9 a 9.5 ˘ 0.1 b 5.4 ˘ 0.1 b 4.3 ˘ 0.3
18:1n-7 3.6 ˘ 0.1 3.5 ˘ 0.1 3.4 ˘ 0.1
Total SFA 33.80 ˘ 0.13 34.70 ˘ 0.80 33.70 ˘ 0.40
Total MUFA a 13.50 ˘ 0.12 b 8.95 ˘ 0.30 b 7.75 ˘ 1.10
18:2n-6 (LA) b 17.50 ˘ 0.20 a 18.7 ˘ 0.40 c 5.60 ˘ 0.03
20:4n-6 (AA) a 23.30 ˘ 0.30 a 23.5 ˘ 0.20 b 13.30 ˘ 0.15
22:5n-6 n.d a 1.50 ˘ 0.12 a 1.06 ˘ 0.05
20:5n-3 (EPA) n.d n.d 1.30 ˘ 0.01
22:5n-3 (DPA) 1.90 ˘ 0.04 1.02 ˘ 0.02 1.17 ˘ 0.04
22:6n-3 (DHA) b 12.20 ˘ 0.04 b 10.02 ˘ 0.20 a 28.30 ˘ 0.04
Total (n-6) PUFA b 40.80 ˘ 0.20 a 43.80 ˘ 0.60 c 20.00 ˘ 0.16
Total (n-3) PUFA b 14.10 ˘ 0.06 c 11.00 ˘ 0.20 a 30.70 ˘ 0.08
Total PUFA 54.90 ˘ 4.50 54.70 ˘ 4.50 50.70 ˘ 4.40
UI b 215.40 ˘ 1.20 b 215.10 ˘ 0.50 a 260.58 ˘ 1.20
Peroxidisability Index b 156.20 ˘ 1.20 b 149.50 ˘ 1.60 a 201.10 ˘ 0.70
SF: saturated fat enriched diet; n-6 PUFA: n-6 PUFA enriched diet; LCn-3 PUFA: n-3 PUFA
enriched diet; SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA:
polyunsaturated fatty acids; LA: linoleic acid; AA: arachidonic acid; EPA: eicosapentaenoic
acid; DPA: docosahexaenoic acid; DHA: docosahexaenoic acid. Unsaturation index (UI)
was calculated according to the formula: UI = 1 ˆ (% monoenoic acids) + 2 ˆ (% dienoics) +
3 ˆ (% trienoics) + 4 ˆ (% tetraenoics) + 5 ˆ (% pentaenoics) + 6 ˆ (% hexaenoics) or sum
(fatty acid percent) ˆ (number of double bonds). Peroxidatisability index was calculated
from the formula: (% dienoic acids ˆ 1) + (% trienoics ˆ 2) + (% tetraenoics ˆ 3) +
(% pentaenoics ˆ 4) + (% hexaenoics ˆ 5) [17]. n.d: not detected. n = 6 per dietary
group. a, b, c Values not sharing a common letter superscript are significantly different
(ANOVA, p < 0.05).
No significant dietary differences were observed in the membrane phospholipid
total saturated fatty acids or total PUFA. The SF hearts had greater concentrations of
total monounsaturated fatty acids (MUFA). Membrane unsaturation index (UI) and
peroxidisability index (Figure 2A) were significantly greater in LCn-3 PUFA than in




































hearts. The  concentrations of LPO and MDA  in  the  ISCH  region were  significantly greater  in SF 
hearts than in LCn‐3 PUFA hearts (Figure 3A,B). 
IPC:  There were  no  significant  acute  changes  in  LPO  or MDA  in  ISCH  compared  to  non‐I 
regions  within  any  dietary  group  (Figure  3A,B),  nor  were  there  any  significant  between‐diet 
differences within the ISCH regions of IPC + ischaemia hearts. Concentrations of LPO and MDA in 
ISCH regions were significantly lower in IPC + ischaemia hearts than in ischaemia only hearts (p < 
0.0001). Pairwise  comparison  indicated  that  this  IPC difference was evident  in SF and n‐6 PUFA 
diets only. 
Figure 2. Influence of six weeks dietary fat feeding on basal: (A) membrane fatty
acid peroxidisability index; and concentrations of (B) lipid hydroperoxides (LPO);
(C) malondialdehyde (MDA); and (D) antioxidant superoxide dismutase (MnSOD)
of basal or non-I regions of the heart after 180 min of isolated perfusion protocol.
Open columns (SF): saturated fat diet; sha ed columns (n-6): n-6 PUFA rich diet;
filled columns (n-3): LCn-3 PUFA rich fish oil diet. Values are means ˘ SEM. n = 18
per dietary group except peroxidisability index: n = 6. * different from both other
diet groups, p < 0.05. # different from SF group, p < 0.05.
3.2. Basal Properties: Effects of Diet on Oxidative Stress and Antioxidant Activity
The basal a d non-I tissue derived from the three perfusion protocols exhibited
no significant between protocol differences in tissue concentrations of lipid oxidation
products LPO or MDA or anti-oxidants within any dietary group (pooled data shown
in Figure 2). This establishes the non-I measures as representative of the basal state
of the ISCH region.
The concentrations of LPO in basal and non-I tissue were significantly greater
in LCn-3 PUFA than in either n-6 PUFA or SF hearts and greater in n-6 PUFA than
SF hearts (p < 0.05) (Figure 3A). The concentrations of MDA in basal and non-I
tissue were significantly greater in LCn-3 PUFA than in either n-6 PUFA or SF hearts
(p < 0.05), which were not different from each other (Figure 3B).
The activity of MnSOD in basal and non-I tissue was significantly greater in
LCn-3 PUFA hearts, than in SF or n-6 PUFA hearts (Figure 3C). In basal and non-I
tissue there were no significant dietary differences in CuZnSOD activity (basal, non-I
(U¨mg´1 prot in): SF 15.3 ˘ 0.9; n-6 PUFA 16.9 ˘ 0.7; LCn-3 PUFA 17.4 ˘ 0.6 = 18)
(p > 0.05) or GPX (basal, non-I (mU¨mg´1 protein): SF 19.2˘ 1.5; n-6 PUFA 19.7˘ 1.5;
LCn-3 PUFA 21 ˘ 1.2 n = 15). The concentration of α-tocopherol was significantly
greater in n-6 PUFA hearts than in either LCn-3 PUFA or SF hearts (p < 0.05) (basal,





Figure  3.  Influence  of  six weeks  dietary  fat  feeding  on  cardiac  lipid  oxidation  and  antioxidant 
markers  in  ischaemic  (ISCH)  or  non‐ischaemic  (non‐I)  regions  after: Control  normoxic  perfusion 
(basal),  Ischaemia  perfusion,  or  ischaemic  preconditioning  (IPC)  perfusion  protocols:  (A)  lipid 
hydroperoxides (LPO); (B) malondialdehyde (MDA); and (C) superoxide dismutase (MnSOD). Data 
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Figure 3. Influence of six weeks dietary fat feeding on cardiac lipid oxidation
and antioxidant markers in ischaemic (ISCH) or non-ischaemic (non-I) regions
after: Control normoxic perfusion (basal), Ischaemia perfusion, or ischaemic
preconditioning (IPC) perfusion protocols: (A) lipid hydroperoxides (LPO);
(B) malondialdehyde (MDA); and (C) superoxide dismutase (MnSOD). Data are
from hearts that were normoxic throughout (basal), or the non-I and ISCH regions
of hearts subjected to 30 min of regional ischaemia with or without prior IPC. Diet
groups: NN∆—saturated fat (SF); ˝—n-6 PUFA; #—LCn-3 PUFA. Values are
means ˘ SEM. n = 18 per diet, n = 6 per perfusion protocol. * ISCH different from
non-I region within diet, p < 0.05; # n-3 PUFA different from SF p < 0.05; † LCn-3
PUFA and n-6 PUFA different from SF.
3.3. Ischaemic Responses: Effects of Diet and Ischaemic Preconditioning on Oxidative Stress
and Antioxidant Capacity in Hearts Subjected to Regional I/R
Ischaemia: The concentrations of LPO (Figure 3A) and MDA (Figure 3B) were
acutely increased in the ISCH compared to non-I region of n-6 PUFA and SF hearts
(p < 0.01) but not in LCn-3 PUFA hearts. The concentrations of LPO and MDA in
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the ISCH region were significantly greater in SF hearts than in LCn-3 PUFA hearts
(Figure 3A,B).
IPC: There were no significant acute changes in LPO or MDA in ISCH compared
to non-I regions within any dietary group (Figure 3A,B), nor were there any
significant between-diet differences within the ISCH regions of IPC + ischaemia
hearts. Concentrations of LPO and MDA in ISCH regions were significantly lower
in IPC + ischaemia hearts than in ischaemia only hearts (p < 0.0001). Pairwise
comparison indicated that this IPC difference was evident in SF and n-6 PUFA
diets only.
Myocardial MnSOD activity was significantly greater in ISCH compared to
non-I regions of hearts from SF and n-6 PUFA fed rats but not significantly changed
within LCn-3 PUFA hearts (Figure 3C). The perfusion protocol incorporating IPC +
ischaemia had no different effect on MnSOD activity to ischaemia alone.
3.4. Infarct
In hearts subjected to the ischaemia perfusion protocol, infarct size was
significantly smaller in LCn-3 PUFA hearts (ischaemia infarct size (% Iz/r): SF
50 ˘ 1 n = 6; n-6 PUFA 47 ˘ 1 n = 6; LCn-3 PUFA n = 6 11 ˘ 1 n = 6, (p < 0.05)).
In hearts subjected to the IPC + ischaemia protocol, the infarct size was significantly
smaller in the SF and n-6 PUFA hearts than in the corresponding ischaemia group
(p < 0.05). There was no significant difference within the LCn-3 PUFA diet. (IPC +
ischaemia infarct size (% Iz/r): SF 13 ˘ 1 n = 6; n-6 PUFA 12 ˘ 1 n = 6; LCn-3 PUFA
10 ˘ 1 n = 6).
3.5. Associations between Oxidation Biomarkers, Antioxidant and Infarct Size
Ischaemia protocol: Infarct size was positively associated with lipid oxidation
biomarker production in the ISCH region, independent of diet (Table 2). The acute
increases in LPO and MDA (ISCH compared to the non-I region) correlated better
than the absolute ISCH concentrations of LPO and MDA. Lipid oxidation biomarkers
LPO and MDA were correlated in the ISCH region. Ischaemic production of LPO
and MDA and infarct size were inversely associated with the basal (non-I) MnSOD
activity (Table 2). The strongest association was the inverse correlation between basal
MnSOD and infarct size (Figure 4).
IPC: In hearts subjected to the IPC + ischaemia perfusion protocol, infarct
size was not significantly correlated with LPO, MDA or MnSOD concentrations,
and ischaemia-induced increase in MDA but not LPO was correlated with MnSOD
activity. Lipid oxidation biomarkers LPO and MDA were correlated in the ISCH
region (Table 2).
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Pooled analysis of data from both perfusion protocols revealed significant
correlations of infarct size with lipid oxidation markers and with MnSOD. Lipid
oxidation biomarkers LPO and MDA were correlated in the ISCH region (Table 2).
Table 2. Correlations between lipid oxidation products, antioxidants and infarct size.
Dependent Variable Independent Variable Association r2 p for Slope
Ischaemia Protocol
Infarct LPO (ISCH) positive 0.337 * 0.018
Infarct LPO increase positive 0.478 ** 0.004
Infarct MDA (ISCH) positive 0.356 * 0.015
Infarct MDA increase positive 0.517 ** 0.004
Infarct MnSOD (basal) negative 0.851 ** <0.0001
MDA (ISCH) LPO (ISCH) positive 0.481 ** 0.006
LPO increase MnSOD (basal) negative 0.397 ** 0.009
MDA increase MnSOD (basal) negative 0.617 ** 0.001
IPC + Ischaemia Protocol
Infarct LPO (ISCH) positive 0.039 0.483 n.s.
Infarct LPO increase positive 0.147 0.175 n.s.
Infarct MDA (ISCH) positive 0.175 0.150 n.s.
Infarct MDA increase positive 0.009 0.728 n.s.
Infarct MnSOD (basal) negative 0.058 0.335 n.s.
MDA (ISCH) LPO (ISCH) positive 0.764 ** <0.0001
LPO increase MnSOD (basal) negative 0.128 0.174 n.s.
MDA increase MnSOD (basal) negative 0.293 * 0.017
Overall
Infarct LPO increase positive 0.583 ** <0.0001
Infarct MDA increase positive 0.475 ** <0.0001
Infarct MnSOD (basal) negative 0.270 * 0.0012
MDA (ISCH) LPO (ISCH) positive 0.760 ** <0.0001
LPO: lipid hydroperoxides. MDA: malondialdehyde. MnSOD: manganese superoxide
dismutase. ISCH: ischaemic region. Basal: non-ischaemic region of ventricle wall. n.s.:
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in  isolated  rat  hearts  subjected  to  30  min  index  ischaemia  and  120  min  reperfusion.  Rats  fed 
supplemented diets for six weeks—open symbols: saturated fat (SF) diet; shaded symbols: n‐6 PUFA 
diet; closed symbols: LCn‐3 PUFA fish oil diet. 
IPC:  In  hearts  subjected  to  the  IPC  +  ischaemia  perfusion  protocol,  infarct  size  was  not 
significantly correlated with LPO, MDA or MnSOD concentrations, and ischaemia‐induced increase 
Figure 4. Correlation between: basal (non-I) concentration of superoxide dismutase;
and infarct size in isolated rat hearts subjected to 30 min index ischaemia and
120 min reperfusion. Rats fed supplemented diets for six weeks—open symbols:
saturated fat (SF) diet; shaded symbols: n-6 PUFA diet; closed symbols: LCn-3
PUFA fish oil diet.
4. Discussion
A diet rich in LCn-3 PUFA from fish oil modified the fatty acid profile of
myocardial membrane phospholipids, increasing the percentage of fat as DHA
and the peroxidisability index (predicting an increase in risk of oxidative damage),
yet paradoxically reduced the measured oxidative damage following I/R. While
the increased myocardial peroxidation potential was associated with an increase in
basal fatty acid peroxidation, confirming effects of DHA feeding recorded in plasma
and liver [24], it also induced a marked chronic increase in MnSOD (endogenous
antioxidant) activity, and inhibited I/R-induced lipid oxidation and infarction.
Reactive oxygen species act as both the agents of damage and of conservation in IPC,
causing cellular damage yet triggering protective signalling processes [25]. In this
respect, LCn-3 PUFA supplementation reflects both the low level generation of ROS
through lipid peroxidation [26] and up-regulation of endogenous antioxidants that
are implicated as triggers and mediators respectively of late phase IPC [27]. This
aligns fish oil nutritional preconditioning [5] not only with this more persistent form
of IPC (variously known as late, delayed or second window of IPC), but through
LCn-3 PUFA continuous presence as a membrane component, it also provides a
persistent tolerance to I/R injury. This persistent preconditioning is also observed
with repeated stresses like exercise and heat exposure [12]. In contrast, early phase
IPC did not acutely affect basal lipid oxidation or antioxidant activity during the
150 min post preconditioning time course of this study protocol. Moreover, IPC
prevention of lipid oxidation and infarction during the index ischaemia was not
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additive to the effects of fish oil feeding. Admittedly the anti-infarct effects of both
fish oil and IPC could be individually regarded as already maximal.
Fish oil-induced chronic increases in basal lipid oxidation directly correlated
with basal MnSOD antioxidant activity in myocardium, which in turn was negatively
correlated with the I/R-induced increase in lipid oxidation. This interdependence,
which reflects the contrasting damaging influence and homeostatic signalling roles
of ROS in ischaemia and IPC, can explain some of the lack of consistent correlation
between oxidation products and anti-oxidants and sometime failure of oxidation
markers to serve as clear criteria for defining oxidative stress [26]. The effects were
consistent on LPO (an intermediate common to oxidation of all PUFA) and MDA
(a stable end product of a single pathway also not specific for any PUFA family).
Ultimately the infarct size was negatively correlated with MnSOD activity and
directly correlated with the increase in lipid oxidation products in the ISCH region.
Chronic elevation of plasma MnSOD has been previously observed during fish oil
feeding [28], consistent with its persistent elevation over several days following
multiple exposures to TNFα, exercise stress or heat stress [12].
Fish oil induced increases in antioxidant expression and reduced lipid
peroxidation products were also reported in hepatic and renal tissue of immune
suppressed mice [29,30] and hepatic tissue of hypertensive rats [31], conditions
associated with heightened oxidative stress. In those studies, the fish oil diets were
effective independently of varied provision of high or low concentrations of natural
antioxidants in comparative n-6 PUFA or MUFA enriched diets. In the current
study, the n-6 PUFA rich diet with its elevated vitamin E content did not change
the membrane fatty acid composition sufficiently to modulate either membrane
peroxidisability index or endogenous antioxidant enzyme activity relative to the low
PUFA saturated fat enriched diet, and hearts from those diets were equally highly
susceptible to oxidative damage. This is consistent with previous findings that both
membrane effects and cardioprotective effects of n-6 PUFA are readily lost as the
PUFA content is diluted by other fat sources [32,33]. This is not the case for LCn-3
PUFA, which sustain membrane composition [34,35], and cardiac [5,10,32,33,36] and
other functional effects [35] to very low dietary concentrations. The ability of low
(nutritionally relevant) intakes of fish oil to modify membrane composition and
cardiac function, including prevention of I/R arrhythmias is important, since the
provision of extremely high LCn-3 PUFA intakes can be pro-arrhythmic (fish oil
concentrate 4 g/d/20 kg dog, equivalent to ě40/d standard fish oil capsules in an
80 kg man) [37], perhaps representing the harmful effects of excessive oxidation.
Similarly, in a senescence-prone mouse model, high fish oil feeding in conjunction
with high total PUFA enhances oxidative stress and decreases lifespan [38].
The present study suggests that LCn-3 PUFA exert protection from ischaemia by
activating signalling pathways that resemble those involved in late IPC or exercise,
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and we describe this as “nutritional preconditioning”. The current study used a
LCn-3 PUFA intake equivalent to more than 30 g of fish oil per day in humans [34].
However, even very low doses in the range 0.16%–1.25% FO markedly increase
myocardial DHA and peroxidation index (at 0.31% dietary fish oil equivalent
to human 1–2 fish meals per week) DHA is increased from 7.7% to 14.9% of
phospholipid fatty acids and PI is increased from 149 to 164 (calculated from
Slee [34]). This is a dose that modulates skeletal muscle membrane fatty acids
and muscle fatigue [35]. In skeletal muscle, reactive oxygen species capable of
causing cellular damage when in physiological excess can at lower levels also act to
optimise contractile performance and initiate long-term protective adaptations to the
intermittent stress imposed by exercise training [39].
The present study deliberately used a high DHA fish oil, which does not reflect
the composition of most nutritional supplement fish oils, but rather reflects the main
LCn-3 PUFA derived from eating fish [4,40]. As the most abundant n-3 PUFA found
in myocardium, DHA is also the main fatty acid underpinning the cardiac effects of
fish and fish oil [4]. The use of two diets for comparison with fish oil allows specific
attribution of the effects of fish oil feeding to its LCn-3 PUFA content, since similar
total PUFA content was provided in the n-6 and LCn-3 PUFA diets; similar n-6 PUFA
was provided in the SF and LCn-3 PUFA diets; and low saturated fat was provided
in the n-6 PUFA diet, all without effect.
The increased expression of antioxidants within LCn-3 PUFA hearts was
restricted to the mitochondrial form of SOD (MnSOD or SOD2) with CuZnSOD and
GSx unchanged. This suggests localisation of the primarily influence of LCn-3 PUFA
to the mitochondria. Increased MnSOD activity is similarly selectively implicated
in the sustained cardioprotection elicited by heat stress and in late, delayed or
second window of IPC [41], whereas over-expression of cardiac MnSOD in mice
enhances contractile function, slows heart rate and increases efficiency of myocardial
O2 consumption [42], all properties shared by dietary fish oil [5,43,44]. Furthermore,
the fish oil-reduced cardiac oxygen consumption and reduced susceptibility to
I/R-damage and arrhythmias in rats is linked to mitochondrial Ca2+ handling [44].
In contrast, early IPC inhibited acute lipid oxidation and infarction did not involve
upregulation of mitochondrial SOD, confirming its difference from late IPC [41] and
highlighting a difference to the more persistent forms of preconditioning including
exercise [45–47], late IPC [41] and now fish oil-induced nutritional preconditioning.
This study confirmed that increasing myocardial membrane percentage content
of long chain n-3 highly polyunsaturated fatty acids by feeding fish oil, increased
the basal peroxidation of cellular fatty acids, which in turn increased the activity
of endogenous mitochondrial antioxidant superoxide dismutase. When these
hearts were acutely subjected to regional I/R, the stimulated lipid oxidation and
myocardial damage were reduced. The increase in peroxidation index of myocardial
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membranes through fatty acid compositional change and associated chronic mild
elevation in lipid peroxidation products provokes a persistent physiological stress
that might better be described as “oxidative shielding” [48], which if confirmed at
lower fish oil intakes, could explain much of the cardioprotective effect of regular
fish consumption. This readily available and safe nutritional approach appears
to represent a natural form of late preconditioning, which, characterised by its
persistence over time, would be particularly valuable in the clinical setting, where
oxidative insults occur unexpectedly and preclude the use of planned preventative
interventions [41]. The observation, however, also raises the possibility that like
exercise training [45], effects of fish oil nutritional preconditioning may be blunted
by concomitant antioxidant supplementation.
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The Effect of Marine Derived n-3 Fatty Acids
on Adipose Tissue Metabolism and Function
Marijana Todorčević and Leanne Hodson
Abstract: Adipose tissue function is key determinant of metabolic health, with
specific nutrients being suggested to play a role in tissue metabolism. One such
group of nutrients are the n-3 fatty acids, specifically eicosapentaenoic acid (EPA;
20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3). Results from studies where
human, animal and cellular models have been utilised to investigate the effects
of EPA and/or DHA on white adipose tissue/adipocytes suggest anti-obesity and
anti-inflammatory effects. We review here evidence for these effects, specifically
focusing on studies that provide some insight into metabolic pathways or processes.
Of note, limited work has been undertaken investigating the effects of EPA and DHA
on white adipose tissue in humans whilst more work has been undertaken using
animal and cellular models. Taken together it would appear that EPA and DHA
have a positive effect on lowering lipogenesis, increasing lipolysis and decreasing
inflammation, all of which would be beneficial for adipose tissue biology. What
remains to be elucidated is the duration and dose required to see a favourable effect
of EPA and DHA in vivo in humans, across a range of adiposity.
Reprinted from J. Clin. Med. Cite as: Todorčević, M.; Hodson, L. The Effect of Marine
Derived n-3 Fatty Acids on Adipose Tissue Metabolism and Function. J. Clin. Med.
2016, 5, 3.
1. Introduction
Adipose tissue, the largest organ in the human body, was historically considered
to be metabolically inert. However, white adipose tissue is now considered an
endocrine organ as it secretes adipokines (and hormones) which act locally and
distally through autocrine, paracrine and endocrine effects [1]. Although adipose
tissue is comprised of several cell types, including pre-adipocytes, adipocytes,
endothelial cells, fibroblasts, leukocytes and macrophages [2], all of which may
impact on tissue function, one of the main functions of adipocytes/adipose tissue
is to store fatty acids [3]. Adipose tissue acts to “buffer” the influx of dietary fat
into the circulation [3,4], with excess dietary fat being stored in adipose tissue rather
than “overflowing” to non-adipose organs. Ectopic fat deposition has been proposed
to underlie obesity-associated metabolic diseases [5]. An increase in adipose tissue
mass may alter the function of the tissue. For example, when adipose tissue starts
to expand (such as with excess nutrition) macrophages infiltrate and orchestrate
inflammatory responses via molecules such as tumor necrosis factor α (TNFα),
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interleukin 6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1), all of which
have been implicated in the development of pathological changes in adipose tissue
physiology [6–9]. Intriguingly, a proportion of overweight/obese individuals remain
metabolically healthy even with further weight gain, whilst others do not; it has
recently been suggested this is due to an increased capacity of adipose tissue for
lipogenesis [10]. Multiple factors have been suggested to impact on the function of
adipose tissue, however as the tissue is the primary site for dietary fat storage and
reflects dietary fat intakes [11] it is reasonable to suggest that the composition or type
of fat that the tissue is exposed to may also influence the function.
A class of fatty acids that has received a lot of attention over the last 30 years
is the n-3 (or ω-3) fatty acids, specifically those derived from marine sources. n-3
fatty acids have been suggested to lower the risk of a number of non-communicable
metabolic diseases including cardiovascular disease, obesity and diabetes [12–14].
Here we review the effect of long chain n-3 polyunsaturated fatty acids (LCPUFA),
specifically eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA,
22:6n-3) on white adipose tissue metabolism and function. Although other n-3 fatty
acids such as α-linolenic acid (ALA, 18:3n-3) and docosapentanoic acid (DPA, 22:5n-3)
are of potential interest, data are limited. A number of reviews on the effect of fish oil
or n-3 fatty acids on adipose tissue have previously been undertaken [15–20], therefore
we have chosen to review the evidence from human, animal (rodent and fish) and
in vitro cellular studies regarding the specific effects EPA and DHA have on the
metabolism and function of white adipose tissue from different depots. Specifically,
we will discuss the mechanisms by which EPA and DHA are proposed to reduce
adiposity along with discussion regarding how n-3 fatty acids may influence markers
of adipose tissue inflammation and cytokine production.
2. Dietary Sources of Eicosapentaenoic Acid (EPA) and Docosahexaenoic
Acid (DHA)
EPA and DHA, commonly referred to as fish oil fatty acids, are not synthesized
de novo by fish. Fish accumulate them through consumption of water plants, such
as plankton and algae, which are part of the marine food chain [21]. Therefore, if
plankton and algae are not a dietary component or if fish oil is replaced by other
feed sources, such as in fish farming where a vegetable-oil based diet rich in linoleic
acid (18:2n-6) and oleic acid (18:1n-9) may be given, the EPA and DHA content of the
fish will decrease [22,23]. Marine fish tend to have higher amounts of EPA and DHA
than freshwater fish. Fish typically store EPA and DHA mainly as triacylglycerol, at
the middle position (sn-2) of the glycerol backbone however, in krill, a shrimp-like
crustacean that feed off algae in deep ocean waters, 30%–65% of EPA and DHA is in
phospholipids [24].
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Within the human diet, EPA and DHA can be produced from ALA but the
capacity of conversion is low in humans, although higher in women of child-bearing
age than men [25]. Thus, it is likely that the majority of EPA and DHA within the
body, for most individuals are derived from fish and fish oil intakes. Fish oil is often
considered to be the best source of EPA and DHA however, as mentioned above, the
amount of EPA and DHA varies amongst species and within a species according to
environmental variables such as diet, temperature and salinity of the water.
3. Fatty Acid Composition of Adipose Tissue
As the fatty acid composition of adipose tissue has a half-life between
6 months and 2 years, it reflects long-term dietary intake along with endogenous
metabolism [11]. The abundance of EPA and DHA in human subcutaneous adipose
tissue is low, typically less than 0.2 for EPA and up to 1.0 mol% for DHA [11]. The
amount of EPA and DHA in adipose tissue has been reported to increase or remain
unchanged with increasing age [26–28], which is suggested to be an age-dependent
effect independent of dietary intake [28].
Studies measuring the change in adipose tissue fatty acid composition, as a
marker of compliance to n-3 supplementation are limited and findings inconsistent
with some [29–32] but not all [33,34] noting small but significant increases in
the abundance of adipose tissue EPA and DHA after varying periods of fish oil
supplementation (Table 1). The inconsistency in findings may in part be explained
by differences in: duration of supplementation, amount of EPA and DHA consumed,
participant age, sex and adiposity, or site where the adipose biopsy was taken.
Elegant work by Katan et al. [30] clearly demonstrated that the levels of DHA
rose more rapidly in subcutaneous abdominal compared to gluteal adipose tissue
depots whilst differences between the depots for EPA were not as obvious (Table 1).
The difference in the appearance of DHA in subcutaneous abdominal compared to
gluteal adipose tissue, may be explained by the fact that dietary fat extraction (from
chylomicron-triacylglycerol) occurs to a greater extent in subcutaneous abdominal
than gluteal adipose tissue [35]. Of note, Katan et al. [30] found that the proportion
of EPA and DHA in subcutaneous abdominal and gluteal adipose tissue was
approximately one-sixth and one-third respectively of dietary intake. It would
be of interest to determine the extent to which the fatty acid composition of visceral
(intra-abdominal) adipose tissue changed with n-3 fatty acid supplementation.
However, as visceral adipose tissue samples are often obtained during elective
surgery, it would be challenging to undertake a well-controlled study. Taken together,
the data presented in Table 1 clearly demonstrate that even with supplementation
the abundance of EPA and DHA in adipose tissue does not increase notably.
This suggests that EPA and DHA are not preferentially stored in adipose tissue
triacylglycerol long-term, rather they may be partitioned to oxidation pathways or
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to storage in other lipid fractions, such as phospholipids; red blood cell and plasma
phospholipids have a notably higher abundance of both EPA and DHA than adipose
tissue [11]. However, a change in adipose tissue fat mass and therefore dilution
of EPA and DHA abundance cannot be ruled out as the majority of studies do not
indicate if there were changes in participants’ body weight over the course of the
study. Changes in fatty acid composition of adipose tissue have been reported with
weight loss, notably there was not change in EPA abundance but an increase in
DHA abundance, without a reported change in n-3 fatty acid intake, over the weight
maintenance period [36]. These changes highlight the importance of weight/fat mass
stability in subjects participating in intervention studies where adipose tissue fatty


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4. The “Anti-Obesity” Effect of EPA and DHA
Measuring an anti-obesity effect of increased EPA and DHA consumption
in humans is challenging, not least as there are many other factors to control for
(e.g., exercise and other dietary components) and methodology sensitive to small
changes in adipose tissue mass needs to be used. In 2009, Buckley and Howe [37]
reviewed the available evidence for an anti-obesity effect of EPA and DHA. They
suggested from the limited human studies, that increased consumption of EPA and
DHA may reduce body fat; the majority of these studies were short-term, with a
small number of subjects. It remains unclear if similar conclusions can be drawn from
longer-term studies. A recent meta-analysis by Du and colleagues [38] identified
randomised, placebo controlled trials where adults were assigned to either fish
oil/marine group for a period of greater than 4 weeks and had reported at least
one anthropometric measure of body composition (i.e., body weight, BMI, waist
circumference or waist to hip ratio). From the 21 studies (a total of 1329 individuals)
they found no evidence to support an anti-obesity role of n-3 LCPUFA [38]. It is
plausible that changes were not detected due to the non-specific and insensitive
methods used to assess changes in body fat. By using computed tomography
Sato et al. [39] noted that 6 months supplementation with EPA only (1800 mg/day)
resulted in a significant decrease in epicardial and visceral adipose tissue mass, with
no change in subcutaneous abdominal adipose tissue, in individuals with confirmed
coronary artery disease. It is possible that subcutaneous abdominal adipose tissue
mass did decrease however it was only measured in a single slice at the level of
the umbilicus, thus changes in other depots would not have been detected. Results
from some, but not all animal studies have suggested EPA and DHA consumption
to have an anti-obesity effect with a lack of increase in fat mass even when an
obesogenic diet is consumed [40], as well as a reduction in body weight if already
obese [41]. Moreover, these studies, along with cellular studies have been used to
tease out the mechanisms involved in this process, as discussed below with data
from human [42–48], animal [40,41,49–55] and cellular [56–69] studies provided in
Tables 2–4.
4.1. Suppression of Fat Deposition and Adipogenesis
A decrease in fatty acid deposition within adipose tissue may occur due
to a decrease in triacylglycerol synthesis via decreased de novo lipogenesis or
re-esterification of fatty acids within the tissue; alternatively it may occur due to
a lower flux of fatty acids to the tissue. In the latter situation, fatty acids could be
repartitioned to other tissues (such as muscle) for disposal, rather than going to
adipose tissue for storage. In humans, the absolute contribution of de novo synthesized
fatty acids to adipose tissue triacylglycerol is potentially small [70] and measuring
adipose tissue de novo lipogenesis (or fatty acid esterification/re-esterification) in vivo
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in humans is challenging. Therefore, it is not surprising that studies have not
been undertaken investigating how EPA and DHA supplementation influence these
processes in humans. Although not a direct measure of fatty acid synthesis or
esterification/re-esterification within the tissue, the measurement of the expression of
genes related to these processes provides some insight to the effect of EPA and DHA
on these processes. Camargo et al. [42] reported that consumption of 4 g/day of fish
oil (containing a total of 1.24 g EPA and DHA) for 12 weeks significantly decreased
the expression of genes related to fatty acid uptake and storage in subcutaneous
obese adipose tissue (Table 2).
Work in animal models has typically found EPA and DHA to limit lipid
accumulation in adipose tissue (Table 3). The majority of studies have reported
lower fad pad mass and adipocytes number and size which was suggested to
occur via suppression of lipogenic genes and, in some studies, a concomitant
activation of lipolytic genes after supplementation with EPA and DHA (Table 3).
Despite reporting a significant decrease in inguinal retroperitoneal fat pad mass
Hainault et al. [52] did not find any significant change in fatty acid synthase (FAS)
activity or mRNA expression in these depots. Of note, one study reported that EPA
and DHA consumption resulted in higher total and perigonadal fat mass than control
group [55]. This discrepancy in findings maybe in part explained that this study
used an LDL receptor deficient (LDLR´{´) mouse model whilst others have typically
used C57Bl/6 mice or Wistar rats.
Studies investigating the effects of dietary EPA and DHA on adipose tissue
function have also been undertaken in fish (Table 3). Todorcevic et al. [40]
demonstrated that a diet supplemented with EPA and DHA (20% of total fatty
acids) for 21 weeks repressed the development of adiposity, regulating triacylglycerol
accumulation in visceral adipose tissue of Atlantic salmon. A positive influence of
dietary EPA and DHA on lipid accumulation in adipose tissue was also reported in
grass carp [71]. Diet containing EPA and DHA, (12% of total fatty acids for 75 days),
suppressed lipid accumulation in intraperitoneal adipose tissue and significantly
up-regulated the expression lipolytic genes including: lipoprotein lipase (LPL),
stearoyl-CoA desaturase 1 (SCD1) and peroxisome proliferator activated receptor α
(PPARα) [71]. Furthermore, similar results were reported by Liu et al. [72] in grass





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The process of adipogenesis (or an increase in fat mass) involves the
differentiation of preadipocytes to mature adipocytes, is a complex and tightly
regulated process involving a cascade of transcription factors which are sensitive
to the nutritional environment [73]. In a comprehensive review by McMillen and
Robinson [74] the role of the nutritional environment an individual is exposed to
before birth and in early infancy impacts on risk of obesity and obesity-related
diseases later in life was discussed. Evidence from animal studies shows that
offspring of mothers fed a diet high in calories or high in fat before birth are
heavier and have a higher percentage body fat throughout life [75,76]. Findings
from human studies are compelling; children born to mothers who are obese during
their pregnancy have an increased incidence of obesity over the life course [75].
Therefore, it has been suggested that targeting maternal nutrition during pregnancy
may reduce risk of obesity in subsequent generations [77]; n-3 fatty acids may
decrease adipogenesis and lipogenesis and thus exposure in utero to these fatty
acids may lower the risk of obesity in offspring. In 2011 Muhlhausler and
colleagues [77] reviewed animal studies to determine the effects of n-3 LCPUFA
supplementation during pregnancy and lactation on postnatal body composition of
offspring. Although 13 potential studies were identified, only four met the inclusion
criteria and the authors found from albeit limited data that there was a suggestion
that the offspring from n-3 LCPUFA supplemented dams had a lower fat mass [77].
In contrast, supplementation of dams with a high DHA diet (5% fat of which DHA
was 0.95% total fatty acids) during pregnancy and lactation resulted in offspring
that had significantly higher total and subcutaneous fat mass (as percentage of total
body weight) at 6 weeks of age, compared to control animals fed a diet containing
the same amount of fat but devoid of n-3 LCPUFA [78]. Thus it remains unclear if
increased exposure in utero to n-3 fatty acids decreases adipogenesis and lipogenesis
and is an area that warrants further investigation.
To date, the majority of in vitro evidence regarding the mechanistic effects of
EPA and DHA on triacylglycerol accumulation/lipid deposition comes from the
clonal murine cell line, 3T3-L1 (Table 4). This cell line offers advantages over primary
cells, as they are homogenous with regards to cellular population and stage of
differentiation; however, their ability to reflect human adipose tissue function and
metabolism remains to be clarified. Primary pre-adipocyte cultures have been shown
to better reflect in vivo adipose function, than cell lines because they can be isolated
from different species and fat depots. The latter is of interest as there are distinct
molecular and biochemical hallmarks between different adipose tissue depots and
at a cellular level; pre-adipocytes isolated from different adipose tissue depots and
cultured in vitro retain depot-specific functional properties [79–81]. Unlike cell lines,
the function and metabolism of primary cells will be influenced by the age, sex,
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and genetics of the donor and therefore consideration is needed when comparing
across studies.
Results from in vitro cellular studies that have added EPA and DHA to media
for periods of 24 h to 3 weeks are mixed; some suggest EPA and DHA to be
anti-adipogenic whilst others find a pro-adipogenic response. EPA and DHA
have been found to inhibit, promote or have no effect on the differentiation of
pre-adipocytes (Table 4). Typically the markers of adipocytes adipogenesis that have
been measured include: the accumulation of triacylglycerol, lipid droplet formation,
expression of master adipogenic transcription factors, and lipid genes. Using 3T3-L1
pre-adipocytes, Kim et al. [59] investigated the effects of DHA alone (6 days) on
lipogenesis and lipolysis and found mean lipid droplet size, percent lipid area, as well
as glycerol-3-phosphate dehydrogenase (GPDH) activity all significantly decreased
whilst basal lipolysis increased in fully differentiated adipocytes. The results from this
work demonstrate the anti-adipogenic effects of DHA via inhibition of triacylglycerol
accumulation and increased lipolysis [59]. When comparing the effects of EPA
and DHA on lipid droplet formation in 3T3-L1 cells it was found that although
both fatty acids reduced the presence of lipid droplets, DHA was more potent
than EPA [56]. In addition to the decreased lipid droplet formation, there were
notable reductions in the expression of key protein involved in this process, including
perilipin A, caveolin-1 and Cidea [56], however there was no effect of DHA on PPARγ
expression [56]. In contrast, Murali et al. [62] reported that incubating 3T3-L1 with
EPA and DHA induced adipogenesis; DHA being more potent than EPA in inducing
the differentiation process. The authors suggested the differential effects of EPA and
DHA on adipognesis could be due to differential accumulation of n-3 fatty acids
in membrane phospholipids [62]. In line with Murali et al. [62], Wojcik et al. [69]
reported increased accumulation of neutral lipids in mature 3T3-L1 adipocytes;
however, others have reported no effect on triacylglycerol accumulation at any stage
of maturation in 3T3-L1 adipocytes [65]. A reduced expression of both adipogenic
and lipogenic genes, including sterol regulatory element-binding protein 1 (SREBP1),
FAS, and peroxisome proliferator-activated receptor γ (PPARγ) after EPA and DHA
treatment of mature adipocytes has been report by some [69] but not by others [67].
Using human breast adipocytes as a cell model, Wang et al. [68] demonstrated
exposure of DHA for 24 h decreased the expression of lipogenic genes, including FAS,
LPL and PPARγ, whilst expression of lipolytic genes was increased. Lee et al. [82]
found EPA to stimulate glycerol and free fatty acids release which was associated
with induction of lipolytic gene expression and suppression of adipogenic gene
expression in 3T3-L1 adipocytes. Treatment of fish primary adipocytes with EPA
and DHA (for 3 weeks) resulted in decreased triacylglycerol accumulation in mature
adipocytes [83]. In an acute study, using mature adipocytes isolated from grass
carp Liu et al. [72] found that 6 h of incubation with EPA and DHA was sufficient
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to notably decreased triacylglycerol accumulation, significantly increased glycerol
release and the expression of genes involved in lipolysis (e.g., adipose triglyceride
lipase (ATGL), hormone-sensitive lipase (HSL)). The findings from in vitro cellular
studies, notably those using primary adipocytes demonstrate that EPA and DHA
inhibit triacylglycerol accumulation, which may be the result of effects mediated
through genes related to lipogenesis and lipolysis.
Overall, the effects of EPA and DHA as well as EPA versus DHA in modifying
adipogensis and lipid accumulation, in particular in humans, and to a lesser extent
in murine models, remain unclear. Plausible reasons the discrepancies in findings
between in vitro cellular studies are likely to be in part due to the use of different
in vitro models, i.e., using primary cells versus immortalized cell lines, studying the
cells at different developmental stages, differences in the concentrations of fatty
acid(s) the cells were exposed to, along with the duration of exposure.
4.2. Adipocyte Apoptosis
To our knowledge, there have been no studies in humans investigating the effect
of n-3 fatty acids on adipocyte apoptosis and only limited work has been undertaken
in animal and in vitro cellular models. Although outside the scope of this review,
there have been a large number of studies investigating the effect of n-3 fatty acids














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Limiting findings from human in vitro and in vivo studies have reported
apoptosis in white adipose tissue along with alternations in adipose tissue mass.
Thus consideration is required when looking at adipose tissue mass in relation
to cell number as they might be partly regulated by pre-adipocyte/adipocyte
apoptosis [85,86]. Nelson-Dooley et al. [87] have suggested targeting apoptotic
pathways in adipocytes as a novel way of treating obesity. Apoptosis is often assessed
by cytomorphological alterations, DNA fragmentation and condensation, detection
of caspases, protein cleavage at specific locations, cell membrane alterations and and
increased mitochondrial membrane permeability [88]. In 2004 Ruszickova et al. [41]
were the first to suggest the concept of n-3 fatty acids and regulation of cellularity
in adipose tissue. Using a rodent model the authors suggested that increased
intakes of EPA and DHA (Table 3) reduced high-fat diet-induced obesity by
decreasing the number of adipocytes in adipose tissue, which could be interpreted
as evidence of a pro-apoptotic effect. Perez-Matute et al. [54] demonstrated increased
levels of histone-associated DNA oligonucleosomal fragments, classical markers
of apoptosis in the white adipose tissue of rats fed a standard diet with additional
oral administration EPA ethyl ester (1 g/kg per day) daily for 5 weeks. Moreover,
they found a cafeteria diet strongly impaired the apoptotic action induced by
EPA and suggested that EPA-induced apoptosis depends on the nutritional and
metabolic status of the animals [54]. High dietary-n-3 fatty acid levels are at increased
susceptibility to fatty acid peroxidation which has been reported to occur in different
tissues within a fish model [89] including adipose tissue [40]. Fish contain a greater
amount of more highly unsaturated fatty acids than mammals which makes them
more prone to fatty acid peroxidation leading to apoptosis [90]. Todorcevic et al. [40]
were the first to demonstrate that high dietary intakes of EPA and DHA induced
oxidative stress and apoptosis in the visceral adipose tissue in Atlantic salmon.
Salmon was fed with diets containing 50% EPA and 55% DHA of total fatty acid
for 21 weeks and found increased activity of caspase-3, indicative of apoptosis
occurring in white adipose tissue. The authors concluded that decreased adipocytes
cell number due to apoptosis, may be one factor explaining the lower triacylglycerol
accumulation occurring in fish white adipose tissue when diets enriched with EPA
and DHA are fed [40]. On the basis of these finding, it would be prudent to suggest
the measurement of adipose tissue apoptotic markers when EPA and DHA, notably
at high dietary doses, are given.
Even though there is a growing literature on the studying the mechanisms
for the inhibitory effects of n-3 fatty acids on proliferation of various tumor cells
(reviewed by [91]) but also on non-cancerous cells [92], there are surprisingly very
few in vitro studies that have investigated the effect of EPA and DHA on adipocyte
apoptosis. Kim et al. [59] reported significant DHA-induced apoptosis in 3T3-L1
post-confluent pre-adipocytes after 48 h incubation with 200 µM/L compared
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to 100 µM/L DHA, demonstrating the inhibitory effects of DHA on adipocyte
differentiation. Todorcevic et al. [93] treated primary antioxidant glutathione (GSH)
depleted salmon adipocytes with high doses of EPA and DHA (600 µM for 6 days)
in present or absence of α tocopherol and showed increased expression of genes
encoding a set of well-known apoptotic markers in the groups with no added α
tocopherol, suggesting that the induction of adipocyte cell death by EPA and DHA
likely plays an important part in the adipose tissue homeostasis especially in animals
exposed to high dietary n-3 fatty acids.
Taken together, the available data from animal and in vitro studies suggests that
high doses of EPA and DHA may induce adipocyte apoptosis. How targeting
the apoptotic pathway in white adipose tissue would decrease obesity and
influence adipose tissue function and overall metabolic health in humans remains to
be elucidated.
4.3. Increased Fatty acid Oxidation (Energy Expenditure)
Although an increase in fatty acid oxidation, via β-oxidation has been suggested
to play a role in a reduction of triacylglycerol accumulation in adipocytes, evidence
for this in white adipose tissue is limited; fatty acid oxidation and mitochondrial
function has been studied more often in brown adipose tissue. The number and
activity of mitochondria within adipocytes has been suggested to contribute to
insulin resistance and type 2 diabetes [94]. Changes in the expression of genes
related to insulin-signaling have been reported to increase, whilst the expression
of genes related to glycolysis, gluconeogenesis and glyceroneogenesis decreased in
subcutaneous abdominal adipose tissue after 12 weeks supplementation with n-3
fatty acids [45] (Table 2). On the basis of these changes, the authors suggested that a
low-fat (fat 28% total energy (TE)) high complex carbohydrate diet supplemented
with 1.24 g/day n-3 fatty acids (EPA and DHA) improved adipose tissue insulin
sensitivity compared to diets high saturated or monounsaturated fat in individuals
with the metabolic syndrome [45]. To lower the risk of obesity-mediated diseases
such as the metabolic syndrome, weight loss is often encouraged to decrease fat
mass; weight loss by calorie restriction has been suggested to increase subcutaneous
abdominal adipose tissue capacity for lipid oxidation [95]. Whether similar changes
occur in subcutaneous gluteal or visceral adipose tissue remains to be determined.
Moreover, it would be of interest to determine if calorie restriction in combination
with EPA and DHA supplementation has an additive effect on up-regulating adipose
tissue fatty acid oxidation in different adipose tissue depots. The amount of EPA and
DHA has varied between studies, with higher doses tending to be used in animal
and in vitro studies, translation to the appropriate dose, along with duration required
to see an effect in humans needs to be elucidated.
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In vivo or in vitro cellular studies investigating the effects of EPA and DHA
on adipose tissue fatty acid oxidation and/or mitochondrial function are sparse.
Specifically measuring markers of adipose tissue fatty acid oxidation in vivo in
humans has not, to our knowledge, been undertaken. This is most likely to be due to
the challenges associated with assessing adipose tissue fatty acid β-oxidation directly.
Surprisingly no study in humans has yet investigated changes in the expression of
relevant genes in adipose tissue before and after supplementation with EPA and DHA.
Fasting whole-body fatty acid oxidation (assessed by indirect calorimetry) has been
reported to increase in young, healthy men (n = 5) after 3 weeks of supplementation
with fish oil (6 g/day) when compared to a control diet containing equal amounts of
total dietary fat [96]. Only a few animal studies have investigated the effect of EPA
and DHA on fatty acid β-oxidation in white adipose tissue (Table 3). Flachs et al. [51]
reported that feeding mice for 4 weeks with diet containing increasing amounts of
EPA and DHA, preferentially up-regulated several mitochondrial regulatory genes,
increased β-oxidation and suppressed lipogenesis in white abdominal fat. Using
a fish model, Atlantic salmon, Todorcevic et al. [40] reported an increase in adipose
tissue fatty acid β-oxidation after fish consumed fish oil rich in EPA and DHA
for 21 weeks.
In vitro cellular studies have found increased β-oxidation in 3T3-L1 adipocytes
after incubation with 100 µM of EPA for 24 h [58]. The increase in β-oxidation
was associated with increased carnitine palmitoyltransferase 1 (CPT-1) activity but
mRNA and protein expression did not change [58]. As EPA treatment increased
the proportion of EPA in mitochondrial membrane lipids, the authors concluded
that the activity of CPT-1 and β-oxidation was due to changes in the structure or
dynamics of the mitochondrial membranes [58]. EPA and DHA are reported to
activate AMP-activated protein kinase (AMPK) in 3T3-L1 adipocytes, which could
be a mechanism for their effect on fatty acid oxidation [97]. Todorcevic et al. [83]
demonstrated that EPA and DHA increased β-oxidation in salmon primary
adipocytes, which may in part explain the concomitant reduction in adipocyte
triacylglycerol. A possible mechanism, by which EPA and DHA may result
in increased fatty acid oxidation and therefore less body fat accumulation, is
through induction of thermogenesis mediated by mitochondrial uncoupling protein-1
(UCP1); the thermogenic capacity of brown adipose tissue (BAT) is associated with
uncoupling whereas white adipose tissue is typically not [98]. In 2013 Flach et al. [98]
reviewed the effect of n-3 fatty acids on mitochondrial oxidative phosphorylation
(OXPHOS) and fatty acid oxidation in white adipose tissue. In this comprehensive
review they reported that in a murine model, supplementation with n-3 fatty acids
in combination with mild calorie restriction induced mitochondrial OXPHOS in
epididymal white adipose tissue only, independent of UCP1 induction; other studies
in rodents have reported increased levels of UCP1 mRNA and/or protein in BAT
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in response to n-3 fatty acid supplementation [98]. Recently, Zhao and Chen [99]
using an in vitro cellular model of isolated stromal-vascular (SV) cells from inguinal
adipose tissue of suggested that EPA enhanced energy dissipation capacity by
recruiting brite adipocytes to stimulate oxidative metabolism. From the limited data
available it appears that EPA and DHA increase fatty acid β-oxidation in adipocytes,
however the mechanisms responsible and the effect on mitochondrial OXPHOS and
thermogenesis in human adipose tissue remains to be elucidated.
5. The “Anti-Inflammatory” Effects of EPA and DHA on Adipose Tissue
An expansion of adipose tissue mass, is often associated with macrophage
infiltration which may lead to inflammatory responses, which have been implicated
in the development of pathological changes in adipose tissue physiology [6–9]. These
changes potentially move the tissue toward a pro-inflammatory phenotype and there
is accumulating evidence suggesting pro-inflammatory processes in adipose tissue
increase the risk of obesity-related disorders, such as insulin resistance [100–103].
For example, several studies reported positive associations between degree of obesity
and the expression of genes related to inflammation in adipose tissue [7,9]. A number
of studies have investigated the “anti-inflammatory” effect of EPA and DHA in white
adipose tissue.
Suppression of Pro-Inflammatory Cytokine Production
Studies investigating the effect of n-3 fatty acid supplementation, for periods
between 8 weeks up to 6 months, on the expression of genes related to inflammation
in human subcutaneous white adipose tissue have been undertaken. Overall
results are variable, with some suggesting consumption of EPA and DHA decreases
the expression of genes related to inflammation, whilst other report no change
(Table 2). For example, Guebre-Egziabher et al. [43] noted decreased expression of
metalloprotease 9 (MMP9) and CD68 in subcutaneous abdominal adipose tissue
on a low not high dose of MaxEPA in a small number (n = 12) of individuals with
chronic kidney disease (CKD) who were randomised to take either a low (n = 6) or
high (n = 6) dose of MaxEPA for 10 weeks. In contrast, Itariu et al. [44] found that
high doses of EPA and DHA (total 4 g/day) for 8 weeks significantly decreased the
expression of genes related to inflammation in subcutaneous obese adipose tissue
and increased production of anti-inflammatory eicosanoids in visceral adipose tissue
(Table 2).
Work in murine models has found consumption of n-3 fatty acids
decreased inflammatory gene expression in white adipose tissue depots (Table 3).
Todoric et al. [104] investigated the effect of an n-3 fatty acid diet on macrophage
infiltration in white adipose tissue of obese, diabetic mice, as well as on gene
expression of several immune genes. They found that consumption of 25.1 mg
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of n-3 fatty acids (containing EPA and DHA) per gram of fat for 6 weeks resulted in a
reduction in macrophage infiltration in combination with decreased expression of
inflammatory genes in white adipose tissue [104]. Sarawathi et al. [55] used LDLR´{´
mice and showed similar results to Todoric et al. [104] despite a gain in white adipose
tissue mass. They reported a diet supplemented with fish oil containing 140 mg EPA
and 95 mg DHA/day for 12 weeks reduced expression of macrophage markers such
as MAC-1 and CD68 as well as inflammatory markers such as TNFα, metalloprotease
3 (MMP3), and serum amyloid A3 (SAA3) in white adipose tissue [55]. Taken together
these data demonstrate that consumption of n-3 fatty acids have the potential to
modulate immune response in adipose tissue.
In vitro studies, using cell-lines and human primary cells, have been utilised to
investigate the potential cellular mechanisms and pathways involved in an n-3
fatty acid mediated alteration in immune response (Table 4). Adiponectin, an
adipocyte-specific protein, is often suggested to be anti-inflammatory cytokine
and it has been postulated that a change in secretion may be associated with
visceral obesity [105]. In vitro cellular work has found that incubation of primary
human adipocytes isolated from subcutaneous adipose tissue with either with EPA
or DHA significantly increased the concentration of secreted adiponectin [106],
which is in agreement with several studies performed using primary cultured rat
adipocytes [107], 3T3-L1 adipocytes [64] and human adipocyte cell lines [66]. From
the work of Oster et al. [64] it appears that EPA and DHA have differential effects
on adiponectin secretion, which may be influenced by the cell model used. They
found DHA increased adiponectin mRNA expression and secreted adiponectin
protein to a greater extent than the same dose of EPA in 3T3-L1 adipocyte after
24 h incubation [64]. In contrast, Tishinsky et al. [99] found using a commercial line
of human adipocytes that EPA significantly increased cellular adiponectin protein
content after 48 h of treatment while DHA did not affect cellular adiponectin protein.
The effects of n-3 fatty acids on the adipokine leptin, have been investigated
in vitro however results show conflicting effects of n-3 fatty acids on leptin mRNA
expression and secretion. EPA has been shown to have a stimulatory effect on leptin
gene expression and secretion in 3T3-L1 adipocytes [108] and primary cultured rat
adipocytes [109]. Reseland et al. [110] reported an opposite effect to the work of
Murata et al. [108] and Perez-Matute et al. [109], where exposure to both EPA and
DHA reduced leptin mRNA expression in 3T3-L1 adipocytes. Furthermore, the
effect of EPA and DHA on leptin expression has been shown to vary depending on
the stage of adipocyte maturation [65]. Thus, the discrepancy in reported results
could be related to differences in different cell models used (primary cells vs. cell
lines) or in measuring the effects of n-3 fatty acids on leptin at different stages of
adipogenesis. Culturing human primary adipocytes in either EPA or DHA resulted
in a down-regulation of IL6 and TNFα secretion [63]. In contrast, differential effects
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of EPA and DHA were found for IL6 secretion in 3T3-L1 cells with EPA increasing
and DHA decreasing secretion [65]; the underlying mechanisms for these responses
were unable to be clarified by the authors. Another divergent finding is that from
Wojcik et al. [69] who noted culturing 3T3-L1 cells in either EPA or DHA increased
TNFα mRNA expression; it is unclear if this lead to increased secretion as it was
not measured. The authors speculated that their finding would not be replicated in
adipose tissue in vivo, as the anti-inflammatory effects of EPA and DHA on TNFα
expression would be modulated through the direct effect of these fatty acids on
macrophages; cells that were not present in their in vitro culture [69]. It remains
unclear if EPA and DHA have a differential effect on anti-inflammatory markers in
human and animal models as typically these fatty acids have been given together
and not directly compared.
6. Conclusions
In recent years evidence demonstrating that an increased consumption of
EPA and DHA may have a beneficial effect on white adipose tissue function and
metabolism is starting to emerge. Although current literature cannot support an
exact mechanistic role of EPA and DHA on adipose tissue biology it is apparent
that these fatty acids have the potential to be potent modulators of adipose tissue
and adipocyte function. More work has been undertaken using animal and cell
models therefore consideration is required regarding the dose and duration of EPA
and DHA, the animal and cell model used (e.g., primary vs. cell-lines). Moreover,
in vitro cellular cells often investigate the effects of EPA and DHA on adipocytes
and it is plausible a different response may be found in whole adipose tissue due
to the presence of other cell types (e.g., macrophages, endothelial cells) and their
interaction with adipocytes. Although the effects of n-3 fatty acid supplementation
on the fatty acid composition of subcutaneous abdominal and gluteal adipose tissue
have been investigated, mechanistic studies (in vivo and in vitro) appears to be limited
to primarily subcutaneous abdominal adipose tissue and/or adipocytes. Evidence
for an effect of n-3 fatty acids in human visceral adipose tissue is sparse and therefore
not well understood. Evidence for a reduction in fat accumulation in animal models,
along with an anti-inflammatory effect appears to be consistent when intakes of
EPA and DHA are high (up to 20% of total fatty acids); however recommendations
for human intakes are between 0.5% and 2% of total energy intake [111]. Thus, the
duration and amount of dietary EPA or DHA required for beneficial effects in human
subcutaneous adipose tissue depots remains to be elucidated.
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